{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Extra Credit Opportuinity\n",
    "\n",
    "# Can You Predit a 20 Day Change in Stock Price?\n",
    "* Get 5 points added to your lowest Major Lab grade (Lab 1, 2, or 3) for completing the extra credit. \n",
    "* Get 10 additional points, if you achieve a lower Mean Absolute Error < 25% OR a Correct direction > 57.6%\n",
    "\n",
    "# Instructions \n",
    "1. Create and execute three original 30 day simulation models (Examples below) trying to improve your MAE each time. \n",
    "2. Pickel your predictions for each run using the .gz file extension and the file names shown below. \n",
    "3. Execute the code in the observations section using the predictions from your best run. \n",
    "4. Update with your own observations. Feel free to add any visuals or tables you need to support your observations.\n",
    "5. State how many Extra Credit points you think you should be awarded.  If you qualify for the 10 additional points, explain how / why you think your model achieves a better result. \n",
    "\n",
    "# Rules\n",
    "* All extra credit work and submissions must be individual.  Do not share your approaches.    \n",
    "* \"Original\" simualtions include you making changes to the models, parameter tuning, feature selection, feature engineering, training record selection strategies etc. to achieve a better result. \n",
    "* Feel free to run more than three simulations, but only include your best 3 simulations in the final submission. \n",
    "* You MUST use the make_cv_folds() function and the train / test folds it creates for the simulation.  DO NOT modify this code in any way.\n",
    "* You MUST use the example code below to execute your simulations.  \n",
    "* Only modify the simuilation code to improve the model predictions.   \n",
    "* You must make a prediction for each of the 30 days and 2,065 test records as shown below.\n",
    "* You must train your model using some or all of the training data for each respective fold (see examples below).\n",
    "* DO NOT mix folds in any way. Use the simulation examples as a starting point. Training records for each fold are 20 days older than the test records you are trying to predict. \n",
    "* DO NOT add new or future training data to the folds!!! \n",
    "* Simulation predictions must be pickled/saved using the filenames: pred_data_e1.gz, pred_data_e2.gz, and pred_data_e3.gz as shown below.\n",
    "* Your work MUST be reproduceable! I will not award any points if I cannot reproduce your work using the cv_folds below!   \n",
    "* You may use any scikit learn tools to create better predictions.\n",
    "* I WILL MAKE A FINAL DETERMINATION ON AWARDING EXTRA CREDIT POINTS. PLEASE ASK IF YOU HAVE QUESTIONS, DO NOT ASSUME.\n",
    "\n",
    "# Things to Consider Trying\n",
    "* Modify TfidfVectorizer() parameters to make better features. \n",
    "* Use different models or model ensembles.\n",
    "* Use sklearn.feature_selection (SelectFromModel, SelectKBest) to select better features.\n",
    "* Try out the AdaBoostRegressor()\n",
    "* Try dimensionality reduction or remove very rare features from the TfidfVectorizer's sparse matrix.  "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "import cv2\n",
    "import numpy as np\n",
    "from sklearn.utils import shuffle\n",
    "import os\n",
    "from collections import deque\n",
    "import copy\n",
    "import matplotlib\n",
    "import matplotlib.pyplot as plt\n",
    "from keras.utils import np_utils\n",
    "#from config import Config\n",
    "%matplotlib inline  "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "UsageError: Line magic function `%tensorflow_version` not found.\n"
     ]
    }
   ],
   "source": [
    "%tensorflow_version 2.4.x"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "import re\n",
    "import nltk\n",
    "import spacy\n",
    "import keras\n",
    "import tensorflow as tf\n",
    "from tensorflow.keras.callbacks import EarlyStopping\n",
    "from tensorflow.keras.utils import plot_model"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "('2.5.0', '2.5.0')"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "tf.__version__, keras.__version__"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Num GPUs Available:  1\n"
     ]
    }
   ],
   "source": [
    "print(\"Num GPUs Available: \", len(tf.config.list_physical_devices('GPU')))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'C:\\\\Users\\\\John Olanipekun\\\\Documents\\\\Machine Learning\\\\SMU_Machine_Learning'"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "os.chdir(r\"C:\\Users\\John Olanipekun\\Documents\\Machine Learning\\SMU_Machine_Learning\")\n",
    "os.getcwd()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "sec_data = pd.read_pickle('SecData.gz')"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Introduction to the Data\n",
    "**This dataframe has the raw text and metadata for 6,215 SEC 10-Q filings.  Field definitions are below:**\n",
    "* CompanyCIK - Used by the SEC to identify each company.\n",
    "* CompanyName - Name of company filing the report\n",
    "* FileType - These should all be '10-Q'.\n",
    "* FileDate - Date the filing was made.\n",
    "* EdgarTextUrl & EdgarHtmlUrl - Links to the report on the SEC's website.\n",
    "* AccessionNumber - A unique identifier assigned automatically to an accepted submission by the SEC.\n",
    "* SecFileName - The SEC quarterly index file where this filing is located. \n",
    "* CompanyTicker - The stock ticker for this company (when available)\n",
    "* FileDate_ClosingPrice - Closing stock price on the FileDate.\n",
    "* FileDate_Plus_20 - The FileDate + 20 days.\n",
    "* FileDate_Plus_20_Price - Closing stock price on the FileDate_Plus_20.\n",
    "* Pct_Change_20 - The percentage change between the FileDate_ClosingPrice and the FileDate_Plus_20_Price.\n",
    "* FileName - The name of this filing on my local filing system in case we need to look at it. \n",
    "* file_text_length - Number of text characters  extracted from the filing. I have removed all filings with less than 25,000 characters.\n",
    "* f_text - The actual raw text extracted from the filing. "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<class 'pandas.core.frame.DataFrame'>\n",
      "DatetimeIndex: 6215 entries, 2021-01-04 to 2021-06-28\n",
      "Data columns (total 16 columns):\n",
      " #   Column                  Non-Null Count  Dtype         \n",
      "---  ------                  --------------  -----         \n",
      " 0   CompanyCIK              6215 non-null   int64         \n",
      " 1   CompanyName             6215 non-null   object        \n",
      " 2   FileType                6215 non-null   object        \n",
      " 3   FileDate                6215 non-null   datetime64[ns]\n",
      " 4   EdgarTextUrl            6215 non-null   object        \n",
      " 5   EdgarHtmlUrl            6215 non-null   object        \n",
      " 6   AccessionNumber         6215 non-null   object        \n",
      " 7   SecFileName             6215 non-null   object        \n",
      " 8   CompanyTicker           6215 non-null   object        \n",
      " 9   FileDate_ClosingPrice   6215 non-null   float64       \n",
      " 10  FileDate_Plus_20        6215 non-null   datetime64[ns]\n",
      " 11  FileDate_Plus_20_Price  6215 non-null   float64       \n",
      " 12  Pct_Change_20           6215 non-null   float64       \n",
      " 13  FileName                6215 non-null   object        \n",
      " 14  file_text_length        6215 non-null   int64         \n",
      " 15  f_text                  6215 non-null   object        \n",
      "dtypes: datetime64[ns](2), float64(3), int64(2), object(9)\n",
      "memory usage: 825.4+ KB\n"
     ]
    }
   ],
   "source": [
    "sec_data.info()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Some Exploratory Data Analyses  "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "**What do the attributes look like?**  "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>CompanyCIK</th>\n",
       "      <th>CompanyName</th>\n",
       "      <th>FileType</th>\n",
       "      <th>FileDate</th>\n",
       "      <th>EdgarTextUrl</th>\n",
       "      <th>EdgarHtmlUrl</th>\n",
       "      <th>AccessionNumber</th>\n",
       "      <th>SecFileName</th>\n",
       "      <th>CompanyTicker</th>\n",
       "      <th>FileDate_ClosingPrice</th>\n",
       "      <th>FileDate_Plus_20</th>\n",
       "      <th>FileDate_Plus_20_Price</th>\n",
       "      <th>Pct_Change_20</th>\n",
       "      <th>FileName</th>\n",
       "      <th>file_text_length</th>\n",
       "      <th>f_text</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>FileDate</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>2021-01-04</th>\n",
       "      <td>66382</td>\n",
       "      <td>HERMAN MILLER INC</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-01-04</td>\n",
       "      <td>edgar/data/66382/0000066382-21-000003.txt</td>\n",
       "      <td>edgar/data/66382/0000066382-21-000003-index.html</td>\n",
       "      <td>0000066382-21-000003</td>\n",
       "      <td>2021-QTR1</td>\n",
       "      <td>MLHR</td>\n",
       "      <td>33.099998</td>\n",
       "      <td>2021-01-22</td>\n",
       "      <td>36.779999</td>\n",
       "      <td>11.117826</td>\n",
       "      <td>66382_0000066382-21-000003.txt</td>\n",
       "      <td>68246</td>\n",
       "      <td>b'10-Q 1 mlhr-20201128.htm 10-Q mlhr-20201128 ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2021-01-04</th>\n",
       "      <td>1098009</td>\n",
       "      <td>America Great Health</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-01-04</td>\n",
       "      <td>edgar/data/1098009/0001185185-20-001804.txt</td>\n",
       "      <td>edgar/data/1098009/0001185185-20-001804-index....</td>\n",
       "      <td>0001185185-20-001804</td>\n",
       "      <td>2021-QTR1</td>\n",
       "      <td>AAGH</td>\n",
       "      <td>0.050000</td>\n",
       "      <td>2021-01-22</td>\n",
       "      <td>0.060000</td>\n",
       "      <td>19.999996</td>\n",
       "      <td>1098009_0001185185-20-001804.txt</td>\n",
       "      <td>48172</td>\n",
       "      <td>b\"10-Q 1 amgreat20190331_10q.htm FORM 10-Q amg...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2021-01-04</th>\n",
       "      <td>1821318</td>\n",
       "      <td>OTR Acquisition Corp.</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-01-04</td>\n",
       "      <td>edgar/data/1821318/0001104659-21-000366.txt</td>\n",
       "      <td>edgar/data/1821318/0001104659-21-000366-index....</td>\n",
       "      <td>0001104659-21-000366</td>\n",
       "      <td>2021-QTR1</td>\n",
       "      <td>OTRA</td>\n",
       "      <td>10.280000</td>\n",
       "      <td>2021-01-22</td>\n",
       "      <td>10.265000</td>\n",
       "      <td>-0.145908</td>\n",
       "      <td>1821318_0001104659-21-000366.txt</td>\n",
       "      <td>88075</td>\n",
       "      <td>b\"10-Q 1 tm2039245d1_10q.htm FORM 10-Q UNITED ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2021-01-05</th>\n",
       "      <td>320187</td>\n",
       "      <td>NIKE, Inc.</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-01-05</td>\n",
       "      <td>edgar/data/320187/0000320187-21-000003.txt</td>\n",
       "      <td>edgar/data/320187/0000320187-21-000003-index.html</td>\n",
       "      <td>0000320187-21-000003</td>\n",
       "      <td>2021-QTR1</td>\n",
       "      <td>NKE</td>\n",
       "      <td>141.229996</td>\n",
       "      <td>2021-01-25</td>\n",
       "      <td>137.550003</td>\n",
       "      <td>-2.605674</td>\n",
       "      <td>320187_0000320187-21-000003.txt</td>\n",
       "      <td>112930</td>\n",
       "      <td>b'10-Q 1 nke-20201130.htm 10-Q nke-20201130 UN...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2021-01-05</th>\n",
       "      <td>276720</td>\n",
       "      <td>PURE CYCLE CORP</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-01-05</td>\n",
       "      <td>edgar/data/276720/0001140361-21-000183.txt</td>\n",
       "      <td>edgar/data/276720/0001140361-21-000183-index.html</td>\n",
       "      <td>0001140361-21-000183</td>\n",
       "      <td>2021-QTR1</td>\n",
       "      <td>PCYO</td>\n",
       "      <td>11.900000</td>\n",
       "      <td>2021-01-25</td>\n",
       "      <td>11.610000</td>\n",
       "      <td>-2.436975</td>\n",
       "      <td>276720_0001140361-21-000183.txt</td>\n",
       "      <td>100672</td>\n",
       "      <td>b'10-Q 1 brhc10018555_10q.htm 10-Q UNITED STAT...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "            CompanyCIK            CompanyName FileType   FileDate  \\\n",
       "FileDate                                                            \n",
       "2021-01-04       66382      HERMAN MILLER INC     10-Q 2021-01-04   \n",
       "2021-01-04     1098009   America Great Health     10-Q 2021-01-04   \n",
       "2021-01-04     1821318  OTR Acquisition Corp.     10-Q 2021-01-04   \n",
       "2021-01-05      320187             NIKE, Inc.     10-Q 2021-01-05   \n",
       "2021-01-05      276720        PURE CYCLE CORP     10-Q 2021-01-05   \n",
       "\n",
       "                                           EdgarTextUrl  \\\n",
       "FileDate                                                  \n",
       "2021-01-04    edgar/data/66382/0000066382-21-000003.txt   \n",
       "2021-01-04  edgar/data/1098009/0001185185-20-001804.txt   \n",
       "2021-01-04  edgar/data/1821318/0001104659-21-000366.txt   \n",
       "2021-01-05   edgar/data/320187/0000320187-21-000003.txt   \n",
       "2021-01-05   edgar/data/276720/0001140361-21-000183.txt   \n",
       "\n",
       "                                                 EdgarHtmlUrl  \\\n",
       "FileDate                                                        \n",
       "2021-01-04   edgar/data/66382/0000066382-21-000003-index.html   \n",
       "2021-01-04  edgar/data/1098009/0001185185-20-001804-index....   \n",
       "2021-01-04  edgar/data/1821318/0001104659-21-000366-index....   \n",
       "2021-01-05  edgar/data/320187/0000320187-21-000003-index.html   \n",
       "2021-01-05  edgar/data/276720/0001140361-21-000183-index.html   \n",
       "\n",
       "                 AccessionNumber SecFileName CompanyTicker  \\\n",
       "FileDate                                                     \n",
       "2021-01-04  0000066382-21-000003   2021-QTR1          MLHR   \n",
       "2021-01-04  0001185185-20-001804   2021-QTR1          AAGH   \n",
       "2021-01-04  0001104659-21-000366   2021-QTR1          OTRA   \n",
       "2021-01-05  0000320187-21-000003   2021-QTR1           NKE   \n",
       "2021-01-05  0001140361-21-000183   2021-QTR1          PCYO   \n",
       "\n",
       "            FileDate_ClosingPrice FileDate_Plus_20  FileDate_Plus_20_Price  \\\n",
       "FileDate                                                                     \n",
       "2021-01-04              33.099998       2021-01-22               36.779999   \n",
       "2021-01-04               0.050000       2021-01-22                0.060000   \n",
       "2021-01-04              10.280000       2021-01-22               10.265000   \n",
       "2021-01-05             141.229996       2021-01-25              137.550003   \n",
       "2021-01-05              11.900000       2021-01-25               11.610000   \n",
       "\n",
       "            Pct_Change_20                          FileName  file_text_length  \\\n",
       "FileDate                                                                        \n",
       "2021-01-04      11.117826    66382_0000066382-21-000003.txt             68246   \n",
       "2021-01-04      19.999996  1098009_0001185185-20-001804.txt             48172   \n",
       "2021-01-04      -0.145908  1821318_0001104659-21-000366.txt             88075   \n",
       "2021-01-05      -2.605674   320187_0000320187-21-000003.txt            112930   \n",
       "2021-01-05      -2.436975   276720_0001140361-21-000183.txt            100672   \n",
       "\n",
       "                                                       f_text  \n",
       "FileDate                                                       \n",
       "2021-01-04  b'10-Q 1 mlhr-20201128.htm 10-Q mlhr-20201128 ...  \n",
       "2021-01-04  b\"10-Q 1 amgreat20190331_10q.htm FORM 10-Q amg...  \n",
       "2021-01-04  b\"10-Q 1 tm2039245d1_10q.htm FORM 10-Q UNITED ...  \n",
       "2021-01-05  b'10-Q 1 nke-20201130.htm 10-Q nke-20201130 UN...  \n",
       "2021-01-05  b'10-Q 1 brhc10018555_10q.htm 10-Q UNITED STAT...  "
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sec_data.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "FileDate\n",
       "2021-01-04     -0.145908\n",
       "2021-01-05     -2.605674\n",
       "2021-01-05     -2.436975\n",
       "2021-01-05     -3.969667\n",
       "2021-01-05      0.831549\n",
       "2021-01-05      0.000000\n",
       "2021-01-05      0.480280\n",
       "2021-01-06     -1.293326\n",
       "2021-01-06     -0.411403\n",
       "2021-01-06     43.272724\n",
       "2021-01-06     -0.407473\n",
       "2021-01-06     -6.119260\n",
       "2021-01-06     -0.909093\n",
       "2021-01-06     -1.918941\n",
       "2021-01-06      1.861329\n",
       "2021-01-06     30.451207\n",
       "2021-01-06     -3.828616\n",
       "2021-01-07     -0.277775\n",
       "2021-01-07     13.079987\n",
       "2021-01-07     10.563387\n",
       "2021-01-07     -0.990548\n",
       "2021-01-07     -3.064729\n",
       "2021-01-07    -15.686269\n",
       "2021-01-07      4.764648\n",
       "2021-01-07    -11.530284\n",
       "2021-01-07      1.865723\n",
       "2021-01-07     -6.818179\n",
       "2021-01-07     -7.322177\n",
       "2021-01-07      8.048822\n",
       "2021-01-07     12.702479\n",
       "2021-01-07    -25.758732\n",
       "2021-01-07     -6.794245\n",
       "2021-01-07     18.667951\n",
       "2021-01-07    182.381210\n",
       "2021-01-07     -5.121380\n",
       "2021-01-07      6.132541\n",
       "2021-01-07      5.891065\n",
       "2021-01-07     -3.021358\n",
       "2021-01-07     -3.381643\n",
       "2021-01-07     -1.900830\n",
       "2021-01-08      0.591711\n",
       "2021-01-08      1.252908\n",
       "2021-01-08     -7.348274\n",
       "2021-01-08     18.421057\n",
       "2021-01-08      1.190475\n",
       "2021-01-08      8.962655\n",
       "2021-01-08     -4.768329\n",
       "2021-01-08      2.675583\n",
       "2021-01-08     39.126481\n",
       "2021-01-08     -3.669725\n",
       "2021-01-08      0.969307\n",
       "2021-01-08     16.099953\n",
       "2021-01-11     26.558266\n",
       "2021-01-11     20.512822\n",
       "2021-01-11     25.475285\n",
       "2021-01-11     -4.245474\n",
       "2021-01-11     17.647051\n",
       "2021-01-11    100.000000\n",
       "Name: Pct_Change_20, dtype: float64"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sec_data.iloc[2:60,12]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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\n",
      "text/plain": [
       "<Figure size 432x288 with 1 Axes>"
      ]
     },
     "metadata": {
      "needs_background": "light"
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Extract Figure and Axes instance\n",
    "fig, ax = plt.subplots()\n",
    "\n",
    "# Create a plot\n",
    "ax.violinplot(sec_data['Pct_Change_20'])\n",
    "\n",
    "# Add title\n",
    "ax.set_title('Violin Plot')\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Comments  \n",
    "The violin plot above confirms the explanation offered during the live session that the percent change is heavily skewed.\n",
    "Most the values are concentrated within single to double digit values while some have 5 digit values up to >50,000.  \n",
    "\n",
    "- This justifies the 'normalization' technique adopted for this attribute."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "**Sample SEC Filing**  \n",
    "Company report"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "FileDate\n",
       "2021-01-04    b'10-Q 1 mlhr-20201128.htm 10-Q mlhr-20201128 ...\n",
       "2021-01-04    b\"10-Q 1 amgreat20190331_10q.htm FORM 10-Q amg...\n",
       "2021-01-04    b\"10-Q 1 tm2039245d1_10q.htm FORM 10-Q UNITED ...\n",
       "2021-01-05    b'10-Q 1 nke-20201130.htm 10-Q nke-20201130 UN...\n",
       "2021-01-05    b'10-Q 1 brhc10018555_10q.htm 10-Q UNITED STAT...\n",
       "2021-01-05    b'10-Q 1 epac-20201130.htm 10-Q epac-20201130 ...\n",
       "2021-01-05    b'10-Q 1 calm-20201128.htm 10-Q calm-20201128 ...\n",
       "2021-01-05    b'10-Q 1 form10-q.htm UNITED STATES SECURITIES...\n",
       "2021-01-05    b'10-Q 1 sgh-10q_20201127.htm 10-Q sgh-10q_202...\n",
       "Name: f_text, dtype: object"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sec_data.loc['2021-01-04':'2021-01-05', 'f_text']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'b\\'10-Q 1 nke-20201130.htm 10-Q nke-20201130 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission File No. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) , , (Address of principal executive offices and zip code) () (Registrant\\\\\\'s telephone number, including area code) SECURITIES REGISTERED PURSUANT TO SECTION 12(B) OF THE ACT: (Title of each class) (Trading symbol) (Name of each exchange on which registered) Indicate by check mark: YES NO  whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.  Accelerated filer  Non-accelerated filer  Smaller reporting company Emerging growth company  if an emerging growth company, if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).  As of December 28, 2020, the number of shares of the Registrant\\\\\\'s Common Stock outstanding were: Class A Class B 1,576,490,011 Table of Contents NIKE, INC. FORM 10-Q TABLE OF CONTENTS PAGE PART I - FINANCIAL INFORMATION 1 ITEM 1. Financial Statements 1 Unaudited Condensed Consolidated Statements of Income 1 Unaudited Condensed Consolidated Statements of Comprehensive Income 2 Unaudited Condensed Consolidated Balance Sheets 3 Unaudited Condensed Consolidated Statements of Cash Flows 4 Unaudited Condensed Consolidated Statements of Shareholders\\\\\\' Equity 5 Notes to the Unaudited Condensed Consolidated Financial Statements 7 ITEM 2. Management\\\\\\'s Discussion and Analysis of Financial Condition and Results of Operations 25 ITEM 3. Quantitative and Qualitative Disclosures about Market Risk 45 ITEM 4. Controls and Procedures 45 PART II - OTHER INFORMATION 47 ITEM 1. Legal Proceedings 47 ITEM 1A. Risk Factors 47 ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds 48 ITEM 6. Exhibits 49 Signatures 50 Table of Contents PART I - FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS NIKE, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME THREE MONTHS ENDED NOVEMBER 30, SIX MONTHS ENDED NOVEMBER 30, (In millions, except per share data) 2020 2019 2020 2019 Revenues $ $ $ $ Cost of sales Gross profit Demand creation expense Operating overhead expense Total selling and administrative expense Interest expense (income), net Other (income) expense, net () () Income before income taxes Income tax expense NET INCOME $ $ $ $ Earnings per common share: Basic $ $ $ $ Diluted $ $ $ $ Weighted average common shares outstanding: Basic Diluted The accompanying Notes to the Unaudited Condensed Consolidated Financial Statements are an integral part of this statement. 1 Table of Contents NIKE, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME THREE MONTHS ENDED NOVEMBER 30, SIX MONTHS ENDED NOVEMBER 30, (Dollars in millions) 2020 2019 2020 2019 Net income $ $ $ $ Other comprehensive income (loss), net of tax: Change in net foreign currency translation adjustment () Change in net gains (losses) on cash flow hedges () () () () Change in net gains (losses) on other () () () Total other comprehensive income (loss), net of tax () () () () TOTAL COMPREHENSIVE INCOME $ $ $ $ The accompanying Notes to the Unaudited Condensed Consolidated Financial Statements are an integral part of this statement. 2 Table of Contents NIKE, INC. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS NOVEMBER 30, MAY 31, (In millions) 2020 2020 ASSETS Current assets: Cash and equivalents $ $ Short-term investments Accounts receivable, net Inventories Prepaid expenses and other current assets Total current assets Property, plant and equipment, net Operating lease right-of-use assets, net Identifiable intangible assets, net Goodwill Deferred income taxes and other assets TOTAL ASSETS $ $ LIABILITIES AND SHAREHOLDERS\\\\\\' EQUITY Current liabilities: Current portion of long-term debt $ $ Notes payable Accounts payable Current portion of operating lease liabilities Accrued liabilities Income taxes payable Total current liabilities Long-term debt Operating lease liabilities Deferred income taxes and other liabilities Redeemable preferred stock Shareholders\\\\\\' equity: Common stock at stated value: Class A convertible  and shares outstanding Class B  and shares outstanding Capital in excess of stated value Accumulated other comprehensive income (loss) () () Retained earnings (deficit) () Total shareholders\\\\\\' equity TOTAL LIABILITIES AND SHAREHOLDERS\\\\\\' EQUITY $ $ The accompanying Notes to the Unaudited Condensed Consolidated Financial Statements are an integral part of this statement. 3 Table of Contents NIKE, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS SIX MONTHS ENDED NOVEMBER 30, (Dollars in millions) 2020 2019 Cash provided (used) by operations: Net income $ $ Adjustments to reconcile net income to net cash provided (used) by operations: Depreciation Deferred income taxes () () Stock-based compensation Amortization, impairment and other Net foreign currency adjustments () Changes in certain working capital components and other assets and liabilities: (Increase) decrease in accounts receivable () () (Increase) decrease in inventories () (Increase) decrease in prepaid expenses, operating lease right-of-use assets and other current and non-current assets () () Increase (decrease) in accounts payable, accrued liabilities, operating lease liabilities and other current and non-current liabilities () () Cash provided (used) by operations Cash provided (used) by investing activities: Purchases of short-term investments () () Maturities of short-term investments Sales of short-term investments Additions to property, plant and equipment () () Other investing activities () Cash provided (used) by investing activities () () Cash provided (used) by financing activities: Increase (decrease) in notes payable () Repayment of borrowings () () Proceeds from exercise of stock options and other stock issuances Repurchase of common stock () Dividends  common and preferred () () Other financing activities () () Cash provided (used) by financing activities () () Effect of exchange rate changes on cash and equivalents () Net increase (decrease) in cash and equivalents () Cash and equivalents, beginning of period CASH AND EQUIVALENTS, END OF PERIOD $ $ Supplemental disclosure of cash flow information: Non-cash additions to property, plant and equipment $ $ Dividends declared and not paid The accompanying Notes to the Unaudited Condensed Consolidated Financial Statements are an integral part of this statement. 4 Table of Contents NIKE, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS\\\\\\' EQUITY COMMON STOCK CAPITAL IN EXCESS OF STATED VALUE ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) RETAINED EARNINGS (DEFICIT) TOTAL CLASS A CLASS B (In millions, except per share data) SHARES AMOUNT SHARES AMOUNT Balance at August 31, 2020 $ $ $ $ () $ $ Stock options exercised Conversion to Class B Common Stock () Dividends on common stock ($ per share) () () Issuance of shares to employees, net of shares withheld for employee taxes () Stock-based compensation Net income Other comprehensive income (loss) () () Balance at November 30, 2020 $ $ $ $ () $ $ COMMON STOCK CAPITAL IN EXCESS OF STATED VALUE ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) RETAINED EARNINGS (DEFICIT) TOTAL CLASS A CLASS B (In millions, except per share data) SHARES AMOUNT SHARES AMOUNT Balance at August 31, 2019 $ $ $ $ $ $ Stock options exercised Repurchase of Class B Common Stock () () () () Dividends on common stock ($ per share) () () Issuance of shares to employees, net of shares withheld for employee taxes () Stock-based compensation Net income Other comprehensive income (loss) () () Balance at November 30, 2019 $ $ $ $ $ $ The accompanying Notes to the Unaudited Condensed Consolidated Financial Statements are an integral part of this statement. 5 Table of Contents COMMON STOCK CAPITAL IN EXCESS OF STATED VALUE ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) RETAINED EARNINGS (DEFICIT) TOTAL CLASS A CLASS B (In millions, except per share data) SHARES AMOUNT SHARES AMOUNT Balance at May 31, 2020 $ $ $ $ () $ () $ Stock options exercised Conversion to Class B Common Stock () Dividends on common stock ($ per share) and preferred stock ($ per share) () () Issuance of shares to employees, net of shares withheld for employee taxes () Stock-based compensation Net income Other comprehensive income (loss) () () Balance at November 30, 2020 $ $ $ $ () $ $ COMMON STOCK CAPITAL IN EXCESS OF STATED VALUE ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) RETAINED EARNINGS (DEFICIT) TOTAL CLASS A CLASS B (In millions, except per share data) SHARES AMOUNT SHARES AMOUNT Balance at May 31, 2019 $ $ $ $ $ $ Stock options exercised Repurchase of Class B Common Stock () () () () Dividends on common stock ($ per share) and preferred stock ($ per share) () () Issuance of shares to employees, net of shares withheld for employee taxes () Stock-based compensation Net income Other comprehensive income (loss) () () Adoption of ASC Topic 842 () () Balance at November 30, 2019 $ $ $ $ $ $ The accompanying Notes to the Unaudited Condensed Consolidated Financial Statements are an integral part of this statement. 6 Table of Contents NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Note 1 Summary of Significant Accounting Policies 8 Note 2 Inventories 8 Note 3 Accrued Liabilities 8 Note 4 Fair Value Measurements 8 Note 5 Short-Term Borrowings and Credit Lines 10 Note 6 Income Taxes 10 Note 7 Stock-Based Compensation 11 Note 8 Earnings Per Share 12 Note 9 Risk Management and Derivatives 12 Note 10 Accumulated Other Comprehensive Income (Loss) 17 Note 11 Revenues 19 Note 12 Operating Segments 21 Note 13 Acquisitions and Divestitures 23 Note 14 Restructuring 24 7 Table of Contents 8 Table of Contents 9 Table of Contents 10 Table of Contents 11 Table of Contents 12 Table of Contents 13 Table of Contents 14 Table of Contents 15 Table of Contents 16 Table of Contents 17 Table of Contents 18 Table of Contents 19 Table of Contents 20 Table of Contents 21 Table of Contents 22 Table of Contents 23 Table of Contents . 24 Table of Contents ITEM 2. MANAGEMENT\\\\\\'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OVERVIEW NIKE designs, develops, markets and sells athletic footwear, apparel, equipment, accessories and services worldwide. We are the largest seller of athletic footwear and apparel in the world. We sell our products through NIKE-owned retail stores and through digital platforms (which we refer to collectively as our NIKE Direct operations), to retail accounts and to a mix of independent distributors, licensees and sales representatives in virtually all countries around the world. Our goal is to deliver value to our shareholders by building a profitable global portfolio of branded footwear, apparel, equipment and accessories businesses. Our strategy is to achieve long-term revenue growth by creating innovative, must-have products, building deep personal consumer connections with our brands and delivering compelling consumer experiences through digital platforms and at retail. Since fiscal 2018, through the Consumer Direct Offense and our Triple Double strategy, we have focused on doubling the impact of innovation, increasing our speed and agility to market and growing our direct connections with consumers. In June 2020, we announced a new digitally empowered phase of the Consumer Direct Offense strategy: Consumer Direct Acceleration. This strategic acceleration will focus on three specific areas. First, creating the marketplace of the future through more premium, consistent and seamless consumer experiences that more closely align with what consumers want and need. This strategy will lead with NIKE Digital and our own stores, as well as through select strategic partners who share our marketplace vision. Second, we will align our product creation and category organizations around a new consumer construct focused on Mens, Women\\\\\\'s and Kids\\\\\\'. This approach is intended to allow us to create product that better meets individual consumer needs, including more specialization of our category approach, while re-aligning and simplifying our offense to accelerate our largest growth opportunities. In particular, we expect to reinvest in our Women\\\\\\'s and Kids\\\\\\' businesses and also simplify our operating model across the remainder of the Company to optimize effectiveness. Third, we will unify investments in data and analytics, demand sensing, insight gathering, inventory management and other areas against an end-to-end technology foundation to accelerate our digital transformation. We believe this unified approach will accelerate growth and unlock more efficiency for our business, while driving speed and responsiveness as we serve consumers globally. As a result of our strategic acceleration, management announced on July 22, 2020, a series of leadership and operating model changes to streamline and speed up our execution. These changes will result in a net reduction of our global workforce and we expect to incur pre-tax charges of approximately $315 million, the majority of which relate to employee termination costs and, to a lesser extent, stock-based compensation expense. These amounts reflect the continued evaluation and variability of our original estimate of employee termination costs and required changes in assumptions used to calculate stock-based compensation expense. For the first six months of fiscal 2021, we incurred pre-tax charges of $218 million and expect all remaining actions to be substantially complete by the end of fiscal 2021. We expect future annual wage-related savings will be reinvested to execute against this next phase of our strategy. For more information related to our organizational realignment and related costs, see Note 14  Restructuring within the accompanying Notes to the Unaudited Condensed Consolidated Financial Statements. COVID-19 UPDATE The COVID-19 pandemic continues to impact our business results and operations globally, causing us to transform the way we operate in order to better serve our consumers. Although uncertainty due to the pandemic continues to exist, our financial results for the second quarter and first six months of fiscal 2021 demonstrate our ability to navigate the dynamic situation. Despite physical retail traffic being below prior year levels, Revenues grew 9% and 4% for the second quarter and first six months of fiscal 2021, respectively, and 7% and 4% on a currency-neutral basis. Through our intentional supply and demand management, inventory levels have declined, and we ended the second quarter of fiscal 2021 with Inventories down 17% compared to May 31, 2020. We reduced discretionary spending while continuing to invest in our digital transformation. As a result, total selling and administrative expense declined 2% for the second quarter and 6% for the first six months of fiscal 2021. However, we expect Demand creation expense to increase in future periods as major sporting events and key sports moments resume following recovery from the pandemic, along with investments in strategic areas to drive growth. Our liquidity position remains strong and we ended the second quarter with $11.8 billion of Cash and equivalents and Short-term investments. Our NIKE Direct business continues to fuel our growth as we navigate through the pandemic, leveraging our digital assets with our store footprint to connect directly with the consumer. On a reported basis, NIKE Direct sales for the second quarter and first six months of fiscal 2021 were $4.3 billion and $8.0 billion, respectively, growing 30% and 22%, respectively, on a currency-neutral basis. NIKE Brand digital remained our fastest growing channel, with growth of 80% and 81% for the second quarter and first six months of fiscal 2021, respectively. During the second quarter of fiscal 2021, we experienced temporary store closures in geographies affected by rising COVID-19 cases; however, more than 80% of our owned stores were open as of January 4, 2021, with some operating on reduced hours. Despite a substantial majority of stores being open during the quarter, we experienced a 25 Table of Contents decline in comparable store sales in EMEA, North America and APLA, primarily due to reduced physical retail traffic, in part resulting from safety-related measures in response to COVID-19. We continue to monitor the ongoing and evolving situation, as well as guidance from international and domestic authorities, including federal, state and local public health authorities and may take additional actions based on their recommendations. In these circumstances, there may be developments outside our control requiring us to adjust our operating plan. As such, we expect that fiscal 2021 will continue to be a time of uncertainty across each of our geographies and we expect each market recovery will be dynamic. While our results for the second quarter and first six months of fiscal 2021 are positive, there remains the risk that COVID-19 could have material adverse impacts on our future revenue growth as well as our overall profitability and may lead to higher than normal inventory levels in various markets, revised payment terms with certain of our wholesale customers, higher sales-related reserves and a volatile effective tax rate driven by changes in the mix of earnings across the Company\\\\\\'s jurisdictions. SECOND QUARTER OVERVIEW For the second quarter of fiscal 2021, NIKE, Inc. Revenues increased 9% to $11.2 billion compared to the second quarter of fiscal 2020. On a currency-neutral basis, Revenues increased 7%. Net income was $1,251 million and diluted earnings per common share was $0.78 for the second quarter of fiscal 2021, compared to Net income of $1,115 million and diluted earnings per common share of $0.70 for the second quarter of fiscal 2020. Income before income taxes increased 17% compared to the second quarter of fiscal 2020, primarily due to higher revenues and lower selling and administrative expense, partially offset by a decline in gross margin. The NIKE Brand, which represents over 90% of NIKE, Inc. Revenues, increased 9% compared to the second quarter of fiscal 2020. On a currency-neutral basis, NIKE Brand revenues grew 8%, driven by higher revenues across all geographies, footwear and apparel, as well as growth in most key categories, primarily Sportswear and the Jordan Brand. Revenues for Converse decreased 1% and 4% on a reported and currency-neutral basis, respectively, as double-digit growth in digital and growth in Asia were more than offset by declines in Europe and North America, primarily due to tighter supply and strategic distribution shifts. Our effective tax rate was 14.1% for the second quarter of fiscal 2021 compared to 10.7% for the second quarter of fiscal 2020, primarily due to changes in the proportion of earnings taxed in the U.S. and an increase in tax associated with the recent finalization of U.S. tax regulations, partially offset by a more favorable impact from stock-based compensation. During the third quarter of fiscal 2020, we entered into definitive agreements to sell our NIKE Brand businesses in Brazil, Argentina, Chile and Uruguay and to shift to a distributor operating model. The transaction with Grupo SBF S.A. to purchase substantially all of our NIKE Brand operations in Brazil closed on December 1, 2020, subsequent to the end of the second quarter of fiscal 2021. Additionally, subsequent to the end of the second quarter of fiscal 2021, we mutually agreed with Grupo Axo to terminate the sale and purchase agreement for the transition of NIKEs businesses in Argentina, Chile and Uruguay to a distributor partnership. However, as we remain committed to selling our NIKE Brand businesses in all three countries to third-party distributors, the assets and liabilities of the entities will remain classified as held-for-sale on our Unaudited Condensed Consolidated Balance Sheets. For more information see Note 13  Acquisitions and Divestitures within the accompanying Notes to the Unaudited Condensed Consolidated Financial Statements. USE OF NON-GAAP FINANCIAL MEASURES Throughout this Quarterly Report on Form 10-Q, we discuss non-GAAP financial measures, including references to wholesale equivalent revenues, currency-neutral revenues as well as Total NIKE Brand earnings before interest and taxes (EBIT) and Total NIKE, Inc. EBIT, which should be considered in addition to, and not in lieu of, the financial measures calculated and presented in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). References to wholesale equivalent revenues are intended to provide context as to the total size of our NIKE Brand market footprint if we had no NIKE Direct operations. NIKE Brand wholesale equivalent revenues consist of (1) sales to external wholesale customers and (2) internal sales from our wholesale operations to our NIKE Direct operations, which are charged at prices comparable to those charged to external wholesale customers. Currency-neutral revenues are calculated using actual exchange rates in use during the comparative prior year period to enhance the visibility of the underlying business trends excluding the impact of translation arising from foreign currency exchange rate fluctuations. EBIT is calculated as Net Income before Interest expense (income), net and Income tax expense in the Unaudited Condensed Consolidated Statements of Income. Management uses these non-GAAP financial measures when evaluating the Company\\\\\\'s performance, including when making financial and operating decisions. Additionally, management believes these non-GAAP financial measures provide investors with additional financial information that should be considered when assessing our underlying business performance and trends. However, references to wholesale equivalent revenues, currency-neutral revenues and EBIT should not be considered in isolation or as a substitute for other financial measures calculated and presented in accordance with U.S. GAAP and may not be comparable to similarly titled non-GAAP measures used by other companies. 26 Table of Contents RESULTS OF OPERATIONS THREE MONTHS ENDED NOVEMBER 30, SIX MONTHS ENDED NOVEMBER 30, (Dollars in millions, except per share data) 2020 2019 % CHANGE 2020 2019 % CHANGE Revenues $ 11,243 $ 10,326 9 % $ 21,837 $ 20,986 4 % Cost of sales 6,396 5,782 11 % 12,249 11,571 6 % Gross profit 4,847 4,544 7 % 9,588 9,415 2 % Gross margin 43.1 % 44.0 % 43.9 % 44.9 % Demand creation expense 729 881 -17 % 1,406 1,899 -26 % Operating overhead expense 2,538 2,443 4 % 4,836 4,753 2 % Total selling and administrative expense 3,267 3,324 -2 % 6,242 6,652 -6 % % of revenues 29.1 % 32.2 % 28.6 % 31.7 % Interest expense (income), net 70 12  135 27  Other (income) expense, net 54 (41)  40 (74)  Income before income taxes 1,456 1,249 17 % 3,171 2,810 13 % Income tax expense 205 134 53 % 402 328 23 % Effective tax rate 14.1 % 10.7 % 12.7 % 11.7 % NET INCOME $ 1,251 $ 1,115 12 % $ 2,769 $ 2,482 12 % Diluted earnings per common share $ 0.78 $ 0.70 11 % $ 1.73 $ 1.56 11 % 27 Table of Contents CONSOLIDATED OPERATING RESULTS REVENUES THREE MONTHS ENDED NOVEMBER 30, SIX MONTHS ENDED NOVEMBER 30, (Dollars in millions) 2020 2019 % CHANGE % CHANGE EXCLUDING CURRENCY CHANGES (1) 2020 2019 % CHANGE % CHANGE EXCLUDING CURRENCY CHANGES (1) NIKE, Inc. Revenues: NIKE Brand Revenues by: Footwear $ 6,801 $ 6,206 10 % 8 % $ 13,569 $ 12,727 7 % 7 % Apparel 3,585 3,287 9 % 7 % 6,460 6,408 1 % 0 % Equipment 347 341 2 % 1 % 718 789 -9 % -9 % Global Brand Divisions (2) 8 10 -20 % -20 % 12 16 -25 % -25 % Total NIKE Brand Revenues 10,741 9,844 9 % 8 % 20,759 19,940 4 % 4 % Converse 476 480 -1 % -4 % 1,039 1,035 0 % -1 % Corporate (3) 26 2   39 11   TOTAL NIKE, INC. REVENUES $ 11,243 $ 10,326 9 % 7 % $ 21,837 $ 20,986 4 % 4 % Supplemental NIKE Brand Revenues Details: NIKE Brand Revenues by: Sales to Wholesale Customers $ 6,423 $ 6,578 -2 % -4 % $ 12,787 $ 13,420 -5 % -5 % Sales through NIKE Direct 4,310 3,256 32 % 30 % 7,960 6,504 22 % 22 % Global Brand Divisions (2) 8 10 -20 % -20 % 12 16 -25 % -25 % TOTAL NIKE BRAND REVENUES $ 10,741 $ 9,844 9 % 8 % $ 20,759 $ 19,940 4 % 4 % (1) The percent change excluding currency changes represents a non-GAAP financial measure. See \"Use of Non-GAAP Financial Measures\" for further information. (2) Global Brand Divisions revenues include NIKE Brand licensing and other miscellaneous revenues that are not part of a geographic operating segment. (3) Corporate revenues primarily consist of foreign currency hedge gains and losses related to revenues generated by entities within the NIKE Brand geographic operating segments and Converse, but managed through our central foreign exchange risk management program. SECOND QUARTER OF FISCAL 2021 COMPARED TO SECOND QUARTER OF FISCAL 2020 On a currency-neutral basis, NIKE, Inc. Revenues grew 7% for the second quarter of fiscal 2021, due to growth across all NIKE Brand geographies, partially offset by lower revenues in Converse. Higher revenues in Greater China and EMEA each contributed approximately 3 percentage points of growth to NIKE, Inc. Revenues, with APLA contributing approximately 1 percentage point of growth. On a currency-neutral basis, NIKE Brand footwear revenues increased 8%, driven by growth in most key categories, primarily Sportswear and the Jordan Brand, partially offset by declines in Running. Unit sales of footwear increased 4% and higher average selling price (ASP) per pair contributed approximately 4 percentage points of footwear revenue growth, primarily due to the favorable impact of growth in our NIKE Direct business, as well as higher full-price ASP, on a wholesale equivalent basis. Currency-neutral NIKE Brand apparel revenues grew 7%, reflecting higher revenues in several key categories, most notably Sportswear and Football (Soccer). Unit sales of apparel increased 9%, while lower ASP per unit reduced apparel revenues by approximately 2 percentage points. Lower ASP per unit was primarily due to lower full-price ASP, in part reflecting higher discounts, as well as an unfavorable full-price mix. On a reported basis, NIKE Direct revenues represented approximately 40% of our total NIKE Brand revenues for the second quarter of fiscal 2021 compared to 33% for the second quarter of fiscal 2020. Digital sales were $2.4 billion for the second quarter of fiscal 2021 compared to $1.3 billion for the second quarter of fiscal 2020. On a currency-neutral basis, NIKE Direct revenues increased 30%, driven by digital sales growth of 80%, which more than offset comparable store sales declines of 4% primarily due to reduced physical retail traffic, in part resulting from safety-related measures in response to COVID-19 . Comparable store sales, which exclude digital sales, comprises revenues from NIKE-owned in-line and factory stores for which all three of the following requirements have been met: (1) the store has been open at least one year, (2) square footage has not changed by more than 15% within the past year and (3) the store has not been permanently repositioned within the past year. Comparable store sales includes revenues from stores that were temporarily closed during the period as a result of COVID-19. Comparable store sales represents a performance measure that we believe is useful information for management and investors in understanding the performance of our established NIKE-owned in-line and factory stores. Management considers this metric when making financial and operating 28 Table of Contents decisions. The method of calculating comparable store sales varies across the retail industry. As a result, our calculation of this metric may not be comparable to similarly titled measures used by other companies. FIRST SIX MONTHS OF FISCAL 2021 COMPARED TO FIRST SIX MONTHS OF FISCAL 2020 On a currency-neutral basis, NIKE, Inc. Revenues grew 4% for the first six months of fiscal 2021, driven by growth in Greater China and EMEA, partially offset by lower revenues in APLA. Higher revenues in Greater China and EMEA each contributed approximately 2 percentage points of growth to NIKE, Inc. Revenues. On a currency-neutral basis, NIKE Brand footwear revenues increased 7%, driven by growth in several key categories, led by Sportswear and the Jordan Brand. Unit sales of footwear increased 2% and higher ASP per pair contributed approximately 5 percentage points of footwear revenue growth, primarily due to higher full-price ASP and the favorable impact of growth in our NIKE Direct business. Currency-neutral NIKE Brand apparel revenues were flat as growth in Sportswear, Football (Soccer) and the Jordan Brand, was offset by declines in all other key categories. Unit sales of apparel increased 1%, while lower ASP per unit reduced apparel revenues by approximately 1 percentage point. Lower ASP per unit was primarily due to lower full-price ASP, in part reflecting higher discounts, as well as unfavorable full-price mix, partially offset by the favorable impact of growth in our NIKE Direct business. On a reported basis, NIKE Direct revenues represented approximately 38% of our total NIKE Brand revenues for the first six months of fiscal 2021 compared to 33% for the first six months of fiscal 2020. Digital sales were $4.4 billion for the first six months of fiscal 2021 compared to $2.4 billion for the first six months of fiscal 2020. On a currency-neutral basis, NIKE Direct revenues increased 22% for the first six months of fiscal 2021, driven by digital sales growth of 81%, partially offset by a 13% decline in comparable store sales driven by reduced physical retail traffic, in part resulting from safety-related measures in response to COVID-19 . GROSS MARGIN THREE MONTHS ENDED NOVEMBER 30, SIX MONTHS ENDED NOVEMBER 30, (Dollars in millions) 2020 2019 % CHANGE 2020 2019 % CHANGE Gross Profit $ 4,847 $ 4,544 7 % $ 9,588 $ 9,415 2 % Gross Margin 43.1 % 44.0 % (90) bps 43.9 % 44.9 % (100) bps For the second quarter and first six months of fiscal 2021, our consolidated gross margin was 90 and 100 basis points lower than the respective prior year period and reflected unfavorable impacts from COVID-19. For the second quarter of fiscal 2021, the change in gross margin primarily reflected the following factors:  Lower margin in our NIKE Direct business, reflecting higher promotions to reduce excess inventory as a result of COVID-19 (decreasing gross margin approximately 80 basis points);  Lower mix of full-price sales (decreasing gross margin approximately 70 basis points);  Higher other costs, in part reflecting higher warehousing and freight as well as restructuring-related costs related to our organizational realignment, partially offset by lower inventory obsolescence (decreasing gross margin approximately 40 basis points);  Unfavorable changes in net foreign currency exchange rates, including hedges, (decreasing gross margin approximately 30 basis points); and  Lower NIKE Brand product costs, on a wholesale equivalent basis, due to favorable product mix, lower air freight and reduced tariffs in North America (increasing gross margin approximately 110 basis points). For the first six months of fiscal 2021, the change in gross margin primarily reflected the following factors:  Lower margin in our NIKE Direct business, reflecting higher promotions to reduce excess inventory as a result of COVID-19 (decreasing gross margin approximately 120 basis points);  Lower mix of full-price sales (decreasing gross margin approximately 70 basis points);  Unfavorable changes in net foreign currency exchange rates, including hedges, (decreasing gross margin approximately 30 basis points);  Higher other costs, in part reflecting higher warehousing and freight as well as restructuring-related costs, partially offset by lower inventory obsolescence and the favorable impact from the release of factory cancellation cost accruals due to higher than anticipated consumer demand (decreasing gross margin approximately 10 basis points); and  Higher NIKE Brand full-price ASP, net of discounts, (increasing gross margin approximately 110 basis points). 29 Table of Contents TOTAL SELLING AND ADMINISTRATIVE EXPENSE THREE MONTHS ENDED NOVEMBER 30, SIX MONTHS ENDED NOVEMBER 30, (Dollars in millions) 2020 2019 % CHANGE 2020 2019 % CHANGE Demand creation expense (1) $ 729 $ 881 -17 % $ 1,406 $ 1,899 -26 % Operating overhead expense 2,538 2,443 4 % 4,836 4,753 2 % Total selling and administrative expense $ 3,267 $ 3,324 -2 % $ 6,242 $ 6,652 -6 % % of revenues 29.1 % 32.2 % (310) bps 28.6 % 31.7 % (310) bps (1) Demand creation expense consists of advertising and promotion costs, including costs of endorsement contracts, complimentary product, television, digital and print advertising and media costs, brand events and retail brand presentation. SECOND QUARTER OF FISCAL 2021 COMPARED TO SECOND QUARTER OF FISCAL 2020 Demand creation expense decreased 17% for the second quarter of fiscal 2021 due primarily to lower advertising and marketing costs, as well as a decline in sports marketing expense and retail brand presentation costs as a result of COVID-19. This activity was partially offset by an increase in digital marketing to support heightened digital demand. Changes in foreign currency exchange rates increased Demand creation expense by approximately 1 percentage point. Operating overhead expense increased 4% primarily due to $137 million of restructuring-related costs associated with changes to our organizational model announced in July 2020, as well as continued investments in digital capabilities to support the Consumer Direct Acceleration strategy. These costs were slightly offset by disciplined expense management including lower wage-related expenses and lower travel and related costs. Changes in foreign currency exchange rates increased Operating overhead expense by approximately 1 percentage point. FIRST SIX MONTHS OF FISCAL 2021 COMPARED TO FIRST SIX MONTHS OF FISCAL 2020 Demand creation expense decreased 26% for the first six months of fiscal 2021, driven by lower advertising and marketing costs, as well as a decline in sports marketing expense and retail brand presentation costs as a result of COVID-19. This activity was partially offset by an increase in digital marketing to support heightened digital demand. Changes in foreign currency exchange rates had an insignificant impact on Demand creation expense. Operating overhead expense increased 2%, primarily due to $184 million of restructuring-related costs associated with changes to our organizational model announced in July 2020, as well as our continued investments in digital capabilities, partially offset by lower travel and related expenses. Changes in foreign currency exchange rates had an insignificant impact on Operating overhead expense. For more information related to our organizational realignment and related costs, see Note 14  Restructuring within the accompanying Notes to the Unaudited Condensed Consolidated Financial Statements. OTHER (INCOME) EXPENSE, NET THREE MONTHS ENDED NOVEMBER 30, SIX MONTHS ENDED NOVEMBER 30, (Dollars in millions) 2020 2019 2020 2019 Other (income) expense, net $ 54 $ (41) $ 40 $ (74) Other (income) expense, net comprises foreign currency conversion gains and losses from the re-measurement of monetary assets and liabilities denominated in non-functional currencies and the impact of certain foreign currency derivative instruments, as well as unusual or non-operating transactions that are outside the normal course of business. For the second quarter of fiscal 2021, Other (income) expense, net changed from $41 million of other income, net to $54 million of other expense, net in the current year, primarily due to a net detrimental change in foreign currency conversion gains and losses, including hedges, as well as a charge related to our planned, strategic distributor partnership transition within APLA. For the first six months of fiscal 2021, Other (income) expense, net changed from $74 million of other income, net to $40 million of other expense, net in the current year, primarily due to charges related to our planned, strategic distributor partnership transition within APLA, as well as a net detrimental change in foreign currency conversion gains and losses, including hedges. For more information related to our distributor partnership transition within APLA, see Note 13  Acquisitions and Divestitures within the accompanying Notes to the Unaudited Condensed Consolidated Financial Statements. We estimate the combination of the translation of foreign currency-denominated profits from our international businesses and the year-over-year change in foreign currency-related gains and losses included in Other (income) expense, net had favorable impacts of approximately $10 million and unfavorable impacts of approximately $28 million on our Income before income taxes for the second quarter and first six months of fiscal 2021, respectively. 30 Table of Contents INCOME TAXES THREE MONTHS ENDED NOVEMBER 30, SIX MONTHS ENDED NOVEMBER 30, 2020 2019 % CHANGE 2020 2019 % CHANGE Effective tax rate 14.1 % 10.7 % 340 bps 12.7 % 11.7 % 100 bps Our effective tax rate was 14.1% for the second quarter of fiscal 2021, compared to 10.7% for the second quarter of fiscal 2020, primarily due to changes in the proportion of earnings taxed in the U.S. and an increase in tax associated with the recent finalization of U.S. tax regulations, partially offset by a more favorable impact from stock-based compensation. Our effective tax rate was 12.7% for the first six months of fiscal 2021, compared to 11.7% for the first six months of fiscal 2020, primarily due to changes in the proportion of earnings taxed in the U.S. and the recognition of a reserve in the first quarter of fiscal 2021 related to Altera Corp. v. Commissioner , partially offset by discrete items which include a more favorable impact from stock-based compensation. Refer to Note 6  Income Taxes within the accompanying Notes to the Unaudited Condensed Consolidated Financial Statements for additional information. 31 Table of Contents OPERATING SEGMENTS Our operating segments are evidence of the structure of the Company\\\\\\'s internal organization. The NIKE Brand segments are defined by geographic regions for operations participating in NIKE Brand sales activity. Each NIKE Brand geographic segment operates predominantly in one industry: the design, development, marketing and selling of athletic footwear, apparel and equipment. The Company\\\\\\'s reportable operating segments for the NIKE Brand are: North America; Europe, Middle East & Africa (EMEA); Greater China; and Asia Pacific & Latin America (APLA), and include results for the NIKE and Jordan brands. The Company\\\\\\'s NIKE Direct operations are managed within each geographic operating segment. Converse is also a reportable operating segment for the Company, and operates predominately in one industry: the design, marketing, licensing and selling of athletic lifestyle sneakers, apparel and accessories. As part of our centrally managed foreign exchange risk management program, standard foreign currency exchange rates are assigned twice per year to each NIKE Brand entity in our geographic operating segments and Converse. These rates are set approximately nine and twelve months in advance of the future selling seasons to which they relate (specifically, for each currency, one standard rate applies to the fall and holiday selling seasons and one standard rate applies to the spring and summer selling seasons) based on average market spot rates in the calendar month preceding the date they are established. Inventories and Cost of sales for geographic operating segments and Converse reflect the use of these standard rates to record non-functional currency product purchases into the entity\\\\\\'s functional currency. Differences between assigned standard foreign currency exchange rates and actual market rates are included in Corporate, together with foreign currency hedge gains and losses generated from our centrally managed foreign exchange risk management program and other conversion gains and losses. The breakdown of revenues is as follows: THREE MONTHS ENDED NOVEMBER 30, SIX MONTHS ENDED NOVEMBER 30, (Dollars in millions) 2020 2019 % CHANGE % CHANGE EXCLUDING CURRENCY CHANGES (1) 2020 2019 % CHANGE % CHANGE EXCLUDING CURRENCY CHANGES (1) North America $ 4,006 $ 3,982 1 % 1 % $ 8,231 $ 8,275 -1 % 0 % Europe, Middle East & Africa 2,958 2,537 17 % 12 % 5,868 5,310 11 % 8 % Greater China 2,298 1,847 24 % 19 % 4,078 3,526 16 % 14 % Asia Pacific & Latin America 1,471 1,468 0 % 5 % 2,570 2,813 -9 % -3 % Global Brand Divisions (2) 8 10 -20 % -20 % 12 16 -25 % -25 % TOTAL NIKE BRAND 10,741 9,844 9 % 8 % 20,759 19,940 4 % 4 % Converse 476 480 -1 % -4 % 1,039 1,035 0 % -1 % Corporate (3) 26 2   39 11   TOTAL NIKE, INC. REVENUES $ 11,243 $ 10,326 9 % 7 % $ 21,837 $ 20,986 4 % 4 % (1) The percent change excluding currency changes represents a non-GAAP financial measure. See \"Use of Non-GAAP Financial Measures\" for further information. (2) Global Brand Divisions revenues include NIKE Brand licensing as well as other miscellaneous revenues that are not part of a geographic operating segment. (3) Corporate revenues primarily consist of foreign currency hedge gains and losses related to revenues generated by entities within the NIKE Brand geographic operating segments and Converse, but managed through our central foreign exchange risk management program. The primary financial measure used by the Company to evaluate performance of individual operating segments is EBIT, which represents Net income before Interest expense (income), net and Income tax expense in the Unaudited Condensed Consolidated Statements of Income. As discussed in Note 12  Operating Segments in the accompanying Notes to the Unaudited Condensed Consolidated Financial Statements, certain corporate costs are not included in EBIT of our operating segments. 32 Table of Contents The breakdown of earnings before interest and taxes is as follows: THREE MONTHS ENDED NOVEMBER 30, SIX MONTHS ENDED NOVEMBER 30, (Dollars in millions) 2020 2019 % CHANGE 2020 2019 % CHANGE North America $ 1,023 $ 875 17 % $ 2,325 $ 1,975 18 % Europe, Middle East & Africa 660 510 29 % 1,352 1,119 21 % Greater China 891 694 28 % 1,579 1,363 16 % Asia Pacific & Latin America 424 377 12 % 704 718 -2 % Global Brand Divisions (841) (872) 4 % (1,694) (1,729) 2 % TOTAL NIKE BRAND (1) 2,157 1,584 36 % 4,266 3,446 24 % Converse 87 90 -3 % 255 228 12 % Corporate (718) (413) -74 % (1,215) (837) -45 % TOTAL NIKE, INC. EARNINGS BEFORE INTEREST AND TAXES (1) 1,526 1,261 21 % 3,306 2,837 17 % Interest expense (income), net 70 12  135 27  TOTAL NIKE, INC. INCOME BEFORE INCOME TAXES $ 1,456 $ 1,249 17 % $ 3,171 $ 2,810 13 % (1) Total NIKE Brand EBIT and Total NIKE, Inc. EBIT represent non-GAAP financial measures. See \"Use of Non-GAAP Financial Measures\" for further information. NORTH AMERICA THREE MONTHS ENDED NOVEMBER 30, SIX MONTHS ENDED NOVEMBER 30, (Dollars in millions) 2020 2019 % CHANGE % CHANGE EXCLUDING CURRENCY CHANGES 2020 2019 % CHANGE % CHANGE EXCLUDING CURRENCY CHANGES Revenues by: Footwear $ 2,512 $ 2,426 4 % 4 % $ 5,469 $ 5,095 7 % 7 % Apparel 1,368 1,417 -3 % -3 % 2,493 2,848 -12 % -12 % Equipment 126 139 -9 % -10 % 269 332 -19 % -19 % TOTAL REVENUES $ 4,006 $ 3,982 1 % 1 % $ 8,231 $ 8,275 -1 % 0 % Revenues by: Sales to Wholesale Customers $ 2,354 $ 2,734 -14 % -14 % $ 5,073 $ 5,598 -9 % -9 % Sales through NIKE Direct 1,652 1,248 32 % 32 % 3,158 2,677 18 % 18 % TOTAL REVENUES $ 4,006 $ 3,982 1 % 1 % $ 8,231 $ 8,275 -1 % 0 % EARNINGS BEFORE INTEREST AND TAXES $ 1,023 $ 875 17 % $ 2,325 $ 1,975 18 % We believe there continues to be a meaningful shift in the way consumers shop for product and make purchasing decisions across each of our geographies. Consumers are demanding a constant flow of fresh and innovative product, and have an expectation for superior service and rapid delivery, all fueled by the shift toward digital and mono-brand experiences in NIKE Direct. We anticipate continued evolution within the retail landscape, driven by shifting consumer traffic patterns across digital and physical channels. Specifically in North America, we remain focused on building long-term momentum with our differentiated strategic wholesale customers and over the last three years have significantly reduced the number of undifferentiated accounts. Additionally, during the second quarter of fiscal 2021, we took further steps towards account and channel consolidation by reprioritizing product allocation to benefit NIKE Direct and our differentiated strategic wholesale customers. We expect over the next two fiscal years, we will more aggressively accelerate these changes as we work to reprofile the shape of the marketplace and recapture wholesale revenue declines over time. SECOND QUARTER OF FISCAL 2021 COMPARED TO SECOND QUARTER OF FISCAL 2020 On a currency-neutral basis, North America revenues for the second quarter of fiscal 2021 increased 1%, largely driven by significant growth in digital. NIKE Direct revenues increased 32% as strong digital sales growth of 107% more than offset an 11% decline in comparable store sales primarily due to reduced physical retail traffic, in part resulting from safety-related measures in response to COVID-19 . Footwear revenues increased 4% on a currency-neutral basis, largely driven by significant growth in digital. Unit sales of footwear decreased 4%, while higher ASP per pair contributed approximately 8 percentage points of footwear revenue growth. Higher ASP per pair was primarily due to the favorable impact of growth in our NIKE Direct business, as well as higher NIKE Direct and full-price ASPs. 33 Table of Contents On a currency-neutral basis, apparel revenues decreased 3%, as growth in Sportswear was more than offset by lower revenues in several key categories, led by Training, and the divestiture of Hurley in the prior year. Unit sales of apparel were flat while lower ASP per unit reduced apparel revenues by approximately 3 percentage points. The decrease in ASP per unit was primarily driven by lower full-price ASP, in part reflecting higher discounts, partially offset by the favorable impact of growth in our NIKE Direct business and higher NIKE Direct ASP. Reported EBIT increased 17% driven by lower selling and administrative expense, gross margin expansion and higher revenues. Gross margin increased approximately 100 basis points primarily due to lower product costs reflecting the impact of lower air freight and reduced tariffs, as well as lower inventory obsolescence. These impacts were partially offset by lower full-price ASP, reflecting higher discounts to reduce excess inventory due to COVID-19 and a lower mix of full-price sales. Selling and administrative expense decreased due to lower demand creation and operating overhead expense. The decrease in demand creation expense reflected lower advertising and marketing costs, as well as a decline in retail brand presentation costs, partially offset by continued investments in digital marketing to support heightened digital demand. Operating overhead expense decreased primarily as a result of lower wage-related expense, partially offset by an increase in professional services costs. FIRST SIX MONTHS OF FISCAL 2021 COMPARED TO FIRST SIX MONTHS OF FISCAL 2020 On a currency-neutral basis, North America revenues for the first six months of fiscal 2021 were flat as growth in Sportswear was offset by declines in nearly all other key categories, led by Training and Running. NIKE Direct revenues increased 18%, primarily due to digital sales growth of 103%, partially offset by comparable store sales contraction of 25%, primarily due to reduced physical retail traffic, in part resulting from safety-related measures in response to COVID-19 . Footwear revenues increased 7% on a currency-neutral basis as growth in Sportswear was partially offset by declines in nearly all other key categories, led by Running. Unit sales of footwear increased 2%, while higher ASP per pair contributed approximately 5 percentage points of footwear revenue growth. Higher ASP per pair was primarily due to higher NIKE Direct and full-price ASPs, as well as the favorable impact of growth in our NIKE Direct business. On a currency-neutral basis, apparel revenues decreased 12%, driven by declines in most key categories, led by Training, NIKE Basketball, as well as the divestiture of Hurley in the prior year. Unit sales of apparel declined 10% and lower ASP per unit reduced apparel revenues by approximately 2 percentage points. The decrease in ASP per unit was driven by lower full-price ASP and a lower mix of full-price sales, partially offset by the favorable impact of growth in our NIKE Direct business and higher NIKE Direct ASP. Reported EBIT increased 18% driven by lower selling and administrative expense and gross margin expansion. Gross margin increased approximately 130 basis points due to higher full-price ASP and lower other costs, partially offset by lower margin in our NIKE Direct business and a lower mix of full-price sales. The decrease in other costs was primarily a result of lower inventory obsolescence and the favorable impact from the release of factory cancellation cost accruals due to an increase in consumer demand. Selling and administrative expense decreased due to lower demand creation expense and operating overhead expense. The decrease in demand creation expense was primarily due to lower advertising and marketing costs, retail brand presentation costs and sports marketing expense, partially offset by continued investments in digital marketing to support heightened digital demand. Operating overhead expense decreased primarily as a result of lower wage-related expense, partially offset by an increase in professional services costs. EUROPE, MIDDLE EAST & AFRICA THREE MONTHS ENDED NOVEMBER 30, SIX MONTHS ENDED NOVEMBER 30, (Dollars in millions) 2020 2019 % CHANGE % CHANGE EXCLUDING CURRENCY CHANGES 2020 2019 % CHANGE % CHANGE EXCLUDING CURRENCY CHANGES Revenues by: Footwear $ 1,731 $ 1,536 13 % 8 % $ 3,533 $ 3,294 7 % 5 % Apparel 1,104 897 23 % 18 % 2,075 1,766 17 % 15 % Equipment 123 104 18 % 16 % 260 250 4 % 3 % TOTAL REVENUES $ 2,958 $ 2,537 17 % 12 % $ 5,868 $ 5,310 11 % 8 % Revenues by: Sales to Wholesale Customers $ 1,985 $ 1,794 11 % 6 % $ 3,958 $ 3,836 3 % 1 % Sales through NIKE Direct 973 743 31 % 25 % 1,910 1,474 30 % 26 % TOTAL REVENUES $ 2,958 $ 2,537 17 % 12 % $ 5,868 $ 5,310 11 % 8 % EARNINGS BEFORE INTEREST AND TAXES $ 660 $ 510 29 % $ 1,352 $ 1,119 21 % 34 Table of Contents SECOND QUARTER OF FISCAL 2021 COMPARED TO SECOND QUARTER OF FISCAL 2020 On a currency-neutral basis, EMEA revenues for the second quarter of fiscal 2021 grew 12%, driven by higher revenues across most territories, led by UK & Ireland, Central Europe and Northern Europe, which grew 32%, 21% and 7%, respectively. Revenues increased in all key categories, led by Sportswear, Football (Soccer) and the Jordan Brand. NIKE Direct revenues increased 25% driven by strong digital sales growth of 96%, partially offset by comparable store sales contraction of 20% primarily due to reduced physical retail traffic, in part resulting from safety-related measures in response to COVID-19 . Currency-neutral footwear revenues grew 8%, driven by higher revenues in nearly all key categories, led by the Jordan Brand, Training and Sportswear. Unit sales of footwear increased 9%, while lower ASP per pair reduced footwear revenues by approximately 1 percentage point, primarily due to unfavorable full-price mix. Currency-neutral apparel revenues increased 18% due to growth in most key categories, led by Football (Soccer) and Sportswear. Unit sales of apparel increased 19%, while lower ASP per unit reduced apparel revenues by approximately 1 percentage point. Lower ASP per unit was primarily due to lower NIKE Direct ASP and a lower mix of NIKE Direct sales, as well as lower off-price ASP, which more than offset higher full-price ASP, in part reflecting lower discounts. Reported EBIT increased 29% as higher revenues and lower selling and administrative expense more than offset a decline in gross margin. Gross margin decreased approximately 200 basis points as lower product costs due to favorable product mix were more than offset by unfavorable changes in standard foreign currency exchange rates, lower margin in our NIKE Direct business, and a lower mix of full-price sales. Lower margin in our NIKE Direct business was driven by higher promotions to reduce excess inventory due to COVID-19. Selling and administrative expense decreased due to lower demand creation expense, while operating overhead expense was flat. Lower demand creation expense was driven by lower advertising and marketing expense. FIRST SIX MONTHS OF FISCAL 2021 COMPARED TO FIRST SIX MONTHS OF FISCAL 2020 On a currency-neutral basis, EMEA revenues for the first six months of fiscal 2021 grew 8%, driven by higher revenues across most territories, led by UK & Ireland and Central Europe, which grew 31% and 17%, respectively. Revenues increased in all key categories, led by Sportswear, the Jordan Brand and Football (Soccer). NIKE Direct revenues increased 26% driven by digital sales growth of 105%, partially offset by a 15% decline in comparable store sales primarily due to reduced physical retail traffic, in part resulting from safety-related measures in response to COVID-19 . Currency-neutral footwear revenues grew 5%, driven by higher revenues in nearly all key categories, led by the Jordan Brand. Unit sales of footwear increased 1% and higher ASP per pair contributed approximately 4 percentage points of footwear revenue growth resulting from higher full-price ASP. Currency-neutral apparel revenues increased 15% due to growth in all key categories, led by Football (Soccer) and Sportswear. Unit sales of apparel increased 14% and higher ASP per unit contributed approximately 1 percentage point of apparel revenue growth. Higher ASP per unit was primarily due to higher full-price ASP, in part reflecting lower discounts. Reported EBIT increased 21% for the first six months of fiscal 2021 as higher revenues and lower selling and administrative expense more than offset a decline in gross margin. Gross margin decreased approximately 290 basis points as lower NIKE Direct margins driven by higher promotions to reduce excess inventory due to COVID-19, unfavorable changes in standard foreign currency exchange rates and a lower mix of full-price sales, more than offset lower product costs. Selling and administrative expense decreased due to lower demand creation and operating overhead expense. The decrease in demand creation expense was driven by lower advertising and marketing costs, as well as lower sports marketing expense. Lower operating overhead expense was primarily due to lower travel and related expenses, partially offset by increases in professional services costs. 35 Table of Contents GREATER CHINA THREE MONTHS ENDED NOVEMBER 30, SIX MONTHS ENDED NOVEMBER 30, (Dollars in millions) 2020 2019 % CHANGE % CHANGE EXCLUDING CURRENCY CHANGES 2020 2019 % CHANGE % CHANGE EXCLUDING CURRENCY CHANGES Revenues by: Footwear $ 1,567 $ 1,247 26 % 20 % $ 2,818 $ 2,411 17 % 15 % Apparel 681 563 21 % 16 % 1,159 1,028 13 % 11 % Equipment 50 37 35 % 29 % 101 87 16 % 14 % TOTAL REVENUES $ 2,298 $ 1,847 24 % 19 % $ 4,078 $ 3,526 16 % 14 % Revenues by: Sales to Wholesale Customers $ 1,159 $ 1,028 13 % 8 % $ 2,123 $ 2,014 5 % 4 % Sales through NIKE Direct 1,139 819 39 % 33 % 1,955 1,512 29 % 27 % TOTAL REVENUES $ 2,298 $ 1,847 24 % 19 % $ 4,078 $ 3,526 16 % 14 % EARNINGS BEFORE INTEREST AND TAXES $ 891 $ 694 28 % $ 1,579 $ 1,363 16 % SECOND QUARTER OF FISCAL 2021 COMPARED TO SECOND QUARTER OF FISCAL 2020 On a currency-neutral basis, Greater China revenues for the second quarter of fiscal 2021 increased 19% due to higher revenues in nearly all key categories, led by Sportswear, the Jordan Brand and NIKE Basketball. NIKE Direct revenues increased 33% due to digital sales growth of 37%, comparable store sales growth of 27% and the addition of new stores. Currency-neutral footwear revenues increased 20% for the second quarter of fiscal 2021 driven by higher revenues in most key categories, primarily Sportswear, the Jordan Brand and NIKE Basketball. Unit sales of footwear increased 24%, while lower ASP per pair reduced footwear revenues by approximately 4 percentage points, driven by lower NIKE Direct and full-price ASPs, as well as unfavorable full-price mix. Currency-neutral apparel revenues grew 16% for the second quarter of fiscal 2021 due to higher revenues in nearly all key categories, led by Sportswear, the Jordan Brand and Training. Unit sales of apparel increased 21%, while lower ASP per unit reduced apparel revenues by approximately 5 percentage points as unfavorable full-price mix and lower NIKE Direct ASP, more than offset higher off-price ASP. Reported EBIT increased 28% for the second quarter of fiscal 2021 as higher revenues and lower selling and administrative expense more than offset a decline in gross margin. Gross margin decreased approximately 260 basis points reflecting unfavorable changes in standard foreign currency exchange rates and lower margin in our NIKE Direct business driven by higher promotions to reduce excess inventory, as well as a lower mix of full-price sales. Selling and administrative expense decreased due to lower demand creation expense, partially offset by higher operating overhead expense. Demand creation expense decreased primarily due to lower advertising and marketing expenses. Growth in operating overhead expense was driven by higher investments within our NIKE Direct operations. FIRST SIX MONTHS OF FISCAL 2021 COMPARED TO FIRST SIX MONTHS OF FISCAL 2020 On a currency-neutral basis, Greater China revenues for the first six months of fiscal 2021 increased 14%, driven by higher revenues in nearly all key categories, led by Sportswear, the Jordan Brand and NIKE Basketball. NIKE Direct revenues increased 27%, driven by digital sales growth of 34%, comparable store sales growth of 20% and the addition of new stores. Currency-neutral footwear revenues increased 15%, driven by growth in most key categories, led by Sportswear, the Jordan Brand and NIKE Basketball. Unit sales of footwear increased 22%, while lower ASP per pair reduced footwear revenues by approximately 7 percentage points. Lower ASP was driven by lower NIKE Direct ASP and unfavorable full-price mix. Currency-neutral apparel revenue growth of 11% was fueled by higher revenues in nearly all key categories, most notably Sportswear and the Jordan Brand. Unit sales of apparel increased 15%, while lower ASP per unit reduced apparel revenues by approximately 4 percentage points. Lower ASP was driven by an unfavorable full-price mix and lower NIKE Direct ASP, slightly offset by higher off-price ASP. Reported EBIT increased 16%, as higher revenues and lower selling and administrative expense more than offset a decline in gross margin. Gross margin decreased approximately 390 basis points primarily due to lower margin in our NIKE Direct business, unfavorable changes in standard foreign currency exchange rates and higher product costs. Selling and administrative expense decreased due to lower demand creation expense, partially offset by higher operating overhead expense. Demand creation expense decreased primarily due to lower advertising and marketing expenses. Growth in operating overhead expense was driven by higher investments within our NIKE Direct operations. 36 Table of Contents ASIA PACIFIC & LATIN AMERICA THREE MONTHS ENDED NOVEMBER 30, SIX MONTHS ENDED NOVEMBER 30, (Dollars in millions) 2020 2019 % CHANGE % CHANGE EXCLUDING CURRENCY CHANGES 2020 2019 % CHANGE % CHANGE EXCLUDING CURRENCY CHANGES Revenues by: Footwear $ 991 $ 997 -1 % 5 % $ 1,749 $ 1,927 -9 % -3 % Apparel 432 410 5 % 9 % 733 766 -4 % 0 % Equipment 48 61 -21 % -17 % 88 120 -27 % -22 % TOTAL REVENUES $ 1,471 $ 1,468 0 % 5 % $ 2,570 $ 2,813 -9 % -3 % Revenues by: Sales to Wholesale Customers $ 925 $ 1,022 -9 % -5 % $ 1,633 $ 1,972 -17 % -11 % Sales through NIKE Direct 546 446 22 % 27 % 937 841 11 % 16 % TOTAL REVENUES $ 1,471 $ 1,468 0 % 5 % $ 2,570 $ 2,813 -9 % -3 % EARNINGS BEFORE INTEREST AND TAXES $ 424 $ 377 12 % $ 704 $ 718 -2 % As discussed previously, we entered into definitive agreements to sell our NIKE Brand businesses in Brazil, Argentina, Chile and Uruguay and shift to a distributor operating model. The impacts of entering into these agreements are included within Corporate and are not reflected in the APLA operating segment results. For more information see Note 13  Acquisitions and Divestitures within the accompanying Notes to the Unaudited Condensed Consolidated Financial Statements. SECOND QUARTER OF FISCAL 2021 COMPARED TO SECOND QUARTER OF FISCAL 2020 On a currency-neutral basis, APLA revenues increased 5% for the second quarter of fiscal 2021. The increase was due to higher revenues across most territories, led by Korea and SOCO (which comprises Argentina, Chile and Uruguay), which increased 17% and 18%, respectively. Revenues increased due to growth in Sportswear and the Jordan Brand, partially offset by lower revenues in all other key categories. NIKE Direct revenues increased 27%, driven by digital sales growth of 92%, partially offset by comparable store sales contraction of 3% primarily due to reduced physical retail traffic, in part resulting from safety-related measures in response to COVID-19 . Currency-neutral footwear revenues increased 5% for the second quarter of fiscal 2021 due to higher revenues in most key categories, primarily the Jordan Brand and Sportswear, partially offset by Running. Unit sales of footwear decreased 6%, while higher ASP per pair contributed approximately 11 percentage points. Higher ASP per pair was driven by higher full-price ASP, in part reflecting inflationary conditions in our SOCO territory, as well as the favorable impact of growth in our NIKE Direct business. Currency-neutral apparel revenues increased 9% for the second quarter of fiscal 2021 due to higher revenues in most key categories, primarily Sportswear. Unit sales of apparel increased 8%, and higher ASP per unit contributed approximately 1 percentage point to apparel revenue growth, driven by higher full-price ASP, in part reflecting inflationary conditions in our SOCO territory. Reported EBIT increased 12% for the second quarter of fiscal 2021 as lower selling and administrative more than offset a decline in gross margin. Gross margin decreased approximately 40 basis points as higher full-price ASP, in part reflecting inflationary conditions in our SOCO territory, was more than offset by higher product costs, lower margin in our NIKE Direct business and unfavorable changes in standard foreign currency exchange rates. Lower margin in our NIKE Direct business was driven by higher promotions to reduce excess inventory due to COVID-19. Selling and administrative expense decreased due to lower demand creation and operating overhead expense. The decrease in demand creation expense was primarily due to lower advertising and marketing costs, as well as a decline in sports marketing expense. Lower operating overhead expense was primarily due to lower travel and related expenses. FIRST SIX MONTHS OF FISCAL 2021 COMPARED TO FIRST SIX MONTHS OF FISCAL 2020 On a currency-neutral basis, APLA revenues decreased 3% for the first six months of fiscal 2021. The decline was due to lower revenues across most territories, led by a 61% decline in our Latin America third-party distributor business due to impacts from COVID-19, partially offset by higher revenues in Korea, which increased 12%. Revenues decreased in most key categories, led by Running and Football (Soccer), partially offset by higher revenues in the Jordan Brand and Sportswear. NIKE Direct revenues increased 16%, primarily fueled by digital sales growth of 91%, partially offset by comparable store sales contraction of 16% primarily due to reduced physical retail traffic, in part resulting from safety-related measures in response to COVID-19 . 37 Table of Contents Currency-neutral footwear revenues decreased 3% for the first six months of fiscal 2021 due to lower revenues in most key categories, primarily Running and Football (Soccer), partially offset by growth in the Jordan Brand. Unit sales of footwear decreased 15%, while higher ASP per pair contributed approximately 12 percentage points of footwear revenue growth, driven by higher full-price ASP, in part reflecting inflationary conditions in our SOCO territory, as well as the favorable impact of growth in our NIKE Direct business. Currency-neutral apparel revenues were flat for the first six months of fiscal 2021, as higher revenues in Sportswear were offset by lower revenues in nearly all other key categories, most notably Running. Unit sales of apparel decreased 3%, offset by higher ASP per unit, which contributed approximately 3 percentage points of apparel revenue growth. Higher ASP per unit was driven by higher full-price ASP, in part reflecting inflationary conditions in our SOCO territory. Reported EBIT decreased 2% for the first six months of fiscal 2021 primarily due to lower revenues and a decline in gross margin, partially offset by lower selling and administrative expense. Gross margin decreased approximately 70 basis points as higher full-price ASP, in part reflecting inflationary conditions in our SOCO territory, was more than offset by higher product costs, lower margin in our NIKE Direct business, unfavorable standard foreign currency exchange rates and a lower mix of full-price sales. Lower margin in our NIKE Direct business was driven by higher promotions to reduce excess inventory due to COVID-19. Selling and administrative expense decreased due to lower demand creation and operating overhead expense. The decrease in demand creation expense was primarily due to lower advertising and marketing expense, as well as a decline in sports marketing costs. Lower operating overhead expense was primarily due to lower travel and related expenses. GLOBAL BRAND DIVISIONS THREE MONTHS ENDED NOVEMBER 30, SIX MONTHS ENDED NOVEMBER 30, (Dollars in millions) 2020 2019 % CHANGE % CHANGE EXCLUDING CURRENCY CHANGES 2020 2019 % CHANGE % CHANGE EXCLUDING CURRENCY CHANGES Revenues $ 8 $ 10 -20 % -20 % $ 12 $ 16 -25 % -25 % Earnings (Loss) Before Interest and Taxes $ (841) $ (872) 4 % $ (1,694) $ (1,729) 2 % Global Brand Divisions primarily represent demand creation and operating overhead expense, including product creation and design expenses that are centrally managed for the NIKE Brand, as well as costs associated with NIKE Direct global digital operations and enterprise technology. Global Brand Divisions revenues include NIKE Brand licensing and other miscellaneous revenues that are not part of a geographic operating segment. SECOND QUARTER OF FISCAL 2021 COMPARED TO SECOND QUARTER OF FISCAL 2020 Global Brand Divisions\\\\\\' loss before interest and taxes decreased 4% for the second quarter of fiscal 2021 driven by lower total selling and administrative expense. Operating overhead expense decreased, primarily due to lower wage-related costs and lower travel and related expenses, partially offset by our continued investment in digital capabilities. Lower demand creation expense was primarily due to lower sports marketing expense, partially offset by higher advertising and marketing costs. FIRST SIX MONTHS OF FISCAL 2021 COMPARED TO FIRST SIX MONTHS OF FISCAL 2020 Global Brand Divisions\\\\\\' loss before interest and taxes decreased 2% for the first six months of fiscal 2021 driven by lower total selling and administrative expense. Lower demand creation expense was primarily due to lower sports marketing costs. The decrease in operating overhead expense was primarily due lower travel and related expenses as well as lower wage-related costs, partially offset by our continued investment in digital capabilities. 38 CONVERSE THREE MONTHS ENDED NOVEMBER 30, SIX MONTHS ENDED NOVEMBER 30, (Dollars in millions) 2020 2019 % CHANGE % CHANGE EXCLUDING CURRENCY CHANGES 2020 2019 % CHANGE % CHANGE EXCLUDING CURRENCY CHANGES Revenues by: Footwear $ 416 $ 416 0 % -3 % $ 929 $ 912 2 % 1 % Apparel 32 30 7 % 0 % 54 56 -4 % -6 % Equipment 7 6 17 % 19 % 16 15 7 % 8 % Other (1) 21 28 -25 % -19 % 40 52 -23 % -18 % TOTAL REVENUES $ 476 $ 480 -1 % -4 % $ 1,039 $ 1,035 0 % -1 % Revenues by: Sales to Wholesale Customers $ 259 $ 286 -9 % -13 % $ 632 $ 653 -3 % -5 % Sales through Direct to Consumer 196 166 18 % 15 % 367 330 11 % 10 % Other (1) 21 28 -25 % -19 % 40 52 -23 % -18 % TOTAL REVENUES $ 476 $ 480 -1 % -4 % $ 1,039 $ 1,035 0 % -1 % EARNINGS BEFORE INTEREST AND TAXES $ 87 $ 90 -3 % $ 255 $ 228 12 % (1) Other revenues consist of territories serviced by third-party licensees who pay royalties to Converse for the use of its registered trademarks and other intellectual property rights. We do not own the Converse trademarks in Japan and accordingly do not earn revenues in Japan. SECOND QUARTER OF FISCAL 2021 COMPARED TO SECOND QUARTER OF FISCAL 2020 On a currency-neutral basis, Converse revenues decreased 4% for the second quarter of fiscal 2021. The decrease in revenues was driven by declines in wholesale revenues in North America and Europe as a result of supply chain management and strategic distribution shifts, partially offset by growth in Asia. Direct to consumer revenues increased 15%, as strong digital sales growth across all geographies more than offset declines from Converse owned stores, reflecting the ongoing impact of COVID-19. Combined unit sales within the wholesale and direct to consumer channels decreased 11%, while ASP increased 9%, primarily due to growth in digital. Reported EBIT decreased 3%, driven by declines in gross margin, partially offset by lower selling and administrative expense. Gross margin decreased approximately 230 basis points as higher full-price ASP due to product mix was offset by lower margin in our direct to consumer channel, higher product costs due to product mix, a lower mix of full-price sales, lower revenues in our licensing business and unfavorable changes in standard foreign currency exchange rates. Lower margin in direct to consumer was driven by higher promotions to reduce excess inventory due to COVID-19. Selling and administrative expense decreased primarily due to lower operating overhead, partially offset by increased demand creation expense. Operating overhead expense decreased primarily due to lower travel and related expenses. Demand creation expense increased primarily as a result of higher advertising costs. FIRST SIX MONTHS OF FISCAL 2021 COMPARED TO FIRST SIX MONTHS OF FISCAL 2020 On a currency-neutral basis, Converse revenues decreased 1% for the first six months of fiscal 2021, driven by lower wholesale revenues in North America, as a result of supply chain management and strategic distribution shifts, partially offset by growth in Asia. Direct to consumer revenues increased 10%, as strong digital sales growth across all geographies more than offset declines from Converse owned stores reflecting the ongoing impact of COVID-19. Combined unit sales within the wholesale and direct to consumer channels decreased 3%, while ASP increased 4%, primarily due to growth in digital. Reported EBIT increased 12%, primarily due to lower selling and administrative expense, partially offset by lower gross margin. Gross margin decreased approximately 220 basis points as higher full-price ASP was more than offset by lower margin in our direct to consumer channel, higher product costs due to product mix, unfavorable changes in standard foreign currency exchange rates and lower revenues in our licensing business. Lower margin in direct to consumer was driven by higher promotions to reduce excess inventory due to COVID-19. Selling and administrative expense decreased due to lower operating overhead and demand creation expense. Operating overhead expense decreased primarily due to lower administrative expenses. Demand creation expense decreased as a result of lower advertising and marketing costs, as well as lower retail brand presentation costs. 39 Table of Contents CORPORATE THREE MONTHS ENDED NOVEMBER 30, SIX MONTHS ENDED NOVEMBER 30, (Dollars in millions) 2020 2019 % CHANGE 2020 2019 % CHANGE Revenues $ 26 $ 2  $ 39 $ 11  Earnings (Loss) Before Interest and Taxes $ (718) $ (413) -74 % $ (1,215) $ (837) -45 % Corporate revenues primarily consist of foreign currency hedge gains and losses related to revenues generated by entities within the NIKE Brand geographic operating segments and Converse, but managed through our central foreign exchange risk management program. The Corporate loss before interest and taxes primarily consists of unallocated general and administrative expenses, including expenses associated with centrally managed departments; depreciation and amortization related to our corporate headquarters; unallocated insurance, benefit and compensation programs, including stock-based compensation; and certain foreign currency gains and losses. In addition to the foreign currency gains and losses recognized in Corporate revenues, foreign currency results in Corporate include gains and losses resulting from the difference between actual foreign currency exchange rates and standard rates used to record non-functional currency denominated product purchases within the NIKE Brand geographic operating segments and Converse; related foreign currency hedge results; conversion gains and losses arising from re-measurement of monetary assets and liabilities in non-functional currencies; and certain other foreign currency derivative instruments. SECOND QUARTER OF FISCAL 2021 COMPARED TO SECOND QUARTER OF FISCAL 2020 Corporate\\\\\\'s loss before interest and taxes increased $305 million for the second quarter of fiscal 2021, primarily due to the following:  an unfavorable change of $276 million in part due to $171 million of restructuring-related costs associated with changes to our organizational model announced in July 2020, as well as a charge related to our planned, strategic distributor partnership transition within APLA;  an unfavorable change in net foreign currency gains and losses of $53 million related to the re-measurement of monetary assets and liabilities denominated in non-functional currencies and the impact of certain foreign currency derivative instruments, reported as a component of consolidated Other (income) expense, net; and  a favorable change of $24 million related to the difference between actual foreign currency exchange rates and standard foreign currency exchange rates assigned to the NIKE Brand geographic operating segments and Converse, net of hedge gains and losses; these results are reported as a component of consolidated gross margin. FIRST SIX MONTHS OF FISCAL 2021 COMPARED TO FIRST SIX MONTHS OF FISCAL 2020 Corporate\\\\\\'s loss before interest and taxes increased $378 million for the first six months of fiscal 2021, primarily due to the following:  an unfavorable change of $416 million in part due to $218 million of restructuring-related costs associated with changes to our organizational model announced in July 2020, as well as charges related to our planned, strategic distributor partnership transition within APLA;  a favorable change of $100 million related to the difference between actual foreign currency exchange rates and standard foreign currency exchange rates assigned to the NIKE Brand geographic operating segments and Converse, net of hedge gains and losses; these results are reported as a component of consolidated gross margin; and  an unfavorable change in net foreign currency gains and losses of $62 million related to the re-measurement of monetary assets and liabilities denominated in non-functional currencies and the impact of certain foreign currency derivative instruments, reported as a component of consolidated Other (income) expense, net . For more information related to our distributor partnership transition within APLA, as well as more information related to our organizational realignment and related costs, see Note 13  Acquisitions and Divestitures and Note 14  Restructuring, respectively, within the accompanying Notes to the Unaudited Condensed Consolidated Financial Statements. 40 Table of Contents FOREIGN CURRENCY EXPOSURES AND HEDGING PRACTICES OVERVIEW As a global company with significant operations outside the United States, in the normal course of business we are exposed to risk arising from changes in currency exchange rates. Our primary foreign currency exposures arise from the recording of transactions denominated in non-functional currencies and the translation of foreign currency denominated results of operations, financial position and cash flows into U.S. Dollars. Our foreign exchange risk management program is intended to lessen both the positive and negative effects of currency fluctuations on our consolidated results of operations, financial position and cash flows. We manage global foreign exchange risk centrally on a portfolio basis to address those risks material to NIKE, Inc. Our hedging policy is designed to partially or entirely offset the impact of exchange rate changes on the underlying net exposures being hedged. Where exposures are hedged, our program has the effect of delaying the impact of exchange rate movements on our Unaudited Condensed Consolidated Financial Statements; the length of the delay is dependent upon hedge horizons. We do not hold or issue derivative instruments for trading or speculative purposes. As of and for the six months ended November 30, 2020, there have been no material changes to the Company\\\\\\'s hedging program or strategy from what was disclosed within the Annual Report on Form 10-K. Refer to Note 4  Fair Value Measurements and Note 9  Risk Management and Derivatives in the accompanying Notes to the Unaudited Condensed Consolidated Financial Statements for additional description of outstanding derivatives at each reported period end. For additional information about our Foreign Currency Exposures and Hedging Practices refer to Part II, Item 7. Management\\\\\\'s Discussion and Analysis of Financial Condition and Results of Operations of our Annual Report on Form 10-K for the fiscal year ended May 31, 2020. TRANSACTIONAL EXPOSURES We conduct business in various currencies and have transactions which subject us to foreign currency risk. Our most significant transactional foreign currency exposures are:  Product Costs  Product purchases denominated in currencies other than the functional currency of the transacting entity and factory input costs from the foreign currency adjustments program with certain factories.  Non-Functional Currency Denominated External Sales  A portion of our NIKE Brand and Converse revenues associated with European operations are earned in currencies other than the Euro (e.g., the British Pound) but are recognized at a subsidiary that uses the Euro as its functional currency. These sales generate a foreign currency exposure.  Other Costs  Non-functional currency denominated costs, such as endorsement contracts, also generate foreign currency risk, though to a lesser extent.  Non-Functional Currency Denominated Monetary Assets and Liabilities  Our global subsidiaries have various assets and liabilities, primarily receivables and payables, including intercompany receivables and payables, denominated in currencies other than their functional currencies. These balance sheet items are subject to re-measurement which may create fluctuations in Other (income) expense, net within our consolidated results of operations. MANAGING TRANSACTIONAL EXPOSURES Transactional exposures are managed on a portfolio basis within our foreign currency risk management program. We manage these exposures by taking advantage of natural offsets and currency correlations that exist within the portfolio and may also elect to use currency forward and option contracts to hedge the remaining effect of exchange rate fluctuations on probable forecasted future cash flows, including certain product cost exposures, non-functional currency denominated external sales and other costs described above. Certain currency forward contracts used to manage the foreign exchange exposure of non-functional currency denominated monetary assets and liabilities subject to re-measurement and embedded derivative contracts are not formally designated as hedging instruments and are recognized in Other (income) expense, net. 41 Table of Contents TRANSLATIONAL EXPOSURES Many of our foreign subsidiaries operate in functional currencies other than the U.S. Dollar. Fluctuations in currency exchange rates create volatility in our reported results as we are required to translate the balance sheets, operational results and cash flows of these subsidiaries into U.S. Dollars for consolidated reporting. The translation of foreign subsidiaries\\\\\\' non-U.S. Dollar denominated balance sheets into U.S. Dollars for consolidated reporting results in a cumulative translation adjustment to Accumulated other comprehensive income (loss) within Shareholders\\\\\\' equity. The impact of foreign exchange rate fluctuations on the translation of our consolidated Revenues was a benefit of approximately $184 million and $73 million for the three and six months ended November 30, 2020, respectively, and a detriment of approximately $233 million and $546 million for the three and six months ended November 30, 2019, respectively. The impact of foreign exchange rate fluctuations on the translation of our Income before income taxes was a benefit of approximately $63 million and $34 million for the three and six months ended November 30, 2020, respectively, and a detriment of approximately $66 million and $152 million for the three and six months ended November 30, 2019, respectively. Management generally identifies hyper-inflationary markets as those markets whose cumulative inflation rate over a three-year period exceeds 100%. Management has concluded our Argentina subsidiary within our APLA operating segment is operating in a hyper-inflationary market. As a result, beginning in the second quarter of fiscal 2019, the functional currency of our Argentina subsidiary changed from the local currency to the U.S. Dollar. As of and for the three and six months ended November 30, 2020, this change did not have a material impact on our results of operations or financial condition and we do not anticipate it will have a material impact in future periods based on current rates. MANAGING TRANSLATIONAL EXPOSURES To minimize the impact of translating foreign currency denominated revenues and expenses into U.S. Dollars for consolidated reporting, certain foreign subsidiaries use excess cash to purchase U.S. Dollar denominated available-for-sale investments. The variable future cash flows associated with the purchase and subsequent sale of these U.S. Dollar denominated investments at non-U.S. Dollar functional currency subsidiaries creates a foreign currency exposure that qualifies for hedge accounting under U.S. GAAP. We utilize forward contracts and/or options to mitigate the variability of the forecasted future purchases and sales of these U.S. Dollar investments. The combination of the purchase and sale of the U.S. Dollar investment and the hedging instrument has the effect of partially offsetting the year-over-year foreign currency translation impact on net earnings in the period the investments are sold. Hedges of the purchase of U.S. Dollar denominated available-for-sale investments are accounted for as cash flow hedges. We estimate the combination of translation of foreign currency-denominated profits from our international businesses and the year-over-year change in foreign currency related gains and losses included in Other (income) expense, net had a favorable impact of approximately $10 million and an unfavorable impact of approximately $28 million on our Income before income taxes for the three months and six months ended November 30, 2020, respectively. LIQUIDITY AND CAPITAL RESOURCES CASH FLOW ACTIVITY Cash provided (used) by operations was an inflow of $3,355 million for the first six months of fiscal 2021, compared to $1,306 million for the first six months of fiscal 2020. Net income, adjusted for non-cash items, generated $3,283 million of operating cash inflow for the first six months of fiscal 2021, compared to $2,906 million for the first six months of fiscal 2020. The net change in working capital and other assets and liabilities resulted in an increase to Cash provided (used) by operations of $72 million for the first six months of fiscal 2021 compared to a decrease of $1,600 million for the first six months of fiscal 2020. This favorable impact on Cash provided (used) by operations was primarily the result of a $1,929 million decrease in Inventories driven by our intentional supply and demand management, as well as strong digital sales growth. Cash provided (used) by investing activities was an outflow of $2,877 million for the first six months of fiscal 2021, compared to $788 million for the first six months of fiscal 2020, driven by the net change in short-term investments. For the first six months of fiscal 2021, the net change in short-term investments (including sales, maturities and purchases) resulted in a cash outflow of $2,789 million compared to $157 million for the first six months of fiscal 2020. Cash provided (used) by financing activities was an outflow of $292 million for the first six months of fiscal 2021 compared to $1,868 million for the first six months of fiscal 2020, with the decrease from the prior period driven by our election to temporarily suspend share repurchases, resulting in no share repurchases for the first six months of fiscal 2021 compared to $1,921 million in the first six months of fiscal 2020. 42 Table of Contents As of November 30, 2020, we had repurchased 45.2 million shares at a cost of approximately $4.0 billion (an average price of $89.00 per share) under the four-year, $15 billion share repurchase program approved by the Board of Directors in June 2018. To enhance our liquidity position in response to COVID-19, during the fourth quarter of fiscal 2020, we elected to temporarily suspend share repurchases under our existing share repurchase program. As such, there were no share repurchases made during the quarter ended November 30, 2020. The existing program remains authorized by the Board of Directors and we may resume share repurchases in the future at any time, depending upon market conditions, our capital needs and other factors. We continue to expect funding of share repurchases will come from operating cash flows, excess cash and/or proceeds from debt. CAPITAL RESOURCES On July 23, 2019, we filed a shelf registration statement (the Shelf) with the U.S. Securities and Exchange Commission (SEC) which permits us to issue an unlimited amount of debt securities from time to time. The Shelf expires on July 23, 2022. Our committed credit facilities remain unchanged from the information previously reported on Form 10-K for the fiscal year ended May 31, 2020. As of November 30, 2020 and May 31, 2020, no amounts were outstanding under our committed credit facilities. We currently have long-term debt ratings of AA- and A1 from Standard and Poor\\\\\\'s Corporation and Moody\\\\\\'s Investor Services, respectively. Any changes to these ratings could result in interest rate and facility fee changes. As of November 30, 2020, we were in full compliance of the covenants under our committed credit facilities and believe it is unlikely we will fail to meet any of the covenants in the foreseeable future. Liquidity is also provided by our $4 billion commercial paper program. During the three months ended November 30, 2020, the maximum amount of commercial paper borrowings outstanding at any point was $112 million. As of November 30, 2020 and May 31, 2020, the Company had $23 million and $248 million of borrowings outstanding at a weighted average interest rate of 1.76% and 1.65%, respectively. We may continue to issue commercial paper or other debt securities depending on general corporate needs. We currently have short-term debt ratings of A1+ and P1 from Standard and Poor\\\\\\'s Corporation and Moody\\\\\\'s Investor Services, respectively. To date, in fiscal 2021, we have not experienced difficulty accessing the credit markets; however, future volatility in the capital markets may increase costs associated with issuing commercial paper or other debt instruments or affect our ability to access those markets. As of November 30, 2020, we had cash, cash equivalents and short-term investments totaling $11.8 billion, primarily consisting of commercial paper, corporate notes, deposits held at major banks, money market funds, U.S. government sponsored enterprise obligations, U.S. Treasury obligations and other investment grade fixed-income securities. Our fixed-income investments are exposed to both credit and interest rate risk. All of our investments are investment grade to minimize our credit risk. While individual securities have varying durations, as of November 30, 2020, the weighted-average days to maturity of our cash equivalents and short-term investments portfolio was 33 days. We believe that existing cash, cash equivalents, short-term investments and cash generated by operations, together with access to external sources of funds as described above, will be sufficient to meet our domestic and foreign capital needs in the foreseeable future. We utilize a variety of tax planning and financing strategies to manage our worldwide cash and deploy funds to locations where they are needed. We indefinitely reinvest a significant portion of our foreign earnings, and our current plans do not demonstrate a need to repatriate these earnings. Should we require additional capital in the United States, we may determine to repatriate indefinitely reinvested foreign funds or raise capital in the United States through debt. Given our existing structure, if we were to repatriate indefinitely reinvested foreign earnings, we would be required to accrue and pay withholding taxes in certain foreign jurisdictions. OFF-BALANCE SHEET ARRANGEMENTS As of November 30, 2020, we did not have any off-balance sheet arrangements that have, or are reasonably likely to have, a material current or future effect on our financial condition, results of operations, liquidity, capital expenditures or capital resources. CONTRACTUAL OBLIGATIONS There have been no significant changes to the contractual obligations reported in our Annual Report on Form 10-K for the fiscal year ended May 31, 2020. NEW ACCOUNTING PRONOUNCEMENTS There have been no material changes in recently issued or adopted accounting standards from those disclosed in our Annual Report on Form 10-K for the fiscal year ended May 31, 2020. 43 Table of Contents CRITICAL ACCOUNTING POLICIES Our discussion and analysis of our financial condition and results of operations are based upon our Unaudited Condensed Consolidated Financial Statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. We believe that the estimates, assumptions and judgments involved in the accounting policies described in the Management\\\\\\'s Discussion and Analysis of Financial Condition and Results of Operations section of our most recent Annual Report on Form 10-K have the greatest potential impact on our financial statements, so we consider these to be our critical accounting policies. Actual results could differ from the estimates we use in applying our critical accounting policies. We are not currently aware of any reasonably likely events or circumstances that would result in materially different amounts being reported. 44 Table of Contents ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK There have been no material changes from the information previously reported under Part II, Item 7A of our Annual Report on Form 10-K for the fiscal year ended May 31, 2020. ITEM 4. CONTROLS AND PROCEDURES We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our Securities Exchange Act of 1934, as amended (\"the Exchange Act\") reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission\\\\\\'s rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. We carry out a variety of ongoing procedures, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, to evaluate the effectiveness of the design and operation of our disclosure controls and procedures. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of November 30, 2020. We are continuing several transformation initiatives to centralize and simplify our business processes and systems. These are long-term initiatives, which we believe will enhance our internal control over financial reporting due to increased automation and further integration of related processes. We will continue to monitor our internal control over financial reporting for effectiveness throughout these transformation initiatives. There have not been any changes in our internal control over financial reporting during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 45 Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS AND ANALYST REPORTS Certain written and oral statements, other than purely historic information, including estimates, projections, statements relating to NIKEs business plans, objectives and expected operating results and the assumptions upon which those statements are based, made or incorporated by reference from time to time by NIKE or its representatives in this report, other reports, filings with the SEC, press releases, conferences or otherwise, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain the words believe, anticipate, expect, estimate, project, will be, will continue, will likely result or words or phrases of similar meaning. Forward-looking statements involve risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. The risks and uncertainties are detailed from time to time in reports filed by NIKE with the SEC, including reports filed on Forms 8-K, 10-Q and 10-K, and include, among others, the following: health epidemics, pandemics and similar outbreaks, including the COVID-19 pandemic; international, national and local political, civil, economic and market conditions; the size and growth of the overall athletic footwear, apparel and equipment markets; intense competition among designers, marketers, distributors and sellers of athletic footwear, apparel and equipment for consumers and endorsers; demographic changes; changes in consumer preferences; popularity of particular designs, categories of products and sports; seasonal and geographic demand for NIKE products; difficulties in anticipating or forecasting changes in consumer preferences, consumer demand for NIKE products and the various market factors described above; difficulties in implementing, operating and maintaining NIKEs increasingly complex information technology systems and controls, including, without limitation, the systems related to demand and supply planning and inventory control; interruptions in data and information technology systems; consumer data security; fluctuations and difficulty in forecasting operating results, including, without limitation, the fact that advance orders may not be indicative of future revenues due to changes in shipment timing, the changing mix of orders with shorter lead times, and discounts, order cancellations and returns; the ability of NIKE to sustain, manage or forecast its growth and inventories; the size, timing and mix of purchases of NIKEs products; increases in the cost of materials, labor and energy used to manufacture products; new product development and introduction; the ability to secure and protect trademarks, patents and other intellectual property; product performance and quality; customer service; adverse publicity, including without limitation, through social media or in connection with brand damaging events; the loss of significant customers or suppliers; dependence on distributors and licensees; business disruptions; increased costs of freight and transportation to meet delivery deadlines; increases in borrowing costs due to any decline in NIKEs debt ratings; changes in business strategy or development plans; general risks associated with doing business outside of the United States, including, without limitation, exchange rate fluctuations, inflation, import duties, tariffs, quotas, political and economic instability and terrorism; the potential impact of new laws, regulations or policy, including, without limitation, tariffs, import/export, trade and immigration regulations or policies; changes in government regulations; the impact of, including business and legal developments relating to, climate change and natural disasters; litigation, regulatory proceedings, sanctions or any other claims asserted against NIKE; the ability to attract and retain qualified employees, and any negative public perception with respect to key personnel or our corporate culture, values or purpose; the effects of NIKEs decision to invest in or divest of businesses and other factors referenced or incorporated by reference in this report and other reports. 46 Table of Contents PART II - OTHER INFORMATION ITEM 1. LEGAL PROCEEDINGS There have been no material developments with respect to the information previously reported under Part I, Item 3 of our Annual Report on Form 10-K for the fiscal year ended May 31, 2020. ITEM 1A. RISK FACTORS There have been no material changes in our risk factors from those disclosed in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended May 31, 2020. 47 Table of Contents ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS In June 2018, the Board of Directors approved a four-year, $15 billion share repurchase program. As of November 30, 2020, the Company had repurchased 45.2 million shares at an average price of $89.00 per share for a total approximate cost of $4.0 billion under this program. To enhance our liquidity position in response to COVID-19, during the fourth quarter of fiscal 2020, we elected to temporarily suspend share repurchases under our existing share repurchase program. As such, there were no share repurchases made during the quarter ended November 30, 2020. The existing program remains authorized by the Board of Directors and we may resume share repurchases in the future at any time, depending upon market conditions, our capital needs and other factors. 48 Table of Contents ITEM 6. EXHIBITS (a) EXHIBITS: 3. Exhibits: 3.1 Restated Articles of Incorporation, as amended (incorporated by reference to Exhibit 3.1 to the Company\\\\\\'s Quarterly Report on Form 10-Q for the fiscal quarter ended November 30, 2015). 3.2 Fifth Restated Bylaws, as amended (incorporated by reference to Exhibit 3.1 to the Company\\\\\\'s Current Report on Form 8-K filed June 19, 2020). 4.1 Restated Articles of Incorporation, as amended (see Exhibit 3.1). 4.2 Fifth Restated Bylaws, as amended (see Exhibit 3.2). 10.1 NIKE, Inc. Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company\\\\\\'s Current Report on Form 8-K filed September 18, 2020) . 31.1 Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer. 31.2 Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer. 32.1 Section 1350 Certificate of Chief Executive Officer. 32.2 Section 1350 Certificate of Chief Financial Officer. 101.INS XBRL Instance Document. 101.SCH XBRL Taxonomy Extension Schema Document. 101.CAL XBRL Taxonomy Extension Calculation Linkbase Document. 101.DEF XBRL Taxonomy Extension Definition Document. 101.LAB XBRL Taxonomy Extension Label Linkbase Document. 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document. 104 Cover Page Interactive Data File (formatted in iXBRL Exhibit 101)  Furnished herewith 49 Table of Contents SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NIKE, INC. an Oregon Corporation By: /s/ MATTHEW FRIEND Matthew Friend Chief Financial Officer and Authorized Officer Date: January 5, 2021 50\\' b\\'EX-31.1 2 nke-11302020xexhibit311.htm EX-31.1 Document Exhibit 31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, John J. Donahoe II, certify that: 1. I have reviewed this quarterly report on Form 10-Q for the quarter ended November 30, 2020 of NIKE, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c) evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d) disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and 5. The registrants other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of the registrants board of directors (or persons performing the equivalent functions): a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting. Dated: January 5, 2021 /s/ John J. Donahoe II John J. Donahoe II Chief Executive Officer\\' b\\'EX-31.2 3 nke-11302020xexhibit312.htm EX-31.2 Document Exhibit 31.2 Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Matthew Friend, certify that: 1. I have reviewed this quarterly report on Form 10-Q for the quarter ended November 30, 2020 of NIKE, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c) evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d) disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and 5. The registrants other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of the registrants board of directors (or persons performing the equivalent functions): a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting. Dated: January 5, 2021 /s/ Matthew Friend Matthew Friend Chief Financial Officer\\' b\\'EX-32.1 4 nke-11302020xexhibit321.htm EX-32.1 Document Exhibit 32.1 Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the following certifications are being made to accompany the Registrants quarterly report on Form 10-Q for the fiscal quarter ended November 30, 2020. Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of NIKE, Inc. (the Company) hereby certifies, to such officers knowledge, that: (i) the Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended November 30, 2020 (the Report) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and (ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: January 5, 2021 /s/ John J. Donahoe II John J. Donahoe II Chief Executive Officer\\' b\\'EX-32.2 5 nke-11302020xexhibit322.htm EX-32.2 Document Exhibit 32.2 Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the following certifications are being made to accompany the Registrants quarterly report on Form 10-Q for the fiscal quarter ended November 30, 2020. Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of NIKE, Inc. (the Company) hereby certifies, to such officers knowledge, that: (i) the Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended November 30, 2020 (the Report) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and (ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: January 5, 2021 /s/ Matthew Friend Matthew Friend Chief Financial Officer\\''"
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sec_data.iloc[3, 15]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Can I convert number to words?\n",
    "https://www.geeksforgeeks.org/text-preprocessing-in-python-set-1/  \n",
    "\n",
    "Yes I can:\n",
    "- A percevied advantage of numbers in words versus digits is that 211,233 is not at all similar to 212,333. But in words, with bi grams applied, some semantics can be captured thereby making these values similar to some extent.\n",
    "- Some numbers are delimited by commas, remove commas and apply the inflect module.\n",
    "- The inflect module still yields commas but these can be removed after the fact to the right words without these added commas.\n",
    "- see below for examples.\n",
    "- Then we can use our word embeddings with n-gram to capture semantic representation of the numbers \n",
    "    - e.g. one thousand is not 'one' and 'thousand' but 'one thousand'.\n",
    "- This worked in most cases but see here for a result:\n",
    "    - 'Gross Profit four thousand eight hundred and fortyseven'\n",
    "    - I think it is still better than the raw numbers. \n",
    "    \n",
    "The inflect module is popular but I adapted the code from geekforgeeks.\n",
    "\n",
    "A big disadvantage of taking out punctuations is losing sentence delimiters.\n",
    "- this should not be a problem for a word level parsing but will be an issue for phrases and paragraph level parsing.\n",
    "\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## CHANGE THESE VARIABLES TO PREVENT PLAGIARISM"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'b10Q one nke20201130htm 10Q nke20201130 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington DC twenty thousand five hundred and fortynine FORM Mark One QUARTERLY REPORT PURSUANT TO SECTION thirteen OR 15D OF THE SECURITIES EXCHANGE ACT OF one thousand nine hundred and thirtyfour FOR THE QUARTERLY PERIOD ENDED OR TRANSITION REPORT PURSUANT TO SECTION thirteen OR 15D OF THE SECURITIES EXCHANGE ACT OF one thousand nine hundred and thirtyfour FOR THE TRANSITION PERIOD FROM TO Commission File No Exact name of Registrant as specified in its charter State or other jurisdiction of incorporation or organization IRS Employer Identification No Address of principal executive offices and zip code Registrants telephone number including area code SECURITIES REGISTERED PURSUANT TO SECTION 12B OF THE ACT Title of each class Trading symbol Name of each exchange on which registered Indicate by check mark YES NO whether the registrant one has filed all reports required to be filed by Section thirteen or 15d of the Securities Exchange Act of one thousand nine hundred and thirtyfour during the preceding twelve months or for such shorter period that the registrant was required to file such reports and two has been subject to such filing requirements for the past ninety days whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule four hundred and five of Regulation ST two hundred and thirtytwo thousand four hundred and five of this chapter during the preceding twelve months or for such shorter period that the registrant was required to submit such files whether the registrant is a large accelerated filer an accelerated filer a nonaccelerated filer a smaller reporting company or an emerging growth company See the definitions of large accelerated filer accelerated filer smaller reporting company and emerging growth company in Rule 12b2 of the Exchange Act Accelerated filer Nonaccelerated filer Smaller reporting company Emerging growth company if an emerging growth company if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13a of the Exchange Act whether the registrant is a shell company as defined in Rule 12b2 of the Act As of December twentyeight two thousand and twenty the number of shares of the Registrants Common Stock outstanding were Class A Class B one billion five hundred and seventysix million four hundred and ninety thousand and eleven Table of Contents NIKE INC FORM 10Q TABLE OF CONTENTS PAGE PART I FINANCIAL INFORMATION one ITEM one Financial Statements one Unaudited Condensed Consolidated Statements of Income one Unaudited Condensed Consolidated Statements of Comprehensive Income two Unaudited Condensed Consolidated Balance Sheets three Unaudited Condensed Consolidated Statements of Cash Flows four Unaudited Condensed Consolidated Statements of Shareholders Equity five Notes to the Unaudited Condensed Consolidated Financial Statements seven ITEM two Managements Discussion and Analysis of Financial Condition and Results of Operations twentyfive ITEM three Quantitative and Qualitative Disclosures about Market Risk fortyfive ITEM four Controls and Procedures fortyfive PART II OTHER INFORMATION fortyseven ITEM one Legal Proceedings fortyseven ITEM 1A Risk Factors fortyseven ITEM two Unregistered Sales of Equity Securities and Use of Proceeds fortyeight ITEM six Exhibits fortynine Signatures fifty Table of Contents PART I FINANCIAL INFORMATION ITEM one FINANCIAL STATEMENTS NIKE INC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME THREE MONTHS ENDED NOVEMBER thirty SIX MONTHS ENDED NOVEMBER thirty In millions except per share data two thousand and twenty two thousand and nineteen two thousand and twenty two thousand and nineteen Revenues Cost of sales Gross profit Demand creation expense Operating overhead expense Total selling and administrative expense Interest expense income net Other income expense net Income before income taxes Income tax expense NET INCOME Earnings per common share Basic Diluted Weighted average common shares outstanding Basic Diluted The accompanying Notes to the Unaudited Condensed Consolidated Financial Statements are an integral part of this statement one Table of Contents NIKE INC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME THREE MONTHS ENDED NOVEMBER thirty SIX MONTHS ENDED NOVEMBER thirty Dollars in millions two thousand and twenty two thousand and nineteen two thousand and twenty two thousand and nineteen Net income Other comprehensive income loss net of tax Change in net foreign currency translation adjustment Change in net gains losses on cash flow hedges Change in net gains losses on other Total other comprehensive income loss net of tax TOTAL COMPREHENSIVE INCOME The accompanying Notes to the Unaudited Condensed Consolidated Financial Statements are an integral part of this statement two Table of Contents NIKE INC UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS NOVEMBER thirty MAY thirtyone In millions two thousand and twenty two thousand and twenty ASSETS Current assets Cash and equivalents Shortterm investments Accounts receivable net Inventories Prepaid expenses and other current assets Total current assets Property plant and equipment net Operating lease rightofuse assets net Identifiable intangible assets net Goodwill Deferred income taxes and other assets TOTAL ASSETS LIABILITIES AND SHAREHOLDERS EQUITY Current liabilities Current portion of longterm debt Notes payable Accounts payable Current portion of operating lease liabilities Accrued liabilities Income taxes payable Total current liabilities Longterm debt Operating lease liabilities Deferred income taxes and other liabilities Redeemable preferred stock Shareholders equity Common stock at stated value Class A convertible and shares outstanding Class B and shares outstanding Capital in excess of stated value Accumulated other comprehensive income loss Retained earnings deficit Total shareholders equity TOTAL LIABILITIES AND SHAREHOLDERS EQUITY The accompanying Notes to the Unaudited Condensed Consolidated Financial Statements are an integral part of this statement three Table of Contents NIKE INC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS SIX MONTHS ENDED NOVEMBER thirty Dollars in millions two thousand and twenty two thousand and nineteen Cash provided used by operations Net income Adjustments to reconcile net income to net cash provided used by operations Depreciation Deferred income taxes Stockbased compensation Amortization impairment and other Net foreign currency adjustments Changes in certain working capital components and other assets and liabilities Increase decrease in accounts receivable Increase decrease in inventories Increase decrease in prepaid expenses operating lease rightofuse assets and other current and noncurrent assets Increase decrease in accounts payable accrued liabilities operating lease liabilities and other current and noncurrent liabilities Cash provided used by operations Cash provided used by investing activities Purchases of shortterm investments Maturities of shortterm investments Sales of shortterm investments Additions to property plant and equipment Other investing activities Cash provided used by investing activities Cash provided used by financing activities Increase decrease in notes payable Repayment of borrowings Proceeds from exercise of stock options and other stock issuances Repurchase of common stock Dividends common and preferred Other financing activities Cash provided used by financing activities Effect of exchange rate changes on cash and equivalents Net increase decrease in cash and equivalents Cash and equivalents beginning of period CASH AND EQUIVALENTS END OF PERIOD Supplemental disclosure of cash flow information Noncash additions to property plant and equipment Dividends declared and not paid The accompanying Notes to the Unaudited Condensed Consolidated Financial Statements are an integral part of this statement four Table of Contents NIKE INC UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS EQUITY COMMON STOCK CAPITAL IN EXCESS OF STATED VALUE ACCUMULATED OTHER COMPREHENSIVE INCOME LOSS RETAINED EARNINGS DEFICIT TOTAL CLASS A CLASS B In millions except per share data SHARES AMOUNT SHARES AMOUNT Balance at August thirtyone two thousand and twenty Stock options exercised Conversion to Class B Common Stock Dividends on common stock per share Issuance of shares to employees net of shares withheld for employee taxes Stockbased compensation Net income Other comprehensive income loss Balance at November thirty two thousand and twenty COMMON STOCK CAPITAL IN EXCESS OF STATED VALUE ACCUMULATED OTHER COMPREHENSIVE INCOME LOSS RETAINED EARNINGS DEFICIT TOTAL CLASS A CLASS B In millions except per share data SHARES AMOUNT SHARES AMOUNT Balance at August thirtyone two thousand and nineteen Stock options exercised Repurchase of Class B Common Stock Dividends on common stock per share Issuance of shares to employees net of shares withheld for employee taxes Stockbased compensation Net income Other comprehensive income loss Balance at November thirty two thousand and nineteen The accompanying Notes to the Unaudited Condensed Consolidated Financial Statements are an integral part of this statement five Table of Contents COMMON STOCK CAPITAL IN EXCESS OF STATED VALUE ACCUMULATED OTHER COMPREHENSIVE INCOME LOSS RETAINED EARNINGS DEFICIT TOTAL CLASS A CLASS B In millions except per share data SHARES AMOUNT SHARES AMOUNT Balance at May thirtyone two thousand and twenty Stock options exercised Conversion to Class B Common Stock Dividends on common stock per share and preferred stock per share Issuance of shares to employees net of shares withheld for employee taxes Stockbased compensation Net income Other comprehensive income loss Balance at November thirty two thousand and twenty COMMON STOCK CAPITAL IN EXCESS OF STATED VALUE ACCUMULATED OTHER COMPREHENSIVE INCOME LOSS RETAINED EARNINGS DEFICIT TOTAL CLASS A CLASS B In millions except per share data SHARES AMOUNT SHARES AMOUNT Balance at May thirtyone two thousand and nineteen Stock options exercised Repurchase of Class B Common Stock Dividends on common stock per share and preferred stock per share Issuance of shares to employees net of shares withheld for employee taxes Stockbased compensation Net income Other comprehensive income loss Adoption of ASC Topic eight hundred and fortytwo Balance at November thirty two thousand and nineteen The accompanying Notes to the Unaudited Condensed Consolidated Financial Statements are an integral part of this statement six Table of Contents NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Note one Summary of Significant Accounting Policies eight Note two Inventories eight Note three Accrued Liabilities eight Note four Fair Value Measurements eight Note five ShortTerm Borrowings and Credit Lines ten Note six Income Taxes ten Note seven StockBased Compensation eleven Note eight Earnings Per Share twelve Note nine Risk Management and Derivatives twelve Note ten Accumulated Other Comprehensive Income Loss seventeen Note eleven Revenues nineteen Note twelve Operating Segments twentyone Note thirteen Acquisitions and Divestitures twentythree Note fourteen Restructuring twentyfour seven Table of Contents eight Table of Contents nine Table of Contents ten Table of Contents eleven Table of Contents twelve Table of Contents thirteen Table of Contents fourteen Table of Contents fifteen Table of Contents sixteen Table of Contents seventeen Table of Contents eighteen Table of Contents nineteen Table of Contents twenty Table of Contents twentyone Table of Contents twentytwo Table of Contents twentythree Table of Contents twentyfour Table of Contents ITEM two MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OVERVIEW NIKE designs develops markets and sells athletic footwear apparel equipment accessories and services worldwide We are the largest seller of athletic footwear and apparel in the world We sell our products through NIKEowned retail stores and through digital platforms which we refer to collectively as our NIKE Direct operations to retail accounts and to a mix of independent distributors licensees and sales representatives in virtually all countries around the world Our goal is to deliver value to our shareholders by building a profitable global portfolio of branded footwear apparel equipment and accessories businesses Our strategy is to achieve longterm revenue growth by creating innovative musthave products building deep personal consumer connections with our brands and delivering compelling consumer experiences through digital platforms and at retail Since fiscal two thousand and eighteen through the Consumer Direct Offense and our Triple Double strategy we have focused on doubling the impact of innovation increasing our speed and agility to market and growing our direct connections with consumers In June two thousand and twenty we announced a new digitally empowered phase of the Consumer Direct Offense strategy Consumer Direct Acceleration This strategic acceleration will focus on three specific areas First creating the marketplace of the future through more premium consistent and seamless consumer experiences that more closely align with what consumers want and need This strategy will lead with NIKE Digital and our own stores as well as through select strategic partners who share our marketplace vision Second we will align our product creation and category organizations around a new consumer construct focused on Mens Womens and Kids This approach is intended to allow us to create product that better meets individual consumer needs including more specialization of our category approach while realigning and simplifying our offense to accelerate our largest growth opportunities In particular we expect to reinvest in our Womens and Kids businesses and also simplify our operating model across the remainder of the Company to optimize effectiveness Third we will unify investments in data and analytics demand sensing insight gathering inventory management and other areas against an endtoend technology foundation to accelerate our digital transformation We believe this unified approach will accelerate growth and unlock more efficiency for our business while driving speed and responsiveness as we serve consumers globally As a result of our strategic acceleration management announced on July twentytwo two thousand and twenty a series of leadership and operating model changes to streamline and speed up our execution These changes will result in a net reduction of our global workforce and we expect to incur pretax charges of approximately three hundred and fifteen million the majority of which relate to employee termination costs and to a lesser extent stockbased compensation expense These amounts reflect the continued evaluation and variability of our original estimate of employee termination costs and required changes in assumptions used to calculate stockbased compensation expense For the first six months of fiscal two thousand and twentyone we incurred pretax charges of two hundred and eighteen million and expect all remaining actions to be substantially complete by the end of fiscal two thousand and twentyone We expect future annual wagerelated savings will be reinvested to execute against this next phase of our strategy For more information related to our organizational realignment and related costs see Note fourteen Restructuring within the accompanying Notes to the Unaudited Condensed Consolidated Financial Statements COVID19 UPDATE The COVID19 pandemic continues to impact our business results and operations globally causing us to transform the way we operate in order to better serve our consumers Although uncertainty due to the pandemic continues to exist our financial results for the second quarter and first six months of fiscal two thousand and twentyone demonstrate our ability to navigate the dynamic situation Despite physical retail traffic being below prior year levels Revenues grew nine and four for the second quarter and first six months of fiscal two thousand and twentyone respectively and seven and four on a currencyneutral basis Through our intentional supply and demand management inventory levels have declined and we ended the second quarter of fiscal two thousand and twentyone with Inventories down seventeen compared to May thirtyone two thousand and twenty We reduced discretionary spending while continuing to invest in our digital transformation As a result total selling and administrative expense declined two for the second quarter and six for the first six months of fiscal two thousand and twentyone However we expect Demand creation expense to increase in future periods as major sporting events and key sports moments resume following recovery from the pandemic along with investments in strategic areas to drive growth Our liquidity position remains strong and we ended the second quarter with one hundred and eighteen billion of Cash and equivalents and Shortterm investments Our NIKE Direct business continues to fuel our growth as we navigate through the pandemic leveraging our digital assets with our store footprint to connect directly with the consumer On a reported basis NIKE Direct sales for the second quarter and first six months of fiscal two thousand and twentyone were fortythree billion and eighty billion respectively growing thirty and twentytwo respectively on a currencyneutral basis NIKE Brand digital remained our fastest growing channel with growth of eighty and eightyone for the second quarter and first six months of fiscal two thousand and twentyone respectively During the second quarter of fiscal two thousand and twentyone we experienced temporary store closures in geographies affected by rising COVID19 cases however more than eighty of our owned stores were open as of January four two thousand and twentyone with some operating on reduced hours Despite a substantial majority of stores being open during the quarter we experienced a twentyfive Table of Contents decline in comparable store sales in EMEA North America and APLA primarily due to reduced physical retail traffic in part resulting from safetyrelated measures in response to COVID19 We continue to monitor the ongoing and evolving situation as well as guidance from international and domestic authorities including federal state and local public health authorities and may take additional actions based on their recommendations In these circumstances there may be developments outside our control requiring us to adjust our operating plan As such we expect that fiscal two thousand and twentyone will continue to be a time of uncertainty across each of our geographies and we expect each market recovery will be dynamic While our results for the second quarter and first six months of fiscal two thousand and twentyone are positive there remains the risk that COVID19 could have material adverse impacts on our future revenue growth as well as our overall profitability and may lead to higher than normal inventory levels in various markets revised payment terms with certain of our wholesale customers higher salesrelated reserves and a volatile effective tax rate driven by changes in the mix of earnings across the Companys jurisdictions SECOND QUARTER OVERVIEW For the second quarter of fiscal two thousand and twentyone NIKE Inc Revenues increased nine to one hundred and twelve billion compared to the second quarter of fiscal two thousand and twenty On a currencyneutral basis Revenues increased seven Net income was one thousand two hundred and fiftyone million and diluted earnings per common share was seventyeight for the second quarter of fiscal two thousand and twentyone compared to Net income of one thousand one hundred and fifteen million and diluted earnings per common share of seventy for the second quarter of fiscal two thousand and twenty Income before income taxes increased seventeen compared to the second quarter of fiscal two thousand and twenty primarily due to higher revenues and lower selling and administrative expense partially offset by a decline in gross margin The NIKE Brand which represents over ninety of NIKE Inc Revenues increased nine compared to the second quarter of fiscal two thousand and twenty On a currencyneutral basis NIKE Brand revenues grew eight driven by higher revenues across all geographies footwear and apparel as well as growth in most key categories primarily Sportswear and the Jordan Brand Revenues for Converse decreased one and four on a reported and currencyneutral basis respectively as doubledigit growth in digital and growth in Asia were more than offset by declines in Europe and North America primarily due to tighter supply and strategic distribution shifts Our effective tax rate was one hundred and fortyone for the second quarter of fiscal two thousand and twentyone compared to one hundred and seven for the second quarter of fiscal two thousand and twenty primarily due to changes in the proportion of earnings taxed in the US and an increase in tax associated with the recent finalization of US tax regulations partially offset by a more favorable impact from stockbased compensation During the third quarter of fiscal two thousand and twenty we entered into definitive agreements to sell our NIKE Brand businesses in Brazil Argentina Chile and Uruguay and to shift to a distributor operating model The transaction with Grupo SBF SA to purchase substantially all of our NIKE Brand operations in Brazil closed on December one two thousand and twenty subsequent to the end of the second quarter of fiscal two thousand and twentyone Additionally subsequent to the end of the second quarter of fiscal two thousand and twentyone we mutually agreed with Grupo Axo to terminate the sale and purchase agreement for the transition of NIKEs businesses in Argentina Chile and Uruguay to a distributor partnership However as we remain committed to selling our NIKE Brand businesses in all three countries to thirdparty distributors the assets and liabilities of the entities will remain classified as heldforsale on our Unaudited Condensed Consolidated Balance Sheets For more information see Note thirteen Acquisitions and Divestitures within the accompanying Notes to the Unaudited Condensed Consolidated Financial Statements USE OF NONGAAP FINANCIAL MEASURES Throughout this Quarterly Report on Form 10Q we discuss nonGAAP financial measures including references to wholesale equivalent revenues currencyneutral revenues as well as Total NIKE Brand earnings before interest and taxes EBIT and Total NIKE Inc EBIT which should be considered in addition to and not in lieu of the financial measures calculated and presented in accordance with accounting principles generally accepted in the United States of America US GAAP References to wholesale equivalent revenues are intended to provide context as to the total size of our NIKE Brand market footprint if we had no NIKE Direct operations NIKE Brand wholesale equivalent revenues consist of one sales to external wholesale customers and two internal sales from our wholesale operations to our NIKE Direct operations which are charged at prices comparable to those charged to external wholesale customers Currencyneutral revenues are calculated using actual exchange rates in use during the comparative prior year period to enhance the visibility of the underlying business trends excluding the impact of translation arising from foreign currency exchange rate fluctuations EBIT is calculated as Net Income before Interest expense income net and Income tax expense in the Unaudited Condensed Consolidated Statements of Income Management uses these nonGAAP financial measures when evaluating the Companys performance including when making financial and operating decisions Additionally management believes these nonGAAP financial measures provide investors with additional financial information that should be considered when assessing our underlying business performance and trends However references to wholesale equivalent revenues currencyneutral revenues and EBIT should not be considered in isolation or as a substitute for other financial measures calculated and presented in accordance with US GAAP and may not be comparable to similarly titled nonGAAP measures used by other companies twentysix Table of Contents RESULTS OF OPERATIONS THREE MONTHS ENDED NOVEMBER thirty SIX MONTHS ENDED NOVEMBER thirty Dollars in millions except per share data two thousand and twenty two thousand and nineteen CHANGE two thousand and twenty two thousand and nineteen CHANGE Revenues eleven thousand two hundred and fortythree ten thousand three hundred and twentysix nine twentyone thousand eight hundred and thirtyseven twenty thousand nine hundred and eightysix four Cost of sales six thousand three hundred and ninetysix five thousand seven hundred and eightytwo eleven twelve thousand two hundred and fortynine eleven thousand five hundred and seventyone six Gross profit four thousand eight hundred and fortyseven four thousand five hundred and fortyfour seven nine thousand five hundred and eightyeight nine thousand four hundred and fifteen two Gross margin four hundred and thirtyone four hundred and forty four hundred and thirtynine four hundred and fortynine Demand creation expense seven hundred and twentynine eight hundred and eightyone seventeen one thousand four hundred and six one thousand eight hundred and ninetynine twentysix Operating overhead expense two thousand five hundred and thirtyeight two thousand four hundred and fortythree four four thousand eight hundred and thirtysix four thousand seven hundred and fiftythree two Total selling and administrative expense three thousand two hundred and sixtyseven three thousand three hundred and twentyfour two six thousand two hundred and fortytwo six thousand six hundred and fiftytwo six of revenues two hundred and ninetyone three hundred and twentytwo two hundred and eightysix three hundred and seventeen Interest expense income net seventy twelve one hundred and thirtyfive twentyseven Other income expense net fiftyfour fortyone forty seventyfour Income before income taxes one thousand four hundred and fiftysix one thousand two hundred and fortynine seventeen three thousand one hundred and seventyone two thousand eight hundred and ten thirteen Income tax expense two hundred and five one hundred and thirtyfour fiftythree four hundred and two three hundred and twentyeight twentythree Effective tax rate one hundred and fortyone one hundred and seven one hundred and twentyseven one hundred and seventeen NET INCOME one thousand two hundred and fiftyone one thousand one hundred and fifteen twelve two thousand seven hundred and sixtynine two thousand four hundred and eightytwo twelve Diluted earnings per common share seventyeight seventy eleven one hundred and seventythree one hundred and fiftysix eleven twentyseven Table of Contents CONSOLIDATED OPERATING RESULTS REVENUES THREE MONTHS ENDED NOVEMBER thirty SIX MONTHS ENDED NOVEMBER thirty Dollars in millions two thousand and twenty two thousand and nineteen CHANGE CHANGE EXCLUDING CURRENCY CHANGES one two thousand and twenty two thousand and nineteen CHANGE CHANGE EXCLUDING CURRENCY CHANGES one NIKE Inc Revenues NIKE Brand Revenues by Footwear six thousand eight hundred and one six thousand two hundred and six ten eight thirteen thousand five hundred and sixtynine twelve thousand seven hundred and twentyseven seven seven Apparel three thousand five hundred and eightyfive three thousand two hundred and eightyseven nine seven six thousand four hundred and sixty six thousand four hundred and eight one zero Equipment three hundred and fortyseven three hundred and fortyone two one seven hundred and eighteen seven hundred and eightynine nine nine Global Brand Divisions two eight ten twenty twenty twelve sixteen twentyfive twentyfive Total NIKE Brand Revenues ten thousand seven hundred and fortyone nine thousand eight hundred and fortyfour nine eight twenty thousand seven hundred and fiftynine nineteen thousand nine hundred and forty four four Converse four hundred and seventysix four hundred and eighty one four one thousand and thirtynine one thousand and thirtyfive zero one Corporate three twentysix two thirtynine eleven TOTAL NIKE INC REVENUES eleven thousand two hundred and fortythree ten thousand three hundred and twentysix nine seven twentyone thousand eight hundred and thirtyseven twenty thousand nine hundred and eightysix four four Supplemental NIKE Brand Revenues Details NIKE Brand Revenues by Sales to Wholesale Customers six thousand four hundred and twentythree six thousand five hundred and seventyeight two four twelve thousand seven hundred and eightyseven thirteen thousand four hundred and twenty five five Sales through NIKE Direct four thousand three hundred and ten three thousand two hundred and fiftysix thirtytwo thirty seven thousand nine hundred and sixty six thousand five hundred and four twentytwo twentytwo Global Brand Divisions two eight ten twenty twenty twelve sixteen twentyfive twentyfive TOTAL NIKE BRAND REVENUES ten thousand seven hundred and fortyone nine thousand eight hundred and fortyfour nine eight twenty thousand seven hundred and fiftynine nineteen thousand nine hundred and forty four four one The percent change excluding currency changes represents a nonGAAP financial measure See Use of NonGAAP Financial Measures for further information two Global Brand Divisions revenues include NIKE Brand licensing and other miscellaneous revenues that are not part of a geographic operating segment three Corporate revenues primarily consist of foreign currency hedge gains and losses related to revenues generated by entities within the NIKE Brand geographic operating segments and Converse but managed through our central foreign exchange risk management program SECOND QUARTER OF FISCAL two thousand and twentyone COMPARED TO SECOND QUARTER OF FISCAL two thousand and twenty On a currencyneutral basis NIKE Inc Revenues grew seven for the second quarter of fiscal two thousand and twentyone due to growth across all NIKE Brand geographies partially offset by lower revenues in Converse Higher revenues in Greater China and EMEA each contributed approximately three percentage points of growth to NIKE Inc Revenues with APLA contributing approximately one percentage point of growth On a currencyneutral basis NIKE Brand footwear revenues increased eight driven by growth in most key categories primarily Sportswear and the Jordan Brand partially offset by declines in Running Unit sales of footwear increased four and higher average selling price ASP per pair contributed approximately four percentage points of footwear revenue growth primarily due to the favorable impact of growth in our NIKE Direct business as well as higher fullprice ASP on a wholesale equivalent basis Currencyneutral NIKE Brand apparel revenues grew seven reflecting higher revenues in several key categories most notably Sportswear and Football Soccer Unit sales of apparel increased nine while lower ASP per unit reduced apparel revenues by approximately two percentage points Lower ASP per unit was primarily due to lower fullprice ASP in part reflecting higher discounts as well as an unfavorable fullprice mix On a reported basis NIKE Direct revenues represented approximately forty of our total NIKE Brand revenues for the second quarter of fiscal two thousand and twentyone compared to thirtythree for the second quarter of fiscal two thousand and twenty Digital sales were twentyfour billion for the second quarter of fiscal two thousand and twentyone compared to thirteen billion for the second quarter of fiscal two thousand and twenty On a currencyneutral basis NIKE Direct revenues increased thirty driven by digital sales growth of eighty which more than offset comparable store sales declines of four primarily due to reduced physical retail traffic in part resulting from safetyrelated measures in response to COVID19 Comparable store sales which exclude digital sales comprises revenues from NIKEowned inline and factory stores for which all three of the following requirements have been met one the store has been open at least one year two square footage has not changed by more than fifteen within the past year and three the store has not been permanently repositioned within the past year Comparable store sales includes revenues from stores that were temporarily closed during the period as a result of COVID19 Comparable store sales represents a performance measure that we believe is useful information for management and investors in understanding the performance of our established NIKEowned inline and factory stores Management considers this metric when making financial and operating twentyeight Table of Contents decisions The method of calculating comparable store sales varies across the retail industry As a result our calculation of this metric may not be comparable to similarly titled measures used by other companies FIRST SIX MONTHS OF FISCAL two thousand and twentyone COMPARED TO FIRST SIX MONTHS OF FISCAL two thousand and twenty On a currencyneutral basis NIKE Inc Revenues grew four for the first six months of fiscal two thousand and twentyone driven by growth in Greater China and EMEA partially offset by lower revenues in APLA Higher revenues in Greater China and EMEA each contributed approximately two percentage points of growth to NIKE Inc Revenues On a currencyneutral basis NIKE Brand footwear revenues increased seven driven by growth in several key categories led by Sportswear and the Jordan Brand Unit sales of footwear increased two and higher ASP per pair contributed approximately five percentage points of footwear revenue growth primarily due to higher fullprice ASP and the favorable impact of growth in our NIKE Direct business Currencyneutral NIKE Brand apparel revenues were flat as growth in Sportswear Football Soccer and the Jordan Brand was offset by declines in all other key categories Unit sales of apparel increased one while lower ASP per unit reduced apparel revenues by approximately one percentage point Lower ASP per unit was primarily due to lower fullprice ASP in part reflecting higher discounts as well as unfavorable fullprice mix partially offset by the favorable impact of growth in our NIKE Direct business On a reported basis NIKE Direct revenues represented approximately thirtyeight of our total NIKE Brand revenues for the first six months of fiscal two thousand and twentyone compared to thirtythree for the first six months of fiscal two thousand and twenty Digital sales were fortyfour billion for the first six months of fiscal two thousand and twentyone compared to twentyfour billion for the first six months of fiscal two thousand and twenty On a currencyneutral basis NIKE Direct revenues increased twentytwo for the first six months of fiscal two thousand and twentyone driven by digital sales growth of eightyone partially offset by a thirteen decline in comparable store sales driven by reduced physical retail traffic in part resulting from safetyrelated measures in response to COVID19 GROSS MARGIN THREE MONTHS ENDED NOVEMBER thirty SIX MONTHS ENDED NOVEMBER thirty Dollars in millions two thousand and twenty two thousand and nineteen CHANGE two thousand and twenty two thousand and nineteen CHANGE Gross Profit four thousand eight hundred and fortyseven four thousand five hundred and fortyfour seven nine thousand five hundred and eightyeight nine thousand four hundred and fifteen two Gross Margin four hundred and thirtyone four hundred and forty ninety bps four hundred and thirtynine four hundred and fortynine one hundred bps For the second quarter and first six months of fiscal two thousand and twentyone our consolidated gross margin was ninety and one hundred basis points lower than the respective prior year period and reflected unfavorable impacts from COVID19 For the second quarter of fiscal two thousand and twentyone the change in gross margin primarily reflected the following factors Lower margin in our NIKE Direct business reflecting higher promotions to reduce excess inventory as a result of COVID19 decreasing gross margin approximately eighty basis points Lower mix of fullprice sales decreasing gross margin approximately seventy basis points Higher other costs in part reflecting higher warehousing and freight as well as restructuringrelated costs related to our organizational realignment partially offset by lower inventory obsolescence decreasing gross margin approximately forty basis points Unfavorable changes in net foreign currency exchange rates including hedges decreasing gross margin approximately thirty basis points and Lower NIKE Brand product costs on a wholesale equivalent basis due to favorable product mix lower air freight and reduced tariffs in North America increasing gross margin approximately one hundred and ten basis points For the first six months of fiscal two thousand and twentyone the change in gross margin primarily reflected the following factors Lower margin in our NIKE Direct business reflecting higher promotions to reduce excess inventory as a result of COVID19 decreasing gross margin approximately one hundred and twenty basis points Lower mix of fullprice sales decreasing gross margin approximately seventy basis points Unfavorable changes in net foreign currency exchange rates including hedges decreasing gross margin approximately thirty basis points Higher other costs in part reflecting higher warehousing and freight as well as restructuringrelated costs partially offset by lower inventory obsolescence and the favorable impact from the release of factory cancellation cost accruals due to higher than anticipated consumer demand decreasing gross margin approximately ten basis points and Higher NIKE Brand fullprice ASP net of discounts increasing gross margin approximately one hundred and ten basis points twentynine Table of Contents TOTAL SELLING AND ADMINISTRATIVE EXPENSE THREE MONTHS ENDED NOVEMBER thirty SIX MONTHS ENDED NOVEMBER thirty Dollars in millions two thousand and twenty two thousand and nineteen CHANGE two thousand and twenty two thousand and nineteen CHANGE Demand creation expense one seven hundred and twentynine eight hundred and eightyone seventeen one thousand four hundred and six one thousand eight hundred and ninetynine twentysix Operating overhead expense two thousand five hundred and thirtyeight two thousand four hundred and fortythree four four thousand eight hundred and thirtysix four thousand seven hundred and fiftythree two Total selling and administrative expense three thousand two hundred and sixtyseven three thousand three hundred and twentyfour two six thousand two hundred and fortytwo six thousand six hundred and fiftytwo six of revenues two hundred and ninetyone three hundred and twentytwo three hundred and ten bps two hundred and eightysix three hundred and seventeen three hundred and ten bps one Demand creation expense consists of advertising and promotion costs including costs of endorsement contracts complimentary product television digital and print advertising and media costs brand events and retail brand presentation SECOND QUARTER OF FISCAL two thousand and twentyone COMPARED TO SECOND QUARTER OF FISCAL two thousand and twenty Demand creation expense decreased seventeen for the second quarter of fiscal two thousand and twentyone due primarily to lower advertising and marketing costs as well as a decline in sports marketing expense and retail brand presentation costs as a result of COVID19 This activity was partially offset by an increase in digital marketing to support heightened digital demand Changes in foreign currency exchange rates increased Demand creation expense by approximately one percentage point Operating overhead expense increased four primarily due to one hundred and thirtyseven million of restructuringrelated costs associated with changes to our organizational model announced in July two thousand and twenty as well as continued investments in digital capabilities to support the Consumer Direct Acceleration strategy These costs were slightly offset by disciplined expense management including lower wagerelated expenses and lower travel and related costs Changes in foreign currency exchange rates increased Operating overhead expense by approximately one percentage point FIRST SIX MONTHS OF FISCAL two thousand and twentyone COMPARED TO FIRST SIX MONTHS OF FISCAL two thousand and twenty Demand creation expense decreased twentysix for the first six months of fiscal two thousand and twentyone driven by lower advertising and marketing costs as well as a decline in sports marketing expense and retail brand presentation costs as a result of COVID19 This activity was partially offset by an increase in digital marketing to support heightened digital demand Changes in foreign currency exchange rates had an insignificant impact on Demand creation expense Operating overhead expense increased two primarily due to one hundred and eightyfour million of restructuringrelated costs associated with changes to our organizational model announced in July two thousand and twenty as well as our continued investments in digital capabilities partially offset by lower travel and related expenses Changes in foreign currency exchange rates had an insignificant impact on Operating overhead expense For more information related to our organizational realignment and related costs see Note fourteen Restructuring within the accompanying Notes to the Unaudited Condensed Consolidated Financial Statements OTHER INCOME EXPENSE NET THREE MONTHS ENDED NOVEMBER thirty SIX MONTHS ENDED NOVEMBER thirty Dollars in millions two thousand and twenty two thousand and nineteen two thousand and twenty two thousand and nineteen Other income expense net fiftyfour fortyone forty seventyfour Other income expense net comprises foreign currency conversion gains and losses from the remeasurement of monetary assets and liabilities denominated in nonfunctional currencies and the impact of certain foreign currency derivative instruments as well as unusual or nonoperating transactions that are outside the normal course of business For the second quarter of fiscal two thousand and twentyone Other income expense net changed from fortyone million of other income net to fiftyfour million of other expense net in the current year primarily due to a net detrimental change in foreign currency conversion gains and losses including hedges as well as a charge related to our planned strategic distributor partnership transition within APLA For the first six months of fiscal two thousand and twentyone Other income expense net changed from seventyfour million of other income net to forty million of other expense net in the current year primarily due to charges related to our planned strategic distributor partnership transition within APLA as well as a net detrimental change in foreign currency conversion gains and losses including hedges For more information related to our distributor partnership transition within APLA see Note thirteen Acquisitions and Divestitures within the accompanying Notes to the Unaudited Condensed Consolidated Financial Statements We estimate the combination of the translation of foreign currencydenominated profits from our international businesses and the yearoveryear change in foreign currencyrelated gains and losses included in Other income expense net had favorable impacts of approximately ten million and unfavorable impacts of approximately twentyeight million on our Income before income taxes for the second quarter and first six months of fiscal two thousand and twentyone respectively thirty Table of Contents INCOME TAXES THREE MONTHS ENDED NOVEMBER thirty SIX MONTHS ENDED NOVEMBER thirty two thousand and twenty two thousand and nineteen CHANGE two thousand and twenty two thousand and nineteen CHANGE Effective tax rate one hundred and fortyone one hundred and seven three hundred and forty bps one hundred and twentyseven one hundred and seventeen one hundred bps Our effective tax rate was one hundred and fortyone for the second quarter of fiscal two thousand and twentyone compared to one hundred and seven for the second quarter of fiscal two thousand and twenty primarily due to changes in the proportion of earnings taxed in the US and an increase in tax associated with the recent finalization of US tax regulations partially offset by a more favorable impact from stockbased compensation Our effective tax rate was one hundred and twentyseven for the first six months of fiscal two thousand and twentyone compared to one hundred and seventeen for the first six months of fiscal two thousand and twenty primarily due to changes in the proportion of earnings taxed in the US and the recognition of a reserve in the first quarter of fiscal two thousand and twentyone related to Altera Corp v Commissioner partially offset by discrete items which include a more favorable impact from stockbased compensation Refer to Note six Income Taxes within the accompanying Notes to the Unaudited Condensed Consolidated Financial Statements for additional information thirtyone Table of Contents OPERATING SEGMENTS Our operating segments are evidence of the structure of the Companys internal organization The NIKE Brand segments are defined by geographic regions for operations participating in NIKE Brand sales activity Each NIKE Brand geographic segment operates predominantly in one industry the design development marketing and selling of athletic footwear apparel and equipment The Companys reportable operating segments for the NIKE Brand are North America Europe Middle East Africa EMEA Greater China and Asia Pacific Latin America APLA and include results for the NIKE and Jordan brands The Companys NIKE Direct operations are managed within each geographic operating segment Converse is also a reportable operating segment for the Company and operates predominately in one industry the design marketing licensing and selling of athletic lifestyle sneakers apparel and accessories As part of our centrally managed foreign exchange risk management program standard foreign currency exchange rates are assigned twice per year to each NIKE Brand entity in our geographic operating segments and Converse These rates are set approximately nine and twelve months in advance of the future selling seasons to which they relate specifically for each currency one standard rate applies to the fall and holiday selling seasons and one standard rate applies to the spring and summer selling seasons based on average market spot rates in the calendar month preceding the date they are established Inventories and Cost of sales for geographic operating segments and Converse reflect the use of these standard rates to record nonfunctional currency product purchases into the entitys functional currency Differences between assigned standard foreign currency exchange rates and actual market rates are included in Corporate together with foreign currency hedge gains and losses generated from our centrally managed foreign exchange risk management program and other conversion gains and losses The breakdown of revenues is as follows THREE MONTHS ENDED NOVEMBER thirty SIX MONTHS ENDED NOVEMBER thirty Dollars in millions two thousand and twenty two thousand and nineteen CHANGE CHANGE EXCLUDING CURRENCY CHANGES one two thousand and twenty two thousand and nineteen CHANGE CHANGE EXCLUDING CURRENCY CHANGES one North America four thousand and six three thousand nine hundred and eightytwo one one eight thousand two hundred and thirtyone eight thousand two hundred and seventyfive one zero Europe Middle East Africa two thousand nine hundred and fiftyeight two thousand five hundred and thirtyseven seventeen twelve five thousand eight hundred and sixtyeight five thousand three hundred and ten eleven eight Greater China two thousand two hundred and ninetyeight one thousand eight hundred and fortyseven twentyfour nineteen four thousand and seventyeight three thousand five hundred and twentysix sixteen fourteen Asia Pacific Latin America one thousand four hundred and seventyone one thousand four hundred and sixtyeight zero five two thousand five hundred and seventy two thousand eight hundred and thirteen nine three Global Brand Divisions two eight ten twenty twenty twelve sixteen twentyfive twentyfive TOTAL NIKE BRAND ten thousand seven hundred and fortyone nine thousand eight hundred and fortyfour nine eight twenty thousand seven hundred and fiftynine nineteen thousand nine hundred and forty four four Converse four hundred and seventysix four hundred and eighty one four one thousand and thirtynine one thousand and thirtyfive zero one Corporate three twentysix two thirtynine eleven TOTAL NIKE INC REVENUES eleven thousand two hundred and fortythree ten thousand three hundred and twentysix nine seven twentyone thousand eight hundred and thirtyseven twenty thousand nine hundred and eightysix four four one The percent change excluding currency changes represents a nonGAAP financial measure See Use of NonGAAP Financial Measures for further information two Global Brand Divisions revenues include NIKE Brand licensing as well as other miscellaneous revenues that are not part of a geographic operating segment three Corporate revenues primarily consist of foreign currency hedge gains and losses related to revenues generated by entities within the NIKE Brand geographic operating segments and Converse but managed through our central foreign exchange risk management program The primary financial measure used by the Company to evaluate performance of individual operating segments is EBIT which represents Net income before Interest expense income net and Income tax expense in the Unaudited Condensed Consolidated Statements of Income As discussed in Note twelve Operating Segments in the accompanying Notes to the Unaudited Condensed Consolidated Financial Statements certain corporate costs are not included in EBIT of our operating segments thirtytwo Table of Contents The breakdown of earnings before interest and taxes is as follows THREE MONTHS ENDED NOVEMBER thirty SIX MONTHS ENDED NOVEMBER thirty Dollars in millions two thousand and twenty two thousand and nineteen CHANGE two thousand and twenty two thousand and nineteen CHANGE North America one thousand and twentythree eight hundred and seventyfive seventeen two thousand three hundred and twentyfive one thousand nine hundred and seventyfive eighteen Europe Middle East Africa six hundred and sixty five hundred and ten twentynine one thousand three hundred and fiftytwo one thousand one hundred and nineteen twentyone Greater China eight hundred and ninetyone six hundred and ninetyfour twentyeight one thousand five hundred and seventynine one thousand three hundred and sixtythree sixteen Asia Pacific Latin America four hundred and twentyfour three hundred and seventyseven twelve seven hundred and four seven hundred and eighteen two Global Brand Divisions eight hundred and fortyone eight hundred and seventytwo four one thousand six hundred and ninetyfour one thousand seven hundred and twentynine two TOTAL NIKE BRAND one two thousand one hundred and fiftyseven one thousand five hundred and eightyfour thirtysix four thousand two hundred and sixtysix three thousand four hundred and fortysix twentyfour Converse eightyseven ninety three two hundred and fiftyfive two hundred and twentyeight twelve Corporate seven hundred and eighteen four hundred and thirteen seventyfour one thousand two hundred and fifteen eight hundred and thirtyseven fortyfive TOTAL NIKE INC EARNINGS BEFORE INTEREST AND TAXES one one thousand five hundred and twentysix one thousand two hundred and sixtyone twentyone three thousand three hundred and six two thousand eight hundred and thirtyseven seventeen Interest expense income net seventy twelve one hundred and thirtyfive twentyseven TOTAL NIKE INC INCOME BEFORE INCOME TAXES one thousand four hundred and fiftysix one thousand two hundred and fortynine seventeen three thousand one hundred and seventyone two thousand eight hundred and ten thirteen one Total NIKE Brand EBIT and Total NIKE Inc EBIT represent nonGAAP financial measures See Use of NonGAAP Financial Measures for further information NORTH AMERICA THREE MONTHS ENDED NOVEMBER thirty SIX MONTHS ENDED NOVEMBER thirty Dollars in millions two thousand and twenty two thousand and nineteen CHANGE CHANGE EXCLUDING CURRENCY CHANGES two thousand and twenty two thousand and nineteen CHANGE CHANGE EXCLUDING CURRENCY CHANGES Revenues by Footwear two thousand five hundred and twelve two thousand four hundred and twentysix four four five thousand four hundred and sixtynine five thousand and ninetyfive seven seven Apparel one thousand three hundred and sixtyeight one thousand four hundred and seventeen three three two thousand four hundred and ninetythree two thousand eight hundred and fortyeight twelve twelve Equipment one hundred and twentysix one hundred and thirtynine nine ten two hundred and sixtynine three hundred and thirtytwo nineteen nineteen TOTAL REVENUES four thousand and six three thousand nine hundred and eightytwo one one eight thousand two hundred and thirtyone eight thousand two hundred and seventyfive one zero Revenues by Sales to Wholesale Customers two thousand three hundred and fiftyfour two thousand seven hundred and thirtyfour fourteen fourteen five thousand and seventythree five thousand five hundred and ninetyeight nine nine Sales through NIKE Direct one thousand six hundred and fiftytwo one thousand two hundred and fortyeight thirtytwo thirtytwo three thousand one hundred and fiftyeight two thousand six hundred and seventyseven eighteen eighteen TOTAL REVENUES four thousand and six three thousand nine hundred and eightytwo one one eight thousand two hundred and thirtyone eight thousand two hundred and seventyfive one zero EARNINGS BEFORE INTEREST AND TAXES one thousand and twentythree eight hundred and seventyfive seventeen two thousand three hundred and twentyfive one thousand nine hundred and seventyfive eighteen We believe there continues to be a meaningful shift in the way consumers shop for product and make purchasing decisions across each of our geographies Consumers are demanding a constant flow of fresh and innovative product and have an expectation for superior service and rapid delivery all fueled by the shift toward digital and monobrand experiences in NIKE Direct We anticipate continued evolution within the retail landscape driven by shifting consumer traffic patterns across digital and physical channels Specifically in North America we remain focused on building longterm momentum with our differentiated strategic wholesale customers and over the last three years have significantly reduced the number of undifferentiated accounts Additionally during the second quarter of fiscal two thousand and twentyone we took further steps towards account and channel consolidation by reprioritizing product allocation to benefit NIKE Direct and our differentiated strategic wholesale customers We expect over the next two fiscal years we will more aggressively accelerate these changes as we work to reprofile the shape of the marketplace and recapture wholesale revenue declines over time SECOND QUARTER OF FISCAL two thousand and twentyone COMPARED TO SECOND QUARTER OF FISCAL two thousand and twenty On a currencyneutral basis North America revenues for the second quarter of fiscal two thousand and twentyone increased one largely driven by significant growth in digital NIKE Direct revenues increased thirtytwo as strong digital sales growth of one hundred and seven more than offset an eleven decline in comparable store sales primarily due to reduced physical retail traffic in part resulting from safetyrelated measures in response to COVID19 Footwear revenues increased four on a currencyneutral basis largely driven by significant growth in digital Unit sales of footwear decreased four while higher ASP per pair contributed approximately eight percentage points of footwear revenue growth Higher ASP per pair was primarily due to the favorable impact of growth in our NIKE Direct business as well as higher NIKE Direct and fullprice ASPs thirtythree Table of Contents On a currencyneutral basis apparel revenues decreased three as growth in Sportswear was more than offset by lower revenues in several key categories led by Training and the divestiture of Hurley in the prior year Unit sales of apparel were flat while lower ASP per unit reduced apparel revenues by approximately three percentage points The decrease in ASP per unit was primarily driven by lower fullprice ASP in part reflecting higher discounts partially offset by the favorable impact of growth in our NIKE Direct business and higher NIKE Direct ASP Reported EBIT increased seventeen driven by lower selling and administrative expense gross margin expansion and higher revenues Gross margin increased approximately one hundred basis points primarily due to lower product costs reflecting the impact of lower air freight and reduced tariffs as well as lower inventory obsolescence These impacts were partially offset by lower fullprice ASP reflecting higher discounts to reduce excess inventory due to COVID19 and a lower mix of fullprice sales Selling and administrative expense decreased due to lower demand creation and operating overhead expense The decrease in demand creation expense reflected lower advertising and marketing costs as well as a decline in retail brand presentation costs partially offset by continued investments in digital marketing to support heightened digital demand Operating overhead expense decreased primarily as a result of lower wagerelated expense partially offset by an increase in professional services costs FIRST SIX MONTHS OF FISCAL two thousand and twentyone COMPARED TO FIRST SIX MONTHS OF FISCAL two thousand and twenty On a currencyneutral basis North America revenues for the first six months of fiscal two thousand and twentyone were flat as growth in Sportswear was offset by declines in nearly all other key categories led by Training and Running NIKE Direct revenues increased eighteen primarily due to digital sales growth of one hundred and three partially offset by comparable store sales contraction of twentyfive primarily due to reduced physical retail traffic in part resulting from safetyrelated measures in response to COVID19 Footwear revenues increased seven on a currencyneutral basis as growth in Sportswear was partially offset by declines in nearly all other key categories led by Running Unit sales of footwear increased two while higher ASP per pair contributed approximately five percentage points of footwear revenue growth Higher ASP per pair was primarily due to higher NIKE Direct and fullprice ASPs as well as the favorable impact of growth in our NIKE Direct business On a currencyneutral basis apparel revenues decreased twelve driven by declines in most key categories led by Training NIKE Basketball as well as the divestiture of Hurley in the prior year Unit sales of apparel declined ten and lower ASP per unit reduced apparel revenues by approximately two percentage points The decrease in ASP per unit was driven by lower fullprice ASP and a lower mix of fullprice sales partially offset by the favorable impact of growth in our NIKE Direct business and higher NIKE Direct ASP Reported EBIT increased eighteen driven by lower selling and administrative expense and gross margin expansion Gross margin increased approximately one hundred and thirty basis points due to higher fullprice ASP and lower other costs partially offset by lower margin in our NIKE Direct business and a lower mix of fullprice sales The decrease in other costs was primarily a result of lower inventory obsolescence and the favorable impact from the release of factory cancellation cost accruals due to an increase in consumer demand Selling and administrative expense decreased due to lower demand creation expense and operating overhead expense The decrease in demand creation expense was primarily due to lower advertising and marketing costs retail brand presentation costs and sports marketing expense partially offset by continued investments in digital marketing to support heightened digital demand Operating overhead expense decreased primarily as a result of lower wagerelated expense partially offset by an increase in professional services costs EUROPE MIDDLE EAST AFRICA THREE MONTHS ENDED NOVEMBER thirty SIX MONTHS ENDED NOVEMBER thirty Dollars in millions two thousand and twenty two thousand and nineteen CHANGE CHANGE EXCLUDING CURRENCY CHANGES two thousand and twenty two thousand and nineteen CHANGE CHANGE EXCLUDING CURRENCY CHANGES Revenues by Footwear one thousand seven hundred and thirtyone one thousand five hundred and thirtysix thirteen eight three thousand five hundred and thirtythree three thousand two hundred and ninetyfour seven five Apparel one thousand one hundred and four eight hundred and ninetyseven twentythree eighteen two thousand and seventyfive one thousand seven hundred and sixtysix seventeen fifteen Equipment one hundred and twentythree one hundred and four eighteen sixteen two hundred and sixty two hundred and fifty four three TOTAL REVENUES two thousand nine hundred and fiftyeight two thousand five hundred and thirtyseven seventeen twelve five thousand eight hundred and sixtyeight five thousand three hundred and ten eleven eight Revenues by Sales to Wholesale Customers one thousand nine hundred and eightyfive one thousand seven hundred and ninetyfour eleven six three thousand nine hundred and fiftyeight three thousand eight hundred and thirtysix three one Sales through NIKE Direct nine hundred and seventythree seven hundred and fortythree thirtyone twentyfive one thousand nine hundred and ten one thousand four hundred and seventyfour thirty twentysix TOTAL REVENUES two thousand nine hundred and fiftyeight two thousand five hundred and thirtyseven seventeen twelve five thousand eight hundred and sixtyeight five thousand three hundred and ten eleven eight EARNINGS BEFORE INTEREST AND TAXES six hundred and sixty five hundred and ten twentynine one thousand three hundred and fiftytwo one thousand one hundred and nineteen twentyone thirtyfour Table of Contents SECOND QUARTER OF FISCAL two thousand and twentyone COMPARED TO SECOND QUARTER OF FISCAL two thousand and twenty On a currencyneutral basis EMEA revenues for the second quarter of fiscal two thousand and twentyone grew twelve driven by higher revenues across most territories led by UK Ireland Central Europe and Northern Europe which grew thirtytwo twentyone and seven respectively Revenues increased in all key categories led by Sportswear Football Soccer and the Jordan Brand NIKE Direct revenues increased twentyfive driven by strong digital sales growth of ninetysix partially offset by comparable store sales contraction of twenty primarily due to reduced physical retail traffic in part resulting from safetyrelated measures in response to COVID19 Currencyneutral footwear revenues grew eight driven by higher revenues in nearly all key categories led by the Jordan Brand Training and Sportswear Unit sales of footwear increased nine while lower ASP per pair reduced footwear revenues by approximately one percentage point primarily due to unfavorable fullprice mix Currencyneutral apparel revenues increased eighteen due to growth in most key categories led by Football Soccer and Sportswear Unit sales of apparel increased nineteen while lower ASP per unit reduced apparel revenues by approximately one percentage point Lower ASP per unit was primarily due to lower NIKE Direct ASP and a lower mix of NIKE Direct sales as well as lower offprice ASP which more than offset higher fullprice ASP in part reflecting lower discounts Reported EBIT increased twentynine as higher revenues and lower selling and administrative expense more than offset a decline in gross margin Gross margin decreased approximately two hundred basis points as lower product costs due to favorable product mix were more than offset by unfavorable changes in standard foreign currency exchange rates lower margin in our NIKE Direct business and a lower mix of fullprice sales Lower margin in our NIKE Direct business was driven by higher promotions to reduce excess inventory due to COVID19 Selling and administrative expense decreased due to lower demand creation expense while operating overhead expense was flat Lower demand creation expense was driven by lower advertising and marketing expense FIRST SIX MONTHS OF FISCAL two thousand and twentyone COMPARED TO FIRST SIX MONTHS OF FISCAL two thousand and twenty On a currencyneutral basis EMEA revenues for the first six months of fiscal two thousand and twentyone grew eight driven by higher revenues across most territories led by UK Ireland and Central Europe which grew thirtyone and seventeen respectively Revenues increased in all key categories led by Sportswear the Jordan Brand and Football Soccer NIKE Direct revenues increased twentysix driven by digital sales growth of one hundred and five partially offset by a fifteen decline in comparable store sales primarily due to reduced physical retail traffic in part resulting from safetyrelated measures in response to COVID19 Currencyneutral footwear revenues grew five driven by higher revenues in nearly all key categories led by the Jordan Brand Unit sales of footwear increased one and higher ASP per pair contributed approximately four percentage points of footwear revenue growth resulting from higher fullprice ASP Currencyneutral apparel revenues increased fifteen due to growth in all key categories led by Football Soccer and Sportswear Unit sales of apparel increased fourteen and higher ASP per unit contributed approximately one percentage point of apparel revenue growth Higher ASP per unit was primarily due to higher fullprice ASP in part reflecting lower discounts Reported EBIT increased twentyone for the first six months of fiscal two thousand and twentyone as higher revenues and lower selling and administrative expense more than offset a decline in gross margin Gross margin decreased approximately two hundred and ninety basis points as lower NIKE Direct margins driven by higher promotions to reduce excess inventory due to COVID19 unfavorable changes in standard foreign currency exchange rates and a lower mix of fullprice sales more than offset lower product costs Selling and administrative expense decreased due to lower demand creation and operating overhead expense The decrease in demand creation expense was driven by lower advertising and marketing costs as well as lower sports marketing expense Lower operating overhead expense was primarily due to lower travel and related expenses partially offset by increases in professional services costs thirtyfive Table of Contents GREATER CHINA THREE MONTHS ENDED NOVEMBER thirty SIX MONTHS ENDED NOVEMBER thirty Dollars in millions two thousand and twenty two thousand and nineteen CHANGE CHANGE EXCLUDING CURRENCY CHANGES two thousand and twenty two thousand and nineteen CHANGE CHANGE EXCLUDING CURRENCY CHANGES Revenues by Footwear one thousand five hundred and sixtyseven one thousand two hundred and fortyseven twentysix twenty two thousand eight hundred and eighteen two thousand four hundred and eleven seventeen fifteen Apparel six hundred and eightyone five hundred and sixtythree twentyone sixteen one thousand one hundred and fiftynine one thousand and twentyeight thirteen eleven Equipment fifty thirtyseven thirtyfive twentynine one hundred and one eightyseven sixteen fourteen TOTAL REVENUES two thousand two hundred and ninetyeight one thousand eight hundred and fortyseven twentyfour nineteen four thousand and seventyeight three thousand five hundred and twentysix sixteen fourteen Revenues by Sales to Wholesale Customers one thousand one hundred and fiftynine one thousand and twentyeight thirteen eight two thousand one hundred and twentythree two thousand and fourteen five four Sales through NIKE Direct one thousand one hundred and thirtynine eight hundred and nineteen thirtynine thirtythree one thousand nine hundred and fiftyfive one thousand five hundred and twelve twentynine twentyseven TOTAL REVENUES two thousand two hundred and ninetyeight one thousand eight hundred and fortyseven twentyfour nineteen four thousand and seventyeight three thousand five hundred and twentysix sixteen fourteen EARNINGS BEFORE INTEREST AND TAXES eight hundred and ninetyone six hundred and ninetyfour twentyeight one thousand five hundred and seventynine one thousand three hundred and sixtythree sixteen SECOND QUARTER OF FISCAL two thousand and twentyone COMPARED TO SECOND QUARTER OF FISCAL two thousand and twenty On a currencyneutral basis Greater China revenues for the second quarter of fiscal two thousand and twentyone increased nineteen due to higher revenues in nearly all key categories led by Sportswear the Jordan Brand and NIKE Basketball NIKE Direct revenues increased thirtythree due to digital sales growth of thirtyseven comparable store sales growth of twentyseven and the addition of new stores Currencyneutral footwear revenues increased twenty for the second quarter of fiscal two thousand and twentyone driven by higher revenues in most key categories primarily Sportswear the Jordan Brand and NIKE Basketball Unit sales of footwear increased twentyfour while lower ASP per pair reduced footwear revenues by approximately four percentage points driven by lower NIKE Direct and fullprice ASPs as well as unfavorable fullprice mix Currencyneutral apparel revenues grew sixteen for the second quarter of fiscal two thousand and twentyone due to higher revenues in nearly all key categories led by Sportswear the Jordan Brand and Training Unit sales of apparel increased twentyone while lower ASP per unit reduced apparel revenues by approximately five percentage points as unfavorable fullprice mix and lower NIKE Direct ASP more than offset higher offprice ASP Reported EBIT increased twentyeight for the second quarter of fiscal two thousand and twentyone as higher revenues and lower selling and administrative expense more than offset a decline in gross margin Gross margin decreased approximately two hundred and sixty basis points reflecting unfavorable changes in standard foreign currency exchange rates and lower margin in our NIKE Direct business driven by higher promotions to reduce excess inventory as well as a lower mix of fullprice sales Selling and administrative expense decreased due to lower demand creation expense partially offset by higher operating overhead expense Demand creation expense decreased primarily due to lower advertising and marketing expenses Growth in operating overhead expense was driven by higher investments within our NIKE Direct operations FIRST SIX MONTHS OF FISCAL two thousand and twentyone COMPARED TO FIRST SIX MONTHS OF FISCAL two thousand and twenty On a currencyneutral basis Greater China revenues for the first six months of fiscal two thousand and twentyone increased fourteen driven by higher revenues in nearly all key categories led by Sportswear the Jordan Brand and NIKE Basketball NIKE Direct revenues increased twentyseven driven by digital sales growth of thirtyfour comparable store sales growth of twenty and the addition of new stores Currencyneutral footwear revenues increased fifteen driven by growth in most key categories led by Sportswear the Jordan Brand and NIKE Basketball Unit sales of footwear increased twentytwo while lower ASP per pair reduced footwear revenues by approximately seven percentage points Lower ASP was driven by lower NIKE Direct ASP and unfavorable fullprice mix Currencyneutral apparel revenue growth of eleven was fueled by higher revenues in nearly all key categories most notably Sportswear and the Jordan Brand Unit sales of apparel increased fifteen while lower ASP per unit reduced apparel revenues by approximately four percentage points Lower ASP was driven by an unfavorable fullprice mix and lower NIKE Direct ASP slightly offset by higher offprice ASP Reported EBIT increased sixteen as higher revenues and lower selling and administrative expense more than offset a decline in gross margin Gross margin decreased approximately three hundred and ninety basis points primarily due to lower margin in our NIKE Direct business unfavorable changes in standard foreign currency exchange rates and higher product costs Selling and administrative expense decreased due to lower demand creation expense partially offset by higher operating overhead expense Demand creation expense decreased primarily due to lower advertising and marketing expenses Growth in operating overhead expense was driven by higher investments within our NIKE Direct operations thirtysix Table of Contents ASIA PACIFIC LATIN AMERICA THREE MONTHS ENDED NOVEMBER thirty SIX MONTHS ENDED NOVEMBER thirty Dollars in millions two thousand and twenty two thousand and nineteen CHANGE CHANGE EXCLUDING CURRENCY CHANGES two thousand and twenty two thousand and nineteen CHANGE CHANGE EXCLUDING CURRENCY CHANGES Revenues by Footwear nine hundred and ninetyone nine hundred and ninetyseven one five one thousand seven hundred and fortynine one thousand nine hundred and twentyseven nine three Apparel four hundred and thirtytwo four hundred and ten five nine seven hundred and thirtythree seven hundred and sixtysix four zero Equipment fortyeight sixtyone twentyone seventeen eightyeight one hundred and twenty twentyseven twentytwo TOTAL REVENUES one thousand four hundred and seventyone one thousand four hundred and sixtyeight zero five two thousand five hundred and seventy two thousand eight hundred and thirteen nine three Revenues by Sales to Wholesale Customers nine hundred and twentyfive one thousand and twentytwo nine five one thousand six hundred and thirtythree one thousand nine hundred and seventytwo seventeen eleven Sales through NIKE Direct five hundred and fortysix four hundred and fortysix twentytwo twentyseven nine hundred and thirtyseven eight hundred and fortyone eleven sixteen TOTAL REVENUES one thousand four hundred and seventyone one thousand four hundred and sixtyeight zero five two thousand five hundred and seventy two thousand eight hundred and thirteen nine three EARNINGS BEFORE INTEREST AND TAXES four hundred and twentyfour three hundred and seventyseven twelve seven hundred and four seven hundred and eighteen two As discussed previously we entered into definitive agreements to sell our NIKE Brand businesses in Brazil Argentina Chile and Uruguay and shift to a distributor operating model The impacts of entering into these agreements are included within Corporate and are not reflected in the APLA operating segment results For more information see Note thirteen Acquisitions and Divestitures within the accompanying Notes to the Unaudited Condensed Consolidated Financial Statements SECOND QUARTER OF FISCAL two thousand and twentyone COMPARED TO SECOND QUARTER OF FISCAL two thousand and twenty On a currencyneutral basis APLA revenues increased five for the second quarter of fiscal two thousand and twentyone The increase was due to higher revenues across most territories led by Korea and SOCO which comprises Argentina Chile and Uruguay which increased seventeen and eighteen respectively Revenues increased due to growth in Sportswear and the Jordan Brand partially offset by lower revenues in all other key categories NIKE Direct revenues increased twentyseven driven by digital sales growth of ninetytwo partially offset by comparable store sales contraction of three primarily due to reduced physical retail traffic in part resulting from safetyrelated measures in response to COVID19 Currencyneutral footwear revenues increased five for the second quarter of fiscal two thousand and twentyone due to higher revenues in most key categories primarily the Jordan Brand and Sportswear partially offset by Running Unit sales of footwear decreased six while higher ASP per pair contributed approximately eleven percentage points Higher ASP per pair was driven by higher fullprice ASP in part reflecting inflationary conditions in our SOCO territory as well as the favorable impact of growth in our NIKE Direct business Currencyneutral apparel revenues increased nine for the second quarter of fiscal two thousand and twentyone due to higher revenues in most key categories primarily Sportswear Unit sales of apparel increased eight and higher ASP per unit contributed approximately one percentage point to apparel revenue growth driven by higher fullprice ASP in part reflecting inflationary conditions in our SOCO territory Reported EBIT increased twelve for the second quarter of fiscal two thousand and twentyone as lower selling and administrative more than offset a decline in gross margin Gross margin decreased approximately forty basis points as higher fullprice ASP in part reflecting inflationary conditions in our SOCO territory was more than offset by higher product costs lower margin in our NIKE Direct business and unfavorable changes in standard foreign currency exchange rates Lower margin in our NIKE Direct business was driven by higher promotions to reduce excess inventory due to COVID19 Selling and administrative expense decreased due to lower demand creation and operating overhead expense The decrease in demand creation expense was primarily due to lower advertising and marketing costs as well as a decline in sports marketing expense Lower operating overhead expense was primarily due to lower travel and related expenses FIRST SIX MONTHS OF FISCAL two thousand and twentyone COMPARED TO FIRST SIX MONTHS OF FISCAL two thousand and twenty On a currencyneutral basis APLA revenues decreased three for the first six months of fiscal two thousand and twentyone The decline was due to lower revenues across most territories led by a sixtyone decline in our Latin America thirdparty distributor business due to impacts from COVID19 partially offset by higher revenues in Korea which increased twelve Revenues decreased in most key categories led by Running and Football Soccer partially offset by higher revenues in the Jordan Brand and Sportswear NIKE Direct revenues increased sixteen primarily fueled by digital sales growth of ninetyone partially offset by comparable store sales contraction of sixteen primarily due to reduced physical retail traffic in part resulting from safetyrelated measures in response to COVID19 thirtyseven Table of Contents Currencyneutral footwear revenues decreased three for the first six months of fiscal two thousand and twentyone due to lower revenues in most key categories primarily Running and Football Soccer partially offset by growth in the Jordan Brand Unit sales of footwear decreased fifteen while higher ASP per pair contributed approximately twelve percentage points of footwear revenue growth driven by higher fullprice ASP in part reflecting inflationary conditions in our SOCO territory as well as the favorable impact of growth in our NIKE Direct business Currencyneutral apparel revenues were flat for the first six months of fiscal two thousand and twentyone as higher revenues in Sportswear were offset by lower revenues in nearly all other key categories most notably Running Unit sales of apparel decreased three offset by higher ASP per unit which contributed approximately three percentage points of apparel revenue growth Higher ASP per unit was driven by higher fullprice ASP in part reflecting inflationary conditions in our SOCO territory Reported EBIT decreased two for the first six months of fiscal two thousand and twentyone primarily due to lower revenues and a decline in gross margin partially offset by lower selling and administrative expense Gross margin decreased approximately seventy basis points as higher fullprice ASP in part reflecting inflationary conditions in our SOCO territory was more than offset by higher product costs lower margin in our NIKE Direct business unfavorable standard foreign currency exchange rates and a lower mix of fullprice sales Lower margin in our NIKE Direct business was driven by higher promotions to reduce excess inventory due to COVID19 Selling and administrative expense decreased due to lower demand creation and operating overhead expense The decrease in demand creation expense was primarily due to lower advertising and marketing expense as well as a decline in sports marketing costs Lower operating overhead expense was primarily due to lower travel and related expenses GLOBAL BRAND DIVISIONS THREE MONTHS ENDED NOVEMBER thirty SIX MONTHS ENDED NOVEMBER thirty Dollars in millions two thousand and twenty two thousand and nineteen CHANGE CHANGE EXCLUDING CURRENCY CHANGES two thousand and twenty two thousand and nineteen CHANGE CHANGE EXCLUDING CURRENCY CHANGES Revenues eight ten twenty twenty twelve sixteen twentyfive twentyfive Earnings Loss Before Interest and Taxes eight hundred and fortyone eight hundred and seventytwo four one thousand six hundred and ninetyfour one thousand seven hundred and twentynine two Global Brand Divisions primarily represent demand creation and operating overhead expense including product creation and design expenses that are centrally managed for the NIKE Brand as well as costs associated with NIKE Direct global digital operations and enterprise technology Global Brand Divisions revenues include NIKE Brand licensing and other miscellaneous revenues that are not part of a geographic operating segment SECOND QUARTER OF FISCAL two thousand and twentyone COMPARED TO SECOND QUARTER OF FISCAL two thousand and twenty Global Brand Divisions loss before interest and taxes decreased four for the second quarter of fiscal two thousand and twentyone driven by lower total selling and administrative expense Operating overhead expense decreased primarily due to lower wagerelated costs and lower travel and related expenses partially offset by our continued investment in digital capabilities Lower demand creation expense was primarily due to lower sports marketing expense partially offset by higher advertising and marketing costs FIRST SIX MONTHS OF FISCAL two thousand and twentyone COMPARED TO FIRST SIX MONTHS OF FISCAL two thousand and twenty Global Brand Divisions loss before interest and taxes decreased two for the first six months of fiscal two thousand and twentyone driven by lower total selling and administrative expense Lower demand creation expense was primarily due to lower sports marketing costs The decrease in operating overhead expense was primarily due lower travel and related expenses as well as lower wagerelated costs partially offset by our continued investment in digital capabilities thirtyeight CONVERSE THREE MONTHS ENDED NOVEMBER thirty SIX MONTHS ENDED NOVEMBER thirty Dollars in millions two thousand and twenty two thousand and nineteen CHANGE CHANGE EXCLUDING CURRENCY CHANGES two thousand and twenty two thousand and nineteen CHANGE CHANGE EXCLUDING CURRENCY CHANGES Revenues by Footwear four hundred and sixteen four hundred and sixteen zero three nine hundred and twentynine nine hundred and twelve two one Apparel thirtytwo thirty seven zero fiftyfour fiftysix four six Equipment seven six seventeen nineteen sixteen fifteen seven eight Other one twentyone twentyeight twentyfive nineteen forty fiftytwo twentythree eighteen TOTAL REVENUES four hundred and seventysix four hundred and eighty one four one thousand and thirtynine one thousand and thirtyfive zero one Revenues by Sales to Wholesale Customers two hundred and fiftynine two hundred and eightysix nine thirteen six hundred and thirtytwo six hundred and fiftythree three five Sales through Direct to Consumer one hundred and ninetysix one hundred and sixtysix eighteen fifteen three hundred and sixtyseven three hundred and thirty eleven ten Other one twentyone twentyeight twentyfive nineteen forty fiftytwo twentythree eighteen TOTAL REVENUES four hundred and seventysix four hundred and eighty one four one thousand and thirtynine one thousand and thirtyfive zero one EARNINGS BEFORE INTEREST AND TAXES eightyseven ninety three two hundred and fiftyfive two hundred and twentyeight twelve one Other revenues consist of territories serviced by thirdparty licensees who pay royalties to Converse for the use of its registered trademarks and other intellectual property rights We do not own the Converse trademarks in Japan and accordingly do not earn revenues in Japan SECOND QUARTER OF FISCAL two thousand and twentyone COMPARED TO SECOND QUARTER OF FISCAL two thousand and twenty On a currencyneutral basis Converse revenues decreased four for the second quarter of fiscal two thousand and twentyone The decrease in revenues was driven by declines in wholesale revenues in North America and Europe as a result of supply chain management and strategic distribution shifts partially offset by growth in Asia Direct to consumer revenues increased fifteen as strong digital sales growth across all geographies more than offset declines from Converse owned stores reflecting the ongoing impact of COVID19 Combined unit sales within the wholesale and direct to consumer channels decreased eleven while ASP increased nine primarily due to growth in digital Reported EBIT decreased three driven by declines in gross margin partially offset by lower selling and administrative expense Gross margin decreased approximately two hundred and thirty basis points as higher fullprice ASP due to product mix was offset by lower margin in our direct to consumer channel higher product costs due to product mix a lower mix of fullprice sales lower revenues in our licensing business and unfavorable changes in standard foreign currency exchange rates Lower margin in direct to consumer was driven by higher promotions to reduce excess inventory due to COVID19 Selling and administrative expense decreased primarily due to lower operating overhead partially offset by increased demand creation expense Operating overhead expense decreased primarily due to lower travel and related expenses Demand creation expense increased primarily as a result of higher advertising costs FIRST SIX MONTHS OF FISCAL two thousand and twentyone COMPARED TO FIRST SIX MONTHS OF FISCAL two thousand and twenty On a currencyneutral basis Converse revenues decreased one for the first six months of fiscal two thousand and twentyone driven by lower wholesale revenues in North America as a result of supply chain management and strategic distribution shifts partially offset by growth in Asia Direct to consumer revenues increased ten as strong digital sales growth across all geographies more than offset declines from Converse owned stores reflecting the ongoing impact of COVID19 Combined unit sales within the wholesale and direct to consumer channels decreased three while ASP increased four primarily due to growth in digital Reported EBIT increased twelve primarily due to lower selling and administrative expense partially offset by lower gross margin Gross margin decreased approximately two hundred and twenty basis points as higher fullprice ASP was more than offset by lower margin in our direct to consumer channel higher product costs due to product mix unfavorable changes in standard foreign currency exchange rates and lower revenues in our licensing business Lower margin in direct to consumer was driven by higher promotions to reduce excess inventory due to COVID19 Selling and administrative expense decreased due to lower operating overhead and demand creation expense Operating overhead expense decreased primarily due to lower administrative expenses Demand creation expense decreased as a result of lower advertising and marketing costs as well as lower retail brand presentation costs thirtynine Table of Contents CORPORATE THREE MONTHS ENDED NOVEMBER thirty SIX MONTHS ENDED NOVEMBER thirty Dollars in millions two thousand and twenty two thousand and nineteen CHANGE two thousand and twenty two thousand and nineteen CHANGE Revenues twentysix two thirtynine eleven Earnings Loss Before Interest and Taxes seven hundred and eighteen four hundred and thirteen seventyfour one thousand two hundred and fifteen eight hundred and thirtyseven fortyfive Corporate revenues primarily consist of foreign currency hedge gains and losses related to revenues generated by entities within the NIKE Brand geographic operating segments and Converse but managed through our central foreign exchange risk management program The Corporate loss before interest and taxes primarily consists of unallocated general and administrative expenses including expenses associated with centrally managed departments depreciation and amortization related to our corporate headquarters unallocated insurance benefit and compensation programs including stockbased compensation and certain foreign currency gains and losses In addition to the foreign currency gains and losses recognized in Corporate revenues foreign currency results in Corporate include gains and losses resulting from the difference between actual foreign currency exchange rates and standard rates used to record nonfunctional currency denominated product purchases within the NIKE Brand geographic operating segments and Converse related foreign currency hedge results conversion gains and losses arising from remeasurement of monetary assets and liabilities in nonfunctional currencies and certain other foreign currency derivative instruments SECOND QUARTER OF FISCAL two thousand and twentyone COMPARED TO SECOND QUARTER OF FISCAL two thousand and twenty Corporates loss before interest and taxes increased three hundred and five million for the second quarter of fiscal two thousand and twentyone primarily due to the following an unfavorable change of two hundred and seventysix million in part due to one hundred and seventyone million of restructuringrelated costs associated with changes to our organizational model announced in July two thousand and twenty as well as a charge related to our planned strategic distributor partnership transition within APLA an unfavorable change in net foreign currency gains and losses of fiftythree million related to the remeasurement of monetary assets and liabilities denominated in nonfunctional currencies and the impact of certain foreign currency derivative instruments reported as a component of consolidated Other income expense net and a favorable change of twentyfour million related to the difference between actual foreign currency exchange rates and standard foreign currency exchange rates assigned to the NIKE Brand geographic operating segments and Converse net of hedge gains and losses these results are reported as a component of consolidated gross margin FIRST SIX MONTHS OF FISCAL two thousand and twentyone COMPARED TO FIRST SIX MONTHS OF FISCAL two thousand and twenty Corporates loss before interest and taxes increased three hundred and seventyeight million for the first six months of fiscal two thousand and twentyone primarily due to the following an unfavorable change of four hundred and sixteen million in part due to two hundred and eighteen million of restructuringrelated costs associated with changes to our organizational model announced in July two thousand and twenty as well as charges related to our planned strategic distributor partnership transition within APLA a favorable change of one hundred million related to the difference between actual foreign currency exchange rates and standard foreign currency exchange rates assigned to the NIKE Brand geographic operating segments and Converse net of hedge gains and losses these results are reported as a component of consolidated gross margin and an unfavorable change in net foreign currency gains and losses of sixtytwo million related to the remeasurement of monetary assets and liabilities denominated in nonfunctional currencies and the impact of certain foreign currency derivative instruments reported as a component of consolidated Other income expense net For more information related to our distributor partnership transition within APLA as well as more information related to our organizational realignment and related costs see Note thirteen Acquisitions and Divestitures and Note fourteen Restructuring respectively within the accompanying Notes to the Unaudited Condensed Consolidated Financial Statements forty Table of Contents FOREIGN CURRENCY EXPOSURES AND HEDGING PRACTICES OVERVIEW As a global company with significant operations outside the United States in the normal course of business we are exposed to risk arising from changes in currency exchange rates Our primary foreign currency exposures arise from the recording of transactions denominated in nonfunctional currencies and the translation of foreign currency denominated results of operations financial position and cash flows into US Dollars Our foreign exchange risk management program is intended to lessen both the positive and negative effects of currency fluctuations on our consolidated results of operations financial position and cash flows We manage global foreign exchange risk centrally on a portfolio basis to address those risks material to NIKE Inc Our hedging policy is designed to partially or entirely offset the impact of exchange rate changes on the underlying net exposures being hedged Where exposures are hedged our program has the effect of delaying the impact of exchange rate movements on our Unaudited Condensed Consolidated Financial Statements the length of the delay is dependent upon hedge horizons We do not hold or issue derivative instruments for trading or speculative purposes As of and for the six months ended November thirty two thousand and twenty there have been no material changes to the Companys hedging program or strategy from what was disclosed within the Annual Report on Form 10K Refer to Note four Fair Value Measurements and Note nine Risk Management and Derivatives in the accompanying Notes to the Unaudited Condensed Consolidated Financial Statements for additional description of outstanding derivatives at each reported period end For additional information about our Foreign Currency Exposures and Hedging Practices refer to Part II Item seven Managements Discussion and Analysis of Financial Condition and Results of Operations of our Annual Report on Form 10K for the fiscal year ended May thirtyone two thousand and twenty TRANSACTIONAL EXPOSURES We conduct business in various currencies and have transactions which subject us to foreign currency risk Our most significant transactional foreign currency exposures are Product Costs Product purchases denominated in currencies other than the functional currency of the transacting entity and factory input costs from the foreign currency adjustments program with certain factories NonFunctional Currency Denominated External Sales A portion of our NIKE Brand and Converse revenues associated with European operations are earned in currencies other than the Euro eg the British Pound but are recognized at a subsidiary that uses the Euro as its functional currency These sales generate a foreign currency exposure Other Costs Nonfunctional currency denominated costs such as endorsement contracts also generate foreign currency risk though to a lesser extent NonFunctional Currency Denominated Monetary Assets and Liabilities Our global subsidiaries have various assets and liabilities primarily receivables and payables including intercompany receivables and payables denominated in currencies other than their functional currencies These balance sheet items are subject to remeasurement which may create fluctuations in Other income expense net within our consolidated results of operations MANAGING TRANSACTIONAL EXPOSURES Transactional exposures are managed on a portfolio basis within our foreign currency risk management program We manage these exposures by taking advantage of natural offsets and currency correlations that exist within the portfolio and may also elect to use currency forward and option contracts to hedge the remaining effect of exchange rate fluctuations on probable forecasted future cash flows including certain product cost exposures nonfunctional currency denominated external sales and other costs described above Certain currency forward contracts used to manage the foreign exchange exposure of nonfunctional currency denominated monetary assets and liabilities subject to remeasurement and embedded derivative contracts are not formally designated as hedging instruments and are recognized in Other income expense net fortyone Table of Contents TRANSLATIONAL EXPOSURES Many of our foreign subsidiaries operate in functional currencies other than the US Dollar Fluctuations in currency exchange rates create volatility in our reported results as we are required to translate the balance sheets operational results and cash flows of these subsidiaries into US Dollars for consolidated reporting The translation of foreign subsidiaries nonUS Dollar denominated balance sheets into US Dollars for consolidated reporting results in a cumulative translation adjustment to Accumulated other comprehensive income loss within Shareholders equity The impact of foreign exchange rate fluctuations on the translation of our consolidated Revenues was a benefit of approximately one hundred and eightyfour million and seventythree million for the three and six months ended November thirty two thousand and twenty respectively and a detriment of approximately two hundred and thirtythree million and five hundred and fortysix million for the three and six months ended November thirty two thousand and nineteen respectively The impact of foreign exchange rate fluctuations on the translation of our Income before income taxes was a benefit of approximately sixtythree million and thirtyfour million for the three and six months ended November thirty two thousand and twenty respectively and a detriment of approximately sixtysix million and one hundred and fiftytwo million for the three and six months ended November thirty two thousand and nineteen respectively Management generally identifies hyperinflationary markets as those markets whose cumulative inflation rate over a threeyear period exceeds one hundred Management has concluded our Argentina subsidiary within our APLA operating segment is operating in a hyperinflationary market As a result beginning in the second quarter of fiscal two thousand and nineteen the functional currency of our Argentina subsidiary changed from the local currency to the US Dollar As of and for the three and six months ended November thirty two thousand and twenty this change did not have a material impact on our results of operations or financial condition and we do not anticipate it will have a material impact in future periods based on current rates MANAGING TRANSLATIONAL EXPOSURES To minimize the impact of translating foreign currency denominated revenues and expenses into US Dollars for consolidated reporting certain foreign subsidiaries use excess cash to purchase US Dollar denominated availableforsale investments The variable future cash flows associated with the purchase and subsequent sale of these US Dollar denominated investments at nonUS Dollar functional currency subsidiaries creates a foreign currency exposure that qualifies for hedge accounting under US GAAP We utilize forward contracts andor options to mitigate the variability of the forecasted future purchases and sales of these US Dollar investments The combination of the purchase and sale of the US Dollar investment and the hedging instrument has the effect of partially offsetting the yearoveryear foreign currency translation impact on net earnings in the period the investments are sold Hedges of the purchase of US Dollar denominated availableforsale investments are accounted for as cash flow hedges We estimate the combination of translation of foreign currencydenominated profits from our international businesses and the yearoveryear change in foreign currency related gains and losses included in Other income expense net had a favorable impact of approximately ten million and an unfavorable impact of approximately twentyeight million on our Income before income taxes for the three months and six months ended November thirty two thousand and twenty respectively LIQUIDITY AND CAPITAL RESOURCES CASH FLOW ACTIVITY Cash provided used by operations was an inflow of three thousand three hundred and fiftyfive million for the first six months of fiscal two thousand and twentyone compared to one thousand three hundred and six million for the first six months of fiscal two thousand and twenty Net income adjusted for noncash items generated three thousand two hundred and eightythree million of operating cash inflow for the first six months of fiscal two thousand and twentyone compared to two thousand nine hundred and six million for the first six months of fiscal two thousand and twenty The net change in working capital and other assets and liabilities resulted in an increase to Cash provided used by operations of seventytwo million for the first six months of fiscal two thousand and twentyone compared to a decrease of one thousand six hundred million for the first six months of fiscal two thousand and twenty This favorable impact on Cash provided used by operations was primarily the result of a one thousand nine hundred and twentynine million decrease in Inventories driven by our intentional supply and demand management as well as strong digital sales growth Cash provided used by investing activities was an outflow of two thousand eight hundred and seventyseven million for the first six months of fiscal two thousand and twentyone compared to seven hundred and eightyeight million for the first six months of fiscal two thousand and twenty driven by the net change in shortterm investments For the first six months of fiscal two thousand and twentyone the net change in shortterm investments including sales maturities and purchases resulted in a cash outflow of two thousand seven hundred and eightynine million compared to one hundred and fiftyseven million for the first six months of fiscal two thousand and twenty Cash provided used by financing activities was an outflow of two hundred and ninetytwo million for the first six months of fiscal two thousand and twentyone compared to one thousand eight hundred and sixtyeight million for the first six months of fiscal two thousand and twenty with the decrease from the prior period driven by our election to temporarily suspend share repurchases resulting in no share repurchases for the first six months of fiscal two thousand and twentyone compared to one thousand nine hundred and twentyone million in the first six months of fiscal two thousand and twenty fortytwo Table of Contents As of November thirty two thousand and twenty we had repurchased four hundred and fiftytwo million shares at a cost of approximately forty billion an average price of eight thousand nine hundred per share under the fouryear fifteen billion share repurchase program approved by the Board of Directors in June two thousand and eighteen To enhance our liquidity position in response to COVID19 during the fourth quarter of fiscal two thousand and twenty we elected to temporarily suspend share repurchases under our existing share repurchase program As such there were no share repurchases made during the quarter ended November thirty two thousand and twenty The existing program remains authorized by the Board of Directors and we may resume share repurchases in the future at any time depending upon market conditions our capital needs and other factors We continue to expect funding of share repurchases will come from operating cash flows excess cash andor proceeds from debt CAPITAL RESOURCES On July twentythree two thousand and nineteen we filed a shelf registration statement the Shelf with the US Securities and Exchange Commission SEC which permits us to issue an unlimited amount of debt securities from time to time The Shelf expires on July twentythree two thousand and twentytwo Our committed credit facilities remain unchanged from the information previously reported on Form 10K for the fiscal year ended May thirtyone two thousand and twenty As of November thirty two thousand and twenty and May thirtyone two thousand and twenty no amounts were outstanding under our committed credit facilities We currently have longterm debt ratings of AA and A1 from Standard and Poors Corporation and Moodys Investor Services respectively Any changes to these ratings could result in interest rate and facility fee changes As of November thirty two thousand and twenty we were in full compliance of the covenants under our committed credit facilities and believe it is unlikely we will fail to meet any of the covenants in the foreseeable future Liquidity is also provided by our four billion commercial paper program During the three months ended November thirty two thousand and twenty the maximum amount of commercial paper borrowings outstanding at any point was one hundred and twelve million As of November thirty two thousand and twenty and May thirtyone two thousand and twenty the Company had twentythree million and two hundred and fortyeight million of borrowings outstanding at a weighted average interest rate of one hundred and seventysix and one hundred and sixtyfive respectively We may continue to issue commercial paper or other debt securities depending on general corporate needs We currently have shortterm debt ratings of A1 and P1 from Standard and Poors Corporation and Moodys Investor Services respectively To date in fiscal two thousand and twentyone we have not experienced difficulty accessing the credit markets however future volatility in the capital markets may increase costs associated with issuing commercial paper or other debt instruments or affect our ability to access those markets As of November thirty two thousand and twenty we had cash cash equivalents and shortterm investments totaling one hundred and eighteen billion primarily consisting of commercial paper corporate notes deposits held at major banks money market funds US government sponsored enterprise obligations US Treasury obligations and other investment grade fixedincome securities Our fixedincome investments are exposed to both credit and interest rate risk All of our investments are investment grade to minimize our credit risk While individual securities have varying durations as of November thirty two thousand and twenty the weightedaverage days to maturity of our cash equivalents and shortterm investments portfolio was thirtythree days We believe that existing cash cash equivalents shortterm investments and cash generated by operations together with access to external sources of funds as described above will be sufficient to meet our domestic and foreign capital needs in the foreseeable future We utilize a variety of tax planning and financing strategies to manage our worldwide cash and deploy funds to locations where they are needed We indefinitely reinvest a significant portion of our foreign earnings and our current plans do not demonstrate a need to repatriate these earnings Should we require additional capital in the United States we may determine to repatriate indefinitely reinvested foreign funds or raise capital in the United States through debt Given our existing structure if we were to repatriate indefinitely reinvested foreign earnings we would be required to accrue and pay withholding taxes in certain foreign jurisdictions OFFBALANCE SHEET ARRANGEMENTS As of November thirty two thousand and twenty we did not have any offbalance sheet arrangements that have or are reasonably likely to have a material current or future effect on our financial condition results of operations liquidity capital expenditures or capital resources CONTRACTUAL OBLIGATIONS There have been no significant changes to the contractual obligations reported in our Annual Report on Form 10K for the fiscal year ended May thirtyone two thousand and twenty NEW ACCOUNTING PRONOUNCEMENTS There have been no material changes in recently issued or adopted accounting standards from those disclosed in our Annual Report on Form 10K for the fiscal year ended May thirtyone two thousand and twenty fortythree Table of Contents CRITICAL ACCOUNTING POLICIES Our discussion and analysis of our financial condition and results of operations are based upon our Unaudited Condensed Consolidated Financial Statements which have been prepared in accordance with accounting principles generally accepted in the United States of America The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets liabilities revenues and expenses and related disclosure of contingent assets and liabilities We believe that the estimates assumptions and judgments involved in the accounting policies described in the Managements Discussion and Analysis of Financial Condition and Results of Operations section of our most recent Annual Report on Form 10K have the greatest potential impact on our financial statements so we consider these to be our critical accounting policies Actual results could differ from the estimates we use in applying our critical accounting policies We are not currently aware of any reasonably likely events or circumstances that would result in materially different amounts being reported fortyfour Table of Contents ITEM three QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK There have been no material changes from the information previously reported under Part II Item 7A of our Annual Report on Form 10K for the fiscal year ended May thirtyone two thousand and twenty ITEM four CONTROLS AND PROCEDURES We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our Securities Exchange Act of one thousand nine hundred and thirtyfour as amended the Exchange Act reports is recorded processed summarized and reported within the time periods specified in the Securities and Exchange Commissions rules and forms and that such information is accumulated and communicated to our management including our Chief Executive Officer and Chief Financial Officer as appropriate to allow for timely decisions regarding required disclosure In designing and evaluating the disclosure controls and procedures management recognizes that any controls and procedures no matter how well designed and operated can provide only reasonable assurance of achieving the desired control objectives and management is required to apply its judgment in evaluating the costbenefit relationship of possible controls and procedures We carry out a variety of ongoing procedures under the supervision and with the participation of our management including our Chief Executive Officer and Chief Financial Officer to evaluate the effectiveness of the design and operation of our disclosure controls and procedures Based on the foregoing our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of November thirty two thousand and twenty We are continuing several transformation initiatives to centralize and simplify our business processes and systems These are longterm initiatives which we believe will enhance our internal control over financial reporting due to increased automation and further integration of related processes We will continue to monitor our internal control over financial reporting for effectiveness throughout these transformation initiatives There have not been any changes in our internal control over financial reporting during our most recent fiscal quarter that have materially affected or are reasonably likely to materially affect our internal control over financial reporting fortyfive Table of Contents SPECIAL NOTE REGARDING FORWARDLOOKING STATEMENTS AND ANALYST REPORTS Certain written and oral statements other than purely historic information including estimates projections statements relating to NIKEs business plans objectives and expected operating results and the assumptions upon which those statements are based made or incorporated by reference from time to time by NIKE or its representatives in this report other reports filings with the SEC press releases conferences or otherwise are forwardlooking statements within the meaning of the Private Securities Litigation Reform Act of one thousand nine hundred and ninetyfive and Section 21E of the Securities Exchange Act of one thousand nine hundred and thirtyfour as amended Forwardlooking statements include without limitation any statement that may predict forecast indicate or imply future results performance or achievements and may contain the words believe anticipate expect estimate project will be will continue will likely result or words or phrases of similar meaning Forwardlooking statements involve risks and uncertainties which may cause actual results to differ materially from the forwardlooking statements The risks and uncertainties are detailed from time to time in reports filed by NIKE with the SEC including reports filed on Forms 8K 10Q and 10K and include among others the following health epidemics pandemics and similar outbreaks including the COVID19 pandemic international national and local political civil economic and market conditions the size and growth of the overall athletic footwear apparel and equipment markets intense competition among designers marketers distributors and sellers of athletic footwear apparel and equipment for consumers and endorsers demographic changes changes in consumer preferences popularity of particular designs categories of products and sports seasonal and geographic demand for NIKE products difficulties in anticipating or forecasting changes in consumer preferences consumer demand for NIKE products and the various market factors described above difficulties in implementing operating and maintaining NIKEs increasingly complex information technology systems and controls including without limitation the systems related to demand and supply planning and inventory control interruptions in data and information technology systems consumer data security fluctuations and difficulty in forecasting operating results including without limitation the fact that advance orders may not be indicative of future revenues due to changes in shipment timing the changing mix of orders with shorter lead times and discounts order cancellations and returns the ability of NIKE to sustain manage or forecast its growth and inventories the size timing and mix of purchases of NIKEs products increases in the cost of materials labor and energy used to manufacture products new product development and introduction the ability to secure and protect trademarks patents and other intellectual property product performance and quality customer service adverse publicity including without limitation through social media or in connection with brand damaging events the loss of significant customers or suppliers dependence on distributors and licensees business disruptions increased costs of freight and transportation to meet delivery deadlines increases in borrowing costs due to any decline in NIKEs debt ratings changes in business strategy or development plans general risks associated with doing business outside of the United States including without limitation exchange rate fluctuations inflation import duties tariffs quotas political and economic instability and terrorism the potential impact of new laws regulations or policy including without limitation tariffs importexport trade and immigration regulations or policies changes in government regulations the impact of including business and legal developments relating to climate change and natural disasters litigation regulatory proceedings sanctions or any other claims asserted against NIKE the ability to attract and retain qualified employees and any negative public perception with respect to key personnel or our corporate culture values or purpose the effects of NIKEs decision to invest in or divest of businesses and other factors referenced or incorporated by reference in this report and other reports fortysix Table of Contents PART II OTHER INFORMATION ITEM one LEGAL PROCEEDINGS There have been no material developments with respect to the information previously reported under Part I Item three of our Annual Report on Form 10K for the fiscal year ended May thirtyone two thousand and twenty ITEM 1A RISK FACTORS There have been no material changes in our risk factors from those disclosed in Part I Item 1A of our Annual Report on Form 10K for the fiscal year ended May thirtyone two thousand and twenty fortyseven Table of Contents ITEM two UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS In June two thousand and eighteen the Board of Directors approved a fouryear fifteen billion share repurchase program As of November thirty two thousand and twenty the Company had repurchased four hundred and fiftytwo million shares at an average price of eight thousand nine hundred per share for a total approximate cost of forty billion under this program To enhance our liquidity position in response to COVID19 during the fourth quarter of fiscal two thousand and twenty we elected to temporarily suspend share repurchases under our existing share repurchase program As such there were no share repurchases made during the quarter ended November thirty two thousand and twenty The existing program remains authorized by the Board of Directors and we may resume share repurchases in the future at any time depending upon market conditions our capital needs and other factors fortyeight Table of Contents ITEM six EXHIBITS a EXHIBITS three Exhibits thirtyone Restated Articles of Incorporation as amended incorporated by reference to Exhibit thirtyone to the Companys Quarterly Report on Form 10Q for the fiscal quarter ended November thirty two thousand and fifteen thirtytwo Fifth Restated Bylaws as amended incorporated by reference to Exhibit thirtyone to the Companys Current Report on Form 8K filed June nineteen two thousand and twenty fortyone Restated Articles of Incorporation as amended see Exhibit thirtyone fortytwo Fifth Restated Bylaws as amended see Exhibit thirtytwo one hundred and one NIKE Inc Stock Incentive Plan incorporated by reference to Exhibit one hundred and one to the Companys Current Report on Form 8K filed September eighteen two thousand and twenty three hundred and eleven Rule 13a14a15d14a Certification of Chief Executive Officer three hundred and twelve Rule 13a14a15d14a Certification of Chief Financial Officer three hundred and twentyone Section one thousand three hundred and fifty Certificate of Chief Executive Officer three hundred and twentytwo Section one thousand three hundred and fifty Certificate of Chief Financial Officer 101INS XBRL Instance Document 101SCH XBRL Taxonomy Extension Schema Document 101CAL XBRL Taxonomy Extension Calculation Linkbase Document 101DEF XBRL Taxonomy Extension Definition Document 101LAB XBRL Taxonomy Extension Label Linkbase Document 101PRE XBRL Taxonomy Extension Presentation Linkbase Document one hundred and four Cover Page Interactive Data File formatted in iXBRL Exhibit one hundred and one Furnished herewith fortynine Table of Contents SIGNATURES Pursuant to the requirements of the Securities Exchange Act of one thousand nine hundred and thirtyfour the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized NIKE INC an Oregon Corporation By s MATTHEW FRIEND Matthew Friend Chief Financial Officer and Authorized Officer Date January five two thousand and twentyone fifty bEX311 two nke11302020xexhibit311htm EX311 Document Exhibit three hundred and eleven Certification of Chief Executive Officer Pursuant to Section three hundred and two of the SarbanesOxley Act of two thousand and two I John J Donahoe II certify that one I have reviewed this quarterly report on Form 10Q for the quarter ended November thirty two thousand and twenty of NIKE Inc two Based on my knowledge this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made in light of the circumstances under which such statements were made not misleading with respect to the period covered by this report three Based on my knowledge the financial statements and other financial information included in this report fairly present in all material respects the financial condition results of operations and cash flows of the registrant as of and for the periods presented in this report four The registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures as defined in Exchange Act Rules 13a15e and 15d15e and internal control over financial reporting as defined in Exchange Act Rules 13a15f and 15d15f for the registrant and have a designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the registrant including its consolidated subsidiaries is made known to us by others within those entities particularly during the period in which this report is being prepared b designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles c evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation and d disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter the registrants fourth fiscal quarter in the case of an annual report that has materially affected or is reasonably likely to materially affect the registrants internal control over financial reporting and five The registrants other certifying officer and I have disclosed based on our most recent evaluation of internal control over financial reporting to the registrants auditors and the audit committee of the registrants board of directors or persons performing the equivalent functions a all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record process summarize and report financial information and b any fraud whether or not material that involves management or other employees who have a significant role in the registrants internal control over financial reporting Dated January five two thousand and twentyone s John J Donahoe II John J Donahoe II Chief Executive Officer bEX312 three nke11302020xexhibit312htm EX312 Document Exhibit three hundred and twelve Certification of Chief Financial Officer Pursuant to Section three hundred and two of the SarbanesOxley Act of two thousand and two I Matthew Friend certify that one I have reviewed this quarterly report on Form 10Q for the quarter ended November thirty two thousand and twenty of NIKE Inc two Based on my knowledge this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made in light of the circumstances under which such statements were made not misleading with respect to the period covered by this report three Based on my knowledge the financial statements and other financial information included in this report fairly present in all material respects the financial condition results of operations and cash flows of the registrant as of and for the periods presented in this report four The registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures as defined in Exchange Act Rules 13a15e and 15d15e and internal control over financial reporting as defined in Exchange Act Rules 13a15f and 15d15f for the registrant and have a designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the registrant including its consolidated subsidiaries is made known to us by others within those entities particularly during the period in which this report is being prepared b designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles c evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation and d disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter the registrants fourth fiscal quarter in the case of an annual report that has materially affected or is reasonably likely to materially affect the registrants internal control over financial reporting and five The registrants other certifying officer and I have disclosed based on our most recent evaluation of internal control over financial reporting to the registrants auditors and the audit committee of the registrants board of directors or persons performing the equivalent functions a all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record process summarize and report financial information and b any fraud whether or not material that involves management or other employees who have a significant role in the registrants internal control over financial reporting Dated January five two thousand and twentyone s Matthew Friend Matthew Friend Chief Financial Officer bEX321 four nke11302020xexhibit321htm EX321 Document Exhibit three hundred and twentyone Pursuant to eighteen USC Section one thousand three hundred and fifty as adopted pursuant to Section nine hundred and six of the SarbanesOxley Act of two thousand and two the following certifications are being made to accompany the Registrants quarterly report on Form 10Q for the fiscal quarter ended November thirty two thousand and twenty Certification of Chief Executive Officer Pursuant to eighteen USC Section one thousand three hundred and fifty as adopted pursuant to Section nine hundred and six of the SarbanesOxley Act of two thousand and two the undersigned officer of NIKE Inc the Company hereby certifies to such officers knowledge that i the Quarterly Report on Form 10Q of the Company for the fiscal quarter ended November thirty two thousand and twenty the Report fully complies with the requirements of Section 13a or Section 15d as applicable of the Securities Exchange Act of one thousand nine hundred and thirtyfour as amended and ii the information contained in the Report fairly presents in all material respects the financial condition and results of operations of the Company Dated January five two thousand and twentyone s John J Donahoe II John J Donahoe II Chief Executive Officer bEX322 five nke11302020xexhibit322htm EX322 Document Exhibit three hundred and twentytwo Pursuant to eighteen USC Section one thousand three hundred and fifty as adopted pursuant to Section nine hundred and six of the SarbanesOxley Act of two thousand and two the following certifications are being made to accompany the Registrants quarterly report on Form 10Q for the fiscal quarter ended November thirty two thousand and twenty Certification of Chief Financial Officer Pursuant to eighteen USC Section one thousand three hundred and fifty as adopted pursuant to Section nine hundred and six of the SarbanesOxley Act of two thousand and two the undersigned officer of NIKE Inc the Company hereby certifies to such officers knowledge that i the Quarterly Report on Form 10Q of the Company for the fiscal quarter ended November thirty two thousand and twenty the Report fully complies with the requirements of Section 13a or Section 15d as applicable of the Securities Exchange Act of one thousand nine hundred and thirtyfour as amended and ii the information contained in the Report fairly presents in all material respects the financial condition and results of operations of the Company Dated January five two thousand and twentyone s Matthew Friend Matthew Friend Chief Financial Officer'"
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "import inflect\n",
    "import string\n",
    "import re\n",
    "p = inflect.engine()\n",
    "  \n",
    "# convert number into words\n",
    "def convert_number(text):\n",
    "    # remove punctuation\n",
    "    #def remove_punctuation(text):\n",
    "    translator = str.maketrans(' ', ' ', string.punctuation)\n",
    "    text=text.translate(translator)\n",
    "    # split string into list of words\n",
    "    temp_str = text.split()\n",
    "    # initialise empty list\n",
    "    new_string = []\n",
    "  \n",
    "    for word in temp_str:\n",
    "        # if word is a digit, convert the digit\n",
    "        # to numbers and append into the new_string list\n",
    "        if word.isdigit():\n",
    "            temp = p.number_to_words(word)\n",
    "            new_string.append(temp)\n",
    "  \n",
    "        # append the word as it is\n",
    "        else:\n",
    "            new_string.append(word)\n",
    "  \n",
    "    # join the words of new_string to form a string\n",
    "    temp_str = ' '.join(new_string)\n",
    "    temp_str=temp_str.translate(translator) #removes the added commas applied during word rep of numericals.\n",
    "    return temp_str\n",
    "  \n",
    "input_str = 'There are 1,130 and 4,006 balls in this bag, and 12,456 in the other one.'\n",
    "#input_str1 = sec_data.iloc[3,15]\n",
    "convert_number(sec_data.iloc[3,15])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [],
   "source": [
    "#Can apply this to a list?\n",
    "#creates a column with the normalized text corpus.\n",
    "len_corp = len(sec_data)\n",
    "sec_data['norm_txt'] = [convert_number(sec_data.iloc[i,15]) for i in range(len_corp)]\n",
    "    "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 84,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<class 'pandas.core.frame.DataFrame'>\n",
      "DatetimeIndex: 6215 entries, 2021-01-04 to 2021-06-28\n",
      "Data columns (total 17 columns):\n",
      " #   Column                  Non-Null Count  Dtype         \n",
      "---  ------                  --------------  -----         \n",
      " 0   CompanyCIK              6215 non-null   int64         \n",
      " 1   CompanyName             6215 non-null   object        \n",
      " 2   FileType                6215 non-null   object        \n",
      " 3   FileDate                6215 non-null   datetime64[ns]\n",
      " 4   EdgarTextUrl            6215 non-null   object        \n",
      " 5   EdgarHtmlUrl            6215 non-null   object        \n",
      " 6   AccessionNumber         6215 non-null   object        \n",
      " 7   SecFileName             6215 non-null   object        \n",
      " 8   CompanyTicker           6215 non-null   object        \n",
      " 9   FileDate_ClosingPrice   6215 non-null   float64       \n",
      " 10  FileDate_Plus_20        6215 non-null   datetime64[ns]\n",
      " 11  FileDate_Plus_20_Price  6215 non-null   float64       \n",
      " 12  Pct_Change_20           6215 non-null   float64       \n",
      " 13  FileName                6215 non-null   object        \n",
      " 14  file_text_length        6215 non-null   int64         \n",
      " 15  f_text                  6215 non-null   object        \n",
      " 16  norm_txt                6215 non-null   object        \n",
      "dtypes: datetime64[ns](2), float64(3), int64(2), object(10)\n",
      "memory usage: 1.0+ MB\n"
     ]
    }
   ],
   "source": [
    "sec_data.info()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['b10Q one wba20201130htm 10Q wba20201130 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington DC twenty thousand five hundred and fortynine FORM Mark One QUARTERLY REPORT PURSUANT TO SECTION thirteen OR 15d OF THE SECURITIES EXCHANGE ACT OF one thousand nine hundred and thirtyfour For the Quarterly Period Ended TRANSITION REPORT PURSUANT TO SECTION thirteen OR 15d OF THE SECURITIES EXCHANGE ACT OF one thousand nine hundred and thirtyfour For the Transition Period From to Commission File Number Exact name of registrant as specified in its charter State or Other Jurisdiction of Incorporation or Organization IRS Employer Identification No Address of principal executive offices Zip Code Registrants telephone number including area code Former name former address and former fiscal year if changed since last report Securities registered pursuant to Section 12b of the Act Title of each class Trading Symbols Name of each exchange on which registered Indicate by check mark whether the registrant one has filed all reports required to be filed by Section thirteen or 15d of the Securities Exchange Act of one thousand nine hundred and thirtyfour during the preceding twelve months or for such shorter period that the registrant was required to file such reports and two has been subject to such filing requirements for the past ninety days No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule four hundred and five of Regulation ST two hundred and thirtytwo thousand four hundred and five of this chapter during the preceding twelve months or for such shorter period that the registrant was required to submit such files No Indicate by check mark whether the registrant is a large accelerated filer an accelerated filer a nonaccelerated filer smaller reporting company or an emerging growth company See the definitions of large accelerated filer accelerated filer smaller reporting company and emerging growth company in Rule 12b2 of the Exchange Act Accelerated filer Nonaccelerated filer Smaller reporting company Emerging growth company If an emerging growth company indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13a of the Exchange Act Indicate by check mark whether the registrant is a shell company as defined in Rule 12b2 of the Act Yes No The number of shares outstanding of the registrants Common Stock one par value as of December thirtyone two thousand and twenty was WALGREENS BOOTS ALLIANCE INC FORM 10Q FOR THE THREE MONTHS ENDED NOVEMBER thirty two thousand and twenty TABLE OF CONTENTS PART I FINANCIAL INFORMATION Item one Consolidated Condensed Financial Statements Unaudited a Balance Sheets three b Statements of Equity four c Statements of Earnings five d Statements of Comprehensive Income six e Statements of Cash Flows seven f Notes to Financial Statements eight Item two Managements discussion and analysis of financial condition and results of operations thirtythree a Introduction and Segments thirtythree b Factors Affecting Comparability thirtyfour c Executive Summary thirtyeight d Results of Operations by Segments thirtynine e NonGAAP Measures fortyfive f Liquidity and Capital Resources fortyeight g Cautionary Note Regarding Forwardlooking Statements fiftythree Item three Quantitative and qualitative disclosure about market risk fiftyfive Item four Controls and procedures fiftysix PART II OTHER INFORMATION Item one Legal proceedings fiftyseven Item 1A Risk factors fiftyseven Item two Unregistered sales of equity securities and use of proceeds fiftyseven Item five Other information fiftyeight Item six Exhibits fiftyeight two Part I Financial Information Item one Consolidated Condensed Financial Statements Unaudited WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES CONSOLIDATED CONDENSED BALANCE SHEETS UNAUDITED in millions except shares and per share amounts November thirty two thousand and twenty August thirtyone two thousand and twenty Assets Current assets Cash and cash equivalents Accounts receivable net Inventories Other current assets Total current assets Noncurrent assets Property plant and equipment net Operating lease rightofuse assets Goodwill Intangible assets net Equity method investments see note five Other noncurrent assets Total noncurrent assets Total assets Liabilities redeemable noncontrolling interest and equity Current liabilities Shortterm debt Trade accounts payable see note sixteen Operating lease obligation Accrued expenses and other liabilities Income taxes Total current liabilities Noncurrent liabilities Longterm debt Operating lease obligation Deferred income taxes Other noncurrent liabilities Total noncurrent liabilities Commitments and contingencies see note ten Total Liabilities Redeemable noncontrolling interest Equity Preferred stock par value authorized million shares issued Common stock par value authorized billion shares issued at November thirty two thousand and twenty and August thirtyone two thousand and twenty Paidin capital Retained earnings Accumulated other comprehensive loss Treasury stock at cost shares at November thirty two thousand and twenty and shares at August thirtyone two thousand and twenty Total Walgreens Boots Alliance Inc shareholders equity Noncontrolling interests Total equity Total liabilities redeemable noncontrolling interest and equity The accompanying notes to Consolidated Condensed Financial Statements are an integral part of these statements WBA Q1 FY2021 Form 10Q three WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES CONSOLIDATED CONDENSED STATEMENTS OF EQUITY UNAUDITED For the three months ended November thirty two thousand and twenty in millions except shares Three months ended November thirty two thousand and twenty Equity attributable to Walgreens Boots Alliance Inc Common stock shares Common stock amount Treasury stock amount Paidin capital Accumulated other comprehensive income loss Retained earnings Noncontrolling interests Total equity August thirtyone two thousand and twenty Net earnings loss Other comprehensive income loss net of tax Dividends declared Treasury stock purchases Employee stock purchase and option plans Stockbased compensation Adoption of new accounting standards Business combination Other November thirty two thousand and twenty Three months ended November thirty two thousand and nineteen Equity attributable to Walgreens Boots Alliance Inc Common stock shares Common stock amount Treasury stock amount Paidin capital Accumulated other comprehensive income loss Retained earnings Noncontrolling interests Total equity August thirtyone two thousand and nineteen Net earnings loss Other comprehensive income loss net of tax Dividends declared Treasury stock purchases Employee stock purchase and option plans Stockbased compensation Adoption of new accounting standards November thirty two thousand and nineteen The accompanying notes to Consolidated Condensed Financial Statements are an integral part of these statements WBA Q1 FY2021 Form 10Q four WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS UNAUDITED in millions except per share amounts Three months ended November thirty two thousand and twenty two thousand and nineteen Sales Cost of sales Gross profit Selling general and administrative expenses Equity earnings loss in AmerisourceBergen Operating income loss Other income expense Earnings loss before interest and income tax provision Interest expense net Earnings loss before income tax provision Income tax provision benefit Post tax earnings loss from other equity method investments Net earnings loss Net earnings loss attributable to noncontrolling interests Net earnings loss attributable to Walgreens Boots Alliance Inc Net earnings loss per common share Basic Diluted Weighted average common shares outstanding Basic Diluted The accompanying notes to Consolidated Condensed Financial Statements are an integral part of these statements WBA Q1 FY2021 Form 10Q five WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME UNAUDITED in millions Three months ended November thirty two thousand and twenty two thousand and nineteen Comprehensive income Net earnings loss Other comprehensive income loss net of tax Pensionpostretirement obligations Unrealized gain loss on cash flow hedges Net investment hedges Share of other comprehensive income loss of equity method investments Currency translation adjustments Total other comprehensive income Total comprehensive income loss Comprehensive income attributable to noncontrolling interests Comprehensive income loss attributable to Walgreens Boots Alliance Inc The accompanying notes to Consolidated Condensed Financial Statements are an integral part of these statements WBA Q1 FY2021 Form 10Q six WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS UNAUDITED in millions Three months ended November thirty two thousand and twenty two thousand and nineteen Cash flows from operating activities Net earnings loss Adjustments to reconcile net earnings loss to net cash provided by operating activities Depreciation and amortization Deferred income taxes Stock compensation expense Equity earnings loss from equity method investments Other Changes in operating assets and liabilities Accounts receivable net Inventories Other current assets Trade accounts payable Accrued expenses and other liabilities Income taxes Other noncurrent assets and liabilities Net cash provided by operating activities Cash flows from investing activities Additions to property plant and equipment Proceeds from saleleaseback transactions Proceeds from sale of other assets Business investment and asset acquisitions net of cash acquired Other Net cash used for investing activities Cash flows from financing activities Net change in shortterm debt with maturities of three months or less Proceeds from debt Payments of debt Stock purchases Proceeds related to employee stock plans Cash dividends paid Other Net cash used for financing activities Effect of exchange rate changes on cash cash equivalents and restricted cash Changes in cash cash equivalents and restricted cash Net increase decrease in cash cash equivalents and restricted cash Cash cash equivalents and restricted cash at beginning of period Cash cash equivalents and restricted cash at end of period The accompanying notes to Consolidated Condensed Financial Statements are an integral part of these statements WBA Q1 FY2021 Form 10Q seven WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS UNAUDITED Note one WBA Q1 FY2021 Form 10Q eight WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS UNAUDITED Note two WBA Q1 FY2021 Form 10Q nine WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS UNAUDITED Note three WBA Q1 FY2021 Form 10Q ten WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS UNAUDITED Note four WBA Q1 FY2021 Form 10Q eleven WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS UNAUDITED WBA Q1 FY2021 Form 10Q twelve WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS UNAUDITED Note five WBA Q1 FY2021 Form 10Q thirteen WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS UNAUDITED Note six WBA Q1 FY2021 Form 10Q fourteen WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS UNAUDITED WBA Q1 FY2021 Form 10Q fifteen WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS UNAUDITED Note seven WBA Q1 FY2021 Form 10Q sixteen WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS UNAUDITED WBA Q1 FY2021 Form 10Q seventeen WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS UNAUDITED WBA Q1 FY2021 Form 10Q eighteen WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS UNAUDITED Note eight WBA Q1 FY2021 Form 10Q nineteen WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS UNAUDITED WBA Q1 FY2021 Form 10Q twenty WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS UNAUDITED Note nine WBA Q1 FY2021 Form 10Q twentyone WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS UNAUDITED Note ten WBA Q1 FY2021 Form 10Q twentytwo WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS UNAUDITED WBA Q1 FY2021 Form 10Q twentythree WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS UNAUDITED Note eleven Note twelve WBA Q1 FY2021 Form 10Q twentyfour WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS UNAUDITED Note thirteen WBA Q1 FY2021 Form 10Q twentyfive WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS UNAUDITED Note fourteen WBA Q1 FY2021 Form 10Q twentysix WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS UNAUDITED WBA Q1 FY2021 Form 10Q twentyseven WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS UNAUDITED Note fifteen Note sixteen WBA Q1 FY2021 Form 10Q twentyeight WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS UNAUDITED Note seventeen WBA Q1 FY2021 Form 10Q twentynine WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS UNAUDITED Note eighteen WBA Q1 FY2021 Form 10Q thirty WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS UNAUDITED WBA Q1 FY2021 Form 10Q thirtyone WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS UNAUDITED Note nineteen WBA Q1 FY2021 Form 10Q thirtytwo WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES MANAGEMENTS DISCUSSION AND ANALYSIS Item two Managements discussion and analysis of financial condition and results of operations The following discussion and analysis of our financial condition and results of operations should be read together with the financial statements and the related notes included elsewhere herein and the Consolidated Condensed Financial Statements accompanying notes and managements discussion and analysis of financial condition and results of operations and other disclosures contained in the Walgreens Boots Alliance Inc Annual Report on Form 10K for the fiscal year ended August thirtyone two thousand and twenty This discussion contains forwardlooking statements that involve risks and uncertainties Our actual results may differ materially from those discussed in forwardlooking statements Factors that might cause a difference include but are not limited to those discussed below under Cautionary note regarding forwardlooking statements and in item 1A risk factors in our Form 10K for the fiscal year ended August thirtyone two thousand and twenty References herein to the Company we us or our refer to Walgreens Boots Alliance Inc and its subsidiaries except as otherwise indicated or the context otherwise requires Certain amounts in the managements discussion and analysis of financial condition and results of operations may not add due to rounding All percentages have been calculated using unrounded amounts for the three months ended November thirty two thousand and twenty and November thirty two thousand and nineteen INTRODUCTION AND SEGMENTS Walgreens Boots Alliance Inc Walgreens Boots Alliance and its subsidiaries are a global leader in retail and wholesale pharmacy Its operations are conducted through three reportable segments sometimes referred to herein as divisions Retail Pharmacy USA Retail Pharmacy International and Pharmaceutical Wholesale See Note fourteen Segment reporting and Note fifteen Sales to the Consolidated Condensed Financial Statements for further information RECENT DEVELOPMENTS Pharmaceutical Wholesale Transaction On January six two thousand and twentyone the Company entered into a Share Purchase Agreement the Share Purchase Agreement with AmerisourceBergen Pursuant to the terms and subject to the conditions set forth in the Share Purchase Agreement AmerisourceBergen will purchase the majority of the Companys Alliance Healthcare business Business for approximately billion comprised of billion in cash subject to certain purchase price adjustments and million shares of AmerisourceBergen common stock the Transaction Alliance Healthcares investment in China and Italy and its operations in Germany are not part of the Transaction The Transaction is subject to the satisfaction of customary closing conditions including receipt of applicable regulatory approvals The Company will account for the Transaction as a business disposition and report the financial results of the Business as discontinued operations beginning in the second quarter of fiscal year two thousand and twentyone In connection with the Transaction the Company and AmerisounceBergen also agreed to a i threeyear extension through two thousand and twentynine of the US pharmaceutical distribution agreement pursuant to which branded and generic pharmaceutical products are sourced from AmerisourceBergen in the US ii a threeyear extension of the agreement that provides AmerisourceBergen the ability to access generics pharmaceutical products through Walgreens Boots Alliance Development GmbH the Companys global sourcing enterprise iii a distribution agreement pursuant to which AmerisourceBergen will supply branded and generic pharmaceutical products to the Companys Boots UK business following the closing of the Transaction and iv explore a series of strategic initiatives designed to create incremental growth and efficiencies in sourcing logistics and distribution See Note nineteen Subsequent events to the Consolidated Condensed Financial Statements for additional information VillageMD investment Subsequent to November thirty two thousand and twenty the Company and VillageMD announced that the Company has accelerated its investment in VillageMD to support the opening of six hundred to seven hundred Village Medical at Walgreens primary care clinics in more than thirty US markets within the next four years with the intent to build hundreds more thereafter In July two thousand and twenty the Company and VillageMD announced an expansion of their partnership and the intent to open five hundred to seven hundred clinics over a fiveyear period supported by the Companys investment in VillageMD over three years of ten billion in equity and convertible debt which included an initial two hundred and fifty million equity investment The Company has now completed the remaining WBA Q1 FY2021 Form 10Q thirtythree WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES MANAGEMENTS DISCUSSION AND ANALYSIS seven hundred and fifty million investment which will allow the Company to increase the minimum number of clinics to six hundred and expand the rollout at a faster pace See Note nineteen Subsequent events to the Consolidated Condensed Financial Statements for additional information FACTORS AFFECTING OUR RESULTS AND COMPARABILITY The Company has been and we expect it to continue to be affected by a number of factors that may cause actual results to differ from our historical results or current expectations These factors include the impact of the coronavirus COVID19 COVID19 pandemic on our operations and financial results the financial performance of our equity method investees including AmerisourceBergen the influence of certain holidays seasonality foreign currency rates changes in vendor payer and customer relationships and terms and associated reimbursement pressure strategic transactions and acquisitions joint ventures and other strategic collaborations changes in laws including US tax law changes changes in trade tariffs including trade relations between the US and China and international relations including the UKs withdrawal from the European Union and its impact on our operations and prospects and those of our customers and counterparties the timing and magnitude of cost reduction initiatives including under our Transformational Cost Management Program as defined below the timing and severity of the cough cold and flu season fluctuations in variable costs the impacts of looting natural disasters war terrorism and other catastrophic events and changes in general economic conditions in the markets in which the Company operates These and other factors can affect the Companys operations and net earnings for any period and may cause such results not to be comparable to the same period in previous years The results presented in this report are not necessarily indicative of future operating results Estimated COVID19 impacts and uncertainties COVID19 has severely impacted and is expected to continue to impact the economies of the US the UK and other countries around the world COVID19 has created significant public health concerns as well as significant volatility uncertainty and economic disruption in every region in which we operate all of which have adversely affected and may continue to adversely affect our industries and our business operations Further financial and credit markets have experienced and may again experience volatility Policies and initiatives designed to reduce the transmission of COVID19 have resulted in among other things temporary closure or reduced hours of operation of certain store locations in US UK and other countries reduced customer traffic and sales in our retail pharmacies and the adoption of workfromhome policies COVID19 continued to affect global economic conditions during the three months ended November thirty two thousand and twenty The Company expects this will continue in the second quarter of fiscal two thousand and twentyone including a weaker cough cold and flu season The situation surrounding COVID19 remains fluid and we are actively managing our response in collaboration with customers government officials team members and business partners and assessing potential impacts to our financial position and operating results as well as developments in our business As COVID19 impacts the economies of the US UK and other countries around the world the Company has put preparedness plans in place at our facilities to maintain continuity of our operations while also taking steps to keep our team members healthy and safe During the three months ended November thirty two thousand and twenty we experienced certain adverse impacts of COVID19 Sales were negatively impacted with the majority of the decline within the Retail Pharmacy International division This reflected a reduction in footfall in Boots UK stores as a second national lockdown was declared in November and social distancing measures remained in place Globally pharmacy volume was impacted by a decline in doctor visits and gross margin was negatively impacted by higher supply chain costs in the UK The Company took measures to keep stores open incurring incremental selling general and administrative expenses including higher employee costs and store expenses related to social distancing and incremental cleaning and COVID19 drivethru testing sites expenses The Company also took certain actions during the three months ended November thirty two thousand and twenty to partly mitigate the impact of COVID19 through cost containment across the Company including temporary store closures and decreasing store hours and reducing rent at some locations However operating income was significantly and adversely impacted during the three months ended November thirty two thousand and twenty as a result of COVID19 In response to COVID19 various domestic and foreign federal state and local governmental legislation regulations orders policies and initiatives have been implemented designed to reduce the transmission of COVID19 as well as to help address economic and market volatility and instability resulting from COVID19 The Company has assessed and will continue to assess the impact of these governmental actions on the Company It has participated in certain of these programs including for example availing itself to certain tax deferrals which were introduced by the CARES Act in the US and certain tax deferral and benefit and employee wage support in the UK and may continue to do so in the future WBA Q1 FY2021 Form 10Q thirtyfour WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES MANAGEMENTS DISCUSSION AND ANALYSIS The Company has also taken a number of proactive actions consistent with regulatory directives such as digital order ahead drivethru with an increased range of products available for drivethru pickup and curbside collection and put in place new delivery options available nationwide in the US To continue to work with customers and manage through the pandemic the Company launched a new COVID19 testing program for businesses in fiscal two thousand and twenty Since the launch of the program the Company has administered more than twentyeight million COVID19 tests across the US The Company has worked with the federal and state government to help administer COVID19 vaccines to residents and staff at more than thirtyfive thousand longterm care facilities in fortynine states The opportunity from the distribution of vaccinations is likely to be partly offset by new COVID19 related lockdowns and restrictions and by increased growth investments As a result of COVID19 a portion of our global workforce including employees and extended workforce rapidly shifted to a work from home environment beginning in March two thousand and twenty and many continue to work remotely While our system of internal controls were not specifically designed and implemented to accommodate for this shift we have evaluated and concluded that these changes to the working environment did not have a material effect on the Companys internal control over financial reporting during the most recent quarter as further described in Item four Controls and procedures below The Company will continue to monitor and assess the COVID19 situation and its internal controls and seek to mitigate any impact on their design and operating effectiveness The Company anticipates additional mandates and directives including revisions thereto from foreign federal state county and city authorities throughout the continuation of the COVID19 pandemic and for some time thereafter The impact of this activity on the US and global economies and consumer customer and health care utilization patterns depends upon the evolving factors and future developments related to COVID19 As a result the financial andor operational impact these COVID19 related governmental actions and inactions will have on our businesses operating results cash flows andor financial condition is uncertain but the impact singularly or collectively could be material and adverse We continue to closely monitor the impact of COVID19 on our business and geographies including how it is impacting our customers team members suppliers vendors business partners and distribution channels However the future impact that COVID19 will have on our financial position and operating results may be affected by numerous uncertainties including the severity of the virus the duration of the outbreak governmental business or other actions impacts on our supply chain the effect on customer demand store closures or changes and our operations The health of our workforce and our ability to meet staffing needs in our stores distribution facilities wholesale operations and other critical functions cannot be predicted but is vital to our operations The impacts of a potential worsening of global economic conditions and continued disruptions to and volatility in the credit and financial markets and consumer spending as well as other unanticipated consequences remain unknown Further additional waves of COVID19 in fiscal two thousand and twentyone or beyond could cause many of the impacts to the Company described herein to return or be exacerbated The circumstances containment and impacts of COVID19 remain fluid due to rising incident rates and associated additional lockdowns The Companys current expectations described above are forwardlooking statements and our actual results may differ Factors that might cause a difference include but are not limited to those discussed below under Cautionary note regarding forwardlooking statements and in Item 1A Risk factors in our Form 10K for the fiscal year ended August thirtyone two thousand and twenty Pharmaceutical wholesale business in Germany On November one two thousand and twenty the Company and McKesson Corporation closed a transaction to form a combined pharmaceutical wholesale business in Germany as part of a strategic alliance The Company owns a controlling equity interest in the combined business which is consolidated by the Company and reported within the Pharmaceutical Wholesale segment in its financial statements The Company accounted for this acquisition as a business combination involving noncash purchase consideration of million consisting of the issuance of an equity interest in the combined business See Note two Acquisitions to the Consolidated Condensed Financial Statements for further information The potential impacts of Brexit As a result of a referendum in June two thousand and sixteen the UK withdrew from the European Union Brexit on January thirtyone two thousand and twenty It began a transition period in which to negotiate a new trading relationship for goods and services that ended on December thirtyone two thousand and twenty On December twentyfour two thousand and twenty the EU and UK agreed to a trade deal with no tariffs nor quotas on products regulatory and customs cooperation mechanisms as well as provisions ensuring a level playing field for open and fair competition Since the referendum there have been periods of significant volatility in the global stock markets and currency exchange rates as well as challenging market conditions in the UK Given the lack of comparable precedent it is unclear what financial trade regulatory and legal implications the agreed Brexit trade deal will have on our business particularly our UK and other European WBA Q1 FY2021 Form 10Q thirtyfive WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES MANAGEMENTS DISCUSSION AND ANALYSIS operations however Brexit and its related effects could have a material adverse impact on the Companys consolidated financial position and results of operations TRANSFORMATIONAL COST MANAGEMENT PROGRAM On December twenty two thousand and eighteen the Company announced a transformational cost management program that is currently expected to deliver in excess of twenty billion of annual cost savings by fiscal two thousand and twentytwo the Transformational Cost Management Program The Transformational Cost Management Program which is multifaceted and includes divisional optimization initiatives global smart spending global smart organization and the transformation of the Companys information technology IT capabilities is designed to help the Company achieve increased cost efficiencies To date the Company has taken actions across all aspects of the Transformational Cost Management Program The actions under the Transformational Cost Management Program focus on all reportable segments and the Companys global functions Divisional optimization within each of the Companys segments includes activities such as optimization of stores including current plans to close approximately two hundred Boots stores in the UK and approximately two hundred and fifty stores in the US The Company currently estimates that the Transformational Cost Management Program will result in cumulative pretax charges to its generally accepted accounting principles in the US GAAP financial results of approximately twentyone billion to twentyfour billion of which eighteen billion to twentyone billion are expected to be recorded as exit and disposal activities The Company estimates that approximately eighty of the cumulative pretax charges will be associated with cash expenditures primarily related to employee severance and business transition costs IT transformation costs and lease and real estate payments The Company currently estimates that it will recognize aggregate pretax charges to its GAAP financial results related to Transformational Cost Management Program as follows Transformational Cost Management Program Activities Range of Charges Lease obligations and other real estate costs one three hundred and fifty to four hundred million Asset impairments two three hundred and fifty to four hundred million Employee severance and business transition costs eight hundred and fifty to nine hundred and fifty million Information technology transformation and other exit costs two hundred and fifty to three hundred million Total cumulative pretax exit and disposal costs eighteen to twentyone billion Other IT transformation costs three hundred to three hundred and fifty million Total estimated pretax costs twentyone to twentyfour billion one Includes impairments relating to operating lease rightofuse and finance lease assets two Primarily related to asset writeoffs from store closures information technology and other asset writeoffs In addition to the impacts discussed above as a result of the actions related to store closures taken under the Transformational Cost Management Program the Company recorded five hundred and eight million of transition adjustments to decrease retained earnings due to the adoption of the new lease accounting standard Topic eight hundred and fortytwo on September one two thousand and nineteen Since the inception of the Transformational Cost Management Program to November thirty two thousand and twenty the Company has recognized aggregate cumulative pretax charges to its financial results in accordance with GAAP of fourteen billion of which twelve billion are recorded as exit and disposal activities See Note three Exit and disposal activities for additional information These charges included two hundred and sixtyfour million related to lease obligations and other real estate costs three hundred and fiftyfour million in asset impairments four hundred and seventyone million in employee severance and business transition costs one hundred and fortysix million of information technology transformation and other exit costs and one hundred and thirtynine million other information technology costs Costs under the Transformational Cost Management Program which were primarily recorded in selling general and administrative expenses for the three months ended November thirty two thousand and twenty and November thirty two thousand and nineteen were as follows in millions WBA Q1 FY2021 Form 10Q thirtysix WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES MANAGEMENTS DISCUSSION AND ANALYSIS Three months ended November thirty two thousand and twenty Retail Pharmacy USA Retail Pharmacy International Pharmaceutical Wholesale Walgreens Boots Alliance Inc Lease obligations and other real estate costs twentytwo twentytwo Asset impairments four four Employee severance and business transition costs twentyone twentyeight two fiftyone Information technology transformation and other exit costs ten six one six Total pretax exit and disposal costs fiftyeight twentytwo four eightythree Other IT transformation costs thirteen six two twentyone Total pretax costs seventy twentyeight six one hundred and four Three months ended November thirty two thousand and nineteen Retail Pharmacy USA Retail Pharmacy International Pharmaceutical Wholesale Walgreens Boots Alliance Inc Lease obligations and other real estate costs one one Asset impairments eight three eleven Employee severance and business transition costs thirtyfour one five forty Information technology transformation and other exit costs seven four one twelve Total pretax exit and disposal costs fortynine nine six sixtyfour Other IT transformation costs seventeen three one twentyone Total pretax costs sixtysix twelve seven eightysix Transformational Cost Management Program charges are recognized as the costs are incurred over time in accordance with GAAP The Company treats charges related to the Transformational Cost Management Program as special items impacting comparability of results in its earnings disclosures The amounts and timing of all estimates are subject to change until finalized The actual amounts and timing may vary materially based on various factors See Cautionary note regarding forwardlooking statements below INVESTMENT IN AMERISOURCEBERGEN As of November thirty two thousand and twenty the Company owned fiftysix million eight hundred and fiftyfour thousand eight hundred and sixtyseven shares of AmerisourceBergen common stock representing approximately twentyeight of its outstanding common stock based on most recent share count publicly reported by AmerisourceBergen and may subject to certain conditions acquire up to an additional eight million three hundred and ninetyeight thousand seven hundred and fiftytwo AmerisourceBergen shares in the open market The Company accounts for its investment in AmerisourceBergen using the equity method of accounting subject to a twomonth reporting lag with the net earnings loss attributable to the investment classified within the operating income loss of the Companys Pharmaceutical Wholesale segment The Company recognized equity losses in AmerisourceBergen of one thousand three hundred and seventythree million during the three months ended November thirty two thousand and twenty These equity losses are primarily due to AmerisourceBergen recognition of fiftysix billion net of tax charges related to its ongoing opioid litigation in its financial statements for the three months period ended September thirty two thousand and twenty The financial performance of AmerisourceBergen will impact the Companys results of operations Additionally a substantial and sustained decline in the price of AmerisourceBergens common stock could trigger an impairment evaluation of our investment These considerations may materially and adversely affect the Companys financial condition and results of operations For more information see Note five Equity method investments to the Consolidated Condensed Financial Statements On January six two thousand and twentyone the Company entered into a Share Purchase Agreement with AmerisourceBergen pursuant to which AmerisourceBergen will purchase the majority of the Companys pharmaceutical wholesale operations among other assets for six thousand two hundred and seventyfive billion in cash subject to customary purchase price adjustments and two million shares of common stock of AmerisourceBergen See Recent Developments above and Note nineteen Subsequent events to the Consolidated Condensed Financial Statements for additional information WBA Q1 FY2021 Form 10Q thirtyseven WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES MANAGEMENTS DISCUSSION AND ANALYSIS EXECUTIVE SUMMARY The following table presents certain key financial statistics in millions except per share amounts Three months ended November thirty two thousand and twenty two thousand and nineteen Sales thirtysix thousand three hundred and seven thirtyfour thousand three hundred and thirtynine Gross profit seven thousand one hundred and thirtynine seven thousand two hundred and sixtythree Selling general and administrative expenses six thousand two hundred and seven six thousand two hundred and sixtytwo Equity earnings loss in AmerisourceBergen one thousand three hundred and seventythree thirteen Operating income loss four hundred and forty one thousand and thirteen Adjusted operating income NonGAAP measure one one thousand three hundred and eighteen one thousand four hundred and sixtythree Earnings loss before interest and income tax provision three hundred and eighty one thousand and fortyeight Net earnings loss attributable to Walgreens Boots Alliance Inc three hundred and eight eight hundred and fortyfive Adjusted net earnings attributable to Walgreens Boots Alliance Inc NonGAAP measure one one thousand and fiftytwo one thousand two hundred and twentytwo Net earnings loss per common share diluted thirtysix ninetyfive Adjusted net earnings per common share diluted NonGAAP measure one one hundred and twentytwo one hundred and thirtyseven Percentage increases decreases Three months ended November thirty two thousand and twenty two thousand and nineteen Sales fiftyseven sixteen Gross profit seventeen fifty Selling general and administrative expenses nine three Operating income loss one thousand four hundred and thirtyfive two hundred and seventysix Adjusted operating income NonGAAP measure one ninetynine one hundred and fiftysix Earnings loss before interest and income tax provision one thousand three hundred and sixtythree two hundred and sixtyfive Net earnings loss attributable to Walgreens Boots Alliance Inc one thousand three hundred and sixtyfour two hundred and fortyeight Adjusted net earnings attributable to Walgreens Boots Alliance Inc NonGAAP measure one one hundred and thirtynine one hundred and eighteen Net earnings loss per common share diluted one thousand three hundred and seventysix one hundred and ninetyeight Adjusted net earnings per common share diluted NonGAAP measure one one hundred and twelve sixty Percent to sales Three months ended November thirty two thousand and twenty two thousand and nineteen Gross margin one hundred and ninetyseven two hundred and eleven Selling general and administrative expenses one hundred and seventyone one hundred and eightytwo one See NonGAAP Measures below for a reconciliation to the most directly comparable financial measure calculated in accordance with GAAP and related disclosures WBA Q1 FY2021 Form 10Q thirtyeight WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES MANAGEMENTS DISCUSSION AND ANALYSIS WALGREENS BOOTS ALLIANCE RESULTS OF OPERATIONS Net earnings loss Net loss attributable to the Company for the three months ended November thirty two thousand and twenty was three hundred and eight million compared to net earnings of eight hundred and fortyfive million for the prior year period Diluted net loss per share was thirtysix compared to diluted net earnings ninetyfive for the prior year quarter The decreases in net earnings and diluted earnings per share are primarily due to the charges reflected in the Companys equity earnings loss in AmerisourceBergen Other income for the three months ended November thirty two thousand and twenty was sixty million compared to income of thirtyfive million for the prior year quarter primarily reflecting equity earnings from other equity investments Interest was a net expense of one hundred and forty million and one hundred and sixtysix million for the three months ended November thirty two thousand and twenty and two thousand and nineteen respectively The effective tax rate for the three months ended November thirty two thousand and twenty was three hundred and eightytwo compared to thirtysix for the prior year quarter The increase in the effective tax rate for the three months ended November thirty two thousand and twenty was primarily due to the discrete tax effect of equity earnings in AmerisourceBergen Adjusted net earnings NonGAAP measure Adjusted net earnings attributable to Walgreens Boots Alliance for the three months ended November thirty two thousand and twenty decreased one hundred and thirtynine to eleven billion a decrease of one hundred and fortythree on a constant currency basis compared with the prior year quarter Adjusted diluted net earnings per share decreased one hundred and twelve to one hundred and twentytwo a decrease of one hundred and sixteen on a constant currency basis compared with the prior year quarter The decreases in adjusted net earnings and adjusted diluted net earnings per share for the three months ended November thirty two thousand and twenty primarily reflect COVID19 impacts across the retail businesses and lower US pharmacy reimbursement partially offset by cost savings from the Transformational Cost Management Program US retail gross margin and US pharmacy procurement savings The decrease in adjusted diluted net earnings per share for the three months ended November thirty two thousand and twenty was partially offset by a lower number of shares outstanding compared with the prior year quarter See NonGAAP Measures below for a reconciliation to the most directly comparable financial measure calculated in accordance with GAAP and related disclosures RESULTS OF OPERATIONS BY SEGMENT Retail Pharmacy USA This division comprises the Companys retail pharmacy business operating in the US FINANCIAL PERFORMANCE in millions except location amounts Three months ended November thirty two thousand and twenty two thousand and nineteen Sales twentyseven thousand one hundred and sixtythree twentysix thousand one hundred and thirtythree Gross profit five thousand six hundred and seventeen five thousand six hundred and ninetyone Selling general and administrative expenses four thousand eight hundred and twentyfive four thousand eight hundred and fortythree Operating income seven hundred and ninetytwo eight hundred and fortyeight Adjusted operating income NonGAAP measure one nine hundred and eightynine one thousand one hundred and fiftyfive Number of prescriptions two two thousand and fortysix two thousand one hundred and thirty 30day equivalent prescriptions twentythree two thousand nine hundred and seventythree two thousand nine hundred and forty Number of locations at period end nine thousand and one nine thousand one hundred and seventyfive WBA Q1 FY2021 Form 10Q thirtynine WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES MANAGEMENTS DISCUSSION AND ANALYSIS Percentage increases decreases Three months ended November thirty two thousand and twenty two thousand and nineteen Sales thirtynine sixteen Gross profit thirteen fiftytwo Selling general and administrative expenses four two Operating income sixtysix two hundred and seventythree Adjusted operating income NonGAAP measure one one hundred and fortyfour one hundred and sixtytwo Comparable sales four thirtyseven sixteen Pharmacy sales fiftynine twentynine Comparable pharmacy sales four fifty twentyfive Retail sales twentytwo twentytwo Comparable retail sales four four five Comparable number of prescription twentyfour twentyfive one Comparable 30day equivalent prescriptions two hundred and thirtyfour twentyseven twentyeight Percent to sales Three months ended November thirty two thousand and twenty two thousand and nineteen Gross margin two hundred and seven two hundred and eighteen Selling general and administrative expenses one hundred and seventyeight one hundred and eightyfive one See NonGAAP Measures below for a reconciliation to the most directly comparable financial measure calculated in accordance with GAAP and related disclosures two Includes immunizations three Includes the adjustment to convert prescriptions greater than eightyfour days to the equivalent of three 30day prescriptions This adjustment reflects the fact that these prescriptions include approximately three times the amount of product days supplied compared to a normal prescription four Comparable sales are defined as sales from stores that have been open for at least twelve consecutive months without closure for seven or more consecutive days including due to looting or store damage and without a major remodel or being subject to a natural disaster in the past twelve months as well as ecommerce sales Ecommerce sales include digitally initiated sales online or through mobile applications Relocated stores are not included as comparable sales for the first twelve months after the relocation Acquired stores are not included as comparable sales for the first twelve months after acquisition or conversion when applicable whichever is later Comparable sales comparable pharmacy sales comparable retail sales comparable number of prescriptions and comparable number of 30day equivalent prescriptions refer to total sales pharmacy sales retail sales number of prescriptions and number of 30day equivalent prescriptions respectively Comparable retail sales for previous periods have been restated to include ecommerce sales The method of calculating comparable sales varies across the retail industry As a result our method of calculating comparable sales may not be the same as other retailers methods Sales for the three months ended November thirty two thousand and twenty and two thousand and nineteen The Retail Pharmacy USA divisions sales for the three months ended November thirty two thousand and twenty increased thirtynine compared with the prior year quarter to two hundred and seventytwo billion Comparable sales increased thirtyseven compared with the prior year quarter Pharmacy sales increased fiftynine for the three months ended November thirty two thousand and twenty compared with the prior year quarter and represented seven hundred and sixtyeight of the divisions sales The increase is primarily due to lower generic utilization and higher volume In the prior year quarter pharmacy sales increased twentynine and represented seven hundred and fiftyfour of the divisions sales Comparable pharmacy sales increased fifty for the three months ended November thirty two thousand and twenty compared to an increase of twentyfive in the prior year quarter The effect of generic drugs which have a lower retail price replacing brand name drugs reduced prescription sales by four in the WBA Q1 FY2021 Form 10Q forty WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES MANAGEMENTS DISCUSSION AND ANALYSIS three months ended November thirty two thousand and twenty compared to a reduction of twentyfive in the prior year quarter The effect of generics mix on division sales caused a reduction of three for the three months ended November thirty two thousand and twenty compared to a reduction of eighteen for the prior year quarter Third party sales where reimbursement is received from managed care organizations governmental agencies employers or private insurers were nine hundred and seventyfive of prescription sales for the three months ended November thirty two thousand and twenty compared to nine hundred and sixtynine in the prior year quarter The total number of prescriptions including immunizations filled for the three months ended November thirty two thousand and twenty was two thousand and fortysix million compared to two thousand one hundred and thirty million in the prior year quarter Prescriptions including immunizations filled adjusted to 30day equivalents were two thousand nine hundred and seventythree million in the three months ended November thirty two thousand and twenty compared to two thousand nine hundred and forty million in the prior year quarter Retail sales decreased twentytwo for the three months ended November thirty two thousand and twenty compared with the prior year quarter and represented two hundred and thirtyone of the divisions sales In the prior year quarter retail sales decreased twentytwo and comprised two hundred and fortysix of the divisions sales Comparable retail sales increased four in the three months ended November thirty two thousand and twenty compared to a decrease of five in the prior year quarter The current period was impacted by a weaker cough cold and flu season and decrease in discretionary categories offset by increase in health and wellness excluding cough cold and flu categories Operating income for the three months ended November thirty two thousand and twenty and two thousand and nineteen Retail Pharmacy USA divisions operating income for the three months ended November thirty two thousand and twenty decreased sixtysix compared with the prior year quarter to seven hundred and ninetytwo million The decrease was primarily due to pharmacy reimbursement pressure and adverse COVID19 impacts partly offset by savings from the Transformational Cost Management Program and acquisitionrelated costs related to Rite Aid stores in the prior year quarter results Gross margin was two hundred and seven for the three months ended November thirty two thousand and twenty compared to two hundred and eighteen in the prior year quarter Gross margin was negatively impacted in the current period by pharmacy margins which were negatively impacted by reimbursement pressure and COVID19 impacts Selling general and administrative expenses as a percentage of sales were one hundred and seventyeight for the three months ended November thirty two thousand and twenty compared to one hundred and eightyfive in the prior year quarter As a percentage of sales expenses were lower in the current period primarily due to savings related to the Transformational Cost Management Program partially offset by COVID19 impacts and higher growth investment Adjusted operating income NonGAAP measure for the three months ended November thirty two thousand and twenty and two thousand and nineteen Retail Pharmacy USA divisions adjusted operating income for the three months ended November thirty two thousand and twenty decreased compared with the prior year quarter one hundred and fortyfour to nine hundred and eightynine million The decrease was primarily due to lower pharmacy margins which were negatively impacted by increased reimbursement pressure and COVID19 impacts See NonGAAP Measures below for a reconciliation to the most directly comparable financial measure calculated in accordance with GAAP and related disclosures Retail Pharmacy International This division comprises the Companys retail pharmacy businesses operating in countries outside the US and in currencies other than the US dollar including the British pound sterling Euro Chilean peso and Mexican peso and therefore the divisions results are impacted by movements in foreign currency exchange rates See Item three Quantitative and qualitative disclosure about market risk foreign currency exchange rate risk for further information on currency risk FINANCIAL PERFORMANCE in millions except location amounts Three months ended November thirty two thousand and twenty two thousand and nineteen Sales two thousand five hundred and seventyfour two thousand seven hundred and fortyfive Gross profit nine hundred and sixtyone one thousand and fiftysix Selling general and administrative expenses nine hundred and twentyeight one thousand and twelve Operating income thirtyfour fortyfour Adjusted operating income NonGAAP measure one eightyfour seventynine Number of locations at period end four thousand three hundred and ninetyfour four thousand five hundred and seventyeight WBA Q1 FY2021 Form 10Q fortyone WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES MANAGEMENTS DISCUSSION AND ANALYSIS Percentage increases decreases Three months ended November thirty two thousand and twenty two thousand and nineteen Sales sixtytwo fiftyfour Gross profit ninety sixtythree Selling general and administrative expenses eightyfour thirtyfive Operating income loss two hundred and twentyseven four hundred and thirtyseven Adjusted operating income loss NonGAAP measure one sixtyfour four hundred and five Comparable sales in constant currency two thirtyone fourteen Pharmacy sales one thirtyseven Comparable pharmacy sales in constant currency two thirtyeight six Retail sales ninetyeight sixtythree Comparable retail sales in constant currency two seventysix twentyfive Percent to sales Three months ended November thirty two thousand and twenty two thousand and nineteen Gross margin three hundred and seventythree three hundred and eightyfive Selling general and administrative expenses three hundred and sixty three hundred and sixtynine one See NonGAAP Measures below for a reconciliation to the most directly comparable financial measure calculated in accordance with GAAP and related disclosures two Comparable sales in constant currency are defined as sales from stores that have been open for at least twelve consecutive months without closure for seven or more consecutive days including due to looting or store damage and without a major remodel or being subject to a natural disaster in the past twelve months as well as ecommerce sales Ecommerce sales include digitally initiated sales online or through mobile applications Relocated stores are not included as comparable stores for the first twelve months after the relocation Acquired stores are not included as comparable sales for the first twelve months after acquisition or conversion when applicable whichever is later Comparable sales in constant currency comparable pharmacy sales in constant currency and comparable retail sales in constant currency refer to total sales pharmacy sales and retail sales respectively Comparable retail sales in constant currency for previous periods have been restated to include ecommerce sales The method of calculating comparable sales in constant currency varies across the retail industry As a result our method of calculating comparable sales in constant currency may not be the same as other retailers methods The Company presents certain information related to current period operating results in constant currency which is a nonGAAP financial measure Comparable sales in constant currency comparable pharmacy sales in constant currency and comparable retail sales in constant currency exclude the effects of fluctuations in foreign currency exchange rates See NonGAAP Measures Sales for the three months ended November thirty two thousand and twenty and two thousand and nineteen Retail Pharmacy International divisions sales for the three months ended November thirty two thousand and twenty decreased compared to the prior year quarter sixtytwo to twentysix billion Sales were positively impacted in the quarter by nineteen percentage points fiftythree million as a result of currency translation Comparable sales in constant currency decreased thirtyone primarily due to lower retail sales in Boots UK including COVID19 impacts Pharmacy sales increased one for the three months ended November thirty two thousand and twenty compared to the prior year quarter and represented three hundred and eightynine of the divisions sales The positive impact of currency translation on pharmacy sales in the quarter was fifteen percentage points Comparable pharmacy sales in constant currency increased thirtyeight from the prior year quarter primarily due to higher National Health Service NHS reimbursement levels in the UK and pharmacy volumes in Mexico This is partially offset by lower UK prescription volume and reduced demand for pharmacy services during the COVID19 pandemic in the UK WBA Q1 FY2021 Form 10Q fortytwo WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES MANAGEMENTS DISCUSSION AND ANALYSIS Retail sales decreased ninetyeight for the three months ended November thirty two thousand and twenty compared to the prior year quarter and represented six hundred and eleven of the divisions sales The positive impact of currency translation on retail sales in the quarter was twentytwo percentage points Comparable retail sales in constant currency decreased seventysix from the prior year quarter reflecting lower retail sales in Boots UK including COVID19 impacts Operating income for the three months ended November thirty two thousand and twenty and two thousand and nineteen Retail Pharmacy International divisions operating income for the three months ended November thirty two thousand and twenty decreased compared to the prior year quarter two hundred and twentyseven to thirtyfour million The decrease reflects increased investment in the Transformational Cost Management Program Excluding the impact of the increased investment in the Transformational Cost Management Program the lower footfall is fully mitigated by decisive cost management actions and strong performance of Bootscom Gross profit decreased ninety from the prior year quarter Gross profit in the quarter was positively impacted by twentythree percentage points twentyfour million as a result of currency translation Excluding the impact of currency translation the decrease was primarily due to lower retail sales in Boots UK and higher fulfillment costs partially offset by favorable timing of NHS reimbursement Selling general and administrative expenses decreased eightyfour from the prior year quarter Expenses in the quarter were negatively impacted by twenty percentage points twentyone million as a result of currency translation Excluding the impact of currency translation the decrease was due to short term cost mitigation and savings from the Transformational Cost Management Program As a percentage of sales selling general and administrative expenses were three hundred and sixty in the three months ended November thirty two thousand and twenty compared to three hundred and sixtynine in the prior year quarter Adjusted operating income NonGAAP measure for the three months ended November thirty two thousand and twenty and two thousand and nineteen Retail Pharmacy International divisions adjusted operating income for the three months ended November thirty two thousand and twenty increased sixtyfour to eightyfour million compared to the prior year quarter Adjusted operating income in the quarter was positively impacted by fiftyeight percentage points five million as a result of currency translation Excluding the impact of currency translation the increase was mainly due to decisive cost management actions and strong performance of Bootscom mitigating the impact of lower footfall See NonGAAP Measures below for a reconciliation to the most directly comparable financial measure calculated in accordance with GAAP and related disclosures Pharmaceutical Wholesale This division includes the Companys pharmaceutical wholesale businesses operating in currencies other than the US dollar including the British pound sterling Euro and Turkish lira and thus the divisions results are impacted by movements in foreign currency exchange rates See Item three Quantitative and qualitative disclosure about market risk foreign currency exchange rate risk for further information on currency risk On January six two thousand and twentyone the Company entered into a Share Purchase Agreement with AmerisourceBergen pursuant to which AmerisourceBergen will purchase the majority of the Companys pharmaceutical wholesale operations among other assets for six thousand two hundred and seventyfive billion in cash subject to customary purchase price adjustments and two million shares of common stock of AmerisourceBergen See Recent Developments above and Note nineteen Subsequent events to the Consolidated Condensed Financial Statements for additional information FINANCIAL PERFORMANCE in millions Three months ended November thirty two thousand and twenty two thousand and nineteen Sales seven thousand one hundred and twentyfive six thousand and seven Gross profit five hundred and sixty five hundred and seventeen Selling general and administrative expenses four hundred and fiftyfive four hundred and seven Equity earnings loss in AmerisourceBergen one thousand three hundred and seventythree thirteen Operating income loss one thousand two hundred and sixtyeight one hundred and twentytwo Adjusted operating income NonGAAP measure one two hundred and fortyfour two hundred and twentynine WBA Q1 FY2021 Form 10Q fortythree WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES MANAGEMENTS DISCUSSION AND ANALYSIS Percentage increases decreases Three months ended November thirty two thousand and twenty two thousand and nineteen Sales one hundred and eightysix fiftytwo Gross profit eightyfive eight Selling general and administrative expenses one hundred and sixteen twentynine Operating income loss eleven thousand four hundred and six two hundred and fifteen Adjusted operating income NonGAAP measure one sixtyseven fortyone Comparable sales in constant currency two eightythree eightythree Percent to sales Three months ended November thirty two thousand and twenty two thousand and nineteen Gross margin seventynine eightysix Selling general and administrative expenses sixtyfour sixtyeight one See NonGAAP Measures below for a reconciliation to the most directly comparable financial measure calculated in accordance with GAAP and related disclosures two Comparable sales in constant currency are defined as sales excluding acquisitions and dispositions The Company presents certain information related to current period operating results in constant currency which is a nonGAAP financial measure Comparable sales in constant currency exclude the effects of fluctuations in foreign currency exchange rates See NonGAAP Measures below Sales for the three months ended November thirty two thousand and twenty and two thousand and nineteen Pharmaceutical Wholesale divisions sales for the three months ended November thirty two thousand and twenty including results of the Companys new combined business in Germany which were consolidated as of November increased one hundred and eightysix compared to the prior year quarter to seventyone billion Sales were positively impacted in the quarter by twentythree percentage points one hundred and thirtyseven million as a result of currency translation Comparable sales in constant currency which exclude the incremental impact of the joint venture increased eightythree compared to the prior year quarter primarily due to growth in emerging markets and COVID19 related sales in France Operating income loss for the three months ended November thirty two thousand and twenty and two thousand and nineteen Pharmaceutical Wholesale divisions operating loss for the three months ended November thirty two thousand and twenty was thirteen billion including fourteen billion loss from the Companys share of equity earnings in AmerisourceBergen This compared with operating income of one hundred and twentytwo million in the prior year quarter including thirteen million from the Companys equity earnings in AmerisourceBergen Operating loss in the quarter was negatively impacted by eighteen percentage points two million as a result of currency translation The operating loss is primarily due to fourteen billion related to the Companys share of equity loss in AmerisourceBergen partially offset by sales growth Gross profit increased eightyfive from the prior year quarter Gross profit in the quarter was positively impacted by twentyfour percentage points twelve million as a result of currency translation Excluding the currency translation impact the increase was primarily due to sales growth partially offset by lower gross margins Selling general and administrative expenses increased one hundred and sixteen from the prior year quarter Expenses in the quarter were negatively impacted by thirtyfive percentage points fourteen million as a result of currency translation Excluding the currency translation impact the increase was due to additional costs due to impact of sales growth and from the companys new joint venture in Germany As a percentage of sales selling general and administrative expenses for the three months ended November thirty two thousand and twenty were sixtyfour compared to sixtyeight in the prior year quarter WBA Q1 FY2021 Form 10Q fortyfour WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES MANAGEMENTS DISCUSSION AND ANALYSIS Adjusted operating income NonGAAP measure for the three months ended November thirty two thousand and twenty and two thousand and nineteen Pharmaceutical Wholesale divisions adjusted operating income for the three months ended November thirty two thousand and twenty which includes one hundred and eight million from the Companys share of adjusted equity earnings in AmerisourceBergen increased sixtyseven compared to the prior year quarter to two hundred and fortyfour million Adjusted operating income in the quarter was negatively impacted by seven percentage points two million as a result of currency translation Excluding the impact of currency translation the increase in adjusted operating income was primarily due to sales growth and a higher contribution of adjusted equity earnings from AmerisourceBergen See NonGAAP Measures below for a reconciliation to the most directly comparable financial measure calculated in accordance with GAAP and related disclosures NONGAAP MEASURES The following information provides reconciliations of the supplemental nonGAAP financial measures as defined under the rules of the SEC presented herein to the most directly comparable financial measures calculated and presented in accordance with GAAP The Company has provided the nonGAAP financial measures which are not calculated or presented in accordance with GAAP as supplemental information and in addition to the financial measures that are calculated and presented in accordance with GAAP These supplemental nonGAAP financial measures are presented because the Companys management has evaluated its financial results both including and excluding the adjusted items or the effects of foreign currency translation as applicable and believes that the supplemental nonGAAP financial measures presented provide additional perspective and insights when analyzing the core operating performance of the Company from period to period and trends in its historical operating results These supplemental nonGAAP financial measures should not be considered superior to as a substitute for or as an alternative to and should be considered in conjunction with the GAAP financial measures presented The Company also presents certain information related to current period operating results in constant currency which is a nonGAAP financial measure These amounts are calculated by translating current period results at the foreign currency exchange rates used in the comparable period in the prior year The Company presents such constant currency financial information because it has significant operations outside of the US reporting in currencies other than the US dollar and such presentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations NONGAAP RECONCILIATION in millions Three months ended November thirty two thousand and twenty Retail Pharmacy USA Retail Pharmacy International Pharmaceutical Wholesale Eliminations Walgreens Boots Alliance Inc Operating income loss GAAP seven hundred and ninetytwo thirtyfour one thousand two hundred and sixtyeight one four hundred and forty Adjustments to equity earnings loss in AmerisourceBergen one thousand four hundred and eightyone one thousand four hundred and eightyone Acquisitionrelated amortization seventysix twenty twenty one hundred and sixteen Transformational cost management seventy twentyeight six one hundred and four LIFO provision thirtythree thirtythree Acquisitionrelated costs seventeen two five twentythree Adjusted operating income NonGAAP measure nine hundred and eightynine eightyfour two hundred and fortyfour one one thousand three hundred and eighteen WBA Q1 FY2021 Form 10Q fortyfive WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES MANAGEMENTS DISCUSSION AND ANALYSIS in millions Three months ended November thirty two thousand and nineteen Retail Pharmacy USA Retail Pharmacy International Pharmaceutical Wholesale Eliminations Walgreens Boots Alliance Inc Operating income GAAP eight hundred and fortyeight fortyfour one hundred and twentytwo one thousand and thirteen Adjustments to equity earnings in AmerisourceBergen eighty eighty Acquisitionrelated amortization seventyseven twentytwo nineteen one hundred and eighteen Transformational cost management sixtysix twelve seven eightysix LIFO provision thirtythree thirtythree Acquisitionrelated costs one hundred and twentytwo one one hundred and twentyfour Store optimization nine nine Adjusted operating income NonGAAP measure one thousand one hundred and fiftyfive seventynine two hundred and twentynine one thousand four hundred and sixtythree Three months ended November thirty two thousand and twenty two thousand and nineteen Net earnings loss attributable to Walgreens Boots Alliance Inc GAAP three hundred and eight eight hundred and fortyfive Adjustments to operating income loss Adjustments to equity earnings loss in AmerisourceBergen one one thousand four hundred and eightyone eighty Acquisitionrelated amortization two one hundred and sixteen one hundred and eighteen Transformational cost management three one hundred and four eightysix LIFO provision four thirtythree thirtythree Acquisitionrelated costs five twentythree one hundred and twentyfour Store optimization three nine Total adjustments to operating income loss one thousand seven hundred and fiftynine four hundred and fortynine Adjustments to other income expense Net investment hedging gain loss six nine eleven Gain on sale of equity method investment seven one Total adjustments to other income expense nine twelve Adjustments to income tax provision US tax law changes eight six Tax impact of adjustments eight sixtyseven eighty Equity method noncash tax eight three hundred and fortysix two Total adjustments to income tax provision four hundred and twelve eightyeight Adjustments to post tax equity earnings from other equity method investments Adjustments to equity earnings in other equity method investments nine thirteen twentyeight Total adjustments to post tax equity earnings from other equity method investments thirteen twentyeight Adjustments to net earnings loss attributable to noncontrolling interests WBA Q1 FY2021 Form 10Q fortysix WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES MANAGEMENTS DISCUSSION AND ANALYSIS Acquisitionrelated amortization two four LIFO provision four three Total adjustments to net earnings loss attributable to noncontrolling interests eight Adjusted net earnings attributable to Walgreens Boots Alliance Inc NonGAAP measure one thousand and fiftytwo one thousand two hundred and twentytwo Diluted net earnings loss per common share GAAP ten thirtysix ninetyfive Adjustments to operating income loss two hundred and three fifty Adjustments to other income expense one one Adjustments to income tax provision fortyeight ten Adjustments to equity earnings in other equity method investments nine one three Adjustments to net earnings loss attributable to noncontrolling interests one Adjusted diluted net earnings per common share NonGAAP measure eleven one hundred and twentytwo one hundred and thirtyseven Weighted average common shares outstanding diluted in millions eleven eight thousand six hundred and fiftythree eight thousand nine hundred and twentysix one Adjustments to equity earnings loss in AmerisourceBergen consist of the Companys proportionate share of nonGAAP adjustments reported by AmerisourceBergen consistent with the Companys nonGAAP measures The Company recognized equity losses in AmerisourceBergen of one thousand three hundred and seventythree million during the three months ended November thirty two thousand and twenty These equity losses are primarily due to AmerisourceBergen recognition of fiftysix billion net of tax charges related to its ongoing opioid litigation in its financial statements for the three months period ended September thirty two thousand and twenty two Acquisitionrelated amortization includes amortization of acquisitionrelated intangible assets and inventory valuation adjustments Amortization of acquisitionrelated intangible assets includes amortization of intangibles assets such as customer relationships trade names trademarks and contract intangibles Intangible asset amortization excluded from the related nonGAAP measure represents the entire amount recorded within the Companys GAAP financial statements the revenue generated by the associated intangible assets has not been excluded from the related nonGAAP measures Amortization expense unlike the related revenue is not affected by operations of any particular period unless an intangible asset becomes impaired or the estimated useful life of an intangible asset is revised These charges are primarily recorded within selling general and administrative expenses Business combination accounting principles require us to measure acquired inventory at fair value The fair value of the inventory reflects cost of acquired inventory and a portion of the expected profit margin The acquisitionrelated inventory valuation adjustments excludes the expected profit margin component from cost of sales recorded under the business combination accounting principles three Transformational Cost Management Program and Store Optimization Program charges are costs associated with a formal restructuring plan These charges are primarily recorded within selling general and administrative expenses These costs do not reflect current operating performance and are impacted by the timing of restructuring activity four The Companys Retail Pharmacy USA segment inventory is accounted for using the lastinfirstout LIFO method This adjustment represents the impact on cost of sales as if Retail Pharmacy USA segment inventory is accounted for using firstin firstout FIFO method The LIFO provision is affected by changes in inventory quantities product mix and manufacturer pricing practices which may be impacted by market and other external influences Therefore the Company cannot control the amounts recognized or timing of these items five Acquisitionrelated costs are transaction and integration costs associated with certain merger and acquisition related activities These costs include all charges incurred on certain mergers and acquisition related activities for example including costs related to integration efforts for successful merger and acquisition activities These charges are primarily recorded within selling general and administrative expenses These costs are significantly impacted by the timing and complexity of the underlying merger and acquisition related activities and do not reflect the Companys current operating performance six Gain or loss on certain derivative instruments used as economic hedges of the Companys net investments in foreign subsidiaries These charges are recorded within other income expense We do not believe this volatility related to marktomarket adjustment on the underlying derivative instruments reflects the Companys operational performance seven Includes significant gain on sale of equity method investment and related adjustments WBA Q1 FY2021 Form 10Q fortyseven WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES MANAGEMENTS DISCUSSION AND ANALYSIS eight Adjustments to income tax provision include adjustments to the GAAP basis tax provision commensurate with nonGAAP adjustments and certain discrete tax items including US tax law changes a UK tax rate change and equity method noncash tax These charges are recorded within income tax provision benefit nine Adjustments to post tax equity earnings from other equity method investments consist of the proportionate share of certain equity method investees noncash items or unusual or infrequent items consistent with the Companys nonGAAP adjustments These charges are recorded within post tax earnings loss from other equity method investments Although the Company may have shareholder rights and board representation commensurate with its ownership interests in these equity method investees adjustments relating to equity method investments are not intended to imply that the Company has direct control over their operations and resulting revenue and expenses Moreover these nonGAAP financial measures have limitations in that they do not reflect all revenue and expenses of these equity method investees ten Due to the antidilutive effect resulting from the reported net loss the impact of potentially dilutive securities on the per share amounts has been omitted from the quarterly calculation of weightedaverage common shares outstanding for diluted earnings per share for the three months ended November thirty two thousand and twenty eleven Includes impact of potentially dilutive securities in the quarterly calculation of weightedaverage common shares diluted for adjusted diluted net earnings per common share calculation purposes for the three months ended November thirty two thousand and twenty The Company considers certain metrics presented in this report such as comparable sales comparable pharmacy sales comparable retail sales comparable number of prescriptions and comparable 30day equivalent prescriptions to be key performance indicators because the Companys management has evaluated its results of operations using these metrics and believes that these key performance indicators presented provide additional perspective and insights when analyzing the core operating performance of the Company from period to period and trends in its historical operating results These key performance indicators should not be considered superior to as a substitute for or as an alternative to and should be considered in conjunction with the GAAP financial measures presented herein These measures which are described in more detail in this report may not be comparable to similarlytitled performance indicators used by other companies LIQUIDITY AND CAPITAL RESOURCES Cash and cash equivalents were eleven billion including four billion in nonUS jurisdictions as of November thirty two thousand and twenty compared to eight billion including three billion in nonUS jurisdictions as of November thirty two thousand and nineteen Shortterm investment objectives are primarily to minimize risk and maintain liquidity To attain these objectives investment limits are placed on the amount type and issuer of securities Investments are principally in US Treasury money market funds The Companys longterm capital policy is to maintain a strong balance sheet and financial flexibility reinvest in its core strategies invest in strategic opportunities that reinforce its core strategies and meet return requirements and return surplus cash flow to stockholders in the form of dividends and share repurchases over the long term In June two thousand and eighteen the Companys Board of Directors reviewed and refined the Companys dividend policy to set forth the Companys current intention to increase its dividend each year Cash provided by operations and the incurrence of debt are the principal sources of funds for expansion investments acquisitions remodeling programs dividends to stockholders and stock repurchases Net cash provided by operating activities for the three months ended November thirty two thousand and twenty was twelve billion compared to eleven billion for the prior year quarter The one billion increase in cash provided by operating activities reflects higher cash inflows from trade accounts payable income taxes and noncurrent assets and liabilities partially offset by higher cash outflows from accrued expenses and other liabilities accounts receivables and inventories Changes in accrued expenses and other liabilities are mainly driven by a noncomparable two thousand and twentyone bonus payment Changes in trade accounts payables income taxes and other noncurrent assets and liabilities are mainly driven by timing of collections and payments Net cash used for investing activities was two hundred and fiftynine million for the three months ended November thirty two thousand and twenty compared to four hundred and two million for the prior year quarter This change in net cash used for investing activities includes two hundred and thirtyone million in proceeds from saleleaseback transactions for the three months ended November thirty two thousand and twenty compared to one hundred and fortyseven million for the prior year quarter Business investment and asset acquisitions were seventyseven million for the three months ended November thirty two thousand and twenty compared to one hundred and eighty million for the prior year quarter WBA Q1 FY2021 Form 10Q fortyeight WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES MANAGEMENTS DISCUSSION AND ANALYSIS For the three months ended November thirty two thousand and twenty additions to property plant and equipment were four hundred and thirtyone million compared to three hundred and eightyseven million in the prior year quarter Capital expenditures by reporting segment were as follows in millions Three months ended November thirty two thousand and twenty two thousand and nineteen Retail Pharmacy USA three hundred and fiftythree three hundred and three Retail Pharmacy International fiftyeight seventy Pharmaceutical Wholesale twentyone thirteen Total four hundred and thirtyone three hundred and eightyseven Significant capital expenditures primarily relate to growth initiatives and information technology projects Net cash used for financing activities for the three months ended November thirty two thousand and twenty was three hundred and fiftytwo million compared to eight hundred and sixtysix million in the prior year period In the three months ended November thirty two thousand and twenty there were thirtythree billion in net debt proceeds primarily from revolving credit facilities described below and commercial paper debt compared to fortyseven billion in net proceeds in the prior year period For the three months ended November thirty two thousand and twenty there were thirtytwo billion in payments of debt made primarily for revolving credit facilities and commercial paper debt compared to fortyseven billion for the three months ended November thirty two thousand and nineteen The Company repurchased shares totaling one hundred and ten million to support the needs of its employee stock plans for the three months ended November thirty two thousand and twenty compared to four hundred and seventythree million in the prior year quarter which also included stock repurchase program described below Proceeds related to employee stock plans were four million during the three months ended November thirty two thousand and twenty compared to fourteen million during the three months ended November thirty two thousand and nineteen Cash dividends paid were four hundred and five million during the three months ended November thirty two thousand and twenty compared to four hundred and ten million for the prior year quarter The Company expects to fund its working capital needs capital expenditures pending acquisitions dividend payments and debt service obligations from liquidity sources including cash flow from operations availability under existing credit facilities commercial paper programs working capital financing arrangements and current cash and investment balances The Company believes that these sources and the ability to obtain other financing will provide adequate cash funds for the Companys foreseeable working capital needs capital expenditures pending acquisitions dividend payments and debt service obligations for at least the next twelve months The Companys cash requirements are subject to change as business conditions warrant and opportunities arise The timing and size of any new business ventures or acquisitions that the Company may complete may also impact its cash requirements Additionally the Companys cash requirements and its ability to generate cash flow have been and may continue to be adversely affected by COVID19 and the resulting market volatility and instability For further information regarding the impact of COVID19 on the Company including on its liquidity and capital resources please see Item 1A Risk factors in the Companys Annual Report on Form 10K for the fiscal year ended August thirtyone two thousand and twenty See Item three Qualitative and quantitative disclosures about market risk below for a discussion of certain financing and market risks Stock repurchase program In June two thousand and eighteen the Companys Board of Directors approved a stock repurchase program the June two thousand and eighteen stock repurchase program which authorized the repurchase of up to one hundred billion of the Companys common stock of which the Company had repurchased eighty billion as of November thirty two thousand and twenty The June two thousand and eighteen stock repurchase program has no specified expiration date In July two thousand and twenty the Company announced that it was suspending activities under this program The Company may continue to repurchase stock to offset anticipated dilution from equity incentive plans The Company determines the timing and amount of repurchases including repurchases to offset anticipated dilution from equity incentive plans based on its assessment of various factors including prevailing market conditions alternate uses of capital liquidity and the economic environment The Company has repurchased and may from time to time in the future repurchase shares on the open market through Rule 10b51 plans which enable the Company to repurchase shares at times when we otherwise might be precluded from doing so under federal securities laws Commercial paper The Company periodically borrows under its commercial paper program and may borrow under it in future periods The Company had average daily US commercial paper outstanding of sixteen billion and twentynine billion at a weighted average interest rate of sixtythree and two hundred and fiftyfive for the three months ended November thirty two thousand and twenty and two thousand and nineteen respectively A subsidiary of the Company WBA Q1 FY2021 Form 10Q fortynine WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES MANAGEMENTS DISCUSSION AND ANALYSIS had average daily commercial paper outstanding which was issued under the Joint HM Treasury and Bank of Englands COVID Corporate Financing Facility commercial paper program of three hundred million or approximately four hundred and one million at a weighted average interest rate of fortythree for the three months ended November thirty two thousand and twenty The subsidiarys repayment obligations are guaranteed by the Company Financing actions On August twentynine two thousand and eighteen the Company entered into a revolving credit agreement the August two thousand and eighteen Revolving Credit Agreement with the lenders and letter of credit issuers from time to time party thereto The August two thousand and eighteen Revolving Credit Agreement is an unsecured revolving credit facility with aggregate commitment in the amount of thirtyfive billion with a letter of credit subfacility commitment amount of five hundred million The facility termination date is the earlier of a August twentynine two thousand and twentythree subject to extension thereof pursuant to the August two thousand and eighteen Revolving Credit Agreement and b the date of termination in whole of the aggregate amount of the revolving commitments pursuant to the August two thousand and eighteen Revolving Credit Agreement Borrowings under the August two thousand and eighteen Revolving Credit Agreement will bear interest at a fluctuating rate per annum equal to at the Companys option the alternate base rate or the Eurocurrency rate in each case plus an applicable margin calculated based on the Companys credit ratings As of November thirty two thousand and twenty there were no borrowings outstanding under the August two thousand and eighteen Revolving Credit Agreement On November thirty two thousand and eighteen the Company entered into a ten billion credit agreement consisting of a five hundred million senior unsecured revolving credit facility and a five hundred million senior unsecured term loan facility with the lenders from time to time party thereto on March twentyfive two thousand and nineteen the Company entered into an amendment to such credit agreement such credit agreement as so amended the November two thousand and eighteen Credit Agreement reflecting certain changes to the borrowing notice provisions thereto On April two two thousand and twenty the Company entered into a second amendment to the November two thousand and eighteen Credit Agreement such credit agreement as so further amended the Amended November two thousand and eighteen Credit Agreement which amendment became effective as of May twentynine two thousand and twenty As of May twentynine two thousand and twenty the five hundred million revolving credit facility portion of the November two thousand and eighteen Credit Agreement was converted into a term loan facility such that the Amended November two thousand and eighteen Credit Agreement consists of a ten billion senior unsecured term loan facility The facility termination date is the earlier of a May twentynine two thousand and twentyone and b the date of acceleration of all loans under the Amended November two thousand and eighteen Credit Agreement pursuant to its terms Borrowings under the Amended November two thousand and eighteen Credit Agreement will bear interest at a fluctuating rate per annum equal to at the Companys option the alternate base rate or the Eurocurrency rate plus an applicable margin of one hundred and twentyfive in the case of Eurocurrency rate loans and one hundred and twentyfive in the case of alternative base rate loans As of November thirty two thousand and twenty there were nine billion of borrowings outstanding under the Amended November two thousand and eighteen Credit Agreement On December five two thousand and eighteen the Company entered into a ten billion term loan credit agreement with the lenders from time to time party thereto and on August nine two thousand and nineteen the Company entered into an amendment to such credit agreement such credit agreement as so amended the December two thousand and eighteen Credit Agreement to permit the Company to borrow repay and reborrow amounts borrowed thereunder prior to the maturity date On April two two thousand and twenty the Company amended and restated the December two thousand and eighteen Credit Agreement such credit agreement as so amended and restated the AR December two thousand and eighteen Credit Agreement The A R December two thousand and eighteen Credit Agreement governs a twenty billion senior unsecured revolving credit facility consisting of the initial ten billion senior unsecured revolving facility the Initial Commitments previously governed by the December two thousand and eighteen Credit Agreement and a new ten billion senior unsecured revolving credit facility the New Commitments The facility termination date is the earlier of a January twentynine two thousand and twentyone the Initial Maturity Date which date shall be extended to February twentysix two thousand and twentyone or July thirtyone two thousand and twentyone pursuant to the terms of the A R December two thousand and eighteen Credit Agreement if the Company extends the maturity date of certain of its existing credit agreements or enters into new bank or bond financings with a certain maturity date and above an aggregate principal amount as described in the A R December two thousand and eighteen Credit Agreement and b the date of termination in whole of the aggregate amount of the commitments pursuant to the A R December two thousand and eighteen Credit Agreement Borrowings under the AR December two thousand and eighteen Credit Agreement will bear interest at a fluctuating rate per annum equal to at the Companys option the alternate base rate or the Eurocurrency rate plus an applicable margin of i in the case of the Initial Facility from April two two thousand and twenty through and including the Initial Maturity Date seventyfive in the case of Eurocurrency rate loans and zero in the case of alternate base rate loans and ii in the case of the New Facility and the Initial Facility after the Initial Maturity Date one hundred and fifty in the case of Eurocurrency rate loans and fifty in the case of alternate base rate loans As of November thirty two thousand and twenty there were seven billion borrowings outstanding under the AR December two thousand and eighteen Credit Agreement Concurrently with the execution of the two thousand and twenty Revolving Credit Agreement described above the AR December two thousand and eighteen Credit Agreement was partially terminated in accordance with its terms and conditions by the cancellation of one billion of New Commitments thereby reducing the amount available to one billion of Initial Commitments thereunder as of December twentythree two thousand and twenty The AR was also amended to set the final maturity date under the agreement at January twentynine two thousand and twentyone On January eighteen two thousand and nineteen the Company entered into a twenty billion 364day revolving credit agreement as extended the January two thousand and nineteen 364Day Revolving Credit Agreement with the lenders from time to time party thereto The January two thousand and nineteen 364Day WBA Q1 FY2021 Form 10Q fifty WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES MANAGEMENTS DISCUSSION AND ANALYSIS Revolving Credit Agreement is a senior unsecured 364day revolving credit facility with an original facility termination date of three hundred and sixtyfour days following January thirtyone two thousand and nineteen subject to extension On December eighteen two thousand and nineteen the Company entered into an Extension Agreement the Extension Agreement relating to the January two thousand and nineteen 364Day Revolving Credit Agreement with the lenders party thereto and Mizuho as administrative agent The Extension Agreement extended the Maturity Date as defined in the January two thousand and nineteen 364Day Revolving Credit Agreement for an additional period of three hundred and sixtyfour days to January twentyeight two thousand and twentyone Such extension became effective on January thirty 2020Borrowings under the January two thousand and nineteen 364Day Revolving Credit Agreement will bear interest at a fluctuating rate per annum equal to at the Companys option the alternate base rate or the Eurocurrency rate in each case plus an applicable margin calculated based on the Companys credit ratings As of November thirty two thousand and twenty there were no borrowings outstanding under the January 364Day Revolving Credit Agreement The January two thousand and nineteen 364Day Revolving Credit Agreement was partially terminated in accordance with its terms and conditions reducing the amount available to five billion as of December twentythree two thousand and twenty concurrently with the execution of the two thousand and twenty Revolving Credit Agreement described below On August thirty two thousand and nineteen the Company entered into three five hundred million revolving credit agreements together the August two thousand and nineteen Revolving Credit Agreements and each individually an August two thousand and nineteen Revolving Credit Agreement with the lenders from time to time party thereto Each of the August two thousand and nineteen Revolving Credit Agreements are senior unsecured revolving credit facilities with facility termination dates of the earlier of a eighteen months following August thirty two thousand and nineteen subject to extension thereof pursuant to the applicable August two thousand and nineteen Revolving Credit Agreement and b the date of termination in whole of the aggregate amount of the commitments pursuant to the applicable August two thousand and nineteen Revolving Credit Agreement Borrowings under each of the August two thousand and nineteen Revolving Credit Agreements will bear interest at a fluctuating rate per annum equal to at the Companys option the alternate base rate or the Eurocurrency rate plus an applicable margin of ninetyfive in the case of Eurocurrency rate loans As of November thirty two thousand and twenty there were no borrowings outstanding under the August two thousand and nineteen Revolving Credit Agreements The August two thousand and nineteen Revolving Credit Agreements were terminated in accordance with their terms and conditions as of December twentythree two thousand and twenty The August two thousand and nineteen Revolving Credit Agreements were terminated concurrently with the execution of the two thousand and twenty Revolving Credit Agreement described below The Company entered into a seven hundred and fifty million revolving credit agreement on April one two thousand and twenty the April two thousand and twenty Revolving Bilateral Credit Agreement and a one thousand three hundred and twentyfive billion revolving credit agreement on April two two thousand and twenty the April two thousand and twenty Revolving Club Credit Agreement and together with the April two thousand and twenty Revolving Bilateral Credit Agreement the Other April two thousand and twenty Revolving Credit Agreements with the lenders from time to time party thereto Each of the Other April two thousand and twenty Revolving Credit Agreements is a senior unsecured revolving credit facility with a facility termination date of the earlier of a March thirtyone two thousand and twentyone which date shall be shortened pursuant to the terms of the applicable Other April two thousand and twenty Revolving Credit Agreement if the Company does not extend the maturity date of certain of its existing credit agreements or enter into new bank or bond financings with a certain maturity date and above an aggregate principal amount as described in the applicable Other April two thousand and twenty Revolving Credit Agreement and b the date of termination in whole of the aggregate amount of the commitments pursuant to the applicable Other April two thousand and twenty Revolving Credit Agreement Borrowings under the Other April two thousand and twenty Revolving Credit Agreements will bear interest at a fluctuating rate per annum equal to at the Companys option the Eurocurrency rate or the alternate base rate plus an applicable margin of one hundred and twentyfive in the case of Eurocurrency rate loans As of November thirty two thousand and twenty there were no borrowings outstanding under the Other April two thousand and twenty Revolving Credit Agreements The other April two thousand and twenty Revolving Credit Agreements were terminated in accordance with their terms and conditions as of December twentythree two thousand and twenty The other April two thousand and twenty Revolving Credit Agreements were terminated concurrently with the execution of the two thousand and twenty Revolving Credit Agreement described below On April seven two thousand and twenty the Company and with WBA Financial Services Limited a private limited company incorporated under the laws of England and Wales WBAFSL as coborrowers entered into a five hundred million revolving credit agreement the April seven two thousand and twenty Revolving Credit Agreement with the lenders from time to time party thereto The April seven two thousand and twenty Revolving Credit Agreement is a senior unsecured revolving credit facility with a facility termination date of the earlier of a 364days from April seven two thousand and twenty and b the date of termination in whole of the aggregate amount of the commitments pursuant to the April seven two thousand and twenty Revolving Credit Agreement The Company and WBAFSL are coborrowers under the April seven two thousand and twenty Revolving Credit Agreement Pursuant to the terms of the April seven two thousand and twenty Revolving Credit Agreement the Company provides a guarantee of any obligations of WBAFSL under the April seven two thousand and twenty Revolving Credit Agreement Borrowings under the April seven two thousand and twenty Revolving Credit Agreement will bear interest at a fluctuating rate per annum equal to at the Companys option the Eurocurrency rate or the alternate base rate plus an applicable margin of one hundred and fifty in the case of Eurocurrency rate loans As of November thirty two thousand and twenty there were no borrowings outstanding under the April seven two thousand and twenty Revolving Credit Agreement The April seven two thousand and twenty Revolving Credit Agreement was terminated in accordance with its terms and conditions on December twentythree two thousand and twenty The April seven two thousand and twenty Revolving Credit Agreement was terminated concurrently with the execution of the two thousand and twenty Revolving Credit Agreement described below WBA Q1 FY2021 Form 10Q fiftyone WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES MANAGEMENTS DISCUSSION AND ANALYSIS On April fifteen two thousand and twenty the Company issued in an underwritten public offering five billion of three hundred and twenty notes due two thousand and thirty and ten billion of four hundred and ten notes due two thousand and fifty Total issuance costs relating to the notes including underwriting discounts and estimated offering expenses were one hundred and thirtythree million On October twenty two thousand and twenty the Company redeemed in full the four hundred million aggregate principal amount outstanding of its two thousand eight hundred and seventyfive notes due two thousand and twenty issued by the Company on November twenty two thousand and fourteen On December twentythree two thousand and twenty the Company entered into a revolving credit agreement the two thousand and twenty Revolving Credit Agreement with the lenders from time to time party thereto The two thousand and twenty Revolving Credit Agreement includes a i a one hundred and twentyfive billion senior unsecured 364day revolving credit facility the 364Day Facility and ii a two hundred and twentyfive billion senior unsecured 18month revolving credit facility with a swing line subfacility commitment amount of three hundred and fifty million The 364Day Facilitys termination date is the earlier of i three hundred and sixtyfour days from December twentythree two thousand and twenty the effective date subject to the extension thereof pursuant to the two thousand and twenty Revolving Credit Agreement and ii the date of termination in whole of the aggregate amount of the revolving commitments under the 364Day Facility pursuant to the two thousand and twenty Revolving Credit Agreement The 18Month Facilitys termination date is the earlier of i eighteen months from the effective date subject to the extension thereof pursuant to the two thousand and twenty Revolving Credit Agreement and ii the date of termination in whole of the aggregate amount of the revolving commitments under the 18Month Facility pursuant to the two thousand and twenty Revolving Credit Agreement After the entry into the two thousand and twenty Revolving Credit Agreement and the full or partial termination of the Companys other credit agreements as discussed herein as of December twentythree two thousand and twenty the Company had an aggregate borrowing capacity of ninetyfive billion including funds already drawn Debt covenants Each of the Companys credit facilities described above contain a covenant to maintain as of the last day of each fiscal quarter a ratio of consolidated debt to total capitalization not to exceed sixty thousand one hundred subject to increase in certain circumstances set forth in the applicable credit agreement As of November thirty two thousand and twenty the Company was in compliance with all such applicable covenants Credit ratings As of January six two thousand and twentyone the credit ratings of Walgreens Boots Alliance were Rating agency Longterm debt rating Commercial paper rating Outlook Fitch BBB F3 Negative Moodys Baa2 P2 Negative Standard Poors BBB A2 Negative In assessing the Companys credit strength each rating agency considers various factors including the Companys business model capital structure financial policies and financial performance There can be no assurance that any particular rating will be assigned or maintained The Companys credit ratings impact its borrowing costs access to capital markets and operating lease costs The rating agency ratings are not recommendations to buy sell or hold the Companys debt securities or commercial paper Each rating may be subject to revision or withdrawal at any time by the assigning rating agency and should be evaluated independently of any other rating AmerisourceBergen relationship As of November thirty two thousand and twenty the Company owned fiftysix million eight hundred and fiftyfour thousand eight hundred and sixtyseven AmerisourceBergen common shares representing approximately twentyeight of the outstanding common stock based on most recent share count publicly reported by AmerisourceBergen and had designated one member of AmerisourceBergens board of directors As of November thirty two thousand and twenty the Company can acquire up to an additional eight million three hundred and ninetyeight thousand seven hundred and fiftytwo AmerisourceBergen shares in the open market and thereafter designate another member of AmerisourceBergens board of directors subject in each case to applicable legal and contractual requirements The amount of permitted open market purchases is subject to increase or decrease in certain circumstances Subject to applicable legal and contractual requirements share purchases may be made from time to time in open market transactions or pursuant to instruments and plans complying with Rule 10b51 See Note five Equity method investments to the Consolidated Condensed Financial Statements for further information WBA Q1 FY2021 Form 10Q fiftytwo WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES MANAGEMENTS DISCUSSION AND ANALYSIS On January six two thousand and twentyone the Company entered into a Share Purchase Agreement with AmerisourceBergen pursuant to which AmerisourceBergen will purchase the majority of the Companys pharmaceutical wholesale operations among other assets for six thousand two hundred and seventyfive billion in cash subject to customary purchase price adjustments and two million shares of common stock of AmerisourceBergen See Recent Developments above and Note nineteen Subsequent events to the Consolidated Condensed Financial Statements for additional information OFFBALANCE SHEET ARRANGEMENTS The Company does not have any unconsolidated special purpose entities and except as described herein the Company does not have significant exposure to any offbalance sheet arrangements The term offbalance sheet arrangement generally means any transaction agreement or other contractual arrangement to which an entity not consolidated by the Company is a party under which we have i any obligation arising under a guarantee contract derivative instrument or variable interest or ii a retained or contingent interest in assets transferred to such entity or similar arrangement that serves as credit liquidity or market risk support for such assets At November thirty two thousand and twenty the Company had seventeen million of guarantees outstanding and no amounts issued under letters of credit CONTRACTUAL OBLIGATIONS AND COMMITMENTS There have been no material changes outside of the ordinary course of business in the Companys outstanding contractual obligations disclosed in the Companys Annual Report on Form 10K for the year ended August thirtyone two thousand and twenty CRITICAL ACCOUNTING POLICIES The Consolidated Condensed Financial Statements are prepared in accordance with GAAP and include amounts based on managements prudent judgments and estimates Actual results may differ from these estimates Management believes that any reasonable deviation from those judgments and estimates would not have a material impact on our consolidated financial position or results of operations To the extent that the estimates used differ from actual results however adjustments to the statement of earnings and corresponding balance sheet accounts would be necessary These adjustments would be made in future periods For a discussion of our significant accounting policies please see the Companys Annual Report on Form 10K for the fiscal year ended August thirtyone two thousand and twenty Some of the more significant estimates include business combinations leases goodwill and indefinitelived intangible asset impairment cost of sales and inventory equity method investments pension and postretirement benefits and income taxes See Note seventeen New accounting pronouncements to the Consolidated Condensed Financial Statements for additional information NEW ACCOUNTING PRONOUNCEMENTS A discussion of new accounting pronouncements is described in Note seventeen New accounting pronouncements to the Consolidated Condensed Financial Statements of this Quarterly Report on Form 10Q and is incorporated herein by reference CAUTIONARY NOTE REGARDING FORWARDLOOKING STATEMENTS This report and other documents that we file or furnish with the SEC contain forwardlooking statements that are based on current expectations estimates forecasts and projections about our future performance our business our beliefs and our managements assumptions In addition we or others on our behalf may make forwardlooking statements in press releases or written statements on the Companys website or in our communications and discussions with investors and analysts in the normal course of business through meetings webcasts phone calls conference calls and other communications Some of such forwardlooking statements may be based on certain data and forecasts relating to our business and industry that we have obtained from internal surveys market research publicly available information and industry publications Industry publications surveys and market research generally state that the information they provide has been obtained from sources believed to be reliable but that the accuracy and completeness of such information is not guaranteed Statements that are not historical facts are forwardlooking statements including without limitation those regarding estimates of and goals for future financial and operating performance as well as forwardlooking statements concerning the potential impacts on our business of the spread and impact of COVID19 the expected execution and effect of our business strategies our costsavings and growth initiatives pilot programs strategic partnerships and initiatives and restructuring activities and the amounts and timing of their expected impact and delivery of estimated cost savings the withdrawal of the UK from the European Union and its possible effects our amended and restated asset purchase agreement with Rite Aid and the transactions contemplated thereby and their possible timing and effects our commercial agreement with AmerisourceBergen the arrangements and transactions contemplated by our framework agreement with AmerisourceBergen and their possible effects the closing of the sale of certain pharmaceutical wholesale operations to AmerisourceBergen pursuant to the Share Purchase Agreement dated January six two thousand and twentyone estimates of the impact of developments on our earnings earnings per share and other financial and operating metrics cough cold and flu season prescription volume pharmacy sales trends prescription margins and reimbursement rates changes in generic WBA Q1 FY2021 Form 10Q fiftythree WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES MANAGEMENTS DISCUSSION AND ANALYSIS prescription drug prices retail margins number and location of new store openings network participation vendor payer and customer relationships and terms possible new contracts or contract extensions competition economic and business conditions outcomes of litigation and regulatory matters the level of capital expenditures industry trends demographic trends growth strategies financial results cost reduction initiatives impairment or other charges acquisition and joint venture synergies competitive strengths and changes in legislation or regulations All statements in the future tense and all statements accompanied by words such as expect likely outlook forecast preliminary pilot would could should can will project intend plan goal guidance target aim continue sustain synergy transform accelerate model longterm on track on schedule headwind tailwind believe seek estimate anticipate upcoming to come may possible assume and variations of such words and similar expressions are intended to identify such forwardlooking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of one thousand nine hundred and ninetyfive These forwardlooking statements are not guarantees of future performance and are subject to risks uncertainties and assumptions known or unknown that could cause actual results to vary materially from those indicated or anticipated including but not limited to those relating to the impact of private and public thirdparty payers efforts to reduce prescription drug reimbursements risks relating to the spread and impact of COVID19 including the adverse impact on the global economy as well as our business the risks associated with the withdrawal of the UK from the European Union fluctuations in foreign currency exchange rates the timing and magnitude of the impact of branded to generic drug conversions and changes in generic drug prices our ability to realize synergies and achieve financial tax and operating results in the amounts and at the times anticipated the inherent risks challenges and uncertainties associated with forecasting financial results of large complex organizations in rapidly evolving industries particularly over longer time periods and during periods with increased volatility and uncertainties supply arrangements including our commercial agreement with AmerisourceBergen the arrangements and transactions contemplated by our framework agreement with AmerisourceBergen and their possible effects the risks associated with our equity method investment in AmerisourceBergen circumstances that could give rise to the termination crosstermination or modification of any of our contractual obligations the amount of costs fees expenses and charges incurred in connection with strategic transactions whether the costs and charges associated with restructuring initiatives including the Transformational Cost Management Program and Store Optimization Program will exceed estimates our ability to realize expected savings and benefits from costsavings initiatives including the Transformational Cost Management Program and Store Optimization Program restructuring activities and acquisitions and joint ventures in the amounts and at the times anticipated the timing and amount of any impairment or other charges the timing and severity of cough cold and flu season risks relating to looting and vandalism in regions in which we operate and the scope and magnitude of any property damage inventory loss or other adverse impacts risks related to pilot programs and new business initiatives and ventures generally including the risks that anticipated benefits may not be realized changes in managements plans and assumptions the risks associated with governance and control matters the ability to retain key personnel changes in economic and business conditions generally or in particular markets in which we participate changes in financial markets credit ratings and interest rates the risks relating to the terms timing and magnitude of any share repurchase activity the risks associated with international business operations including international trade policies tariffs including tariff negotiations between the US and China and relations the risks associated with cybersecurity or privacy breaches related to customer information changes in vendor customer and payer relationships and terms including changes in network participation and reimbursement terms and the associated impacts on volume and operating results risks related to competition including changes in market dynamics participants product and service offerings retail formats and competitive positioning risks associated with new business areas and activities risks associated with acquisitions divestitures joint ventures and strategic investments including those relating to the asset acquisition from Rite Aid the risks associated with the integration of complex businesses the impact of regulatory restrictions and outcomes of legal and regulatory matters and risks associated with changes in laws including those related to the December two thousand and seventeen US tax law changes regulations or interpretations thereof These and other risks assumptions and uncertainties are described in Item 1A Risk factors in the Walgreens Boots Alliance Annual Report on Form 10K for the fiscal year ended August thirtyone two thousand and twenty and in other documents that we file or furnish with the SEC Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect actual results may vary materially from those indicated or anticipated by such forwardlooking statements All forwardlooking statements we make or that are made on our behalf are qualified by these cautionary statements Accordingly you are cautioned not to place undue reliance on these forwardlooking statements which speak only as of the date they are made Except to the extent required by law we do not undertake and expressly disclaim any duty or obligation to update publicly any forwardlooking statement after the date of this report whether as a result of new information future events changes in assumptions or otherwise WBA Q1 FY2021 Form 10Q fiftyfour WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES ITEM three QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Item three Quantitative and qualitative disclosure about market risk Interest rate risk The Company is exposed to interest rate volatility with regard to existing variablerate debt instruments and future incurrences of fixed or variablerate debt which exposure primarily relates to movements in various interest rates such as US treasury rates and commercial paper rates From time to time the Company uses interest rate swaps and forwardstarting interest rate swaps to hedge its exposure to the impact of interest rate changes on existing debt and future debt issuances respectively to reduce the volatility of financing costs and based on current and projected market conditions achieve a desired proportion of fixedrate versus floatingrate debt Generally under these swaps the Company agrees with a counterparty to exchange the difference between fixedrate and floatingrate interest amounts based on an agreed upon notional principal amount The Chief Executive of the UK Financial Conduct Authority the FCA which regulates the London Interbank Offered Rate or LIBOR has announced that the FCA will no longer compel LIBOR panel banks to submit rates for the calculation of LIBOR after two thousand and twentyone That announcement indicates that the continuation of LIBOR on the current basis will not be guaranteed after two thousand and twentyone Moreover it is possible that LIBOR may be discontinued prior to the end of two thousand and twentyone Certain of our credit facilities provide that under certain circumstances set forth in such credit facilities we and the administrative agent may amend the applicable credit facility to replace LIBOR with an alternate benchmark rate giving due consideration to any evolving or then existing convention for similar syndicated credit facilities in the US market for alternative benchmarks Such alternative benchmark rate could include the secured overnight financing rate also known as SOFR published by the Federal Reserve Bank of New York Information regarding the Companys transactions are set forth in Note eight Financial instruments to the Consolidated Condensed Financial Statements These financial instruments are sensitive to changes in interest rates On November thirty two thousand and twenty the Company had no material longterm debt obligations that had floating interest rates The amounts exclude the impact of any associated derivative contracts Foreign currency exchange rate risk The Company is exposed to fluctuations in foreign currency exchange rates primarily with respect to the British pound sterling and Euro and certain other foreign currencies which may affect its net investment in foreign subsidiaries and may cause fluctuations in cash flows related to foreign denominated transactions The Company is also exposed to the translation of foreign currency earnings to the US dollar The Company enters into foreign currency forward contracts to hedge against the effect of exchange rate fluctuations on nonfunctional currency cash flows These transactions are almost exclusively less than twelve months in maturity In addition the Company enters into foreign currency forward contracts that are not designated in hedging relationships to offset in part the impacts of certain intercompany activities primarily associated with intercompany financing transactions The Companys foreign currency derivative instruments are sensitive to changes in exchange rates A hypothetical one change in foreign currency exchange rates versus the US dollar would change the fair value of the foreign currency derivatives held as of November thirty two thousand and twenty by approximately thirtytwo million The foreign currency derivatives are intended to partially hedge anticipated transactions foreign currency trade payables and receivables and net investments in foreign subsidiaries Equity price risk Changes in AmerisourceBergen common stock price may have a significant impact on the fair value of the equity investment in AmerisourceBergen described in Note five Equity method investments to the Consolidated Condensed Financial Statements See Investment in AmerisourceBergen above WBA Q1 FY2021 Form 10Q fiftyfive WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES ITEM four CONTROLS AND PROCEDURES Item four Controls and procedures Evaluation of disclosure controls and procedures Management conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Form 10Q The controls evaluation was conducted under the supervision and with the participation of the Companys management including its Chief Executive Officer CEO and Chief Financial Officer CFO As of the end of the period covered by this report the Company had completed the creation of a combined pharmaceutical wholesale business in Germany with McKesson Corporation The Company accounted for this acquisition as a business combination The scope of managements assessment of the effectiveness of the Companys disclosure controls and procedures did not include the internal controls over financial reporting of the acquired business This exclusion is in accordance with the SEC staffs general guidance that an assessment of a recently acquired business may be omitted from the scope of managements assessment for one year following the acquisition The recognition of goodwill and intangible assets however is covered by our internal controls over mergers and acquisitions which were included in managements assessment of the effectiveness of the Companys internal control over financial reporting as of November thirty two thousand and twenty Based upon the controls evaluation our CEO and CFO have concluded that as of the end of the period covered by this report our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded processed summarized and reported within the time periods specified by the SEC and that such information is accumulated and communicated to management including the CEO and CFO as appropriate to allow timely decisions regarding required disclosure Changes in internal control over financial reporting In the ordinary course of business the Company reviews its internal control over financial reporting and makes changes to its systems and processes that are intended to enhance such controls and increase efficiency while maintaining an effective internal control environment Changes may include such activities as updating existing systems automating manual processes standardizing controls and modifying monitoring controls As a result of COVID19 a portion of our global workforce including employees and extended workforce rapidly shifted to a work from home environment beginning in March two thousand and twenty and many continue to work remotely While our controls were not developed and designed to facilitate or accommodate this shift we have evaluated and concluded that these changes to the working environment did not have a material effect on the Companys internal control over financial reporting during the most recent quarter As we transform our business processes we continue to make strategic changes in how we perform certain key business functions These changes include the continued leveraging of extended workforces via thirdparty outsource arrangements as well as our continued implementation of new information systems Specifically the Company is currently implementing a new enterprise resource planning ERP system This project is a multiyear initiative and is intended to improve the efficiency and effectiveness of certain financial and business transaction processes as well as the underlying systems environment These initiatives are not being implemented in response to any identified internal control deficiency or weakness As these changes occur we will evaluate quarterly whether such changes materially affect or are reasonably likely to materially affect the Companys internal control over financial reporting In connection with the evaluation pursuant to Exchange Act Rule 13a15d of the Companys internal control over financial reporting as defined in Exchange Act Rule 13a15f by the Companys management including its CEO and CFO no changes during the quarter ended November thirty two thousand and twenty were identified that have materially affected or are reasonably likely to materially affect the Companys internal control over financial reporting Inherent limitations on effectiveness of controls Our management including the CEO and CFO do not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud A control system no matter how well designed and operated can provide only reasonable not absolute assurance that the control systems objectives will be met The design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs Further because of the inherent limitations in all control systems no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud if any within the Company have been detected These inherent limitations include the realities that judgments in decisionmaking can be faulty and that breakdowns can occur because of simple error or mistake Controls can also be circumvented by the individual acts of some persons by collusion of two or more people or by management override of the controls The design of any system of controls is based in part on certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions Projections of any evaluation of controls WBA Q1 FY2021 Form 10Q fiftysix WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES ITEM four CONTROLS AND PROCEDURES effectiveness to future periods are subject to risks Over time controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures Part II Other Information Item one Legal proceedings The information in response to this item is incorporated herein by reference to Note ten Commitments and contingencies to the Consolidated Condensed Financial Statements of this Quarterly Report Item one hundred and three of SEC Regulation SK requires disclosure of environmental legal proceedings with or any such legal proceedings known to be contemplated by a governmental authority if management reasonably believes that the proceedings involve potential monetary sanctions exclusive of interest and costs above the lesser of ten million or one of the Companys current assets As previously disclosed the Company has been under investigation by certain counties within the State of California for alleged noncompliance with state hazardous waste regulations The Company has worked with state and local officials in an effort to resolve this matter On November sixteen two thousand and twenty a number of California District Attorneys submitted a complaint and a signed settlement agreement to a California state court in Alameda County People of the State of California v Walgreen Co Case No RG20081172 for review and approval If approved by the court the settlement which includes certain injunctive relief would require the Company to pay penalties and costs and fund supplemental environmental projects in the total amount of thirtyfive million The court approved the settlement Item 1A Risk factors In addition to the other information set forth in this report you should carefully consider the factors discussed in item 1A Risk factors in the Walgreens Boots Alliance Annual Report on Form 10K for the year ended August thirtyone two thousand and twenty which could materially affect our business financial condition or future results Item two Unregistered sales of equity securities and use of proceeds The following table provides information about purchases by the Company during the quarter ended November thirty two thousand and twenty of equity securities that are registered by the Company pursuant to Section twelve of the Exchange Act Subject to applicable law share purchases may be made from time to time in open market transactions privately negotiated transactions including accelerated share repurchase agreements or pursuant to instruments and plans complying with Rule 10b51 Issuer purchases of equity securities Period Total number of shares purchased by month Average price paid per share Total number of shares purchased by month as part of publicly announced repurchase programs one Approximate dollar value of shares that may yet be purchased under the plans or program one ninety thousand one hundred and twenty ninetythree thousand and twenty two billion three million four hundred and nineteen thousand nine hundred and sixty one hundred thousand one hundred and twenty one hundred and three thousand one hundred and twenty one million four hundred and twenty thousand three thousand seven hundred and three two billion three million four hundred and nineteen thousand nine hundred and sixty one hundred and ten thousand one hundred and twenty one hundred and thirteen thousand and twenty one million five hundred and eighty thousand three thousand six hundred and fortysix two billion three million four hundred and nineteen thousand nine hundred and sixty three million three thousand six hundred and seventythree two billion three million four hundred and nineteen thousand nine hundred and sixty one In June two thousand and eighteen Walgreens Boots Alliance authorized a stock repurchase program which authorized the repurchase of up to one hundred billion of Walgreens Boots Alliance common stock This program has no specified expiration date In July two thousand and twenty the Company announced that it had suspended activities under this program WBA Q1 FY2021 Form 10Q fiftyseven WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES PART II OTHER INFORMATION Item five Other information None Item six Exhibits The agreements included as exhibits to this report are included to provide information regarding their terms and not intended to provide any other factual or disclosure information about the Company or the other parties to the agreements The agreements may contain representations and warranties by each of the parties to the applicable agreement that were made solely for the benefit of the other parties to the applicable agreement and should not in all instances be treated as categorical statements of fact but rather as a way of allocating the risk to one of the parties if those statements prove to be inaccurate may have been qualified by disclosures that were made to the other party in connection with the negotiation of the applicable agreement which disclosures are not necessarily reflected in the agreement may apply standards of materiality in a way that is different from what may be viewed as material to you or other investors and were made only as of the date of the applicable agreement or such other date or dates as may be specified in the agreement and are subject to more recent developments Accordingly these representations and warranties may not describe the actual state of affairs as of the date they were made or at any other time Exhibit No Description SEC Document Reference thirtyone Amended and Restated Certificate of Incorporation of Walgreens Boots Alliance Inc Incorporated by reference to Exhibit thirtyone to Walgreens Boots Alliance Incs Current Report on Form 8K12B File No one hundred and thirtysix thousand seven hundred and fiftynine filed with the SEC on December thirtyone two thousand and fourteen thirtytwo Amended and Restated Bylaws of Walgreens Boots Alliance Inc Incorporated by reference to Exhibit thirtyone to Walgreens Boots Alliance Incs Current Report on Form 8K File No one hundred and thirtysix thousand seven hundred and fiftynine filed with the SEC on June ten two thousand and sixteen ten one Form of Performance Share Award agreement effective October two thousand and twenty Incorporated by reference to Exhibit one hundred and one to Walgreens Boots Alliance Incs Current Report on Form 8K File No one hundred and thirtysix thousand seven hundred and fiftynine filed with the SEC on October thirty two thousand and twenty one hundred and two Form of Stock Option Award agreement effective October two thousand and twenty Incorporated by reference to Exhibit one hundred and two to Walgreens Boots Alliance Incs Current Report on Form 8K File No one hundred and thirtysix thousand seven hundred and fiftynine filed with the SEC on October thirty two thousand and twenty one hundred and three Form of Stock Option Award agreement under UK Subplan effective October two thousand and twenty Incorporated by reference to Exhibit one hundred and three to Walgreens Boots Alliance Incs Current Report on Form 8K File No one hundred and thirtysix thousand seven hundred and fiftynine filed with the SEC on October thirty two thousand and twenty one hundred and four Form of Restricted Stock Unit Award agreement effective October two thousand and twenty Incorporated by reference to Exhibit one hundred and four to Walgreens Boots Alliance Incs Current Report on Form 8K File No one hundred and thirtysix thousand seven hundred and fiftynine filed with the SEC on October thirty two thousand and twenty one hundred and five Form of Restricted Stock Unit Award agreement for Executive Chairman effective October two thousand and twenty Incorporated by reference to Exhibit one hundred and five to Walgreens Boots Alliance Incs Current Report on Form 8K File No one hundred and thirtysix thousand seven hundred and fiftynine filed with the SEC on October thirty two thousand and twenty fiftyeight WALGREENS BOOTS ALLIANCE INC AND SUBSIDIARIES PART II OTHER INFORMATION one hundred and six Revolving Credit Agreement dated as of December twentythree two thousand and twenty by and among Walgreens Boots Alliance Inc the Designated Borrowers from time to time party thereto the Lenders from time to time party thereto and Wells Fargo Bank National Association as Administrative Agent and Swing Line Lender Incorporated by reference to Exhibit one hundred and one to Walgreens Boots Alliance Incs Current Report on Form 8K File No one hundred and thirtysix thousand seven hundred and fiftynine filed with the SEC on December twentyeight two thousand and twenty one hundred and seven Amendment No one to Amended and Restated Revolving Credit Agreement dated as of December twentythree two thousand and twenty by and among Walgreens Boots Alliance Inc and Wells Fargo Bank National Association as administrative agent and as sole lender amending that certain Amended and Restated Revolving Credit Agreement dated as of April two two thousand and twenty by and among Walgreens Boots Alliance Inc and Wells Fargo Bank National Association as administrative agent and as sole lender File herewith three hundred and eleven Certification of the Chief Executive Officer pursuant to Section three hundred and two of the SarbanesOxley Act of two thousand and two Filed herewith three hundred and twelve Certification of the Chief Financial Officer pursuant to Section three hundred and two of the SarbanesOxley Act of two thousand and two Filed herewith three hundred and twentyone Certification of the Chief Executive Officer pursuant to Section nine hundred and six of the SarbanesOxley Act of two thousand and two eighteen USC Section one thousand three hundred and fifty Furnished herewith three hundred and twentytwo Certification of the Chief Financial Officer pursuant to Section nine hundred and six of the SarbanesOxley Act of two thousand and two eighteen USC Section one thousand three hundred and fifty Furnished herewith 101INS Inline XBRL Instance Document The following financial information from this Quarterly Report on Form 10Q for the quarter ended November thirty two thousand and twenty formatted in Inline XBRL Extensive Business Reporting Language includes i the Consolidated Condensed Balance Sheets ii the Consolidated Condensed Statements of Equity iii the Consolidated Condensed Statement of Earnings iv the Consolidated Condensed Statements of Comprehensive Income v the Consolidated Condensed Statements of Cash Flows and vi Notes Financial Statements Filed herewith 101SCH Inline XBRL Taxonomy Extension Schema Document Filed herewith 101CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document Filed herewith 101DEF Inline XBRL Taxonomy Extension Definition Linkbase Document Filed herewith 101LAB Inline XBRL Taxonomy Extension Label Linkbase Document Filed herewith 101PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document Filed herewith one hundred and four Cover Page Interactive Data File formatted as Inline XBRL document and included in Exhibit one hundred and one Filed herewith Management contract or compensatory plan or arrangement WBA Q1 FY2021 Form 10Q fiftynine SIGNATURES Pursuant to the requirements of the Securities Exchange Act of one thousand nine hundred and thirtyfour the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized Walgreens Boots Alliance Inc Registrant Dated January seven two thousand and twentyone s James Kehoe James Kehoe Executive Vice President and Global Chief Financial Officer Principal Financial Officer Dated January seven two thousand and twentyone s Heather Dixon Heather Dixon Senior Vice President Global Controller and Chief Accounting Officer Principal Accounting Officer WBA Q1 FY2021 Form 10Q sixty bEX107 two a107amendmenttorevolvingarhtm EX107 Document Execution Version AMENDMENT NO one TO AMENDED AND RESTATED REVOLVING CREDIT AGREEMENT This AMENDMENT NO one TO AMENDED AND RESTATED REVOLVING CREDIT AGREEMENT dated as of December twentythree two thousand and twenty this Amendment is entered into among Walgreens Boots Alliance Inc a Delaware corporation the Borrower and Wells Fargo Bank National Association Wells Fargo as administrative agent in such capacity the Administrative Agent and as the sole Lender as defined below party to the Credit Agreement as defined below as of the date hereof RECITALS WHEREAS the Borrower the Administrative Agent and the lenders from time to time party thereto including Wells Fargo the Lenders entered into an Amended and Restated Revolving Credit Agreement dated as of April two two thousand and twenty as the same may have been amended supplemented or otherwise modified prior to the date hereof and including the schedules and exhibits attached thereto the Credit Agreement pursuant to which the Lenders agreed to extend credit to the Borrower WHEREAS the Borrower has requested that the Credit Agreement be amended as set forth below and Administrative Agent and the Lender party hereto consent to this Amendment NOW THEREFORE for and in consideration of the mutual covenants and agreements herein contained and other good and valuable consideration the receipt and sufficiency of which are hereby acknowledged the Borrower the Administrative Agent and Wells Fargo as the sole Lender as of the date hereof hereby agree as follows one Defined Terms Capitalized terms used and not otherwise defined herein have the meanings assigned to them in the Credit Agreement two Amendments to the Credit Agreement Effective on the Amendment Effective Date as defined below the Credit Agreement shall be amended as follows a Schedule one hundred and one shall be updated to add the following term in the proper alphabetical order Amendment No one Effective Date means December twentythree two thousand and twenty b The definition of Maturity Date contained in Section one hundred and one of the Credit Agreement shall be amended and restated in its entirety as follows Maturity Date means the Initial Maturity Date 93960756v4 c The definition of February Extension Maturity Date July Extension Maturity Date and Updated Unused Commitment Fee contained in Section one hundred and one of the Credit Agreement shall be deleted d The definition of Commitment Fee contained in Section one hundred and one of the Credit Agreement shall be amended and restated in its entirety as follows Commitment Fee means collectively the Existing Unused Commitment Fee and the New Commitment Fee e Section 205ai of the Credit Agreement shall be amended and restated as follows The Borrower agrees to pay to the Administrative Agent for the account of each Existing Lender a commitment fee in Dollars at a per annum rate equal to eleven per annum the Existing Unused Commitment Fee on the daily actual excess of such Existing Lenders Existing Commitment over the outstanding principal amount of such Existing Lenders outstanding Existing Loans such excess such Lenders Actual Existing Facility Unused Commitments as adjusted pursuant to Section 205c accruing from and including the Initial Effective Date to and including the earlier of the Initial Maturity Date and the date on which the Existing Commitments have been terminated in full and all Obligations in respect of the Existing Facility have been paid in full pursuant to Section 207b payable quarterly in arrears on each Payment Date f The chart under the term Existing Facility in Schedule one hundred and one of the Credit Agreement shall be amended and restated in its entirety as follows Applicable Margin for Eurocurrency Existing Loans Applicable Margin for Alternate Base Rate Existing Loans On the Initial Effective Date through and including the Initial Maturity Date or if earlier the Facility Termination Date for the Existing Facility seventyfive zero g Schedule two hundred and one of the Credit Agreement shall be amended and restated in its entirety as follows LENDER EXISTING COMMITMENT AS OF AMENDMENT AND RESTATEMENT EFFECTIVE DATE PRO RATA SHARE OF THE EXISTING FACILITY AS OF THE AMENDMENT AND RESTATEMENT EFFECTIVE DATE NEW COMMITMENT AS OF AMENDMENT NO one EFFECTIVE DATE PRO RATA SHARE OF THE NEW FACILITY AS OF THE AMENDMENT NO one EFFECTIVE DATE Wells Fargo Bank National Association one billion one hundred zero NA three Conditions to Effectiveness This Amendment shall become effective on the date the Amendment Effective Date when the Administrative Agent shall have received counterparts to this Amendment executed by the Borrower and Wells Fargo as sole Lender as of the date hereof two four Representations and Warranties The Borrower represents and warrants that a No Default or Unmatured Default has occurred and is continuing on or as of the Amendment Effective Date and b The representations and warranties contained in Article V of the Credit Agreement other than the representations and warranties contained in Sections five hundred and five and five hundred and six of the Credit Agreement are true and correct in all material respects except to the extent such representations and warranties are qualified by materiality or Material Adverse Effect or similar terms in which case such representations and warranties are be true and correct in all respects as of the Amendment Effective Date except to the extent any such representation or warranty is stated to relate solely to an earlier date in which case such representation or warranty is true and correct in all material respects except to the extent such representations and warranties are qualified with materiality or Material Adverse Effect or similar terms in which case such representations and warranties are true and correct in all respects on and as of such earlier date five Ratification No Novation Except to the extent hereby amended the Credit Agreement and each of the Loan Documents remain in full force and effect and are hereby ratified and affirmed The Credit Agreement as amended by the Amendment is not intended to be and shall not constitute a novation All Loans made and all Obligations incurred under the Credit Agreement which are outstanding on the Amendment Effective Date shall constitute Loans and Obligations respectively under and shall be governed by the terms of the Credit Agreement as amended by the Amendment and the other Loan Documents six Indemnities The Borrower agrees that this Amendment constitutes a Loan Document and Section nine hundred and six of the Credit Agreement is hereby incorporated by reference herein and shall extend to the preparation execution and delivery of this Amendment seven Limitation This Amendment shall be limited precisely as written and except as expressly provided herein shall not be deemed to be a consent granted pursuant to or a waiver or modification of any term or condition of the Credit Agreement or any of the instruments or agreements referred to therein or to prejudice any right or rights which the Administrative Agent or the Lenders may now have or have in the future under or in connection with the Credit Agreement or any of the instruments or agreements referred to therein Unless the context indicates otherwise on and after the Amendment Effective Date whenever the Credit Agreement is referred to in the Credit Agreement the other Loan Documents or any of the instruments agreements or other documents or papers executed or delivered in connection therewith such reference shall be deemed to mean the Credit Agreement as amended by this Amendment eight Counterparts This Amendment may be executed in any number of counterparts and by the different parties hereto in separate counterparts each of which shall be an original and all of which when taken together shall constitute but one and the same instrument A facsimile or pdf copy of a counterpart signature page shall serve as the functional equivalent of a manually executed copy for all purposes three nine Governing Law THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAW OF THE STATE OF NEW YORK ten Consent to Jurisdiction Waiver of Jury Trial Each of Sections one thousand five hundred and two and one thousand five hundred and three of the Credit Agreement are hereby incorporated by reference herein and shall extend to the preparation execution and delivery of this Amendment SIGNATURE PAGES FOLLOW four IN WITNESS WHEREOF the parties hereto have caused this Amendment to be duly executed by their respective authorized officers as of the day and year first above written WALGREENS BOOTS ALLIANCE INC as the Borrower By s John Devlin Name John Devlin Title Treasury Vice President By s Aidan Clare Name Aidan Clare Title Vice President and Global Treasurer Signature Page to Amendment WELLS FARGO BANK NATIONAL ASSOCIATION as the Administrative Agent By s Jordan Harris Name Jordan Harris Title Managing Director WELLS FARGO BANK NATIONAL ASSOCIATION as Lender By s Jordan Harris Name Jordan Harris Title Managing Director Signature Page to Amendment bEX311 three a11302020exhibit311htm EX311 Document EXHIBIT three hundred and eleven CERTIFICATION I Stefano Pessina certify that one I have reviewed this quarterly report on Form 10Q of Walgreens Boots Alliance Inc two Based on my knowledge this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made in light of the circumstances under which such statements were made not misleading with respect to the period covered by this report three Based on my knowledge the financial statements and other financial information included in this report fairly present in all material respects the financial condition results of operations and cash flows of the registrant as of and for the periods presented in this report four The registrants other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures as defined in Exchange Act Rules 13a15e and 15d15e and internal control over financial reporting as defined in Exchange Act Rule 13a15f and 15d15f for the registrant and have a Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the registrant including its consolidated subsidiaries is made known to us by others within those entities particularly during the period in which this report is being prepared b Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles c Evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation and d Disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter the registrants fourth fiscal quarter in the case of an annual report that has materially affected or is reasonably likely to materially affect the registrants internal control over financial reporting and five The registrants other certifying officers and I have disclosed based on our most recent evaluation of internal control over financial reporting to the registrants auditors and the audit committee of the registrants board of directors or persons performing the equivalent functions a All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record process summarize and report financial information and b Any fraud whether or not material that involves management or other employees who have a significant role in the registrants internal control over financial reporting s Stefano Pessina Chief Executive Officer Date January seven two thousand and twentyone Stefano Pessina bEX312 four a11302020exhibit312htm EX312 Document EXHIBIT three hundred and twelve CERTIFICATION I James Kehoe certify that one I have reviewed this quarterly report on Form 10Q of Walgreens Boots Alliance Inc two Based on my knowledge this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made in light of the circumstances under which such statements were made not misleading with respect to the period covered by this report three Based on my knowledge the financial statements and other financial information included in this report fairly present in all material respects the financial condition results of operations and cash flows of the registrant as of and for the periods presented in this report four The registrants other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures as defined in Exchange Act Rules 13a15e and 15d15e and internal control over financial reporting as defined in Exchange Act Rule 13a15f and 15d15f for the registrant and have a Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the registrant including its consolidated subsidiaries is made known to us by others within those entities particularly during the period in which this report is being prepared b Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles c Evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation and d Disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter the registrants fourth fiscal quarter in the case of an annual report that has materially affected or is reasonably likely to materially affect the registrants internal control over financial reporting and five The registrants other certifying officers and I have disclosed based on our most recent evaluation of internal control over financial reporting to the registrants auditors and the audit committee of the registrants board of directors or persons performing the equivalent functions a All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record process summarize and report financial information and b Any fraud whether or not material that involves management or other employees who have a significant role in the registrants internal control over financial reporting s James Kehoe Global Chief Financial Officer Date January seven two thousand and twentyone James Kehoe bEX321 five a11302020exhibit321htm EX321 Document Exhibit three hundred and twentyone CERTIFICATION PURSUANT TO SECTION nine hundred and six OF THE SARBANESOXLEY ACT OF two thousand and two eighteen USC SECTION one thousand three hundred and fifty In connection with the Quarterly Report of Walgreens Boots Alliance Inc a Delaware corporation the Company on Form 10Q for the quarter ended November thirty two thousand and twenty as filed with the Securities and Exchange Commission the Report I Stefano Pessina Chief Executive Officer of the Company certify pursuant to Section nine hundred and six of the SarbanesOxley Act of two thousand and two to the best of my knowledge one The Report fully complies with the requirements of Section 13a or 15d of the Securities Exchange Act of one thousand nine hundred and thirtyfour and two The information contained in the Report fairly presents in all material respects the financial condition and results of operations of the Company s Stefano Pessina Stefano Pessina Chief Executive Officer Dated January seven two thousand and twentyone A signed original of this written statement required by Section nine hundred and six has been provided to Walgreens Boots Alliance Inc and will be retained by Walgreens Boots Alliance Inc and furnished to the Securities and Exchange Commission or its staff upon request bEX322 six a11302020exhibit322htm EX322 Document Exhibit three hundred and twentytwo CERTIFICATION PURSUANT TO SECTION nine hundred and six OF THE SARBANESOXLEY ACT OF two thousand and two eighteen USC SECTION one thousand three hundred and fifty In connection with the Quarterly Report of Walgreens Boots Alliance Inc a Delaware corporation the Company on Form 10Q for the quarter ended November thirty two thousand and twenty as filed with the Securities and Exchange Commission the Report I James Kehoe Global Chief Financial Officer of the Company certify pursuant to Section nine hundred and six of the SarbanesOxley Act of two thousand and two to the best of my knowledge one The Report fully complies with the requirements of Section 13a or 15d of the Securities Exchange Act of one thousand nine hundred and thirtyfour and two The information contained in the Report fairly presents in all material respects the financial condition and results of operations of the Company s James Kehoe James Kehoe Global Chief Financial Officer Dated January seven two thousand and twentyone A signed original of this written statement required by Section nine hundred and six has been provided to Walgreens Boots Alliance Inc and will be retained by Walgreens Boots Alliance Inc and furnished to the Securities and Exchange Commission or its staff upon request',\n",
       " 'b10Q one rell10q20201128htm 10Q rell10q20201128htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington DC twenty thousand five hundred and fortynine FORM Mark One QUARTERLY REPORT PURSUANT TO SECTION thirteen OR 15d OF THE SECURITIES EXCHANGE ACT OF one thousand nine hundred and thirtyfour For the quarterly period ended OR TRANSITION REPORT PURSUANT TO SECTION thirteen OR 15d OF THE SECURITIES EXCHANGE ACT OF one thousand nine hundred and thirtyfour For the transition period from To Commission File Number RICHARDSON ELECTRONICS LTD Exact name of registrant as specified in its charter State or other jurisdiction of incorporation or organization IRS Employer Identification No Address of principal executive offices Registrants telephone number including area code Securities registered pursuant to Section 12b of the Act Title of each class Trading Symbols Name of each exchange on which registered Securities registered pursuant to Section 12g of the Act None Indicate by check mark whether the registrant one has filed all reports required to be filed by Section thirteen or 15d of the Securities Exchange Act of one thousand nine hundred and thirtyfour during the preceding twelve months or for such shorter period that the registrant was required to file such reports and two has been subject to such filing requirements for the past ninety days No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule four hundred and five of Regulation ST two hundred and thirtytwo thousand four hundred and five of this chapter during the preceding twelve months or for such shorter period that the registrant was required to submit such files No Indicate by check mark whether the registrant is a large accelerated filer an accelerated filer a nonaccelerated filer a smaller reporting company or an emerging growth company See the definitions of large accelerated filer accelerated filer smaller reporting company and emerging growth company in Rule 12b2 of the Exchange Act Large Accelerated Filer NonAccelerated Filer Smaller Reporting Company Emerging Growth Company If an emerging growth company indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13a of the Exchange Act Indicate by check mark whether the registrant is a shell company as defined in Rule 12b2 of the Exchange Act Yes No As of January five two thousand and twentyone there were outstanding shares of Common Stock five par value and shares of Class B Common Stock five par value which are convertible into Common Stock of the registrant on a share for share basis TABLE OF CONTENTS Page Part I Financial Information Item one Financial Statements two Consolidated Balance Sheets two Unaudited Consolidated Statements of Comprehensive Income Loss three Unaudited Consolidated Statements of Cash Flows four Unaudited Consolidated Statement of Stockholders Equity five Notes to Unaudited Consolidated Financial Statements seven Item two Managements Discussion and Analysis of Financial Condition and Results of Operations nineteen Item three Quantitative and Qualitative Disclosures About Market Risk twentyfive Item four Controls and Procedures twentyfive Part II Other Information Item one Legal Proceedings twentysix Item 1A Risk Factors twentysix Item two Unregistered Sales of Equity Securities and Use of Proceeds twentysix Item five Other Information twentysix Item six Exhibits twentyseven Exhibit Index twentyseven Signatures twentyeight one PART I FINANCIAL INFORMATION ITEM one FINANCIAL STATEMENTS Richardson Electronics Ltd Consolidated Balance Sheets in thousands except per share amounts Unaudited Audited November twentyeight two thousand and twenty May thirty two thousand and twenty Assets Current assets Cash and cash equivalents Accounts receivable less allowance of and respectively Inventories net Prepaid expenses and other assets Investments current Total current assets Noncurrent assets Property plant and equipment net Intangible assets net Lease ROU asset Noncurrent deferred income taxes Total noncurrent assets Total assets Liabilities and Stockholders Equity Current liabilities Accounts payable Accrued liabilities Lease liability current Total current liabilities Noncurrent liabilities Noncurrent deferred income tax liabilities Lease liability noncurrent Other noncurrent liabilities Total noncurrent liabilities Total liabilities Stockholders equity Common stock par value issued and outstanding shares on November twentyeight two thousand and twenty and shares on May thirty two thousand and twenty Class B common stock convertible par value issued and outstanding shares on November twentyeight two thousand and twenty and May thirty two thousand and twenty Preferred stock par value shares issued Additional paidincapital Retained earnings Accumulated other comprehensive income Total stockholders equity Total liabilities and stockholders equity two Richardson Electronics Ltd Unaudited Consolidated Statements of Comprehensive Income Loss in thousands except per share amounts Three Months Ended Six Months Ended November twentyeight two thousand and twenty November thirty two thousand and nineteen November twentyeight two thousand and twenty November thirty two thousand and nineteen Statements of Comprehensive Income Loss Net sales Cost of sales Gross profit Selling general and administrative expenses Loss on disposal of assets Operating income loss Other expense income Investmentinterest income Foreign exchange loss Other net Total other expense income Income loss before income taxes Income tax provision Net income loss Foreign currency translation gain loss net of tax Comprehensive income loss Net income loss per share Common shares Basic Class B common shares Basic Common shares Diluted Class B common shares Diluted Weighted average number of shares Common shares Basic Class B common shares Basic Common shares Diluted Class B common shares Diluted Dividends per common share Dividends per Class B common share three Richardson Electronics Ltd Unaudited Consolidated Statements of Cash Flows in thousands Three Months Ended Six Months Ended November twentyeight two thousand and twenty November thirty two thousand and nineteen November twentyeight two thousand and twenty November thirty two thousand and nineteen Operating activities Net income loss Adjustments to reconcile net income loss to cash provided by used in operating activities Depreciation and amortization Inventory provisions Loss on disposal of assets Sharebased compensation expense Deferred income taxes Change in assets and liabilities Accounts receivable Inventories Prepaid expenses and other assets Accounts payable Accrued liabilities Other Net cash provided by used in operating activities Investing activities Capital expenditures Proceeds from maturity of investments Purchases of investments Net cash used in provided by investing activities Financing activities Proceeds from issuance of common stock Cash dividends paid Payment of financing lease principal Other Net cash used in financing activities Effect of exchange rate changes on cash and cash equivalents Increase decrease in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period four Richardson Electronics Ltd Unaudited Consolidated Statement of Stockholders Equity in thousands except per share amounts Common Class B Common Par Value Additional Paid In Capital Retained Earnings Accumulated Other Comprehensive Income Total Balance May thirty two thousand and twenty Comprehensive income Net loss Foreign currency translation Sharebased compensation Restricted stock Stock options Common stock Restricted stock issuance Dividends paid to Common per share Class B per share Balance November twentyeight two thousand and twenty Balance August twentynine two thousand and twenty Comprehensive income Net income Foreign currency translation Sharebased compensation Restricted stock Stock options Dividends paid to Common per share Class B per share Balance November twentyeight two thousand and twenty five Common Class B Common Par Value Additional Paid In Capital Retained Earnings Accumulated Other Comprehensive Income Total Balance June one two thousand and nineteen Comprehensive loss Net loss Foreign currency translation Sharebased compensation Restricted stock Stock options Common stock Options exercised Restricted stock issuance Dividends paid to Common per share Class B per share Balance November thirty two thousand and nineteen Balance August thirtyone two thousand and nineteen Comprehensive loss income Net loss Foreign currency translation Sharebased compensation Restricted stock Stock options Common stock Options exercised Restricted stock issuance Dividends paid to Common per share Class B per share Balance November thirty two thousand and nineteen six NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS seven eight nine ten eleven twelve thirteen fourteen fifteen sixteen seventeen eighteen ITEM two MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Certain statements in this report may constitute forwardlooking statements within the meaning of the Private Securities Litigation Reform Act of one thousand nine hundred and ninetyfive The terms may should could anticipate believe continues estimate expect intend objective plan potential project and similar expressions are intended to identify forwardlooking statements These statements are not guarantees of future performance and involve risks uncertainties and assumptions that are difficult to predict These statements are based on managements current expectations intentions or beliefs and are subject to a number of factors assumptions and uncertainties that could cause actual results to differ materially from those described in the forwardlooking statements Factors that could cause or contribute to such differences or that might otherwise impact the business include the risk factors set forth in Item 1A of this quarterly report on Form 10Q for the quarter ended November twentyeight two thousand and twenty as well as our Annual Report on Form 10K filed on August three two thousand and twenty We undertake no obligation to update any such factor or to publicly announce the results of any revisions to any forwardlooking statements contained herein whether as a result of new information future events or otherwise In addition while we do from time to time communicate with securities analysts it is against our policy to disclose to them any material nonpublic information or other confidential commercial information Accordingly stockholders should not assume that we agree with any statement or report issued by any analyst irrespective of the content of the statement or report Thus to the extent that reports issued by securities analysts contain any projections forecasts or opinions such reports are not our responsibility INTRODUCTION Managements Discussion and Analysis of Financial Condition and Results of Operations MDA is intended to assist the reader in better understanding our business results of operations financial condition changes in financial condition critical accounting policies and estimates and significant developments MDA is provided as a supplement to and should be read in conjunction with our consolidated financial statements and the accompanying notes appearing elsewhere in this filing This section is organized as follows Business Overview Results of Operations an analysis and comparison of our consolidated results of operations for the three and six month periods ended November twentyeight two thousand and twenty and November thirty two thousand and nineteen as reflected in our consolidated statements of comprehensive income loss Liquidity Financial Position and Capital Resources a discussion of our primary sources and uses of cash for the six month periods ended November twentyeight two thousand and twenty and November thirty two thousand and nineteen and a discussion of changes in our financial position Business Overview Richardson Electronics Ltd is a leading global provider of engineered solutions power grid and microwave tubes and related consumables power conversion and RF and microwave components high value flat panel detector solutions replacement parts tubes and service training for diagnostic imaging equipment and customized display solutions We serve customers in the alternative energy healthcare aviation broadcast communications industrial marine medical military scientific and semiconductor markets The Companys strategy is to provide specialized technical expertise and engineered solutions based on our core engineering and manufacturing capabilities The Company provides solutions and adds value through designin support systems integration prototype design and manufacturing testing logistics and aftermarket technical service and repair through its global infrastructure Our products include electron tubes and related components microwave generators subsystems used in semiconductor manufacturing and visual technology solutions These products are used to control switch or amplify electrical power signals or are used as display devices in a variety of industrial commercial medical and communication applications We have three operating and reportable segments which we define as follows Power and Microwave Technologies Group PMT combines our core engineered solutions capabilities power grid and microwave tube business with new disruptive RF Wireless and Power technologies As a designer manufacturer technology partner and authorized distributor PMTs strategy is to provide specialized technical expertise and engineered solutions based on our core engineering and manufacturing capabilities on a global basis We provide solutions and add value through designin support systems integration prototype design and manufacturing testing logistics and aftermarket technical service and repairall through our existing global infrastructure PMTs focus is on products for power RF and microwave applications for customers in 5G alternative energy aviation broadcast communications industrial marine medical military scientific and semiconductor markets PMT focuses on various applications including broadcast transmission CO2 laser cutting diagnostic imaging dielectric and induction heating high energy transfer high voltage switching plasma power conversion radar and radiation oncology PMT also offers its customers technical services for both microwave and industrial equipment nineteen Canvys provides customized display solutions serving the corporate enterprise financial healthcare industrial and medical original equipment manufacturers markets Our engineers design manufacture source and support a full spectrum of solutions to match the needs of our customers We offer long term availability and proven custom display solutions that include touch screens protective panels custom enclosures AllInOne computers specialized cabinet finishes application specific software packages and certification services Our volume commitments are lower than the large display manufacturers making us the ideal choice for companies with very specific design requirements We partner with both private label manufacturing companies and leading branded hardware vendors to offer the highest quality display and touch solutions and customized computing platforms Healthcare manufactures repairs refurbishes and distributes high value replacement parts and equipment for the healthcare market including hospitals medical centers asset management companies independent service organizations and multivendor service providers Products include diagnostic imaging replacement parts for CT and MRI systems replacement CT and MRI tubes CT service training MRI coils cold heads and RF amplifiers hydrogen thyratrons klystrons magnetrons flat panel detector upgrades preowned CT systems and additional replacement solutions currently under development for the diagnostic imaging service market Through a combination of newly developed products and partnerships service offerings and training programs we help our customers improve efficiency and deliver better clinical outcomes while lowering the cost of healthcare delivery We currently have operations in the following major geographic regions North America AsiaPacific Europe and Latin America RESULTS OF OPERATIONS Financial Summary Three Months Ended November twentyeight two thousand and twenty The second quarter of fiscal two thousand and twentyone and fiscal two thousand and twenty each contained thirteen weeks Net sales during the second quarter of fiscal two thousand and twentyone were four hundred and twentyfour million an increase of seventy compared to net sales of three hundred and ninetysix million during the second quarter of fiscal two thousand and twenty Gross margin increased to three hundred and thirtyeight during the second quarter of fiscal two thousand and twentyone compared to three hundred and twenty during the second quarter of fiscal two thousand and twenty Selling general and administrative expenses were one hundred and thirtyfive million or three hundred and eighteen of net sales during the second quarter of fiscal two thousand and twentyone compared to one hundred and thirtytwo million or three hundred and thirtytwo of net sales during the second quarter of fiscal two thousand and twenty Operating income during the second quarter of fiscal two thousand and twentyone was nine million compared to operating loss of five million during the second quarter of fiscal two thousand and twenty Net income during the second quarter of fiscal two thousand and twentyone was seven million compared to net loss of six million during the second quarter of fiscal two thousand and twenty Financial Summary Six Months Ended November twentyeight two thousand and twenty The first six months of fiscal two thousand and twentyone and fiscal two thousand and twenty each contained twentysix weeks Net sales during the first six months of fiscal two thousand and twentyone were eight hundred and twelve million an increase of twelve compared to net sales of eight hundred and three million during the first six months of fiscal two thousand and twenty Gross margin increased to three hundred and twentynine during the first six months of fiscal two thousand and twentyone compared to three hundred and nineteen during the first six months of fiscal two thousand and twenty Selling general and administrative expenses were two hundred and sixtyfive million or three hundred and twentysix of net sales during the first six months of fiscal two thousand and twentyone compared to two hundred and sixty million or three hundred and twentyfour of net sales during the first six months of fiscal two thousand and twenty Operating income during the first six months of fiscal two thousand and twentyone was two million compared to operating loss of four million during the first six months of fiscal two thousand and twenty Net loss during the first six months of fiscal two thousand and twentyone was five million compared to net loss of five million during the first six months of fiscal two thousand and twenty twenty Net Sales and Gross Profit Analysis Net sales by segment and percent change during the second quarter and first six months of fiscal two thousand and twentyone and fiscal two thousand and twenty were as follows in thousands Net Sales Three Months Ended FY21 vs FY20 November twentyeight two thousand and twenty November thirty two thousand and nineteen Change PMT thirtytwo thousand nine hundred and twentynine twentynine thousand six hundred and three one hundred and twelve Canvys six thousand seven hundred and one seven thousand eight hundred and fiftysix one hundred and fortyseven Healthcare two thousand seven hundred and eightyeight two thousand one hundred and seventyfive two hundred and eightytwo Total fortytwo thousand four hundred and eighteen thirtynine thousand six hundred and thirtyfour seventy Six Months Ended FY21 vs FY20 November twentyeight two thousand and twenty November thirty two thousand and nineteen Change PMT sixtythree thousand one hundred and eightyone sixty thousand one hundred and seventy fifty Canvys thirteen thousand four hundred and thirteen fifteen thousand one hundred and thirtythree one hundred and fourteen Healthcare four thousand six hundred and thirtysix four thousand nine hundred and eightyfour seventy Total eightyone thousand two hundred and thirty eighty thousand two hundred and eightyseven twelve During the second quarter of fiscal two thousand and twentyone consolidated net sales increased seventy compared to the second quarter of fiscal two thousand and twenty Sales for PMT increased one hundred and twelve sales for Canvys decreased one hundred and fortyseven and sales for Healthcare increased two hundred and eightytwo The increase in PMT was mainly due to growth in various power grid tube product lines strong growth from our Power and Microwave new technology partners in various applications including 5G infrastructure and increased revenue from our Semiconductor Wafer Fabrication customers buying engineered solutions The decrease in Canvys was due to temporarily decreased customer demand globally related to COVID19 The increase in Healthcare was due to a significant increase in demand for the ALTA 750D TM tubes coupled with increased equipment sales in Latin America During the first six months of fiscal two thousand and twentyone consolidated net sales increased twelve compared to the first six months of fiscal two thousand and twenty Sales for PMT increased fifty sales for Canvys decreased one hundred and fourteen and sales for Healthcare decreased seventy The increase in PMT was mainly due to growth in the power grid tube business strong growth in bookings and billings from our power conversion and RF and microwave components and continued growth in the Semiconductor Wafer Fab market The decrease in Canvys was due to continuing struggles in the European market related to the COVID19 impact on demand for equipment partially offset by strong sales in the North American market The decrease in Healthcare was due to the impact of the global pandemic as well as ongoing economic issues in Latin America in the first quarter of fiscal two thousand and twentyone Gross profit by segment and percent of net sales for the second quarter and first six months of fiscal two thousand and twentyone and fiscal two thousand and twenty were as follows in thousands Gross Profit Three Months Ended November twentyeight two thousand and twenty of Net Sales November thirty two thousand and nineteen of Net Sales PMT eleven thousand two hundred and fiftyone three hundred and fortytwo nine thousand three hundred and fortynine three hundred and sixteen Canvys two thousand three hundred and seventynine three hundred and fiftyfive two thousand five hundred and eightyfive three hundred and twentynine Healthcare seven hundred and thirteen two hundred and fiftysix seven hundred and fortysix three hundred and fortythree Total fourteen thousand three hundred and fortythree three hundred and thirtyeight twelve thousand six hundred and eighty three hundred and twenty Six Months Ended November twentyeight two thousand and twenty of Net Sales November thirty two thousand and nineteen of Net Sales PMT twentyone thousand two hundred and twentytwo three hundred and thirtysix nineteen thousand and twentyeight three hundred and sixteen Canvys four thousand six hundred and sixtythree three hundred and fortyeight four thousand nine hundred and six three hundred and twentyfour Healthcare eight hundred and seventeen one hundred and seventysix one thousand six hundred and ninetyseven three hundred and forty Total twentysix thousand seven hundred and two three hundred and twentynine twentyfive thousand six hundred and thirtyone three hundred and nineteen Gross profit reflects the distribution and manufacturing product margin less manufacturing variances inventory obsolescence charges customer returns scrap and cycle count adjustments engineering costs and other provisions twentyone Consolidated gross profit increased to one hundred and fortythree million during the second quarter of fiscal two thousand and twentyone compared to one hundred and twentyseven million during the second quarter of fiscal two thousand and twenty Consolidated gross margin as a percentage of net sales increased to three hundred and thirtyeight during the second quarter of fiscal two thousand and twentyone from three hundred and twenty during the second quarter of fiscal two thousand and twenty primarily due to improved manufacturing efficiencies in PMT and favorable product mix in both PMT and Canvys partially offset by under absorbed manufacturing expenses in Healthcare Consolidated gross profit increased to two hundred and sixtyseven million during the first six months of fiscal two thousand and twentyone compared to two hundred and fiftysix million during the first six months of fiscal two thousand and twenty Consolidated gross margin as a percentage of net sales increased to three hundred and twentynine during the first six months of fiscal two thousand and twentyone from three hundred and nineteen during the first six months of fiscal two thousand and twenty primarily due to improved manufacturing efficiencies in PMT and favorable product mix in both PMT and Canvys as well as foreign currency change impact in Canvys partially offset by under absorbed manufacturing expenses in Healthcare Power and Microwave Technologies Group PMT net sales increased one hundred and twelve to three hundred and twentynine million during the second quarter of fiscal two thousand and twentyone from two hundred and ninetysix million during the second quarter of fiscal two thousand and twenty The increase was mainly due to growth in various power grid tube product lines strong growth from our Power and Microwave new technology partners in various applications including 5G infrastructure and increased revenue from our Semiconductor Wafer Fabrication customers buying engineered solutions Gross margin as a percentage of net sales increased to three hundred and fortytwo during the second quarter of fiscal two thousand and twentyone as compared to three hundred and sixteen during the second quarter of fiscal two thousand and twenty primarily due to favorable product mix and improved manufacturing efficiencies PMT net sales increased fifty to six hundred and thirtytwo million during the first six months of fiscal two thousand and twentyone from six hundred and two million during the first six months of fiscal two thousand and twenty The increase was mainly due to growth in the power grid tube business strong growth in bookings and billings from our power conversion and RF and microwave components and continued growth in the Semiconductor Wafer Fab market Gross margin as a percentage of net sales increased to three hundred and thirtysix during the first six months of fiscal two thousand and twentyone as compared to three hundred and sixteen during the first six months of fiscal two thousand and twenty due to favorable product mix and improved manufacturing efficiencies Canvys Canvys net sales decreased one hundred and fortyseven to sixtyseven million during the second quarter of fiscal two thousand and twentyone from seventynine million during the second quarter of fiscal two thousand and twenty due to temporarily decreased customer demand globally related to COVID19 Gross margin as a percentage of net sales increased to three hundred and fiftyfive during the second quarter of fiscal two thousand and twentyone from three hundred and twentynine during the second quarter of fiscal two thousand and twenty due to favorable product mix Canvys net sales decreased one hundred and fourteen to one hundred and thirtyfour million during the first six months of fiscal two thousand and twentyone from one hundred and fiftyone million during the first six months of fiscal two thousand and twenty primarily due to continuing struggles in the European market related to the COVID19 impact on demand for equipment partially offset by strong sales in the North American market Gross margin as a percentage of net sales increased to three hundred and fortyeight during the first six months of fiscal two thousand and twentyone as compared to three hundred and twentyfour during the first six months of fiscal two thousand and twenty due to favorable product mix and foreign currency change impact Healthcare Healthcare net sales increased two hundred and eightytwo to twentyeight million during the second quarter of fiscal two thousand and twentyone from twentytwo million during the second quarter of fiscal two thousand and twenty The increase in sales was primarily due to a significant increase in demand for the ALTA 750D TM tubes coupled with increased equipment sales in Latin America Gross margin as a percentage of net sales decreased to two hundred and fiftysix during the second quarter of fiscal two thousand and twentyone as compared to three hundred and fortythree during the second quarter of fiscal two thousand and twenty primarily due to under absorbed manufacturing expenses Healthcare net sales decreased seventy to fortysix million during the first six months of fiscal two thousand and twentyone from fifty million during the first six months of fiscal two thousand and twenty due to the impact of the global pandemic as well as ongoing economic issues in Latin America in the first quarter of fiscal two thousand and twentyone Gross margin as a percentage of net sales decreased to one hundred and seventysix during the first six months of fiscal two thousand and twentyone as compared to three hundred and forty during the first six months of fiscal two thousand and twenty due to under absorbed manufacturing expenses Selling General and Administrative Expenses Selling general and administrative expenses increased to one hundred and thirtyfive million during the second quarter of fiscal two thousand and twentyone from one hundred and thirtytwo million in the second quarter of fiscal two thousand and twenty primarily due to higher employee compensation and legal expenses partially offset by lower travel and consulting expenses Selling general and administrative expenses increased to two hundred and sixtyfive million during the first six months of fiscal two thousand and twentyone from two hundred and sixty million in the first six months of fiscal two thousand and twenty primarily due to higher employee compensation and legal expenses partially offset by lower travel and consulting expenses twentytwo Other IncomeExpense Other incomeexpense was expense of one million during the second quarter of fiscal two thousand and twentyone compared to expense of one million during the second quarter of fiscal two thousand and twenty Other incomeexpense during the second quarter of fiscal two thousand and twentyone included one million of foreign exchange losses Other incomeexpense during the second quarter of fiscal two thousand and twenty included one million of investmentinterest income offset by two million of foreign exchange losses Our foreign exchange gains and losses are primarily due to the translation of US dollars held in nonUS entities We currently do not utilize derivative instruments to manage our exposure to foreign currency Other incomeexpense was expense of five million during the first six months of fiscal two thousand and twentyone compared to income of two million during the first six months of fiscal two thousand and twenty Other incomeexpense during the first six months of fiscal two thousand and twentyone included six million of foreign exchange losses partially offset by less than one million of investmentinterest income Other incomeexpense during the first six months of fiscal two thousand and twenty included two million of investmentinterest income Income Tax Provision The income tax provision was one million for both the second quarter of fiscal two thousand and twentyone and the second quarter of fiscal two thousand and twenty The effective income tax rate during the second quarter of fiscal two thousand and twentyone was a tax provision of seventyone as compared to a tax provision of one hundred and fortyeight during the second quarter of fiscal two thousand and twenty The difference in rate during the second quarter of fiscal two thousand and twentyone as compared to the second quarter of fiscal two thousand and twenty reflects changes in our geographical distribution of income loss The seventyone effective income tax rate differs from the federal statutory rate of twentyone as a result of our geographical distribution of income loss and the movement of the valuation allowance against our US state and federal net deferred tax assets We recorded an income tax provision of two million and three million for the first six months of fiscal two thousand and twentyone and the first six months of fiscal two thousand and twenty respectively The effective income tax rate during the first six months of fiscal two thousand and twentyone was a tax provision of six hundred and thirty as compared to a tax provision of one thousand two hundred and thirtysix during the first six months of fiscal two thousand and twenty The difference in rate during the first six months of fiscal two thousand and twentyone as compared to the first six months of fiscal two thousand and twenty reflects changes in our geographical distribution of income loss The six hundred and thirty effective income tax rate differs from the federal statutory rate of twentyone as a result of our geographical distribution of income loss and the movement of the valuation allowance against our US state and federal net deferred tax assets In the normal course of business we are subject to examination by taxing authorities throughout the world Generally years prior to fiscal two thousand and fifteen are closed for examination under the statute of limitation for US federal US state and local or nonUS tax jurisdictions We are currently under examination in Thailand fiscal two thousand and eight through two thousand and eleven Our primary foreign tax jurisdictions are Germany and the Netherlands We have tax years open in Germany beginning in fiscal two thousand and fifteen and the Netherlands beginning in fiscal two thousand and eighteen Net Income Loss and Per Share Data Net income during the second quarter of fiscal two thousand and twentyone was seven million or five per diluted common share and five per Class B diluted common share as compared to net loss of six million during the second quarter of fiscal two thousand and twenty or five per diluted common share and four per Class B diluted common share Net loss during the first six months of fiscal two thousand and twentyone was five million or four per diluted common share and three per Class B diluted common share as compared to net loss of five million during the first six months of fiscal two thousand and twenty or four per diluted common share and three per Class B diluted common share LIQUIDITY FINANCIAL POSITION AND CAPITAL RESOURCES Our operations and cash needs have been primarily financed through cash on hand and investments Cash and cash equivalents were three hundred and seventy million at November twentyeight two thousand and twenty Investments included a CD classified as shortterm investment of ninety million Total cash and investments were four hundred and sixty million at November twentyeight two thousand and twenty Cash cash equivalents and investment at November twentyeight two thousand and twenty consisted of two hundred and sixtyeight million in North America ninetyone million in Europe eleven million in Latin America and ninety million in AsiaPacific Cash cash equivalents and investments were four hundred and sixtyfive million at May thirty two thousand and twenty Cash cash equivalents and investments at May thirty two thousand and twenty consisted of three hundred and six million in North America eightythree million in Europe nine million in Latin America and sixtyseven million in AsiaPacific We repatriated a total of eightyfive million to the United States in fiscal two thousand and twenty from several of our foreign entities This amount includes fortyfour million from our entities in Germany and the Netherlands in the second quarter of fiscal two thousand and twenty fifteen million from our entity in Japan in the third quarter of fiscal two thousand and twenty and ten million from our entity in Italy in the fourth quarter of fiscal two thousand and twenty Although the Tax Cuts and Jobs Act generally eliminated federal income tax on future cash repatriation to the United States cash repatriation may be subject to state and local taxes withholding or similar taxes See Note nine Income Taxes of the notes to our consolidated financial statements in Part II Item eight of our Annual Report on Form 10K for the year ended May thirty two thousand and twenty filed August three two thousand and twenty for further information twentythree The Company continues to monitor the impact of the COVID19 outbreak on its supply chain manufacturing and distribution operations customers and employees as well as the US economy in general However due to the uncertainty as to when governmental restrictions on business will be fully lifted the impact thereof and the duration and widespread nature of the COVID19 outbreak the Company cannot currently predict the longterm impact on its operations and financial results The uncertainties associated with the COVID19 outbreak include potential adverse effects on the overall economy the Companys supply chain transportation services employees and customers The COVID19 outbreak could adversely affect the Companys revenues earnings liquidity and cash flows and may require significant actions in response including expense reductions Conditions surrounding COVID19 change rapidly and additional impacts of which the Company is not currently aware may arise Based on past performance and current expectations w e believe that the existing sources of liquidity including current cash will provide sufficient resources to meet known capital requirements and working capital needs through the next twelve months Cash Flows from Operating Activities The cash provided by used in operating activities primarily resulted from net income loss adjusted for noncash items and changes in our operating assets and liabilities Operating activities provided eleven million of cash during the first six months of fiscal two thousand and twentyone We had a net loss of five million during the first six months of fiscal two thousand and twentyone which included noncash stockbased compensation expense of four million associated with the issuance of stock option and restricted stock awards five million for inventory reserve provisions and depreciation and amortization expense of seventeen million associated with our property and equipment as well as amortization of our intangible assets Changes in our operating assets and liabilities resulted in a use of cash of ten million during the first six months of fiscal two thousand and twentyone net of foreign currency exchange gains and losses included a decrease of twentyfive million in accounts payable an increase in inventory of ten million and an increase in accounts receivable of two million partially offset by an increase in accrued liabilities of thirtyfour million The decrease in our accounts payable was due to timing of payments for some of our larger vendors for both inventory and services The majority of the inventory increase was to support the electron tube and semiconductor wafer fab equipment business The increase in accounts receivable was primarily due to the sales increase compared to the first quarter of fiscal two thousand and twentyone The increase in accrued liabilities is mainly due to timing of employee compensation and payroll tax payments as well as the timing of other payments Operating activities used fourteen million of cash during the first six months of fiscal two thousand and twenty We had a net loss of five million during the first six months of fiscal two thousand and twenty which included noncash stockbased compensation expense of four million associated with the issuance of stock option and restricted stock awards three million for inventory reserve provisions and depreciation and amortization expense of seventeen million associated with our property and equipment as well as amortization of our intangible assets Changes in our operating assets and liabilities resulted in a use of cash of thirtythree million during the first six months of fiscal two thousand and twenty net of foreign currency exchange gains and losses included an increase in inventory of thirtyfour million a decrease of fourteen million in accounts payable and a decrease in accrued liabilities of four million partially offset by a decrease in accounts receivable of eighteen million and a decrease of two million in prepaid expenses and other assets The decrease in our accounts payable was due to timing of payments for some of our larger vendors for both inventory and services The majority of the inventory increase was to support the continued growth of our electron tube and RF and Power Technologies groups Cash Flows from Investing Activities The cash flow provided by and used in investing activities consisted primarily of purchases of investments and capital expenditures partially offset by proceeds from the maturities of investments Cash provided by investing activities of fiftyseven million during the first six months of fiscal two thousand and twentyone included proceeds from the maturities of investments of one hundred and sixty million partially offset by purchases of investments of ninety million and thirteen million in capital expenditures Capital expenditures related primarily to capital used for our Healthcare business and our IT system Cash used in investing activities of fiftyeight million during the first six months of fiscal two thousand and twenty included purchases of investments of one hundred and thirty million and eight million in capital expenditures partially offset by proceeds from the maturities of investments of eighty million Capital expenditures related primarily to capital used for our IT system and Healthcare and LaFox manufacturing businesses Our purchases of investments consisted of CDs Purchasing of future investments may vary from period to period due to interest and foreign currency exchange rates Cash Flows from Financing Activities The cash flow used in financing activities consisted primarily of cash dividends paid Cash used in financing activities of seventeen million during the first six months of fiscal two thousand and twentyone primarily resulted from cash used to pay dividends Cash used in financing activities of sixteen million during the first six months of fiscal two thousand and twenty primarily resulted from cash used to pay dividends twentyfour All future payments of dividends are at the discretion of the Board of Directors Dividend payments will depend on earnings capital requirements operating conditions and such other factors that the Board may deem relevant ITEM three QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Risk Management and Market Sensitive Financial Instruments We are exposed to many different market risks with the various industries we serve The primary financial risk we are exposed to is foreign currency exchange as certain operations assets and liabilities of ours are denominated in foreign currencies We manage these risks through normal operating and financing activities The interpretation and analysis of these disclosures should not be considered in isolation since such variances in exchange rates would likely influence other economic factors Such factors which are not readily quantifiable would likely also affect our operations Additional disclosure regarding various market risks are set forth in Part I Item 1A Risk Factors of our Annual Report on Form 10K for the year ended May thirty two thousand and twenty filed August three two thousand and twenty ITEM four CONTROLS AND PROCEDURES a Evaluation of Disclosure Controls and Procedures Management of the Company with the participation of the Chief Executive Officer and the Chief Financial Officer evaluated the effectiveness of the design and operation of the Companys disclosure controls and procedures as defined in Rules 13a15e and 15d15e of the Securities Exchange Act of one thousand nine hundred and thirtyfour as amended the Exchange Act as of November twentyeight two thousand and twenty Disclosure controls and procedures are intended to provide reasonable assurance that information required to be disclosed in the Companys Exchange Act reports is recorded processed summarized and reported within the time periods specified by the Securities and Exchange Commissions rules and forms and that such information is accumulated and communicated to management including the Companys Chief Executive Officer and Chief Financial Officer as appropriate to allow timely decisions regarding required disclosure Based on this evaluation the Companys Chief Executive Officer and Chief Financial Officer have concluded that the Companys disclosure controls and procedures were effective as of the end of the period covered by this report b Changes in Internal Control over Financial Reporting There were no changes in the Companys internal control over financial reporting identified in connection with the evaluation required by paragraph d of Exchange Act Rules 13a15 or 15d15 that occurred during the second quarter of fiscal two thousand and twentyone that have materially affected or are reasonably likely to materially affect the Companys internal control over financial reporting twentyfive PART II OTHER INFORMATION ITEM one LEGAL PROCEEDINGS On October fifteen two thousand and eighteen Varex Imaging Corporation Varex filed its original Complaint Case No 118cv06911 against Richardson Electronics Ltd Richardson in the Northern District of Illinois which was subsequently amended on November twentyseven two thousand and eighteen Varex alleged counts of infringement of US Patent Nos six million four hundred and fiftysix thousand six hundred and ninetytwo and six million five hundred and nineteen thousand three hundred and seventeen Subsequently on October twentyfour two thousand and eighteen Varex filed a motion for preliminary injunction to stop the sale of Richardsons ALTA750 TM product Richardson filed an opposition to the preliminary injunction In January two thousand and nineteen the Court took evidence on the preliminary injunction issue On September thirty two thousand and nineteen the Court denied Varexs Motion for Preliminary Injunction On August six two thousand and twenty Varex amended its Complaint to add claims of trade secret misappropriation and Richardson moved to dismiss that Amended Complaint on September nine two thousand and twenty Richardson believes the lawsuit to be without merit and a loss is not probable or estimable based on the information at the time the financial statements were issued ITEM 1A RISK FACTORS There have been no material changes to the risk factors previously disclosed in our Annual Report on Form 10K for the year ended May thirty two thousand and twenty filed August three two thousand and twenty ITEM two UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS ITEM five OTHER INFORMATION twentysix ITEM six EXHIBITS Exhibit Index Exhibit Number Description thirtyone Amended and Restated Certificate of Incorporation of the Company incorporated by reference to Annex III of the Proxy Statement dated August twentytwo two thousand and fourteen thirtytwo Amended and Restated ByLaws of the Company incorporated by reference to Exhibit thirtyone to the Companys Current Report on Form 8K filed with the SEC on June fifteen two thousand and seventeen three hundred and eleven Certification of Edward J Richardson pursuant to Section three hundred and two of the SarbanesOxley Act of two thousand and two three hundred and twelve Certification of Robert J Ben pursuant to Section three hundred and two of the SarbanesOxley Act of two thousand and two thirtytwo Certifications pursuant to Section nine hundred and six of the SarbanesOxley Act of two thousand and two one hundred and one one hundred and four The following financial information from our Quarterly Report on Form 10Q for the second quarter of fiscal two thousand and twentyone filed with the SEC on January seven two thousand and twentyone formatted in Inline Extensible Business Reporting Language iXBRL i the Consolidated Balance Sheets ii the Unaudited Consolidated Statements of Comprehensive Income Loss iii the Unaudited Consolidated Statements of Cash Flows iv the Unaudited Consolidated Statement of Stockholders Equity and v Notes to Unaudited Consolidated Financial Statements Cover Page Interactive Data File embedded within the Inline XBRL document twentyseven SIGNATURES Pursuant to the requirements of Section thirteen or 15d of the Securities Exchange Act of one thousand nine hundred and thirtyfour the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized RICHARDSON ELECTRONICS LTD Date January seven two thousand and twentyone By s Robert J Ben Robert J Ben Chief Financial Officer and Chief Accounting Officer on behalf of the Registrant and as Principal Financial Officer twentyeight bEX311 two rellex3116htm EX311 rellex3116htm Exhibit three hundred and eleven CERTIFICATION PURSUANT TO SECTION 302a OF THE SARBANESOXLEY ACT OF two thousand and two I Edward J Richardson certify that one I have reviewed this quarterly report on Form 10Q of Richardson Electronics Ltd for the period ended November twentyeight two thousand and twenty two Based on my knowledge this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made in light of the circumstances under which such statements were made not misleading with respect to the period covered by this report three Based on my knowledge the financial statements and other financial information included in this report fairly present in all material respects the financial condition results of operations and cash flows of the registrant as of and for the periods presented in this report four The registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures as defined in Exchange Act Rules 13a15e and 15d15e and internal control over financial reporting as defined in Exchange Act Rules 13a15f and 15d15f for the registrant and have a Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the registrant including its consolidated subsidiaries is made known to us by others within those entities particularly during the period in which this report is being prepared b Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles c Evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation and d Disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter the registrants fourth fiscal quarter in the case of an annual report that has materially affected or is reasonably likely to materially affect the registrants internal control over financial reporting and five The registrants other certifying officer and I have disclosed based on our most recent evaluation of internal control over financial reporting to the registrants auditors and the audit committee of the registrants board of directors or persons performing the equivalent functions a All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record process summarize and report financial information and b Any fraud whether or not material that involves management or other employees who have a significant role in the registrants internal control over financial reporting Date January seven two thousand and twentyone Signature s Edward J Richardson Edward J Richardson Chairman of the Board and Chief Executive Officer bEX312 three rellex3127htm EX312 rellex3127htm Exhibit three hundred and twelve CERTIFICATION PURSUANT TO SECTION 302a OF THE SARBANESOXLEY ACT OF two thousand and two I Robert J Ben certify that one I have reviewed this quarterly report on Form 10Q of Richardson Electronics Ltd for the period ended November twentyeight two thousand and twenty two Based on my knowledge this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made in light of the circumstances under which such statements were made not misleading with respect to the period covered by this report three Based on my knowledge the financial statements and other financial information included in this report fairly present in all material respects the financial condition results of operations and cash flows of the registrant as of and for the periods presented in this report four The registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures as defined in Exchange Act Rules 13a15e and 15d15e and internal control over financial reporting as defined in Exchange Act Rules 13a15f and 15d15f for the registrant and have a Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the registrant including its consolidated subsidiaries is made known to us by others within those entities particularly during the period in which this report is being prepared b Designed such internal control over financial reporting or caused such internal control over financial reporting to be designed under our supervision to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles c Evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation and d Disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter the registrants fourth fiscal quarter in the case of an annual report that has materially affected or is reasonably likely to materially affect the registrants internal control over financial reporting and five The registrants other certifying officer and I have disclosed based on our most recent evaluation of internal control over financial reporting to the registrants auditors and the audit committee of the registrants board of directors or persons performing the equivalent functions a All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record process summarize and report financial information and b Any fraud whether or not material that involves management or other employees who have a significant role in the registrants internal control over financial reporting Date January seven two thousand and twentyone Signature s Robert J Ben Robert J Ben Chief Financial Officer and Chief Accounting Officer bEX32 four rellex328htm EX32 rellex328htm Exhibit thirtytwo CERTIFICATION PURSUANT TO SECTION nine hundred and six OF THE SARBANESOXLEY ACT OF two thousand and two In connection with the Quarterly Report of Richardson Electronics Ltd the Company on Form 10Q for the period ended November twentyeight two thousand and twenty as filed with the Securities and Exchange Commission on the date hereof the Report I Edward J Richardson Chairman of the Board and Chief Executive Officer of the Company certify pursuant to eighteen USC one thousand three hundred and fifty as adopted pursuant to Section nine hundred and six of the SarbanesOxley Act of two thousand and two that to my knowledge one The Report fully complies with the requirements of section 13a or 15d of the Securities Exchange Act of one thousand nine hundred and thirtyfour as amended and two The information contained in the Report fairly presents in all material respects the financial condition and result of operations of the Company s Edward J Richardson Edward J Richardson Chairman of the Board and Chief Executive Officer January seven two thousand and twentyone CERTIFICATION PURSUANT TO SECTION nine hundred and six OF THE SARBANESOXLEY ACT OF two thousand and two In connection with the Quarterly Report of Richardson Electronics Ltd the Company on Form 10Q for the period ended November twentyeight two thousand and twenty as filed with the Securities and Exchange Commission on the date hereof the Report I Robert J Ben Chief Financial Officer and Chief Accounting Officer of the Company certify pursuant to eighteen USC one thousand three hundred and fifty as adopted pursuant to Section nine hundred and six of the SarbanesOxley Act of two thousand and two that to my knowledge one The Report fully complies with the requirements of section 13a or 15d of the Securities Exchange Act of one thousand nine hundred and thirtyfour as amended and two The information contained in the Report fairly presents in all material respects the financial condition and result of operations of the Company s Robert J Ben Robert J Ben Chief Financial Officer and Chief Accounting Officer January seven two thousand and twentyone']"
      ]
     },
     "execution_count": 21,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#see a sample\n",
    "norm_txt_sample = [sec_data.iloc[i,16] for i in range(20, 22)]\n",
    "norm_txt_sample"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['b\\'10-Q 1 wba-20201130.htm 10-Q wba-20201130 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From _______to _______ Commission File Number (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) , , (Address of principal executive offices) (Zip Code) () (Registrants telephone number, including area code) __________________________________________ Former name, former address and former fiscal year, if changed since last report Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  No  Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  No  Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.  Accelerated filer  Non-accelerated filer  Smaller reporting company Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes No  The number of shares outstanding of the registrants Common Stock, $0.01 par value, as of December 31, 2020 was . WALGREENS BOOTS ALLIANCE, INC. FORM 10-Q FOR THE THREE MONTHS ENDED NOVEMBER 30, 2020 TABLE OF CONTENTS PART I. FINANCIAL INFORMATION Item 1. Consolidated Condensed Financial Statements (Unaudited) a) Balance Sheets 3 b) Statements of Equity 4 c) Statements of Earnings 5 d) Statements of Comprehensive Income 6 e) Statements of Cash Flows 7 f) Notes to Financial Statements 8 Item 2. Managements discussion and analysis of financial condition and results of operations 33 a) Introduction and Segments 33 b) Factors Affecting Comparability 34 c) Executive Summary 38 d) Results of Operations by Segments 39 e) Non-GAAP Measures 45 f) Liquidity and Capital Resources 48 g) Cautionary Note Regarding Forward-looking Statements 53 Item 3. Quantitative and qualitative disclosure about market risk 55 Item 4. Controls and procedures 56 PART II. OTHER INFORMATION Item 1. Legal proceedings 57 Item 1A. Risk factors 57 Item 2. Unregistered sales of equity securities and use of proceeds 57 Item 5. Other information 58 Item 6. Exhibits 58 - 2 - Part I. Financial Information Item 1. Consolidated Condensed Financial Statements (Unaudited) WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES CONSOLIDATED CONDENSED BALANCE SHEETS (UNAUDITED) (in millions, except shares and per share amounts) November 30, 2020 August 31, 2020 Assets Current assets: Cash and cash equivalents $ $ Accounts receivable, net Inventories Other current assets Total current assets Non-current assets: Property, plant and equipment, net Operating lease right-of-use assets Goodwill Intangible assets, net Equity method investments (see note 5) Other non-current assets Total non-current assets Total assets $ $ Liabilities, redeemable noncontrolling interest and equity Current liabilities: Short-term debt $ $ Trade accounts payable (see note 16) Operating lease obligation Accrued expenses and other liabilities Income taxes Total current liabilities Non-current liabilities: Long-term debt Operating lease obligation Deferred income taxes Other non-current liabilities Total non-current liabilities Commitments and contingencies (see note 10) Total Liabilities Redeemable noncontrolling interest Equity: Preferred stock $ par value; authorized million shares, issued Common stock $ par value; authorized billion shares; issued at November 30, 2020 and August 31, 2020 Paid-in capital Retained earnings Accumulated other comprehensive loss () () Treasury stock, at cost; shares at November 30, 2020 and shares at August 31, 2020 () () Total Walgreens Boots Alliance, Inc. shareholders equity Noncontrolling interests Total equity Total liabilities, redeemable noncontrolling interest and equity $ $ The accompanying notes to Consolidated Condensed Financial Statements are an integral part of these statements. WBA Q1 FY2021 Form 10-Q 3 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES CONSOLIDATED CONDENSED STATEMENTS OF EQUITY (UNAUDITED) For the three months ended November 30, 2020 (in millions, except shares) Three months ended November 30, 2020 Equity attributable to Walgreens Boots Alliance, Inc. Common stock shares Common stock amount Treasury stock amount Paid-in capital Accumulated other comprehensive income (loss) Retained earnings Noncontrolling interests Total equity August 31, 2020 $ $ () $ $ () $ $ $ Net earnings (loss)      () () Other comprehensive income (loss), net of tax      Dividends declared      ()  () Treasury stock purchases ()  ()     () Employee stock purchase and option plans  ()    Stock-based compensation       Adoption of new accounting standards      () () () Business combination       Other       November 30, 2020 $ $ () $ $ () $ $ $ Three months ended November 30, 2019 Equity attributable to Walgreens Boots Alliance, Inc. Common stock shares Common stock amount Treasury stock amount Paid-in capital Accumulated other comprehensive income (loss) Retained earnings Noncontrolling interests Total equity August 31, 2019 $ $ () $ $ () $ $ $ Net earnings (loss)      () Other comprehensive income (loss), net of tax      Dividends declared      ()  () Treasury stock purchases ()  ()     () Employee stock purchase and option plans  ()    Stock-based compensation       Adoption of new accounting standards      ()  () November 30, 2019 $ $ () $ $ () $ $ $ The accompanying notes to Consolidated Condensed Financial Statements are an integral part of these statements. WBA Q1 FY2021 Form 10-Q 4 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS (UNAUDITED) (in millions, except per share amounts) Three months ended November 30, 2020 2019 Sales $ $ Cost of sales Gross profit Selling, general and administrative expenses Equity earnings (loss) in AmerisourceBergen () Operating income (loss) () Other income (expense) Earnings (loss) before interest and income tax provision () Interest expense, net Earnings (loss) before income tax provision () Income tax provision (benefit) () Post tax earnings (loss) from other equity method investments () Net earnings (loss) () Net earnings (loss) attributable to noncontrolling interests () Net earnings (loss) attributable to Walgreens Boots Alliance, Inc. $ () $ Net earnings (loss) per common share: Basic $ () $ Diluted $ () $ Weighted average common shares outstanding: Basic Diluted The accompanying notes to Consolidated Condensed Financial Statements are an integral part of these statements. WBA Q1 FY2021 Form 10-Q 5 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (in millions) Three months ended November 30, 2020 2019 Comprehensive income: Net earnings (loss) $ () $ Other comprehensive income (loss), net of tax: Pension/postretirement obligations () Unrealized gain (loss) on cash flow hedges Net investment hedges () () Share of other comprehensive income (loss) of equity method investments () Currency translation adjustments Total other comprehensive income Total comprehensive income (loss) () Comprehensive income attributable to noncontrolling interests Comprehensive income (loss) attributable to Walgreens Boots Alliance, Inc. $ () $ The accompanying notes to Consolidated Condensed Financial Statements are an integral part of these statements. WBA Q1 FY2021 Form 10-Q 6 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) (in millions) Three months ended November 30, 2020 2019 Cash flows from operating activities : Net earnings (loss) $ () $ Adjustments to reconcile net earnings (loss) to net cash provided by operating activities: Depreciation and amortization Deferred income taxes () () Stock compensation expense Equity (earnings) loss from equity method investments () Other () Changes in operating assets and liabilities: Accounts receivable, net () () Inventories () () Other current assets () Trade accounts payable Accrued expenses and other liabilities () Income taxes Other non-current assets and liabilities Net cash provided by operating activities Cash flows from investing activities : Additions to property, plant and equipment () () Proceeds from sale-leaseback transactions Proceeds from sale of other assets Business, investment and asset acquisitions, net of cash acquired () () Other () () Net cash used for investing activities () () Cash flows from financing activities : Net change in short-term debt with maturities of 3 months or less () () Proceeds from debt Payments of debt () () Stock purchases () () Proceeds related to employee stock plans Cash dividends paid () () Other Net cash used for financing activities () () Effect of exchange rate changes on cash, cash equivalents and restricted cash Changes in cash, cash equivalents and restricted cash : Net increase (decrease) in cash, cash equivalents and restricted cash () Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period $ $ The accompanying notes to Consolidated Condensed Financial Statements are an integral part of these statements. WBA Q1 FY2021 Form 10-Q 7 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (UNAUDITED) Note 1. WBA Q1 FY2021 Form 10-Q 8 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (UNAUDITED) Note 2. WBA Q1 FY2021 Form 10-Q 9 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (UNAUDITED) Note 3. WBA Q1 FY2021 Form 10-Q 10 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (UNAUDITED) Note 4. WBA Q1 FY2021 Form 10-Q 11 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (UNAUDITED) WBA Q1 FY2021 Form 10-Q 12 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (UNAUDITED) Note 5. WBA Q1 FY2021 Form 10-Q 13 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (UNAUDITED) Note 6. WBA Q1 FY2021 Form 10-Q 14 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (UNAUDITED) WBA Q1 FY2021 Form 10-Q 15 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (UNAUDITED) Note 7. WBA Q1 FY2021 Form 10-Q 16 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (UNAUDITED) WBA Q1 FY2021 Form 10-Q 17 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (UNAUDITED) WBA Q1 FY2021 Form 10-Q 18 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (UNAUDITED) Note 8. WBA Q1 FY2021 Form 10-Q 19 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (UNAUDITED) WBA Q1 FY2021 Form 10-Q 20 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (UNAUDITED) Note 9. WBA Q1 FY2021 Form 10-Q 21 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (UNAUDITED) Note 10. WBA Q1 FY2021 Form 10-Q 22 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (UNAUDITED) WBA Q1 FY2021 Form 10-Q 23 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (UNAUDITED) Note 11. Note 12. WBA Q1 FY2021 Form 10-Q 24 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (UNAUDITED) Note 13. WBA Q1 FY2021 Form 10-Q 25 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (UNAUDITED) Note 14. WBA Q1 FY2021 Form 10-Q 26 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (UNAUDITED) WBA Q1 FY2021 Form 10-Q 27 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (UNAUDITED) Note 15. Note 16. WBA Q1 FY2021 Form 10-Q 28 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (UNAUDITED) Note 17. WBA Q1 FY2021 Form 10-Q 29 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (UNAUDITED) Note 18. WBA Q1 FY2021 Form 10-Q 30 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (UNAUDITED) WBA Q1 FY2021 Form 10-Q 31 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS (UNAUDITED) Note 19. WBA Q1 FY2021 Form 10-Q 32 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES MANAGEMENT\\\\\\'S DISCUSSION AND ANALYSIS Item 2. Managements discussion and analysis of financial condition and results of operations The following discussion and analysis of our financial condition and results of operations should be read together with the financial statements and the related notes included elsewhere herein and the Consolidated Condensed Financial Statements, accompanying notes and managements discussion and analysis of financial condition and results of operations and other disclosures contained in the Walgreens Boots Alliance, Inc. Annual Report on Form 10-K for the fiscal year ended August 31, 2020. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results may differ materially from those discussed in forward-looking statements. Factors that might cause a difference include, but are not limited to, those discussed below under Cautionary note regarding forward-looking statements, and in item 1A, risk factors, in our Form 10-K for the fiscal year ended August 31, 2020. References herein to the Company, we, us, or our refer to Walgreens Boots Alliance, Inc. and its subsidiaries, except as otherwise indicated or the context otherwise requires. Certain amounts in the management\\\\\\'s discussion and analysis of financial condition and results of operations may not add due to rounding. All percentages have been calculated using unrounded amounts for the three months ended November 30, 2020 and November 30, 2019 . INTRODUCTION AND SEGMENTS Walgreens Boots Alliance, Inc. (Walgreens Boots Alliance) and its subsidiaries are a global leader in retail and wholesale pharmacy. Its operations are conducted through three reportable segments (sometimes referred to herein as \"divisions\"):  Retail Pharmacy USA;  Retail Pharmacy International; and  Pharmaceutical Wholesale. See Note 14, Segment reporting and Note 15, Sales to the Consolidated Condensed Financial Statements for further information. RECENT DEVELOPMENTS Pharmaceutical Wholesale Transaction On January 6, 2021, the Company entered into a Share Purchase Agreement (the Share Purchase Agreement) with AmerisourceBergen. Pursuant to the terms and subject to the conditions set forth in the Share Purchase Agreement, AmerisourceBergen will purchase the majority of the Company\\\\\\'s Alliance Healthcare business (\"Business\") for approximately $ billion, comprised of $ billion in cash, subject to certain purchase price adjustments, and million shares of AmerisourceBergen common stock (the \"Transaction\"). Alliance Healthcares investment in China and Italy and its operations in Germany are not part of the Transaction. The Transaction is subject to the satisfaction of customary closing conditions, including receipt of applicable regulatory approvals. The Company will account for the Transaction as a business disposition and report the financial results of the Business as discontinued operations beginning in the second quarter of fiscal year 2021. In connection with the Transaction, the Company and AmerisounceBergen also agreed to a (i) three-year extension through 2029 of the U.S. pharmaceutical distribution agreement pursuant to which branded and generic pharmaceutical products are sourced from AmerisourceBergen in the U.S., (ii) a three-year extension of the agreement, that provides AmerisourceBergen the ability to access generics pharmaceutical products through Walgreens Boots Alliance Development GmbH, the Companys global sourcing enterprise, (iii) a distribution agreement pursuant to which AmerisourceBergen will supply branded and generic pharmaceutical products to the Companys Boots UK business following the closing of the Transaction and (iv) explore a series of strategic initiatives designed to create incremental growth and efficiencies in sourcing, logistics and distribution. See Note 19, Subsequent events to the Consolidated Condensed Financial Statements for additional information. VillageMD investment Subsequent to November 30, 2020, the Company and VillageMD announced that the Company has accelerated its investment in VillageMD to support the opening of 600 to 700 Village Medical at Walgreens primary care clinics in more than 30 U.S. markets within the next four years, with the intent to build hundreds more thereafter. In July 2020, the Company and VillageMD announced an expansion of their partnership and the intent to open 500 to 700 clinics over a five-year period, supported by the Companys investment in VillageMD over three years of $1.0 billion in equity and convertible debt, which included an initial $250 million equity investment. The Company has now completed the remaining WBA Q1 FY2021 Form 10-Q 33 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES MANAGEMENT\\\\\\'S DISCUSSION AND ANALYSIS $750 million investment, which will allow the Company to increase the minimum number of clinics to 600 and expand the rollout at a faster pace. See Note 19, Subsequent events to the Consolidated Condensed Financial Statements for additional information. FACTORS AFFECTING OUR RESULTS AND COMPARABILITY The Company has been, and we expect it to continue to be affected by a number of factors that may cause actual results to differ from our historical results or current expectations. These factors include: the impact of the coronavirus COVID-19 (\"COVID-19\") pandemic on our operations and financial results; the financial performance of our equity method investees, including AmerisourceBergen; the influence of certain holidays; seasonality; foreign currency rates; changes in vendor, payer and customer relationships and terms and associated reimbursement pressure; strategic transactions and acquisitions, joint ventures and other strategic collaborations; changes in laws, including U.S. tax law changes; changes in trade, tariffs, including trade relations between the U.S. and China, and international relations, including the UK\\\\\\'s withdrawal from the European Union and its impact on our operations and prospects and those of our customers and counterparties; the timing and magnitude of cost reduction initiatives, including under our Transformational Cost Management Program (as defined below); the timing and severity of the cough, cold and flu season; fluctuations in variable costs; the impacts of looting, natural disasters, war, terrorism and other catastrophic events, and changes in general economic conditions in the markets in which the Company operates. These and other factors can affect the Companys operations and net earnings for any period and may cause such results not to be comparable to the same period in previous years. The results presented in this report are not necessarily indicative of future operating results. Estimated COVID-19 impacts and uncertainties COVID-19 has severely impacted, and is expected to continue to impact, the economies of the U.S., the UK and other countries around the world. COVID-19 has created significant public health concerns as well as significant volatility, uncertainty and economic disruption in every region in which we operate, all of which have adversely affected and may continue to adversely affect our industries and our business operations. Further, financial and credit markets have experienced and may again experience volatility. Policies and initiatives designed to reduce the transmission of COVID-19 have resulted in, among other things, temporary closure or reduced hours of operation of certain store locations in U.S., UK and other countries, reduced customer traffic and sales in our retail pharmacies and the adoption of work-from-home policies. COVID-19 continued to affect global economic conditions during the three months ended November 30, 2020. The Company expects this will continue in the second quarter of fiscal 2021 (including a weaker cough, cold and flu season). The situation surrounding COVID-19 remains fluid, and we are actively managing our response in collaboration with customers, government officials, team members and business partners and assessing potential impacts to our financial position and operating results, as well as developments in our business. As COVID-19 impacts the economies of the U.S., UK and other countries around the world, the Company has put preparedness plans in place at our facilities to maintain continuity of our operations, while also taking steps to keep our team members healthy and safe. During the three months ended November 30, 2020, we experienced certain adverse impacts of COVID-19. Sales were negatively impacted with the majority of the decline within the Retail Pharmacy International division. This reflected a reduction in footfall in Boots UK stores as a second national lockdown was declared in November and social distancing measures remained in place. Globally, pharmacy volume was impacted by a decline in doctor visits and gross margin was negatively impacted by higher supply chain costs in the UK. The Company took measures to keep stores open, incurring incremental selling, general and administrative expenses, including higher employee costs and store expenses related to social distancing and incremental cleaning and COVID-19 drive-thru testing sites expenses. The Company also took certain actions during the three months ended November 30, 2020 to partly mitigate the impact of COVID-19 through cost containment across the Company including temporary store closures and decreasing store hours and reducing rent at some locations. However, operating income was significantly and adversely impacted during the three months ended November 30, 2020 as a result of COVID-19. In response to COVID-19, various domestic and foreign federal, state and local governmental legislation, regulations, orders, policies and initiatives have been implemented designed to reduce the transmission of COVID-19, as well as to help address economic and market volatility and instability resulting from COVID-19. The Company has assessed and will continue to assess the impact of these governmental actions on the Company. It has participated in certain of these programs, including for example availing itself to certain tax deferrals which were introduced by the CARES Act in the U.S. and certain tax deferral and benefit and employee wage support in the UK, and may continue to do so in the future. WBA Q1 FY2021 Form 10-Q 34 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES MANAGEMENT\\\\\\'S DISCUSSION AND ANALYSIS The Company has also taken a number of proactive actions consistent with regulatory directives, such as digital \\\\\\'order ahead\\\\\\' drive-thru with an increased range of products available for drive-thru pick-up and curbside collection, and put in place new delivery options available nationwide in the U.S. To continue to work with customers and manage through the pandemic, the Company launched a new COVID-19 testing program for businesses in fiscal 2020. Since the launch of the program, the Company has administered more than 2.8 million COVID-19 tests across the US. The Company has worked with the federal and state government to help administer COVID-19 vaccines to residents and staff at more than 35,000 long-term care facilities in 49 states. The opportunity from the distribution of vaccinations is likely to be partly offset by new COVID-19 related lock-downs and restrictions, and by increased growth investments. As a result of COVID-19, a portion of our global workforce, including employees and extended workforce, rapidly shifted to a work from home environment beginning in March 2020 and many continue to work remotely. While our system of internal controls were not specifically designed and implemented to accommodate for this shift, we have evaluated and concluded that these changes to the working environment did not have a material effect on the Companys internal control over financial reporting during the most recent quarter, as further described in Item 4. Controls and procedures below. The Company will continue to monitor and assess the COVID-19 situation and its internal controls and seek to mitigate any impact on their design and operating effectiveness. The Company anticipates additional mandates and directives, including revisions thereto, from foreign, federal, state, county and city authorities throughout the continuation of the COVID-19 pandemic and for some time thereafter. The impact of this activity on the U.S. and global economies and consumer, customer and health care utilization patterns depends upon the evolving factors and future developments related to COVID-19. As a result, the financial and/or operational impact these COVID-19 related governmental actions and inactions will have on our businesses, operating results, cash flows and/or financial condition is uncertain, but the impact, singularly or collectively, could be material and adverse. We continue to closely monitor the impact of COVID-19 on our business and geographies, including how it is impacting our customers, team members, suppliers, vendors, business partners and distribution channels. However, the future impact that COVID-19 will have on our financial position and operating results may be affected by numerous uncertainties, including the severity of the virus; the duration of the outbreak; governmental, business or other actions; impacts on our supply chain; the effect on customer demand; store closures or changes and our operations. The health of our workforce, and our ability to meet staffing needs in our stores, distribution facilities, wholesale operations and other critical functions cannot be predicted but is vital to our operations. The impacts of a potential worsening of global economic conditions and continued disruptions to, and volatility in, the credit and financial markets and consumer spending, as well as other unanticipated consequences, remain unknown. Further, additional waves of COVID-19 in fiscal 2021 or beyond could cause many of the impacts to the Company described herein to return or be exacerbated. The circumstances, containment and impacts of COVID-19 remain fluid due to rising incident rates and associated additional lockdowns. The Companys current expectations described above are forward-looking statements and our actual results may differ. Factors that might cause a difference include, but are not limited to, those discussed below under Cautionary note regarding forward-looking statements and in Item 1A, Risk factors, in our Form 10-K for the fiscal year ended August 31, 2020. Pharmaceutical wholesale business in Germany On November 1, 2020, the Company and McKesson Corporation closed a transaction to form a combined pharmaceutical wholesale business in Germany, as part of a strategic alliance. The Company owns a % controlling equity interest in the combined business which is consolidated by the Company and reported within the Pharmaceutical Wholesale segment in its financial statements. The Company accounted for this acquisition as a business combination involving noncash purchase consideration of $ million consisting of the issuance of an equity interest in the combined business. See Note 2, Acquisitions to the Consolidated Condensed Financial Statements for further information. The potential impacts of Brexit As a result of a referendum in June 2016, the UK withdrew from the European Union (Brexit) on January 31, 2020. It began a transition period in which to negotiate a new trading relationship for goods and services that ended on December 31, 2020. On December 24, 2020, the EU and UK agreed to a trade deal with no tariffs nor quotas on products, regulatory and customs cooperation mechanisms as well as provisions ensuring a level playing field for open and fair competition. Since the referendum, there have been periods of significant volatility in the global stock markets and currency exchange rates, as well as challenging market conditions in the UK. Given the lack of comparable precedent, it is unclear what financial, trade, regulatory and legal implications the agreed Brexit trade deal will have on our business, particularly our UK and other European WBA Q1 FY2021 Form 10-Q 35 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES MANAGEMENT\\\\\\'S DISCUSSION AND ANALYSIS operations; however, Brexit and its related effects could have a material adverse impact on the Companys consolidated financial position and results of operations. TRANSFORMATIONAL COST MANAGEMENT PROGRAM On December 20, 2018, the Company announced a transformational cost management program that is currently expected to deliver in excess of $2.0 billion of annual cost savings by fiscal 2022 (the Transformational Cost Management Program). The Transformational Cost Management Program, which is multi-faceted and includes divisional optimization initiatives, global smart spending, global smart organization and the transformation of the Companys information technology (IT) capabilities, is designed to help the Company achieve increased cost efficiencies. To date, the Company has taken actions across all aspects of the Transformational Cost Management Program. The actions under the Transformational Cost Management Program focus on all reportable segments and the Companys global functions. Divisional optimization within each of the Companys segments includes activities such as optimization of stores including current plans to close approximately 200 Boots stores in the UK and approximately 250 stores in the U.S.. The Company currently estimates that the Transformational Cost Management Program will result in cumulative pre-tax charges to its generally accepted accounting principles in the U.S. (GAAP) financial results of approximately $2.1 billion to $2.4 billion, of which $1.8 billion to $2.1 billion are expected to be recorded as exit and disposal activities. The Company estimates that approximately 80% of the cumulative pre-tax charges will be associated with cash expenditures, primarily related to employee severance and business transition costs, IT transformation costs and lease and real estate payments. The Company currently estimates that it will recognize aggregate pre-tax charges to its GAAP financial results related to Transformational Cost Management Program as follows: Transformational Cost Management Program Activities Range of Charges Lease obligations and other real estate costs 1 $350 to 400 million Asset impairments 2 $350 to 400 million Employee severance and business transition costs $850 to 950 million Information technology transformation and other exit costs $250 to 300 million Total cumulative pre-tax exit and disposal costs $1.8 to 2.1 billion Other IT transformation costs $300 to 350 million Total estimated pre-tax costs $2.1 to 2.4 billion 1 Includes impairments relating to operating lease right-of-use and finance lease assets. 2 Primarily related to asset write-offs from store closures, information technology and other asset write-offs. In addition to the impacts discussed above, as a result of the actions related to store closures taken under the Transformational Cost Management Program, the Company recorded $508 million of transition adjustments to decrease retained earnings due to the adoption of the new lease accounting standard (Topic 842) on September 1, 2019. Since the inception of the Transformational Cost Management Program to November 30, 2020, the Company has recognized aggregate cumulative pre-tax charges to its financial results in accordance with GAAP of $1.4 billion, of which $1.2 billion are recorded as exit and disposal activities. See Note 3, Exit and disposal activities, for additional information. These charges included $264 million related to lease obligations and other real estate costs, $354 million in asset impairments, $471 million in employee severance and business transition costs, $146 million of information technology transformation and other exit costs and $139 million other information technology costs. Costs under the Transformational Cost Management Program, which were primarily recorded in selling, general and administrative expenses for the three months ended November 30, 2020 and November 30, 2019, were as follows (in millions): WBA Q1 FY2021 Form 10-Q 36 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES MANAGEMENT\\\\\\'S DISCUSSION AND ANALYSIS Three months ended November 30, 2020 Retail Pharmacy USA Retail Pharmacy International Pharmaceutical Wholesale Walgreens Boots Alliance, Inc. Lease obligations and other real estate costs $ 22 $  $  $ 22 Asset impairments 4   4 Employee severance and business transition costs 21 28 2 51 Information technology transformation and other exit costs 10 (6) 1 6 Total pre-tax exit and disposal costs $ 58 $ 22 $ 4 $ 83 Other IT transformation costs 13 6 2 21 Total pre-tax costs $ 70 $ 28 $ 6 $ 104 Three months ended November 30, 2019 Retail Pharmacy USA Retail Pharmacy International Pharmaceutical Wholesale Walgreens Boots Alliance, Inc. Lease obligations and other real estate costs $ 1 $  $  $ 1 Asset impairments 8 3  11 Employee severance and business transition costs 34 1 5 40 Information technology transformation and other exit costs 7 4 1 12 Total pre-tax exit and disposal costs $ 49 $ 9 $ 6 $ 64 Other IT transformation costs 17 3 1 21 Total pre-tax costs $ 66 $ 12 $ 7 $ 86 Transformational Cost Management Program charges are recognized as the costs are incurred over time in accordance with GAAP. The Company treats charges related to the Transformational Cost Management Program as special items impacting comparability of results in its earnings disclosures. The amounts and timing of all estimates are subject to change until finalized. The actual amounts and timing may vary materially based on various factors. See Cautionary note regarding forward-looking statements below. INVESTMENT IN AMERISOURCEBERGEN As of November 30, 2020, the Company owned 56,854,867 shares of AmerisourceBergen common stock (representing approximately 28% of its outstanding common stock based on most recent share count publicly reported by AmerisourceBergen) and may, subject to certain conditions, acquire up to an additional 8,398,752 AmerisourceBergen shares in the open market. The Company accounts for its investment in AmerisourceBergen using the equity method of accounting, subject to a two-month reporting lag, with the net earnings (loss) attributable to the investment classified within the operating income (loss) of the Companys Pharmaceutical Wholesale segment. The Company recognized equity losses in AmerisourceBergen of $1,373 million during the three months ended November 30, 2020. These equity losses are primarily due to AmerisourceBergen recognition of $5.6 billion, net of tax charges related to its ongoing opioid litigation in its financial statements for the three months period ended September 30, 2020. The financial performance of AmerisourceBergen will impact the Companys results of operations. Additionally, a substantial and sustained decline in the price of AmerisourceBergens common stock could trigger an impairment evaluation of our investment. These considerations may materially and adversely affect the Companys financial condition and results of operations. For more information, see Note 5, Equity method investments to the Consolidated Condensed Financial Statements. On January 6, 2021, the Company entered into a Share Purchase Agreement with AmerisourceBergen pursuant to which AmerisourceBergen will purchase the majority of the Company\\\\\\'s pharmaceutical wholesale operations, among other assets, for $6.275 billion in cash (subject to customary purchase price adjustments) and 2 million shares of common stock of AmerisourceBergen. See Recent Developments above and Note 19, Subsequent events to the Consolidated Condensed Financial Statements for additional information. WBA Q1 FY2021 Form 10-Q 37 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES MANAGEMENT\\\\\\'S DISCUSSION AND ANALYSIS EXECUTIVE SUMMARY The following table presents certain key financial statistics. (in millions, except per share amounts) Three months ended November 30, 2020 2019 Sales $ 36,307 $ 34,339 Gross profit 7,139 7,263 Selling, general and administrative expenses 6,207 6,262 Equity earnings (loss) in AmerisourceBergen (1,373) 13 Operating income (loss) (440) 1,013 Adjusted operating income (Non-GAAP measure) 1 1,318 1,463 Earnings (loss) before interest and income tax provision (380) 1,048 Net earnings (loss) attributable to Walgreens Boots Alliance, Inc. (308) 845 Adjusted net earnings attributable to Walgreens Boots Alliance, Inc. (Non-GAAP measure) 1 1,052 1,222 Net earnings (loss) per common share  diluted (0.36) 0.95 Adjusted net earnings per common share  diluted (Non-GAAP measure) 1 1.22 1.37 Percentage increases (decreases) Three months ended November 30, 2020 2019 Sales 5.7 1.6 Gross profit (1.7) (5.0) Selling, general and administrative expenses (0.9) (0.3) Operating income (loss) (143.5) (27.6) Adjusted operating income (Non-GAAP measure) 1 (9.9) (15.6) Earnings (loss) before interest and income tax provision (136.3) (26.5) Net earnings (loss) attributable to Walgreens Boots Alliance, Inc. (136.4) (24.8) Adjusted net earnings attributable to Walgreens Boots Alliance, Inc. (Non-GAAP measure) 1 (13.9) (11.8) Net earnings (loss) per common share  diluted (137.6) (19.8) Adjusted net earnings per common share  diluted (Non-GAAP measure) 1 (11.2) (6.0) Percent to sales Three months ended November 30, 2020 2019 Gross margin 19.7 21.1 Selling, general and administrative expenses 17.1 18.2 1 See --Non-GAAP Measures below for a reconciliation to the most directly comparable financial measure calculated in accordance with GAAP and related disclosures. WBA Q1 FY2021 Form 10-Q 38 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES MANAGEMENT\\\\\\'S DISCUSSION AND ANALYSIS WALGREENS BOOTS ALLIANCE RESULTS OF OPERATIONS Net earnings (loss) Net loss attributable to the Company for the three months ended November 30, 2020 was $308 million compared to net earnings of $845 million for the prior year period. Diluted net loss per share was $0.36 compared to diluted net earnings $0.95 for the prior year quarter. The decreases in net earnings and diluted earnings per share are primarily due to the charges reflected in the Company\\\\\\'s equity earnings (loss) in AmerisourceBergen. Other income for the three months ended November 30, 2020 was $60 million compared to income of $35 million for the prior year quarter, primarily reflecting equity earnings from other equity investments. Interest was a net expense of $140 million and $166 million for the three months ended November 30, 2020 and 2019, respectively. The effective tax rate for the three months ended November 30, 2020 was 38.2% compared to 3.6% for the prior year quarter. The increase in the effective tax rate for the three months ended November 30, 2020 was primarily due to the discrete tax effect of equity earnings in AmerisourceBergen. Adjusted net earnings (Non-GAAP measure) Adjusted net earnings attributable to Walgreens Boots Alliance for the three months ended November 30, 2020 decreased 13.9% to $1.1 billion, a decrease of 14.3% on a constant currency basis, compared with the prior year quarter. Adjusted diluted net earnings per share decreased 11.2% to $1.22, a decrease of 11.6% on a constant currency basis, compared with the prior year quarter. The decreases in adjusted net earnings and adjusted diluted net earnings per share for the three months ended November 30, 2020 primarily reflect COVID-19 impacts across the retail businesses and lower U.S. pharmacy reimbursement, partially offset by cost savings from the Transformational Cost Management Program, U.S. retail gross margin and U.S. pharmacy procurement savings. The decrease in adjusted diluted net earnings per share for the three months ended November 30, 2020 was partially offset by a lower number of shares outstanding compared with the prior year quarter. See --Non-GAAP Measures below for a reconciliation to the most directly comparable financial measure calculated in accordance with GAAP and related disclosures. RESULTS OF OPERATIONS BY SEGMENT Retail Pharmacy USA This division comprises the Company\\\\\\'s retail pharmacy business operating in the U.S.. FINANCIAL PERFORMANCE (in millions, except location amounts) Three months ended November 30, 2020 2019 Sales $ 27,163 $ 26,133 Gross profit 5,617 5,691 Selling, general and administrative expenses 4,825 4,843 Operating income 792 848 Adjusted operating income (Non-GAAP measure) 1 989 1,155 Number of prescriptions 2 204.6 213.0 30-day equivalent prescriptions 2,3 297.3 294.0 Number of locations at period end 9,001 9,175 WBA Q1 FY2021 Form 10-Q 39 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES MANAGEMENT\\\\\\'S DISCUSSION AND ANALYSIS Percentage increases (decreases) Three months ended November 30, 2020 2019 Sales 3.9 1.6 Gross profit (1.3) (5.2) Selling, general and administrative expenses (0.4) 0.2 Operating income (6.6) (27.3) Adjusted operating income (Non-GAAP measure) 1 (14.4) (16.2) Comparable sales 4 3.7 1.6 Pharmacy sales 5.9 2.9 Comparable pharmacy sales 4 5.0 2.5 Retail sales (2.2) (2.2) Comparable retail sales 4 0.4 (0.5) Comparable number of prescription 2,4 (2.5) 0.1 Comparable 30-day equivalent prescriptions 2,3,4 2.7 2.8 Percent to sales Three months ended November 30, 2020 2019 Gross margin 20.7 21.8 Selling, general and administrative expenses 17.8 18.5 1 See --Non-GAAP Measures below for a reconciliation to the most directly comparable financial measure calculated in accordance with GAAP and related disclosures. 2 Includes immunizations. 3 Includes the adjustment to convert prescriptions greater than 84 days to the equivalent of three 30-day prescriptions. This adjustment reflects the fact that these prescriptions include approximately three times the amount of product days supplied compared to a normal prescription. 4 Comparable sales are defined as sales from stores that have been open for at least twelve consecutive months without closure for seven or more consecutive days, including due to looting or store damage, and without a major remodel or being subject to a natural disaster, in the past twelve months as well as e-commerce sales. E-commerce sales include digitally initiated sales online or through mobile applications. Relocated stores are not included as comparable sales for the first twelve months after the relocation. Acquired stores are not included as comparable sales for the first twelve months after acquisition or conversion, when applicable, whichever is later. Comparable sales, comparable pharmacy sales, comparable retail sales, comparable number of prescriptions and comparable number of 30-day equivalent prescriptions refer to total sales, pharmacy sales, retail sales, number of prescriptions and number of 30-day equivalent prescriptions, respectively. Comparable retail sales for previous periods have been restated to include e-commerce sales. The method of calculating comparable sales varies across the retail industry. As a result, our method of calculating comparable sales may not be the same as other retailers methods. Sales for the three months ended November 30, 2020 and 2019 The Retail Pharmacy USA divisions sales for the three months ended November 30, 2020 increased 3.9% compared with the prior year quarter to $27.2 billion. Comparable sales increased 3.7% compared with the prior year quarter. Pharmacy sales increased 5.9% for the three months ended November 30, 2020 compared with the prior year quarter and represented 76.8% of the divisions sales. The increase is primarily due to lower generic utilization and higher volume. In the prior year quarter, pharmacy sales increased 2.9% and represented 75.4% of the divisions sales. Comparable pharmacy sales increased 5.0% for the three months ended November 30, 2020 compared to an increase of 2.5% in the prior year quarter. The effect of generic drugs, which have a lower retail price, replacing brand name drugs reduced prescription sales by 0.4% in the WBA Q1 FY2021 Form 10-Q 40 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES MANAGEMENT\\\\\\'S DISCUSSION AND ANALYSIS three months ended November 30, 2020 compared to a reduction of 2.5% in the prior year quarter. The effect of generics mix on division sales caused a reduction of 0.3% for the three months ended November 30, 2020 compared to a reduction of 1.8% for the prior year quarter. Third party sales, where reimbursement is received from managed care organizations, governmental agencies, employers or private insurers, were 97.5% of prescription sales for the three months ended November 30, 2020 compared to 96.9% in the prior year quarter. The total number of prescriptions (including immunizations) filled for the three months ended November 30, 2020 was 204.6 million compared to 213.0 million in the prior year quarter. Prescriptions (including immunizations) filled adjusted to 30-day equivalents were 297.3 million in the three months ended November 30, 2020 compared to 294.0 million in the prior year quarter. Retail sales decreased 2.2% for the three months ended November 30, 2020 compared with the prior year quarter and represented 23.1% of the divisions sales. In the prior year quarter, retail sales decreased 2.2% and comprised 24.6% of the divisions sales. Comparable retail sales increased 0.4% in the three months ended November 30, 2020 compared to a decrease of 0.5% in the prior year quarter . The current period was impacted by a weaker cough, cold and flu season and decrease in discretionary categories offset by increase in health and wellness, excluding cough, cold and flu categories. Operating income for the three months ended November 30, 2020 and 2019 Retail Pharmacy USA divisions operating income for the three months ended November 30, 2020 decreased 6.6% compared with the prior year quarter to $792 million. The decrease was primarily due to pharmacy reimbursement pressure and adverse COVID-19 impacts partly offset by savings from the Transformational Cost Management Program and acquisition-related costs related to Rite Aid stores in the prior year quarter results. Gross margin was 20.7% for the three months ended November 30, 2020 compared to 21.8% in the prior year quarter. Gross margin was negatively impacted in the current period by pharmacy margins, which were negatively impacted by reimbursement pressure and COVID-19 impacts. Selling, general and administrative expenses as a percentage of sales were 17.8% for the three months ended November 30, 2020 compared to 18.5% in the prior year quarter. As a percentage of sales, expenses were lower in the current period primarily due to savings related to the Transformational Cost Management Program partially offset by COVID-19 impacts and higher growth investment. Adjusted operating income (Non-GAAP measure) for the three months ended November 30, 2020 and 2019 Retail Pharmacy USA divisions adjusted operating income for the three months ended November 30, 2020 decreased compared with the prior year quarter 14.4% to $989 million. The decrease was primarily due to lower pharmacy margins which were negatively impacted by increased reimbursement pressure and COVID-19 impacts. See --Non-GAAP Measures below for a reconciliation to the most directly comparable financial measure calculated in accordance with GAAP and related disclosures. Retail Pharmacy International This division comprises the Company\\\\\\'s retail pharmacy businesses operating in countries outside the U.S. and in currencies other than the U.S. dollar, including the British pound sterling, Euro, Chilean peso and Mexican peso and therefore the divisions results are impacted by movements in foreign currency exchange rates. See Item 3, Quantitative and qualitative disclosure about market risk, foreign currency exchange rate risk, for further information on currency risk. FINANCIAL PERFORMANCE (in millions, except location amounts) Three months ended November 30, 2020 2019 Sales $ 2,574 $ 2,745 Gross profit 961 1,056 Selling, general and administrative expenses 928 1,012 Operating income 34 44 Adjusted operating income (Non-GAAP measure) 1 84 79 Number of locations at period end 4,394 4,578 WBA Q1 FY2021 Form 10-Q 41 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES MANAGEMENT\\\\\\'S DISCUSSION AND ANALYSIS Percentage increases (decreases) Three months ended November 30, 2020 2019 Sales (6.2) (5.4) Gross profit (9.0) (6.3) Selling, general and administrative expenses (8.4) (3.5) Operating income (loss) (22.7) (43.7) Adjusted operating income (loss) (Non-GAAP measure) 1 6.4 (40.5) Comparable sales in constant currency 2 (3.1) (1.4) Pharmacy sales 0.1 (3.7) Comparable pharmacy sales in constant currency 2 3.8 0.6 Retail sales (9.8) (6.3) Comparable retail sales in constant currency 2 (7.6) (2.5) Percent to sales Three months ended November 30, 2020 2019 Gross margin 37.3 38.5 Selling, general and administrative expenses 36.0 36.9 1 See --Non-GAAP Measures below for a reconciliation to the most directly comparable financial measure calculated in accordance with GAAP and related disclosures. 2 Comparable sales in constant currency are defined as sales from stores that have been open for at least twelve consecutive months without closure for seven or more consecutive days, including due to looting or store damage, and without a major remodel or being subject to a natural disaster, in the past twelve months as well as e-commerce sales. E-commerce sales include digitally initiated sales online or through mobile applications. Relocated stores are not included as comparable stores for the first twelve months after the relocation. Acquired stores are not included as comparable sales for the first twelve months after acquisition or conversion, when applicable, whichever is later. Comparable sales in constant currency, comparable pharmacy sales in constant currency and comparable retail sales in constant currency refer to total sales, pharmacy sales and retail sales, respectively. Comparable retail sales in constant currency for previous periods have been restated to include e-commerce sales. The method of calculating comparable sales in constant currency varies across the retail industry. As a result, our method of calculating comparable sales in constant currency may not be the same as other retailers methods. The Company presents certain information related to current period operating results in constant currency, which is a non-GAAP financial measure. Comparable sales in constant currency, comparable pharmacy sales in constant currency and comparable retail sales in constant currency exclude the effects of fluctuations in foreign currency exchange rates. See --Non-GAAP Measures. Sales for the three months ended November 30, 2020 and 2019 Retail Pharmacy International divisions sales for the three months ended November 30, 2020 decreased compared to the prior year quarter 6.2% to $2.6 billion. Sales were positively impacted in the quarter by 1.9 percentage points ($53 million) as a result of currency translation. Comparable sales in constant currency decreased 3.1%, primarily due to lower retail sales in Boots UK, including COVID-19 impacts. Pharmacy sales increased 0.1% for the three months ended November 30, 2020 compared to the prior year quarter and represented 38.9% of the divisions sales. The positive impact of currency translation on pharmacy sales in the quarter was 1.5 percentage points. Comparable pharmacy sales in constant currency increased 3.8% from the prior year quarter primarily due to higher National Health Service (\"NHS\") reimbursement levels in the UK and pharmacy volumes in Mexico. This is partially offset by lower UK prescription volume and reduced demand for pharmacy services during the COVID-19 pandemic in the UK. WBA Q1 FY2021 Form 10-Q 42 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES MANAGEMENT\\\\\\'S DISCUSSION AND ANALYSIS Retail sales decreased 9.8% for the three months ended November 30, 2020 compared to the prior year quarter and represented 61.1% of the divisions sales. The positive impact of currency translation on retail sales in the quarter was 2.2 percentage points. Comparable retail sales in constant currency decreased 7.6% from the prior year quarter reflecting lower retail sales in Boots UK, including COVID-19 impacts. Operating income for the three months ended November 30, 2020 and 2019 Retail Pharmacy International divisions operating income for the three months ended November 30, 2020 decreased compared to the prior year quarter 22.7% to $34 million. The decrease reflects increased investment in the Transformational Cost Management Program. Excluding the impact of the increased investment in the Transformational Cost Management Program, the lower footfall is fully mitigated by decisive cost management actions and strong performance of Boots.com. Gross profit decreased 9.0% from the prior year quarter. Gross profit in the quarter was positively impacted by 2.3 percentage points ($24 million) as a result of currency translation. Excluding the impact of currency translation, the decrease was primarily due to lower retail sales in Boots UK and higher fulfillment costs partially offset by favorable timing of NHS reimbursement. Selling, general and administrative expenses decreased 8.4% from the prior year quarter. Expenses in the quarter were negatively impacted by 2.0 percentage points ($21 million) as a result of currency translation. Excluding the impact of currency translation, the decrease was due to short term cost mitigation and savings from the Transformational Cost Management Program. As a percentage of sales, selling, general and administrative expenses were 36.0% in the three months ended November 30, 2020 compared to 36.9% in the prior year quarter. Adjusted operating income (Non-GAAP measure) for the three months ended November 30, 2020 and 2019 Retail Pharmacy International divisions adjusted operating income for the three months ended November 30, 2020 increased 6.4% to $84 million compared to the prior year quarter. Adjusted operating income in the quarter was positively impacted by 5.8 percentage points ($5 million) as a result of currency translation. Excluding the impact of currency translation, the increase was mainly due to decisive cost management actions and strong performance of Boots.com mitigating the impact of lower footfall. See --Non-GAAP Measures below for a reconciliation to the most directly comparable financial measure calculated in accordance with GAAP and related disclosures. Pharmaceutical Wholesale This division includes the Company\\\\\\'s pharmaceutical wholesale businesses operating in currencies other than the U.S. dollar including the British pound sterling, Euro and Turkish lira, and thus the divisions results are impacted by movements in foreign currency exchange rates. See Item 3, Quantitative and qualitative disclosure about market risk, foreign currency exchange rate risk, for further information on currency risk. On January 6, 2021, the Company entered into a Share Purchase Agreement with AmerisourceBergen pursuant to which AmerisourceBergen will purchase the majority of the Company\\\\\\'s pharmaceutical wholesale operations, among other assets, for $6.275 billion in cash (subject to customary purchase price adjustments) and 2 million shares of common stock of AmerisourceBergen. See Recent Developments above and Note 19, Subsequent events to the Consolidated Condensed Financial Statements for additional information. FINANCIAL PERFORMANCE (in millions) Three months ended November 30, 2020 2019 Sales $ 7,125 $ 6,007 Gross profit 560 517 Selling, general and administrative expenses 455 407 Equity earnings (loss) in AmerisourceBergen (1,373) 13 Operating income (loss) (1,268) 122 Adjusted operating income (Non-GAAP measure) 1 244 229 WBA Q1 FY2021 Form 10-Q 43 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES MANAGEMENT\\\\\\'S DISCUSSION AND ANALYSIS Percentage increases (decreases) Three months ended November 30, 2020 2019 Sales 18.6 5.2 Gross profit 8.5 0.8 Selling, general and administrative expenses 11.6 2.9 Operating income (loss) (1,140.6) (21.5) Adjusted operating income (Non-GAAP measure) 1 6.7 4.1 Comparable sales in constant currency 2 8.3 8.3 Percent to sales Three months ended November 30, 2020 2019 Gross margin 7.9 8.6 Selling, general and administrative expenses 6.4 6.8 1 See --Non-GAAP Measures below for a reconciliation to the most directly comparable financial measure calculated in accordance with GAAP and related disclosures. 2 Comparable sales in constant currency are defined as sales excluding acquisitions and dispositions. The Company presents certain information related to current period operating results in constant currency, which is a non-GAAP financial measure. Comparable sales in constant currency exclude the effects of fluctuations in foreign currency exchange rates. See --Non-GAAP Measures below. Sales for the three months ended November 30, 2020 and 2019 Pharmaceutical Wholesale divisions sales for the three months ended November 30, 2020, including results of the Company\\\\\\'s new combined business in Germany which were consolidated as of November, increased 18.6% compared to the prior year quarter to $7.1 billion. Sales were positively impacted in the quarter by 2.3 percentage points ($137 million) as a result of currency translation. Comparable sales in constant currency which exclude the incremental impact of the joint venture, increased 8.3% compared to the prior year quarter, primarily due to growth in emerging markets and COVID-19 related sales in France. Operating income (loss) for the three months ended November 30, 2020 and 2019 Pharmaceutical Wholesale divisions operating loss for the three months ended November 30, 2020 was $1.3 billion, including $1.4 billion loss from the Company\\\\\\'s share of equity earnings in AmerisourceBergen. This compared with operating income of $122 million in the prior year quarter, including $13 million from the Company\\\\\\'s equity earnings in AmerisourceBergen. Operating loss in the quarter was negatively impacted by 1.8 percentage points ($2 million) as a result of currency translation. The operating loss is primarily due to $1.4 billion related to the Company\\\\\\'s share of equity loss in AmerisourceBergen, partially offset by sales growth. Gross profit increased 8.5% from the prior year quarter. Gross profit in the quarter was positively impacted by 2.4 percentage points ($12 million) as a result of currency translation. Excluding the currency translation impact, the increase was primarily due to sales growth partially offset by lower gross margins. Selling, general and administrative expenses increased 11.6% from the prior year quarter. Expenses in the quarter were negatively impacted by 3.5 percentage points ($14 million) as a result of currency translation. Excluding the currency translation impact, the increase was due to additional costs due to impact of sales growth and from the company\\\\\\'s new joint venture in Germany. As a percentage of sales, selling, general and administrative expenses for the three months ended November 30, 2020 were 6.4% compared to 6.8% in the prior year quarter. WBA Q1 FY2021 Form 10-Q 44 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES MANAGEMENT\\\\\\'S DISCUSSION AND ANALYSIS Adjusted operating income (Non-GAAP measure) for the three months ended November 30, 2020 and 2019 Pharmaceutical Wholesale divisions adjusted operating income for the three months ended November 30, 2020, which includes $108 million from the Companys share of adjusted equity earnings in AmerisourceBergen, increased 6.7% compared to the prior year quarter to $244 million. Adjusted operating income in the quarter was negatively impacted by 0.7 percentage points ($2 million) as a result of currency translation. Excluding the impact of currency translation, the increase in adjusted operating income was primarily due to sales growth and a higher contribution of adjusted equity earnings from AmerisourceBergen. See --Non-GAAP Measures below for a reconciliation to the most directly comparable financial measure calculated in accordance with GAAP and related disclosures. NON-GAAP MEASURES The following information provides reconciliations of the supplemental non-GAAP financial measures, as defined under the rules of the SEC, presented herein to the most directly comparable financial measures calculated and presented in accordance with GAAP. The Company has provided the non-GAAP financial measures, which are not calculated or presented in accordance with GAAP, as supplemental information and in addition to the financial measures that are calculated and presented in accordance with GAAP. These supplemental non-GAAP financial measures are presented because the Company\\\\\\'s management has evaluated its financial results both including and excluding the adjusted items or the effects of foreign currency translation, as applicable, and believes that the supplemental non-GAAP financial measures presented provide additional perspective and insights when analyzing the core operating performance of the Company from period to period and trends in its historical operating results. These supplemental non-GAAP financial measures should not be considered superior to, as a substitute for or as an alternative to, and should be considered in conjunction with, the GAAP financial measures presented. The Company also presents certain information related to current period operating results in constant currency, which is a non-GAAP financial measure. These amounts are calculated by translating current period results at the foreign currency exchange rates used in the comparable period in the prior year. The Company presents such constant currency financial information because it has significant operations outside of the U.S. reporting in currencies other than the U.S. dollar and such presentation provides a framework to assess how its business performed excluding the impact of foreign currency exchange rate fluctuations. NON-GAAP RECONCILIATION (in millions) Three months ended November 30, 2020 Retail Pharmacy USA Retail Pharmacy International Pharmaceutical Wholesale Eliminations Walgreens Boots Alliance, Inc. Operating income (loss) (GAAP) $ 792 $ 34 $ (1,268) $ 1 $ (440) Adjustments to equity earnings (loss) in AmerisourceBergen   1,481  1,481 Acquisition-related amortization 76 20 20  116 Transformational cost management 70 28 6  104 LIFO provision 33    33 Acquisition-related costs 17 2 5  23 Adjusted operating income (Non-GAAP measure) $ 989 $ 84 $ 244 $ 1 $ 1,318 WBA Q1 FY2021 Form 10-Q 45 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES MANAGEMENT\\\\\\'S DISCUSSION AND ANALYSIS (in millions) Three months ended November 30, 2019 Retail Pharmacy USA Retail Pharmacy International Pharmaceutical Wholesale Eliminations Walgreens Boots Alliance, Inc. Operating income (GAAP) $ 848 $ 44 $ 122 $  $ 1,013 Adjustments to equity earnings in AmerisourceBergen   80  80 Acquisition-related amortization 77 22 19  118 Transformational cost management 66 12 7  86 LIFO provision 33    33 Acquisition-related costs 122  1  124 Store optimization 9    9 Adjusted operating income (Non-GAAP measure) $ 1,155 $ 79 $ 229 $  $ 1,463 Three months ended November 30, 2020 2019 Net earnings (loss) attributable to Walgreens Boots Alliance, Inc. (GAAP) $ (308) $ 845 Adjustments to operating income (loss): Adjustments to equity earnings (loss) in AmerisourceBergen 1 1,481 80 Acquisition-related amortization 2 116 118 Transformational cost management 3 104 86 LIFO provision 4 33 33 Acquisition-related costs 5 23 124 Store optimization 3  9 Total adjustments to operating income (loss) 1,759 449 Adjustments to other income (expense): Net investment hedging (gain) loss 6 9 (11) Gain on sale of equity method investment 7  (1) Total adjustments to other income (expense) 9 (12) Adjustments to income tax provision: U.S. tax law changes 8  (6) Tax impact of adjustments 8 (67) (80) Equity method non-cash tax 8 (346) (2) Total adjustments to income tax provision (412) (88) Adjustments to post tax equity earnings from other equity method investments: Adjustments to equity earnings in other equity method investments 9 13 28 Total adjustments to post tax equity earnings from other equity method investments 13 28 Adjustments to net earnings (loss) attributable to noncontrolling interests: WBA Q1 FY2021 Form 10-Q 46 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES MANAGEMENT\\\\\\'S DISCUSSION AND ANALYSIS Acquisition-related amortization 2 (4)  LIFO provision 4 (3)  Total adjustments to net earnings (loss) attributable to noncontrolling interests (8)  Adjusted net earnings attributable to Walgreens Boots Alliance, Inc. (Non-GAAP measure) $ 1,052 $ 1,222 Diluted net earnings (loss) per common share (GAAP) 10 $ (0.36) $ 0.95 Adjustments to operating income (loss) 2.03 0.50 Adjustments to other income (expense) 0.01 (0.01) Adjustments to income tax provision (0.48) (0.10) Adjustments to equity earnings in other equity method investments 9 0.01 0.03 Adjustments to net earnings (loss) attributable to noncontrolling interests (0.01)  Adjusted diluted net earnings per common share (Non-GAAP measure) 11 $ 1.22 $ 1.37 Weighted average common shares outstanding, diluted (in millions) 11 865.3 892.6 1 Adjustments to equity earnings (loss) in AmerisourceBergen consist of the Companys proportionate share of non-GAAP adjustments reported by AmerisourceBergen consistent with the Companys non-GAAP measures. The Company recognized equity losses in AmerisourceBergen of $1,373 million during the three months ended November 30, 2020. These equity losses are primarily due to AmerisourceBergen recognition of $5.6 billion, net of tax, charges related to its ongoing opioid litigation in its financial statements for the three months period ended September 30, 2020. 2 Acquisition-related amortization includes amortization of acquisition-related intangible assets and inventory valuation adjustments. Amortization of acquisition-related intangible assets includes amortization of intangibles assets such as customer relationships, trade names, trademarks and contract intangibles. Intangible asset amortization excluded from the related non-GAAP measure represents the entire amount recorded within the Companys GAAP financial statements, the revenue generated by the associated intangible assets has not been excluded from the related non-GAAP measures. Amortization expense, unlike the related revenue, is not affected by operations of any particular period unless an intangible asset becomes impaired or the estimated useful life of an intangible asset is revised. These charges are primarily recorded within selling, general and administrative expenses. Business combination accounting principles require us to measure acquired inventory at fair value. The fair value of the inventory reflects cost of acquired inventory and a portion of the expected profit margin. The acquisition-related inventory valuation adjustments excludes the expected profit margin component from cost of sales recorded under the business combination accounting principles. 3 Transformational Cost Management Program and Store Optimization Program charges are costs associated with a formal restructuring plan. These charges are primarily recorded within selling, general and administrative expenses. These costs do not reflect current operating performance and are impacted by the timing of restructuring activity. 4 The Companys Retail Pharmacy USA segment inventory is accounted for using the last-in-first-out (LIFO) method. This adjustment represents the impact on cost of sales as if Retail Pharmacy USA segment inventory is accounted for using first-in first-out (FIFO) method. The LIFO provision is affected by changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and other external influences. Therefore, the Company cannot control the amounts recognized or timing of these items. 5 Acquisition-related costs are transaction and integration costs associated with certain merger and acquisition related activities. These costs include all charges incurred on certain mergers and acquisition related activities, for example, including costs related to integration efforts for successful merger and acquisition activities. These charges are primarily recorded within selling, general and administrative expenses. These costs are significantly impacted by the timing and complexity of the underlying merger and acquisition related activities and do not reflect the Companys current operating performance. 6 Gain or loss on certain derivative instruments used as economic hedges of the Companys net investments in foreign subsidiaries. These charges are recorded within other income (expense). We do not believe this volatility related to mark-to-market adjustment on the underlying derivative instruments reflects the Companys operational performance. 7 Includes significant gain on sale of equity method investment and related adjustments. WBA Q1 FY2021 Form 10-Q 47 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES MANAGEMENT\\\\\\'S DISCUSSION AND ANALYSIS 8 Adjustments to income tax provision include adjustments to the GAAP basis tax provision commensurate with non-GAAP adjustments and certain discrete tax items including U.S. tax law changes, a UK tax rate change and equity method non-cash tax. These charges are recorded within income tax provision (benefit). 9 Adjustments to post tax equity earnings from other equity method investments consist of the proportionate share of certain equity method investees non-cash items or unusual or infrequent items consistent with the Companys non-GAAP adjustments. These charges are recorded within post tax earnings (loss) from other equity method investments. Although the Company may have shareholder rights and board representation commensurate with its ownership interests in these equity method investees, adjustments relating to equity method investments are not intended to imply that the Company has direct control over their operations and resulting revenue and expenses. Moreover, these non-GAAP financial measures have limitations in that they do not reflect all revenue and expenses of these equity method investees. 10 Due to the anti-dilutive effect resulting from the reported net loss, the impact of potentially dilutive securities on the per share amounts has been omitted from the quarterly calculation of weighted-average common shares outstanding for diluted earnings per share for the three months ended November 30, 2020. 11 Includes impact of potentially dilutive securities in the quarterly calculation of weighted-average common shares, diluted for adjusted diluted net earnings per common share calculation purposes for the three months ended November 30, 2020. The Company considers certain metrics presented in this report, such as comparable sales, comparable pharmacy sales, comparable retail sales, comparable number of prescriptions, and comparable 30-day equivalent prescriptions, to be key performance indicators because the Companys management has evaluated its results of operations using these metrics and believes that these key performance indicators presented provide additional perspective and insights when analyzing the core operating performance of the Company from period to period and trends in its historical operating results. These key performance indicators should not be considered superior to, as a substitute for or as an alternative to, and should be considered in conjunction with, the GAAP financial measures presented herein. These measures, which are described in more detail in this report, may not be comparable to similarly-titled performance indicators used by other companies. LIQUIDITY AND CAPITAL RESOURCES Cash and cash equivalents were $1.1 billion (including $0.4 billion in non-U.S. jurisdictions) as of November 30, 2020, compared to $0.8 billion (including $0.3 billion in non-U.S. jurisdictions) as of November 30, 2019. Short-term investment objectives are primarily to minimize risk and maintain liquidity. To attain these objectives, investment limits are placed on the amount, type and issuer of securities. Investments are principally in U.S. Treasury money market funds. The Company\\\\\\'s long-term capital policy is to: maintain a strong balance sheet and financial flexibility; reinvest in its core strategies; invest in strategic opportunities that reinforce its core strategies and meet return requirements; and return surplus cash flow to stockholders in the form of dividends and share repurchases over the long term. In June 2018, the Companys Board of Directors reviewed and refined the Companys dividend policy to set forth the Companys current intention to increase its dividend each year. Cash provided by operations and the incurrence of debt are the principal sources of funds for expansion, investments, acquisitions, remodeling programs, dividends to stockholders and stock repurchases. Net cash provided by operating activities for the three months ended November 30, 2020 was $1.2 billion, compared to $1.1 billion for the prior year quarter. The $0.1 billion increase in cash provided by operating activities reflects higher cash inflows from trade accounts payable, income taxes, and non-current assets and liabilities partially offset by higher cash outflows from accrued expenses and other liabilities, accounts receivables and inventories. Changes in accrued expenses and other liabilities are mainly driven by a non-comparable 2021 bonus payment. Changes in trade accounts payables, income taxes and other non-current assets and liabilities are mainly driven by timing of collections and payments. Net cash used for investing activities was $259 million for the three months ended November 30, 2020 compared to $402 million for the prior year quarter. This change in net cash used for investing activities includes $231 million in proceeds from sale-leaseback transactions for the three months ended November 30, 2020 compared to $147 million for the prior year quarter. Business, investment and asset acquisitions were $77 million for the three months ended November 30, 2020 compared to $180 million for the prior year quarter. WBA Q1 FY2021 Form 10-Q 48 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES MANAGEMENT\\\\\\'S DISCUSSION AND ANALYSIS For the three months ended November 30, 2020, additions to property, plant and equipment were $431 million compared to $387 million in the prior year quarter. Capital expenditures by reporting segment were as follows (in millions): Three months ended November 30, 2020 2019 Retail Pharmacy USA $ 353 $ 303 Retail Pharmacy International 58 70 Pharmaceutical Wholesale 21 13 Total $ 431 $ 387 Significant capital expenditures primarily relate to growth initiatives and information technology projects. Net cash used for financing activities for the three months ended November 30, 2020 was $352 million, compared to $866 million in the prior year period. In the three months ended November 30, 2020 there were $3.3 billion in net debt proceeds primarily from revolving credit facilities described below and commercial paper debt compared to $4.7 billion in net proceeds in the prior year period. For the three months ended November 30, 2020 there were $3.2 billion in payments of debt made primarily for revolving credit facilities and commercial paper debt compared to $4.7 billion for the three months ended November 30, 2019. The Company repurchased shares totaling $110 million to support the needs of its employee stock plans for the three months ended November 30, 2020 compared to $473 million in the prior year quarter which also included stock repurchase program described below. Proceeds related to employee stock plans were $4 million during the three months ended November 30, 2020, compared to $14 million during the three months ended November 30, 2019. Cash dividends paid were $405 million during the three months ended November 30, 2020, compared to $410 million for the prior year quarter. The Company expects to fund its working capital needs, capital expenditures, pending acquisitions, dividend payments and debt service obligations from liquidity sources including cash flow from operations, availability under existing credit facilities, commercial paper programs, working capital financing arrangements and current cash and investment balances. The Company believes that these sources, and the ability to obtain other financing will provide adequate cash funds for the Companys foreseeable working capital needs, capital expenditures, pending acquisitions, dividend payments and debt service obligations for at least the next 12 months. The Companys cash requirements are subject to change as business conditions warrant and opportunities arise. The timing and size of any new business ventures or acquisitions that the Company may complete may also impact its cash requirements. Additionally, the Companys cash requirements, and its ability to generate cash flow, have been and may continue to be adversely affected by COVID-19 and the resulting market volatility and instability. For further information regarding the impact of COVID-19 on the Company, including on its liquidity and capital resources, please see Item 1A, Risk factors in the Company\\\\\\'s Annual Report on Form 10-K for the fiscal year ended August 31, 2020. See Item 3, Qualitative and quantitative disclosures about market risk, below for a discussion of certain financing and market risks. Stock repurchase program In June 2018, the Company\\\\\\'s Board of Director\\\\\\'s approved a stock repurchase program (the June 2018 stock repurchase program), which authorized the repurchase of up to $10.0 billion of the Company\\\\\\'s common stock of which the Company had repurchased $8.0 billion as of November 30, 2020. The June 2018 stock repurchase program has no specified expiration date. In July 2020, the Company announced that it was suspending activities under this program. The Company may continue to repurchase stock to offset anticipated dilution from equity incentive plans. The Company determines the timing and amount of repurchases, including repurchases to offset anticipated dilution from equity incentive plans, based on its assessment of various factors, including prevailing market conditions, alternate uses of capital, liquidity and the economic environment. The Company has repurchased, and may from time to time in the future repurchase, shares on the open market through Rule 10b5-1 plans, which enable the Company to repurchase shares at times when we otherwise might be precluded from doing so under federal securities laws. Commercial paper The Company periodically borrows under its commercial paper program and may borrow under it in future periods. The Company had average daily U.S. commercial paper outstanding of $1.6 billion and $2.9 billion at a weighted average interest rate of 0.63% and 2.55% for the three months ended November 30, 2020 and 2019, respectively. A subsidiary of the Company WBA Q1 FY2021 Form 10-Q 49 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES MANAGEMENT\\\\\\'S DISCUSSION AND ANALYSIS had average daily commercial paper outstanding, which was issued under the Joint HM Treasury and Bank of England\\\\\\'s COVID Corporate Financing Facility commercial paper program, of 300 million or approximately $401 million at a weighted average interest rate of 0.43% for the three months ended November 30, 2020. The subsidiary\\\\\\'s repayment obligations are guaranteed by the Company. Financing actions On August 29, 2018, the Company entered into a revolving credit agreement (the August 2018 Revolving Credit Agreement) with the lenders and letter of credit issuers from time to time party thereto. The August 2018 Revolving Credit Agreement is an unsecured revolving credit facility with aggregate commitment in the amount of $3.5 billion, with a letter of credit subfacility commitment amount of $500 million. The facility termination date is the earlier of (a) August 29, 2023, subject to extension thereof pursuant to the August 2018 Revolving Credit Agreement, and (b) the date of termination in whole of the aggregate amount of the revolving commitments pursuant to the August 2018 Revolving Credit Agreement. Borrowings under the August 2018 Revolving Credit Agreement will bear interest at a fluctuating rate per annum equal to, at the Company\\\\\\'s option, the alternate base rate or the Eurocurrency rate, in each case, plus an applicable margin calculated based on the Company\\\\\\'s credit ratings. As of November 30, 2020, there were no borrowings outstanding under the August 2018 Revolving Credit Agreement. On November 30, 2018, the Company entered into a $1.0 billion credit agreement, consisting of a $500 million senior unsecured revolving credit facility and a $500 million senior unsecured term loan facility, with the lenders from time to time party thereto, on March 25, 2019, the Company entered into an amendment to such credit agreement (such credit agreement as so amended, the November 2018 Credit Agreement) reflecting certain changes to the borrowing notice provisions thereto. On April 2, 2020, the Company entered into a second amendment to the November 2018 Credit Agreement (such credit agreement as so further amended, the Amended November 2018 Credit Agreement), which amendment became effective as of May 29, 2020. As of May 29, 2020, the $500 million revolving credit facility portion of the November 2018 Credit Agreement was converted into a term loan facility, such that the Amended November 2018 Credit Agreement consists of a $1.0 billion senior unsecured term loan facility. The facility termination date is the earlier of (a) May 29, 2021 and (b) the date of acceleration of all loans under the Amended November 2018 Credit Agreement pursuant to its terms. Borrowings under the Amended November 2018 Credit Agreement will bear interest at a fluctuating rate per annum equal to, at the Companys option, the alternate base rate or the Eurocurrency rate, plus an applicable margin of 1.25% in the case of Eurocurrency rate loans and 0.125% in the case of alternative base rate loans. As of November 30, 2020, there were $0.9 billion of borrowings outstanding under the Amended November 2018 Credit Agreement. On December 5, 2018, the Company entered into a $1.0 billion term loan credit agreement with the lenders from time to time party thereto and, on August 9, 2019, the Company entered into an amendment to such credit agreement (such credit agreement as so amended, the December 2018 Credit Agreement) to permit the Company to borrow, repay and reborrow amounts borrowed thereunder prior to the maturity date. On April 2, 2020, the Company amended and restated the December 2018 Credit Agreement (such credit agreement as so amended and restated, the A&R December 2018 Credit Agreement). The A &R December 2018 Credit Agreement governs a $2.0 billion senior unsecured revolving credit facility, consisting of the initial $1.0 billion senior unsecured revolving facility (the \"Initial Commitments\") previously governed by the December 2018 Credit Agreement and a new $1.0 billion senior unsecured revolving credit facility (the \"New Commitments\"). The facility termination date is the earlier of (a) January 29, 2021 (the \"Initial Maturity Date\") (which date shall be extended to February 26, 2021 or July 31, 2021 pursuant to the terms of the A &R December 2018 Credit Agreement if the Company extends the maturity date of certain of its existing credit agreements or enters into new bank or bond financings with a certain maturity date and above an aggregate principal amount as described in the A &R December 2018 Credit Agreement ) and (b) the date of termination in whole of the aggregate amount of the commitments pursuant to the A &R December 2018 Credit Agreement. Borrowings under the A&R December 2018 Credit Agreement will bear interest at a fluctuating rate per annum equal to, at the Companys option, the alternate base rate or the Eurocurrency rate, plus an applicable margin of (i) in the case of the Initial Facility from April 2, 2020 through and including the Initial Maturity Date, 0.75% in the case of Eurocurrency rate loans and 0.00% in the case of alternate base rate loans and (ii) in the case of the New Facility and the Initial Facility after the Initial Maturity Date, 1.50% in the case of Eurocurrency rate loans and 0.50% in the case of alternate base rate loans. As of November 30, 2020, there were $0.7 billion borrowings outstanding under the A&R December 2018 Credit Agreement. Concurrently with the execution of the 2020 Revolving Credit Agreement described above, the A&R December 2018 Credit Agreement was partially terminated in accordance with its terms and conditions, by the cancellation of $1 billion of New Commitments, thereby reducing the amount available to $1 billion of Initial Commitments thereunder as of December 23, 2020. The A&R was also amended to set the final maturity date under the agreement at January 29, 2021. On January 18, 2019, the Company entered into a $2.0 billion 364-day revolving credit agreement (as extended, the January 2019 364-Day Revolving Credit Agreement) with the lenders from time to time party thereto. The January 2019 364-Day WBA Q1 FY2021 Form 10-Q 50 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES MANAGEMENT\\\\\\'S DISCUSSION AND ANALYSIS Revolving Credit Agreement is a senior unsecured 364-day revolving credit facility, with an original facility termination date of 364 days following January 31, 2019, subject to extension. On December 18, 2019, the Company entered into an Extension Agreement (the Extension Agreement) relating to the January 2019 364-Day Revolving Credit Agreement with the lenders party thereto and Mizuho, as administrative agent. The Extension Agreement extended the Maturity Date (as defined in the January 2019 364-Day Revolving Credit Agreement) for an additional period of 364 days to January 28, 2021. Such extension became effective on January 30, 2020.Borrowings under the January 2019 364-Day Revolving Credit Agreement will bear interest at a fluctuating rate per annum equal to, at the Company\\\\\\'s option, the alternate base rate or the Eurocurrency rate, in each case, plus an applicable margin calculated based on the Companys credit ratings. As of November 30, 2020, there were no borrowings outstanding under the January 364-Day Revolving Credit Agreement. The January 2019 364-Day Revolving Credit Agreement was partially terminated in accordance with its terms and conditions, reducing the amount available to $0.5 billion as of December 23, 2020, concurrently with the execution of the 2020 Revolving Credit Agreement described below. On August 30, 2019, the Company entered into three $500 million revolving credit agreements (together, the August 2019 Revolving Credit Agreements and each individually, an August 2019 Revolving Credit Agreement) with the lenders from time to time party thereto. Each of the August 2019 Revolving Credit Agreements are senior unsecured revolving credit facilities, with facility termination dates of the earlier of (a) 18 months following August 30, 2019, subject to extension thereof pursuant to the applicable August 2019 Revolving Credit Agreement, and (b) the date of termination in whole of the aggregate amount of the commitments pursuant to the applicable August 2019 Revolving Credit Agreement. Borrowings under each of the August 2019 Revolving Credit Agreements will bear interest at a fluctuating rate per annum equal to, at the Company\\\\\\'s option, the alternate base rate or the Eurocurrency rate, plus an applicable margin of 0.95% in the case of Eurocurrency rate loans. As of November 30, 2020, there were no borrowings outstanding under the August 2019 Revolving Credit Agreements. The August 2019 Revolving Credit Agreements were terminated in accordance with their terms and conditions as of December 23, 2020. The August 2019 Revolving Credit Agreements were terminated concurrently with the execution of the 2020 Revolving Credit Agreement described below. The Company entered into a $750 million revolving credit agreement on April 1, 2020 (the April 2020 Revolving Bilateral Credit Agreement) and a $1.325 billion revolving credit agreement on April 2, 2020 (the April 2020 Revolving Club Credit Agreement and together with the April 2020 Revolving Bilateral Credit Agreement, the Other April 2020 Revolving Credit Agreements) with the lenders from time to time party thereto. Each of the Other April 2020 Revolving Credit Agreements is a senior unsecured revolving credit facility, with a facility termination date of the earlier of (a) March 31, 2021 (which date shall be shortened pursuant to the terms of the applicable Other April 2020 Revolving Credit Agreement if the Company does not extend the maturity date of certain of its existing credit agreements or enter into new bank or bond financings with a certain maturity date and above an aggregate principal amount as described in the applicable Other April 2020 Revolving Credit Agreement ) and (b) the date of termination in whole of the aggregate amount of the commitments pursuant to the applicable Other April 2020 Revolving Credit Agreement. Borrowings under the Other April 2020 Revolving Credit Agreements will bear interest at a fluctuating rate per annum equal to, at the Companys option, the Eurocurrency rate or the alternate base rate, plus an applicable margin of 1.25% in the case of Eurocurrency rate loans. As of November 30, 2020, there were no borrowings outstanding under the Other April 2020 Revolving Credit Agreements. The other April 2020 Revolving Credit Agreements were terminated in accordance with their terms and conditions as of December 23, 2020. The other April 2020 Revolving Credit Agreements were terminated concurrently with the execution of the 2020 Revolving Credit Agreement described below. On April 7, 2020, the Company and with WBA Financial Services Limited, a private limited company incorporated under the laws of England and Wales (WBAFSL), as co-borrowers, entered into a $500 million revolving credit agreement (the April 7, 2020 Revolving Credit Agreement) with the lenders from time to time party thereto. The April 7, 2020 Revolving Credit Agreement is a senior unsecured revolving credit facility, with a facility termination date of the earlier of (a) 364-days from April 7, 2020 and (b) the date of termination in whole of the aggregate amount of the commitments pursuant to the April 7, 2020 Revolving Credit Agreement . The Company and WBAFSL are co-borrowers under the April 7, 2020 Revolving Credit Agreement. Pursuant to the terms of the April 7, 2020 Revolving Credit Agreement, the Company provides a guarantee of any obligations of WBAFSL under the April 7, 2020 Revolving Credit Agreement. Borrowings under the April 7, 2020 Revolving Credit Agreement will bear interest at a fluctuating rate per annum equal to, at the Companys option, the Eurocurrency rate or the alternate base rate, plus an applicable margin of 1.50% in the case of Eurocurrency rate loans. As of November 30, 2020, there were no borrowings outstanding under the April 7, 2020 Revolving Credit Agreement. The April 7, 2020 Revolving Credit Agreement was terminated in accordance with its terms and conditions on December 23, 2020. The April 7, 2020 Revolving Credit Agreement was terminated concurrently with the execution of the 2020 Revolving Credit Agreement described below. WBA Q1 FY2021 Form 10-Q 51 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES MANAGEMENT\\\\\\'S DISCUSSION AND ANALYSIS On April 15, 2020, the Company issued in an underwritten public offering $0.5 billion of 3.20% notes due 2030 and $1.0 billion of 4.10% notes due 2050. Total issuance costs relating to the notes, including underwriting discounts and estimated offering expenses were $13.3 million. On October 20, 2020, the Company redeemed in full the 400 million aggregate principal amount outstanding of its 2.875% notes due 2020 issued by the Company on November 20, 2014. On December 23, 2020, the Company entered into a revolving credit agreement (the 2020 Revolving Credit Agreement) with the lenders from time to time party thereto. The 2020 Revolving Credit Agreement includes a (i) a $1.25 billion senior unsecured 364-day revolving credit facility (the 364-Day Facility) and (ii) a $2.25 billion senior unsecured 18-month revolving credit facility, with a swing line subfacility commitment amount of $350 million. The 364-Day Facilitys termination date is the earlier of (i) 364 days from December 23, 2020, the effective date (subject to the extension thereof pursuant to the 2020 Revolving Credit Agreement) and (ii) the date of termination in whole of the aggregate amount of the revolving commitments under the 364-Day Facility pursuant to the 2020 Revolving Credit Agreement. The 18-Month Facilitys termination date is the earlier of (i) 18 months from the effective date (subject to the extension thereof pursuant to the 2020 Revolving Credit Agreement) and (ii) the date of termination in whole of the aggregate amount of the revolving commitments under the 18-Month Facility pursuant to the 2020 Revolving Credit Agreement. After the entry into the 2020 Revolving Credit Agreement and the full or partial termination of the Companys other credit agreements as discussed herein, as of December 23, 2020, the Company had an aggregate borrowing capacity of $9.5 billion including funds already drawn. Debt covenants Each of the Companys credit facilities described above contain a covenant to maintain, as of the last day of each fiscal quarter, a ratio of consolidated debt to total capitalization not to exceed 0.60:1.00, subject to increase in certain circumstances set forth in the applicable credit agreement. As of November 30, 2020, the Company was in compliance with all such applicable covenants. Credit ratings As of January 6, 2021, the credit ratings of Walgreens Boots Alliance were: Rating agency Long-term debt rating Commercial paper rating Outlook Fitch BBB- F3 Negative Moodys Baa2 P-2 Negative Standard & Poors BBB A-2 Negative In assessing the Companys credit strength, each rating agency considers various factors including the Companys business model, capital structure, financial policies and financial performance. There can be no assurance that any particular rating will be assigned or maintained. The Companys credit ratings impact its borrowing costs, access to capital markets and operating lease costs. The rating agency ratings are not recommendations to buy, sell or hold the Companys debt securities or commercial paper. Each rating may be subject to revision or withdrawal at any time by the assigning rating agency and should be evaluated independently of any other rating. AmerisourceBergen relationship As of November 30, 2020, the Company owned 56,854,867 AmerisourceBergen common shares representing approximately 28% of the outstanding common stock based on most recent share count publicly reported by AmerisourceBergen and had designated one member of AmerisourceBergens board of directors. As of November 30, 2020, the Company can acquire up to an additional 8,398,752 AmerisourceBergen shares in the open market and thereafter designate another member of AmerisourceBergens board of directors, subject in each case to applicable legal and contractual requirements. The amount of permitted open market purchases is subject to increase or decrease in certain circumstances. Subject to applicable legal and contractual requirements, share purchases may be made from time to time in open market transactions or pursuant to instruments and plans complying with Rule 10b5-1. See Note 5, Equity method investments, to the Consolidated Condensed Financial Statements for further information. WBA Q1 FY2021 Form 10-Q 52 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES MANAGEMENT\\\\\\'S DISCUSSION AND ANALYSIS On January 6, 2021, the Company entered into a Share Purchase Agreement with AmerisourceBergen pursuant to which AmerisourceBergen will purchase the majority of the Company\\\\\\'s pharmaceutical wholesale operations, among other assets, for $6.275 billion in cash (subject to customary purchase price adjustments) and 2 million shares of common stock of AmerisourceBergen. See Recent Developments above and Note 19, Subsequent events to the Consolidated Condensed Financial Statements for additional information. OFF-BALANCE SHEET ARRANGEMENTS The Company does not have any unconsolidated special purpose entities and, except as described herein, the Company does not have significant exposure to any off-balance sheet arrangements. The term off-balance sheet arrangement generally means any transaction, agreement or other contractual arrangement to which an entity not consolidated by the Company is a party, under which we have: (i) any obligation arising under a guarantee contract, derivative instrument or variable interest; or (ii) a retained or contingent interest in assets transferred to such entity or similar arrangement that serves as credit, liquidity or market risk support for such assets. At November 30, 2020, the Company had $17 million of guarantees outstanding and no amounts issued under letters of credit. CONTRACTUAL OBLIGATIONS AND COMMITMENTS There have been no material changes, outside of the ordinary course of business, in the Company\\\\\\'s outstanding contractual obligations disclosed in the Company\\\\\\'s Annual Report on Form 10-K for the year ended August 31, 2020. CRITICAL ACCOUNTING POLICIES The Consolidated Condensed Financial Statements are prepared in accordance with GAAP and include amounts based on managements prudent judgments and estimates. Actual results may differ from these estimates. Management believes that any reasonable deviation from those judgments and estimates would not have a material impact on our consolidated financial position or results of operations. To the extent that the estimates used differ from actual results, however, adjustments to the statement of earnings and corresponding balance sheet accounts would be necessary. These adjustments would be made in future periods. For a discussion of our significant accounting policies, please see the Company\\\\\\'s Annual Report on Form 10-K for the fiscal year ended August 31, 2020. Some of the more significant estimates include business combinations, leases, goodwill and indefinite-lived intangible asset impairment, cost of sales and inventory, equity method investments, pension and postretirement benefits and income taxes. See Note 17, New accounting pronouncements, to the Consolidated Condensed Financial Statements for additional information. NEW ACCOUNTING PRONOUNCEMENTS A discussion of new accounting pronouncements is described in Note 17, New accounting pronouncements, to the Consolidated Condensed Financial Statements of this Quarterly Report on Form 10-Q and is incorporated herein by reference. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This report and other documents that we file or furnish with the SEC contain forward-looking statements that are based on current expectations, estimates, forecasts and projections about our future performance, our business, our beliefs and our managements assumptions. In addition, we, or others on our behalf, may make forward-looking statements in press releases or written statements, on the Companys website or in our communications and discussions with investors and analysts in the normal course of business through meetings, webcasts, phone calls, conference calls and other communications. Some of such forward-looking statements may be based on certain data and forecasts relating to our business and industry that we have obtained from internal surveys, market research, publicly available information and industry publications. Industry publications, surveys and market research generally state that the information they provide has been obtained from sources believed to be reliable, but that the accuracy and completeness of such information is not guaranteed. Statements that are not historical facts are forward-looking statements, including, without limitation, those regarding estimates of and goals for future financial and operating performance as well as forward-looking statements concerning the potential impacts on our business of the spread and impact of COVID-19, the expected execution and effect of our business strategies, our cost-savings and growth initiatives, pilot programs, strategic partnerships and initiatives, and restructuring activities and the amounts and timing of their expected impact and delivery of estimated cost savings, the withdrawal of the UK from the European Union and its possible effects our amended and restated asset purchase agreement with Rite Aid and the transactions contemplated thereby and their possible timing and effects, our commercial agreement with AmerisourceBergen, the arrangements and transactions contemplated by our framework agreement with AmerisourceBergen and their possible effects, the closing of the sale of certain pharmaceutical wholesale operations to AmerisourceBergen pursuant to the Share Purchase Agreement dated January 6, 2021, estimates of the impact of developments on our earnings, earnings per share and other financial and operating metrics, cough, cold and flu season, prescription volume, pharmacy sales trends, prescription margins and reimbursement rates, changes in generic WBA Q1 FY2021 Form 10-Q 53 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES MANAGEMENT\\\\\\'S DISCUSSION AND ANALYSIS prescription drug prices, retail margins, number and location of new store openings, network participation, vendor, payer and customer relationships and terms, possible new contracts or contract extensions, competition, economic and business conditions, outcomes of litigation and regulatory matters, the level of capital expenditures, industry trends, demographic trends, growth strategies, financial results, cost reduction initiatives, impairment or other charges, acquisition and joint venture synergies, competitive strengths and changes in legislation or regulations. All statements in the future tense and all statements accompanied by words such as expect, likely, outlook, forecast, preliminary, pilot, would, could, should, can, will, project, intend, plan, goal, guidance, target, aim, continue, sustain, synergy, transform, accelerate, model, long-term, on track, on schedule, headwind, tailwind, believe, seek, estimate, anticipate, upcoming, to come, may, possible, assume, and variations of such words and similar expressions are intended to identify such forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions, known or unknown, that could cause actual results to vary materially from those indicated or anticipated, including, but not limited to, those relating to the impact of private and public third-party payers efforts to reduce prescription drug reimbursements, risks relating to the spread and impact of COVID-19, including the adverse impact on the global economy as well as our business, the risks associated with the withdrawal of the UK from the European Union, fluctuations in foreign currency exchange rates, the timing and magnitude of the impact of branded to generic drug conversions and changes in generic drug prices, our ability to realize synergies and achieve financial, tax and operating results in the amounts and at the times anticipated, the inherent risks, challenges and uncertainties associated with forecasting financial results of large, complex organizations in rapidly evolving industries, particularly over longer time periods, and during periods with increased volatility and uncertainties, supply arrangements including our commercial agreement with AmerisourceBergen, the arrangements and transactions contemplated by our framework agreement with AmerisourceBergen and their possible effects, the risks associated with our equity method investment in AmerisourceBergen, circumstances that could give rise to the termination, cross-termination or modification of any of our contractual obligations, the amount of costs, fees, expenses and charges incurred in connection with strategic transactions, whether the costs and charges associated with restructuring initiatives, including the Transformational Cost Management Program and Store Optimization Program, will exceed estimates, our ability to realize expected savings and benefits from cost-savings initiatives, including the Transformational Cost Management Program and Store Optimization Program, restructuring activities and acquisitions and joint ventures in the amounts and at the times anticipated, the timing and amount of any impairment or other charges, the timing and severity of cough, cold and flu season, risks relating to looting and vandalism in regions in which we operate and the scope and magnitude of any property damage, inventory loss or other adverse impacts, risks related to pilot programs and new business initiatives and ventures generally, including the risks that anticipated benefits may not be realized, changes in managements plans and assumptions, the risks associated with governance and control matters, the ability to retain key personnel, changes in economic and business conditions generally or in particular markets in which we participate, changes in financial markets, credit ratings and interest rates, the risks relating to the terms, timing and magnitude of any share repurchase activity, the risks associated with international business operations, including international trade policies, tariffs, including tariff negotiations between the U.S. and China, and relations, the risks associated with cybersecurity or privacy breaches related to customer information, changes in vendor, customer and payer relationships and terms, including changes in network participation and reimbursement terms and the associated impacts on volume and operating results, risks related to competition including changes in market dynamics, participants, product and service offerings, retail formats and competitive positioning, risks associated with new business areas and activities, risks associated with acquisitions, divestitures, joint ventures and strategic investments, including those relating to the asset acquisition from Rite Aid, the risks associated with the integration of complex businesses, the impact of regulatory restrictions and outcomes of legal and regulatory matters and risks associated with changes in laws, including those related to the December 2017 U.S. tax law changes, regulations or interpretations thereof. These and other risks, assumptions and uncertainties are described in Item 1A, Risk factors, in the Walgreens Boots Alliance Annual Report on Form 10-K for the fiscal year ended August 31, 2020 and in other documents that we file or furnish with the SEC. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. All forward-looking statements we make or that are made on our behalf are qualified by these cautionary statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Except to the extent required by law, we do not undertake, and expressly disclaim, any duty or obligation to update publicly any forward-looking statement after the date of this report, whether as a result of new information, future events, changes in assumptions or otherwise. WBA Q1 FY2021 Form 10-Q 54 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Item 3. Quantitative and qualitative disclosure about market risk Interest rate risk The Company is exposed to interest rate volatility with regard to existing variable-rate debt instruments and future incurrences of fixed or variable-rate debt, which exposure primarily relates to movements in various interest rates, such as U.S treasury rates and commercial paper rates. From time to time, the Company uses interest rate swaps and forward-starting interest rate swaps to hedge its exposure to the impact of interest rate changes on existing debt and future debt issuances respectively, to reduce the volatility of financing costs and, based on current and projected market conditions, achieve a desired proportion of fixed-rate versus floating-rate debt. Generally under these swaps, the Company agrees with a counterparty to exchange the difference between fixed-rate and floating-rate interest amounts based on an agreed upon notional principal amount. The Chief Executive of the UK Financial Conduct Authority (the FCA), which regulates the London Interbank Offered Rate, or LIBOR, has announced that the FCA will no longer compel LIBOR panel banks to submit rates for the calculation of LIBOR after 2021. That announcement indicates that the continuation of LIBOR on the current basis will not be guaranteed after 2021. Moreover, it is possible that LIBOR may be discontinued prior to the end of 2021. Certain of our credit facilities provide that, under certain circumstances set forth in such credit facilities, we and the administrative agent may amend the applicable credit facility to replace LIBOR with an alternate benchmark rate, giving due consideration to any evolving or then existing convention for similar syndicated credit facilities in the U.S. market for alternative benchmarks. Such alternative benchmark rate could include the secured overnight financing rate, also known as SOFR, published by the Federal Reserve Bank of New York Information regarding the Company\\\\\\'s transactions are set forth in Note 8, Financial instruments, to the Consolidated Condensed Financial Statements. These financial instruments are sensitive to changes in interest rates. On November 30, 2020, the Company had no material long-term debt obligations that had floating interest rates. The amounts exclude the impact of any associated derivative contracts. Foreign currency exchange rate risk The Company is exposed to fluctuations in foreign currency exchange rates, primarily with respect to the British pound sterling and Euro, and certain other foreign currencies, which may affect its net investment in foreign subsidiaries and may cause fluctuations in cash flows related to foreign denominated transactions. The Company is also exposed to the translation of foreign currency earnings to the U.S. dollar. The Company enters into foreign currency forward contracts to hedge against the effect of exchange rate fluctuations on non-functional currency cash flows. These transactions are almost exclusively less than 12 months in maturity. In addition, the Company enters into foreign currency forward contracts that are not designated in hedging relationships to offset, in part, the impacts of certain intercompany activities (primarily associated with intercompany financing transactions). The Companys foreign currency derivative instruments are sensitive to changes in exchange rates. A hypothetical 1% change in foreign currency exchange rates versus the U.S. dollar would change the fair value of the foreign currency derivatives held as of November 30, 2020, by approximately $32 million. The foreign currency derivatives are intended to partially hedge anticipated transactions, foreign currency trade payables and receivables and net investments in foreign subsidiaries. Equity price risk Changes in AmerisourceBergen common stock price may have a significant impact on the fair value of the equity investment in AmerisourceBergen described in Note 5, Equity method investments, to the Consolidated Condensed Financial Statements. See --Investment in AmerisourceBergen above. WBA Q1 FY2021 Form 10-Q 55 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES ITEM 4. CONTROLS AND PROCEDURES Item 4. Controls and procedures Evaluation of disclosure controls and procedures Management conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Form 10-Q. The controls evaluation was conducted under the supervision and with the participation of the Companys management, including its Chief Executive Officer (CEO) and Chief Financial Officer (CFO). As of the end of the period covered by this report, the Company had completed the creation of a combined pharmaceutical wholesale business in Germany with McKesson Corporation. The Company accounted for this acquisition as a business combination. The scope of management\\\\\\'s assessment of the effectiveness of the Company\\\\\\'s disclosure controls and procedures did not include the internal controls over financial reporting of the acquired business. This exclusion is in accordance with the SEC staff\\\\\\'s general guidance that an assessment of a recently acquired business may be omitted from the scope of management\\\\\\'s assessment for one year following the acquisition. The recognition of goodwill and intangible assets, however, is covered by our internal controls over mergers and acquisitions, which were included in management\\\\\\'s assessment of the effectiveness of the Company\\\\\\'s internal control over financial reporting as of November 30, 2020. Based upon the controls evaluation, our CEO and CFO have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the SEC, and that such information is accumulated and communicated to management, including the CEO and CFO, as appropriate to allow timely decisions regarding required disclosure. Changes in internal control over financial reporting In the ordinary course of business, the Company reviews its internal control over financial reporting and makes changes to its systems and processes that are intended to enhance such controls and increase efficiency while maintaining an effective internal control environment. Changes may include such activities as updating existing systems, automating manual processes, standardizing controls and modifying monitoring controls. As a result of COVID-19, a portion of our global workforce, including employees and extended workforce, rapidly shifted to a work from home environment beginning in March 2020 and many continue to work remotely. While our controls were not developed and designed to facilitate or accommodate this shift, we have evaluated and concluded that these changes to the working environment did not have a material effect on the Companys internal control over financial reporting during the most recent quarter. As we transform our business processes, we continue to make strategic changes in how we perform certain key business functions. These changes include the continued leveraging of extended workforces via third-party outsource arrangements as well as our continued implementation of new information systems. Specifically, the Company is currently implementing a new enterprise resource planning (ERP) system. This project is a multi-year initiative and is intended to improve the efficiency and effectiveness of certain financial and business transaction processes, as well as the underlying systems environment. These initiatives are not being implemented in response to any identified internal control deficiency or weakness. As these changes occur, we will evaluate quarterly whether such changes materially affect, or are reasonably likely to materially affect, the Company\\\\\\'s internal control over financial reporting. In connection with the evaluation pursuant to Exchange Act Rule 13a-15(d) of the Companys internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f)) by the Companys management, including its CEO and CFO, no changes during the quarter ended November 30, 2020 were identified that have materially affected, or are reasonably likely to materially affect, the Companys internal control over financial reporting. Inherent limitations on effectiveness of controls Our management, including the CEO and CFO, do not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control systems objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls WBA Q1 FY2021 Form 10-Q 56 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES ITEM 4. CONTROLS AND PROCEDURES effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Part II. Other Information Item 1. Legal proceedings The information in response to this item is incorporated herein by reference to Note 10, Commitments and contingencies, to the Consolidated Condensed Financial Statements of this Quarterly Report. Item 103 of SEC Regulation S-K requires disclosure of environmental legal proceedings with, or any such legal proceedings known to be contemplated by, a governmental authority if management reasonably believes that the proceedings involve potential monetary sanctions, exclusive of interest and costs, above the lesser of $1.0 million or 1% of the Companys current assets. As previously disclosed, the Company has been under investigation by certain counties within the State of California for alleged noncompliance with state hazardous waste regulations. The Company has worked with state and local officials in an effort to resolve this matter. On November 16, 2020, a number of California District Attorneys submitted a complaint and a signed settlement agreement to a California state court in Alameda County ( People of the State of California v. Walgreen Co. , Case No. RG20081172 ) for review and approval. If approved by the court, the settlement, which includes certain injunctive relief, would require the Company to pay penalties and costs and fund supplemental environmental projects in the total amount of $3.5 million. The court approved the settlement. Item 1A. Risk factors In addition to the other information set forth in this report, you should carefully consider the factors discussed in item 1A. \"Risk factors\" in the Walgreens Boots Alliance Annual Report on Form 10-K for the year ended August 31, 2020, which could materially affect our business, financial condition or future results. Item 2. Unregistered sales of equity securities and use of proceeds The following table provides information about purchases by the Company during the quarter ended November 30, 2020 of equity securities that are registered by the Company pursuant to Section 12 of the Exchange Act. Subject to applicable law, share purchases may be made from time to time in open market transactions, privately negotiated transactions including accelerated share repurchase agreements, or pursuant to instruments and plans complying with Rule 10b5-1. Issuer purchases of equity securities Period Total number of shares purchased by month Average price paid per share Total number of shares purchased by month as part of publicly announced repurchase programs 1 Approximate dollar value of shares that may yet be purchased under the plans or program 1 09/01/20 - 09/30/20  $   $ 2,003,419,960 10/01/20 - 10/31/20 1,420,000 37.03  2,003,419,960 11/01/20 - 11/30/20 1,580,000 36.46  2,003,419,960 3,000,000 $ 36.73  $ 2,003,419,960 1 In June 2018, Walgreens Boots Alliance authorized a stock repurchase program, which authorized the repurchase of up to $10.0 billion of Walgreens Boots Alliance common stock. This program has no specified expiration date. In July 2020, the Company announced that it had suspended activities under this program. WBA Q1 FY2021 Form 10-Q 57 WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES PART II. OTHER INFORMATION Item 5. Other information None Item 6. Exhibits The agreements included as exhibits to this report are included to provide information regarding their terms and not intended to provide any other factual or disclosure information about the Company or the other parties to the agreements. The agreements may contain representations and warranties by each of the parties to the applicable agreement that were made solely for the benefit of the other parties to the applicable agreement, and:  should not in all instances be treated as categorical statements of fact, but rather as a way of allocating the risk to one of the parties if those statements prove to be inaccurate;  may have been qualified by disclosures that were made to the other party in connection with the negotiation of the applicable agreement, which disclosures are not necessarily reflected in the agreement;  may apply standards of materiality in a way that is different from what may be viewed as material to you or other investors; and  were made only as of the date of the applicable agreement or such other date or dates as may be specified in the agreement and are subject to more recent developments. Accordingly, these representations and warranties may not describe the actual state of affairs as of the date they were made or at any other time. Exhibit No. Description SEC Document Reference 3.1 Amended and Restated Certificate of Incorporation of Walgreens Boots Alliance, Inc. Incorporated by reference to Exhibit 3.1 to Walgreens Boots Alliance, Inc.s Current Report on Form 8-K12B (File No. 1-36759) filed with the SEC on December 31, 2014. 3.2 Amended and Restated Bylaws of Walgreens Boots Alliance, Inc. Incorporated by reference to Exhibit 3.1 to Walgreens Boots Alliance, Inc.s Current Report on Form 8-K (File No. 1-36759) filed with the SEC on June 10, 2016. 10. 1* Form of Performance Share Award agreement (effective October 2020). Incorporated by reference to Exhibit 10.1 to Walgreens Boots Alliance, Inc.s Current Report on Form 8-K (File No. 1-36759) filed with the SEC on October 30, 2020. 10.2* Form of Stock Option Award agreement (effective October 2020). Incorporated by reference to Exhibit 10.2 to Walgreens Boots Alliance, Inc.s Current Report on Form 8-K (File No. 1-36759) filed with the SEC on October 30, 2020. 10.3 * Form of Stock Option Award agreement under UK Sub-plan (effective October 2020). Incorporated by reference to Exhibit 10.3 to Walgreens Boots Alliance, Inc.s Current Report on Form 8-K (File No. 1-36759) filed with the SEC on October 30, 2020. 10.4 * Form of Restricted Stock Unit Award agreement (effective October 2020). Incorporated by reference to Exhibit 10.4 to Walgreens Boots Alliance, Inc.s Current Report on Form 8-K (File No. 1-36759) filed with the SEC on October 30, 2020. 10.5 * Form of Restricted Stock Unit Award agreement for Executive Chairman (effective October 2020). Incorporated by reference to Exhibit 10.5 to Walgreens Boots Alliance, Inc.s Current Report on Form 8-K (File No. 1-36759) filed with the SEC on October 30, 2020. - 58 - WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES PART II. OTHER INFORMATION 10.6 Revolving Credit Agreement, dated as of December 23, 2020, by and among Walgreens Boots Alliance, Inc., the Designated Borrowers from time to time party thereto, the Lenders from time to time party thereto and Wells Fargo Bank, National Association, as Administrative Agent and Swing Line Lender. Incorporated by reference to Exhibit 10.1 to Walgreens Boots Alliance, Inc.s Current Report on Form 8-K (File No. 1-36759) filed with the SEC on December 28, 2020. 10.7 Amendment No. 1 to Amended and Restated Revolving Credit Agreement, dated as of December 23, 2020, by and among Walgreens Boots Alliance Inc. and Wells Fargo Bank, National Association, as administrative agent and as sole lender, amending that certain Amended and Restated Revolving Credit Agreement, dated as of April 2, 2020, by and among Walgreens Boots Alliance, Inc. and Wells Fargo Bank, National Association, as administrative agent and as sole lender. File herewith. 31.1 Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Filed herewith. 31.2 Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Filed herewith. 32.1 Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350. Furnished herewith. 32.2 Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350. Furnished herewith. 101.INS Inline XBRL Instance Document (The following financial information from this Quarterly Report on Form 10-Q for the quarter ended November 30, 2020 formatted in Inline XBRL (Extensive Business Reporting Language) includes: (i) the Consolidated Condensed Balance Sheets; (ii) the Consolidated Condensed Statements of Equity; (iii) the Consolidated Condensed Statement of Earnings; (iv) the Consolidated Condensed Statements of Comprehensive Income; (v) the Consolidated Condensed Statements of Cash Flows; and (vi) Notes Financial Statements). Filed herewith. 101.SCH Inline XBRL Taxonomy Extension Schema Document Filed herewith. 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document Filed herewith. 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document Filed herewith. 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document Filed herewith. 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document Filed herewith. 104 Cover Page Interactive Data File (formatted as Inline XBRL document and included in Exhibit 101) Filed herewith. ___________________________ * Management contract or compensatory plan or arrangement WBA Q1 FY2021 Form 10-Q 59 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Walgreens Boots Alliance, Inc. (Registrant) Dated: January 7, 2021 /s/ James Kehoe James Kehoe Executive Vice President and Global Chief Financial Officer (Principal Financial Officer) Dated: January 7, 2021 /s/ Heather Dixon Heather Dixon Senior Vice President, Global Controller and Chief Accounting Officer (Principal Accounting Officer) WBA Q1 FY2021 Form 10-Q 60\\' b\\'EX-10.7 2 a107amendmenttorevolvingar.htm EX-10.7 Document Execution Version AMENDMENT NO. 1 TO AMENDED AND RESTATED REVOLVING CREDIT AGREEMENT This AMENDMENT NO. 1 TO AMENDED AND RESTATED REVOLVING CREDIT AGREEMENT dated as of December 23, 2020 (this  Amendment ) is entered into among Walgreens Boots Alliance, Inc., a Delaware corporation (the  Borrower ), and Wells Fargo Bank, National Association ( Wells Fargo ), as administrative agent (in such capacity, the  Administrative Agent ) and as the sole Lender (as defined below) party to the Credit Agreement (as defined below) as of the date hereof. RECITALS WHEREAS, the Borrower, the Administrative Agent and the lenders from time to time party thereto (including Wells Fargo, the  Lenders ) entered into an Amended and Restated Revolving Credit Agreement dated as of April 2, 2020 (as the same may have been amended, supplemented or otherwise modified prior to the date hereof and including the schedules and exhibits attached thereto, the  Credit Agreement ), pursuant to which the Lenders agreed to extend credit to the Borrower. WHEREAS, the Borrower has requested that the Credit Agreement be amended as set forth below, and Administrative Agent and the Lender party hereto consent to this Amendment. NOW THEREFORE, for and in consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Borrower, the Administrative Agent and Wells Fargo, as the sole Lender as of the date hereof, hereby agree as follows: 1. Defined Terms . Capitalized terms used and not otherwise defined herein have the meanings assigned to them in the Credit Agreement. 2. Amendments to the Credit Agreement . Effective on the Amendment Effective Date (as defined below), the Credit Agreement shall be amended as follows: (a) Schedule 1.01 shall be updated to add the following term in the proper alphabetical order:  Amendment No. 1 Effective Date  means December 23, 2020. (b) The definition of Maturity Date contained in Section 1.01 of the Credit Agreement shall be amended and restated in its entirety as follows:  Maturity Date  means the Initial Maturity Date. #93960756v4 (c) The definition of February Extension Maturity Date, July Extension Maturity Date and Updated Unused Commitment Fee contained in Section 1.01 of the Credit Agreement shall be deleted. (d) The definition of Commitment Fee contained in Section 1.01 of the Credit Agreement shall be amended and restated in its entirety as follows:  Commitment Fee  means, collectively, the Existing Unused Commitment Fee and the New Commitment Fee. (e) Section 2.05(a)(i) of the Credit Agreement shall be amended and restated as follows: The Borrower agrees to pay to the Administrative Agent for the account of each Existing Lender a commitment fee in Dollars at a per annum rate equal to 0.11% per annum (the  Existing Unused Commitment Fee ) on the daily actual excess of such Existing Lenders Existing Commitment over the outstanding principal amount of such Existing Lenders outstanding Existing Loans (such excess, such Lenders  Actual Existing Facility Unused Commitments ) as adjusted pursuant to Section 2.05(c), accruing from and including the Initial Effective Date to and including the earlier of the Initial Maturity Date and the date on which the Existing Commitments have been terminated in full and all Obligations in respect of the Existing Facility have been paid in full pursuant to Section 2.07(b), payable quarterly in arrears on each Payment Date. (f) The chart under the term Existing Facility in Schedule 1.01 of the Credit Agreement shall be amended and restated in its entirety as follows: Applicable Margin for Eurocurrency Existing Loans Applicable Margin for Alternate Base Rate Existing Loans On the Initial Effective Date through and including the Initial Maturity Date (or, if earlier, the Facility Termination Date for the Existing Facility): 0.75% 0.00% (g) Schedule 2.01 of the Credit Agreement shall be amended and restated in its entirety as follows: LENDER EXISTING COMMITMENT AS OF AMENDMENT AND RESTATEMENT EFFECTIVE DATE PRO RATA SHARE OF THE EXISTING FACILITY AS OF THE AMENDMENT AND RESTATEMENT EFFECTIVE DATE NEW COMMITMENT AS OF AMENDMENT NO. 1 EFFECTIVE DATE PRO RATA SHARE OF THE NEW FACILITY AS OF THE AMENDMENT NO. 1 EFFECTIVE DATE Wells Fargo Bank, National Association $1,000,000,000 100% $0 N/A 3. Conditions to Effectiveness . This Amendment shall become effective on the date (the  Amendment Effective Date ) when the Administrative Agent shall have received counterparts to this Amendment executed by the Borrower and Wells Fargo, as sole Lender as of the date hereof. 2 4. Representations and Warranties. The Borrower represents and warrants that: (a) No Default or Unmatured Default has occurred and is continuing on or as of the Amendment Effective Date; and (b) The representations and warranties contained in Article V of the Credit Agreement (other than the representations and warranties contained in Sections 5.05 and 5.06 of the Credit Agreement) are true and correct in all material respects (except to the extent such representations and warranties are qualified by materiality or Material Adverse Effect or similar terms, in which case such representations and warranties are be true and correct in all respects) as of the Amendment Effective Date, except to the extent any such representation or warranty is stated to relate solely to an earlier date, in which case such representation or warranty is true and correct in all material respects (except to the extent such representations and warranties are qualified with materiality or Material Adverse Effect or similar terms, in which case such representations and warranties are true and correct in all respects) on and as of such earlier date. 5. Ratification; No Novation . Except to the extent hereby amended, the Credit Agreement and each of the Loan Documents remain in full force and effect and are hereby ratified and affirmed. The Credit Agreement, as amended by the Amendment, is not intended to be, and shall not constitute, a novation. All Loans made, and all Obligations incurred, under the Credit Agreement which are outstanding on the Amendment Effective Date shall constitute Loans and Obligations, respectively, under (and shall be governed by the terms of) the Credit Agreement, as amended by the Amendment, and the other Loan Documents. 6. Indemnities . The Borrower agrees that this Amendment constitutes a Loan Document, and Section 9.06 of the Credit Agreement is hereby incorporated by reference herein and shall extend to the preparation, execution and delivery of this Amendment. 7. Limitation . This Amendment shall be limited precisely as written and except as expressly provided herein, shall not be deemed to be a consent granted pursuant to, or a waiver or modification of, any term or condition of the Credit Agreement or any of the instruments or agreements referred to therein or to prejudice any right or rights which the Administrative Agent or the Lenders may now have or have in the future under or in connection with the Credit Agreement or any of the instruments or agreements referred to therein. Unless the context indicates otherwise, on and after the Amendment Effective Date, whenever the Credit Agreement is referred to in the Credit Agreement, the other Loan Documents or any of the instruments, agreements or other documents or papers executed or delivered in connection therewith, such reference shall be deemed to mean the Credit Agreement as amended by this Amendment. 8. Counterparts . This Amendment may be executed in any number of counterparts and by the different parties hereto in separate counterparts, each of which shall be an original and all of which, when taken together, shall constitute but one and the same instrument. A facsimile or .pdf copy of a counterpart signature page shall serve as the functional equivalent of a manually executed copy for all purposes. 3 9. Governing Law . THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK. 10. Consent to Jurisdiction; Waiver of Jury Trial . Each of Sections 15.02 and 15.03 of the Credit Agreement are hereby incorporated by reference herein and shall extend to the preparation, execution and delivery of this Amendment. [SIGNATURE PAGES FOLLOW] 4 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed by their respective authorized officers as of the day and year first above written. WALGREENS BOOTS ALLIANCE, INC. as the Borrower By: /s/ John Devlin Name: John Devlin Title: Treasury Vice President By: /s/ Aidan Clare Name: Aidan Clare Title: Vice President and Global Treasurer [Signature Page to Amendment] WELLS FARGO BANK, NATIONAL ASSOCIATION, as the Administrative Agent By: /s/ Jordan Harris Name: Jordan Harris Title: Managing Director WELLS FARGO BANK, NATIONAL ASSOCIATION, as Lender By: /s/ Jordan Harris Name: Jordan Harris Title: Managing Director [Signature Page to Amendment]\\' b\"EX-31.1 3 a11302020exhibit311.htm EX-31.1 Document EXHIBIT 31.1 CERTIFICATION I, Stefano Pessina, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Walgreens Boots Alliance, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant\\'s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have: a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c) Evaluated the effectiveness of the registrant\\'s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d) Disclosed in this report any change in the registrant\\'s internal control over financial reporting that occurred during the registrant\\'s most recent fiscal quarter (the registrant\\'s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant\\'s internal control over financial reporting; and 5. The registrant\\'s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant\\'s auditors and the audit committee of the registrant\\'s board of directors (or persons performing the equivalent functions): a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant\\'s ability to record, process, summarize and report financial information; and b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant\\'s internal control over financial reporting. /s/ Stefano Pessina Chief Executive Officer Date: January 7, 2021 Stefano Pessina\" b\"EX-31.2 4 a11302020exhibit312.htm EX-31.2 Document EXHIBIT 31.2 CERTIFICATION I, James Kehoe, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Walgreens Boots Alliance, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant\\'s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have: a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c) Evaluated the effectiveness of the registrant\\'s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d) Disclosed in this report any change in the registrant\\'s internal control over financial reporting that occurred during the registrant\\'s most recent fiscal quarter (the registrant\\'s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant\\'s internal control over financial reporting; and 5. The registrant\\'s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant\\'s auditors and the audit committee of the registrant\\'s board of directors (or persons performing the equivalent functions): a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant\\'s ability to record, process, summarize and report financial information; and b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant\\'s internal control over financial reporting. /s/ James Kehoe Global Chief Financial Officer Date: January 7, 2021 James Kehoe\" b\\'EX-32.1 5 a11302020exhibit321.htm EX-32.1 Document Exhibit 32.1 CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. SECTION 1350) In connection with the Quarterly Report of Walgreens Boots Alliance, Inc., a Delaware corporation (the \"Company\"), on Form 10-Q for the quarter ended November 30, 2020 as filed with the Securities and Exchange Commission (the \"Report\"), I, Stefano Pessina, Chief Executive Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge: (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. /s/ Stefano Pessina Stefano Pessina Chief Executive Officer Dated: January 7, 2021 A signed original of this written statement required by Section 906 has been provided to Walgreens Boots Alliance, Inc. and will be retained by Walgreens Boots Alliance, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.\\' b\\'EX-32.2 6 a11302020exhibit322.htm EX-32.2 Document Exhibit 32.2 CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (18 U.S.C. SECTION 1350) In connection with the Quarterly Report of Walgreens Boots Alliance, Inc., a Delaware corporation (the \"Company\"), on Form 10-Q for the quarter ended November 30, 2020 as filed with the Securities and Exchange Commission (the \"Report\"), I, James Kehoe, Global Chief Financial Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge: (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. /s/ James Kehoe James Kehoe Global Chief Financial Officer Dated: January 7, 2021 A signed original of this written statement required by Section 906 has been provided to Walgreens Boots Alliance, Inc. and will be retained by Walgreens Boots Alliance, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.\\'',\n",
       " \"b'10-Q 1 rell-10q_20201128.htm 10-Q rell-10q_20201128.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from To Commission File Number: RICHARDSON ELECTRONICS, LTD. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) , , (Address of principal executive offices) Registrants telephone number, including area code: () Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company and emerging growth company in Rule 12b-2 of the Exchange Act. Large Accelerated Filer   Non-Accelerated Filer  Smaller Reporting Company Emerging Growth Company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No As of January 5, 2021, there were outstanding shares of Common Stock, $0.05 par value and shares of Class B Common Stock, $0.05 par value, which are convertible into Common Stock of the registrant on a share for share basis. TABLE OF CONTENTS Page Part I. Financial Information Item 1. Financial Statements 2 Consolidated Balance Sheets 2 Unaudited Consolidated Statements of Comprehensive Income (Loss) 3 Unaudited Consolidated Statements of Cash Flows 4 Unaudited Consolidated Statement of Stockholders Equity 5 Notes to Unaudited Consolidated Financial Statements 7 Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations 19 Item 3. Quantitative and Qualitative Disclosures About Market Risk 25 Item 4. Controls and Procedures 25 Part II. Other Information Item 1. Legal Proceedings 26 Item 1A. Risk Factors 26 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 26 Item 5. Other Information 26 Item 6. Exhibits 27 Exhibit Index 27 Signatures 28 1 PART I. FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS Richardson Electronics, Ltd. Consolidated Balance Sheets (in thousands, except per share amounts) Unaudited Audited November 28, 2020 May 30, 2020 Assets Current assets: Cash and cash equivalents $ $ Accounts receivable, less allowance of $ and $, respectively Inventories, net Prepaid expenses and other assets Investments - current Total current assets Non-current assets: Property, plant and equipment, net Intangible assets, net Lease ROU asset Non-current deferred income taxes Total non-current assets Total assets $ $ Liabilities and Stockholders Equity Current liabilities: Accounts payable $ $ Accrued liabilities Lease liability current Total current liabilities Non-current liabilities: Non-current deferred income tax liabilities Lease liability non-current Other non-current liabilities Total non-current liabilities Total liabilities Stockholders equity Common stock, $ par value; issued and outstanding shares on November 28, 2020 and shares on May 30, 2020 Class B common stock, convertible, $ par value; issued and outstanding shares on November 28, 2020 and May 30, 2020 Preferred stock, $ par value, shares issued   Additional paid-in-capital Retained earnings Accumulated other comprehensive income Total stockholders equity Total liabilities and stockholders equity $ $ 2 Richardson Electronics, Ltd. Unaudited Consolidated Statements of Comprehensive Income (Loss) (in thousands, except per share amounts) Three Months Ended Six Months Ended November 28, 2020 November 30, 2019 November 28, 2020 November 30, 2019 Statements of Comprehensive Income (Loss) Net sales $ $ $ $ Cost of sales Gross profit Selling, general and administrative expenses Loss on disposal of assets    Operating income (loss) ( ) ( ) Other expense (income): Investment/interest income ( ) ( ) ( ) ( ) Foreign exchange loss Other, net ( ) ( ) ( ) ( ) Total other expense (income) ( ) Income (loss) before income taxes ( ) ( ) ( ) Income tax provision Net income (loss) ( ) ( ) ( ) Foreign currency translation gain (loss), net of tax ( ) Comprehensive income (loss) $ $ ( ) $ $ ( ) Net income (loss) per share Common shares - Basic $ $ ( ) $ ( ) $ ( ) Class B common shares - Basic $ $ ( ) $ ( ) $ ( ) Common shares - Diluted $ $ ( ) $ ( ) $ ( ) Class B common shares - Diluted $ $ ( ) $ ( ) $ ( ) Weighted average number of shares: Common shares  Basic Class B common shares  Basic Common shares  Diluted Class B common shares  Diluted Dividends per common share $ $ $ $ Dividends per Class B common share $ $ $ $ 3 Richardson Electronics, Ltd. Unaudited Consolidated Statements of Cash Flows (in thousands) Three Months Ended Six Months Ended November 28, 2020 November 30, 2019 November 28, 2020 November 30, 2019 Operating activities: Net income (loss) $ $ ( ) $ ( ) $ ( ) Adjustments to reconcile net income (loss) to cash provided by (used in) operating activities: Depreciation and amortization Inventory provisions Loss on disposal of assets    Share-based compensation expense Deferred income taxes ( ) ( ) ( ) Change in assets and liabilities: Accounts receivable ( ) ( ) Inventories ( ) ( ) ( ) Prepaid expenses and other assets ( ) ( ) ( ) Accounts payable ( ) ( ) Accrued liabilities ( ) Other ( ) ( ) ( ) ( ) Net cash provided by (used in) operating activities ( ) Investing activities: Capital expenditures ( ) ( ) ( ) ( ) Proceeds from maturity of investments   Purchases of investments  ( ) ( ) ( ) Net cash (used in) provided by investing activities ( ) ( ) ( ) Financing activities: Proceeds from issuance of common stock   Cash dividends paid ( ) ( ) ( ) ( ) Payment of financing lease principal ( ) ( ) ( ) ( ) Other  ( )   Net cash used in financing activities ( ) ( ) ( ) ( ) Effect of exchange rate changes on cash and cash equivalents ( ) Increase (decrease) in cash and cash equivalents ( ) ( ) Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period $ $ $ $ 4 Richardson Electronics, Ltd. Unaudited Consolidated Statement of Stockholders Equity (in thousands, except per share amounts) Common Class B Common Par Value Additional Paid In Capital Retained Earnings Accumulated Other Comprehensive Income Total Balance May 30, 2020: $ $ $ $ $ Comprehensive income Net loss     ( )  ( ) Foreign currency translation      Share-based compensation: Restricted stock      Stock options      Common stock: Restricted stock issuance  ( )    Dividends paid to: Common ($ per share)     ( )  ( ) Class B ($ per share)     ( )  ( ) Balance November 28, 2020: $ $ $ $ $ Balance August 29, 2020: $ $ $ $ $ Comprehensive income Net income      Foreign currency translation      Share-based compensation: Restricted stock      Stock options      Dividends paid to: Common ($ per share)     ( )  ( ) Class B ($ per share)     ( )  ( ) Balance November 28, 2020: $ $ $ $ $ 5 Common Class B Common Par Value Additional Paid In Capital Retained Earnings Accumulated Other Comprehensive Income Total Balance June 1, 2019: $ $ $ $ $ Comprehensive loss Net loss     ( )  ( ) Foreign currency translation      ( ) ( ) Share-based compensation: Restricted stock      Stock options      Common stock: Options exercised    Restricted stock issuance  ( )    Dividends paid to: Common ($ per share)     ( )  ( ) Class B ($ per share)     ( )  ( ) Balance November 30, 2019: $ $ $ $ $ Balance August 31, 2019: $ $ $ $ $ Comprehensive (loss) income Net loss     ( )  ( ) Foreign currency translation      Share-based compensation: Restricted stock      Stock options      Common stock: Options exercised    Restricted stock issuance ( )   ( )   ( ) Dividends paid to: Common ($ per share)     ( )  ( ) Class B ($ per share)     ( )  ( ) Balance November 30, 2019: $ $ $ $ $ 6 NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS 7 8 9 10 11 12 13 14 15 16 17 18 ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Certain statements in this report may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The terms may, should, could, anticipate, believe, continues, estimate, expect, intend, objective, plan, potential, project and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. These statements are based on managements current expectations, intentions or beliefs and are subject to a number of factors, assumptions and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Factors that could cause or contribute to such differences or that might otherwise impact the business include the risk factors set forth in Item 1A of this quarterly report on Form 10Q for the quarter ended November 28, 2020 as well as our Annual Report on Form 10-K filed on August 3, 2020. We undertake no obligation to update any such factor or to publicly announce the results of any revisions to any forward-looking statements contained herein whether as a result of new information, future events or otherwise. In addition, while we do, from time to time, communicate with securities analysts, it is against our policy to disclose to them any material non-public information or other confidential commercial information. Accordingly, stockholders should not assume that we agree with any statement or report issued by any analyst irrespective of the content of the statement or report. Thus, to the extent that reports issued by securities analysts contain any projections, forecasts or opinions, such reports are not our responsibility. INTRODUCTION Managements Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is intended to assist the reader in better understanding our business, results of operations, financial condition, changes in financial condition, critical accounting policies and estimates and significant developments. MD&A is provided as a supplement to, and should be read in conjunction with, our consolidated financial statements and the accompanying notes appearing elsewhere in this filing. This section is organized as follows:  Business Overview  Results of Operations  an analysis and comparison of our consolidated results of operations for the three and six month periods ended November 28, 2020 and November 30, 2019, as reflected in our consolidated statements of comprehensive income (loss).  Liquidity, Financial Position and Capital Resources  a discussion of our primary sources and uses of cash for the six month periods ended November 28, 2020 and November 30, 2019, and a discussion of changes in our financial position. Business Overview Richardson Electronics, Ltd. is a leading global provider of engineered solutions, power grid and microwave tubes and related consumables; power conversion and RF and microwave components; high value flat panel detector solutions, replacement parts, tubes and service training for diagnostic imaging equipment; and customized display solutions. We serve customers in the alternative energy, healthcare, aviation, broadcast, communications, industrial, marine, medical, military, scientific and semiconductor markets. The Companys strategy is to provide specialized technical expertise and engineered solutions based on our core engineering and manufacturing capabilities. The Company provides solutions and adds value through design-in support, systems integration, prototype design and manufacturing, testing, logistics and aftermarket technical service and repair through its global infrastructure. Our products include electron tubes and related components, microwave generators, subsystems used in semiconductor manufacturing and visual technology solutions. These products are used to control, switch or amplify electrical power signals, or are used as display devices in a variety of industrial, commercial, medical and communication applications. We have three operating and reportable segments, which we define as follows: Power and Microwave Technologies Group (PMT) combines our core engineered solutions capabilities, power grid and microwave tube business with new disruptive RF, Wireless and Power technologies. As a designer, manufacturer, technology partner and authorized distributor, PMTs strategy is to provide specialized technical expertise and engineered solutions based on our core engineering and manufacturing capabilities on a global basis. We provide solutions and add value through design-in support, systems integration, prototype design and manufacturing, testing, logistics and aftermarket technical service and repairall through our existing global infrastructure. PMTs focus is on products for power, RF and microwave applications for customers in 5G, alternative energy, aviation, broadcast, communications, industrial, marine, medical, military, scientific and semiconductor markets. PMT focuses on various applications including broadcast transmission, CO2 laser cutting, diagnostic imaging, dielectric and induction heating, high energy transfer, high voltage switching, plasma, power conversion, radar and radiation oncology. PMT also offers its customers technical services for both microwave and industrial equipment. 19 Canvys provides customized display solutions serving the corporate enterprise, financial, healthcare, industrial and medical original equipment manufacturers markets. Our engineers design, manufacture, source and support a full spectrum of solutions to match the needs of our customers. We offer long term availability and proven custom display solutions that include touch screens, protective panels, custom enclosures, All-In-One computers, specialized cabinet finishes , application specific software packages and certification services. Our volume commitments are lower than the large display manufacturers, making us the ideal choice for companies with very specific design requirements. We partner with both private label manufacturing companies and leading branded hardware vendors to offer the highest quality display and touch solutions and customized computing platforms. Healthcare manufactures, repairs, refurbishes and distributes high value replacement parts and equipment for the healthcare market including hospitals, medical centers, asset management companies, independent service organizations and multi-vendor service providers. Products include diagnostic imaging replacement parts for CT and MRI systems; replacement CT and MRI tubes; CT service training; MRI coils, cold heads and RF amplifiers; hydrogen thyratrons, klystrons, magnetrons; flat panel detector upgrades; pre-owned CT systems; and additional replacement solutions currently under development for the diagnostic imaging service market. Through a combination of newly developed products and partnerships, service offerings and training programs, we help our customers improve efficiency and deliver better clinical outcomes while lowering the cost of healthcare delivery. We currently have operations in the following major geographic regions: North America, Asia/Pacific, Europe and Latin America. RESULTS OF OPERATIONS Financial Summary  Three Months Ended November 28, 2020  The second quarter of fiscal 2021 and fiscal 2020 each contained 13 weeks.  Net sales during the second quarter of fiscal 2021 were $42.4 million, an increase of 7.0%, compared to net sales of $39.6 million during the second quarter of fiscal 2020.  Gross margin increased to 33.8% during the second quarter of fiscal 2021 compared to 32.0% during the second quarter of fiscal 2020.  Selling, general and administrative expenses were $13.5 million, or 31.8% of net sales, during the second quarter of fiscal 2021 compared to $13.2 million, or 33.2% of net sales, during the second quarter of fiscal 2020.  Operating income during the second quarter of fiscal 2021 was $0.9 million compared to operating loss of $0.5 million during the second quarter of fiscal 2020.  Net income during the second quarter of fiscal 2021 was $0.7 million compared to net loss of $0.6 million during the second quarter of fiscal 2020. Financial Summary  Six Months Ended November 28, 2020  The first six months of fiscal 2021 and fiscal 2020 each contained 26 weeks.  Net sales during the first six months of fiscal 2021 were $81.2 million, an increase of 1.2%, compared to net sales of $80.3 million during the first six months of fiscal 2020.  Gross margin increased to 32.9% during the first six months of fiscal 2021 compared to 31.9% during the first six months of fiscal 2020.  Selling, general and administrative expenses were $26.5 million, or 32.6% of net sales, during the first six months of fiscal 2021 compared to $26.0 million, or 32.4% of net sales, during the first six months of fiscal 2020.  Operating income during the first six months of fiscal 2021 was $0.2 million compared to operating loss of $0.4 million during the first six months of fiscal 2020.  Net loss during the first six months of fiscal 2021 was $0.5 million compared to net loss of $0.5 million during the first six months of fiscal 2020. 20 Net Sales and Gross Profit Analysis Net sales by segment and percent change during the second quarter and first six months of fiscal 2021 and fiscal 2020 were as follows ( in thousands ): Net Sales Three Months Ended FY21 vs. FY20 November 28, 2020 November 30, 2019 % Change PMT $ 32,929 $ 29,603 11.2 % Canvys 6,701 7,856 -14.7 % Healthcare 2,788 2,175 28.2 % Total $ 42,418 $ 39,634 7.0 % Six Months Ended FY21 vs. FY20 November 28, 2020 November 30, 2019 % Change PMT $ 63,181 $ 60,170 5.0 % Canvys 13,413 15,133 -11.4 % Healthcare 4,636 4,984 -7.0 % Total $ 81,230 $ 80,287 1.2 % During the second quarter of fiscal 2021, consolidated net sales increased 7.0% compared to the second quarter of fiscal 2020. Sales for PMT increased 11.2%, sales for Canvys decreased 14.7% and sales for Healthcare increased 28.2%. The increase in PMT was mainly due to growth in various power grid tube product lines, strong growth from our Power and Microwave new technology partners in various applications including 5G infrastructure and increased revenue from our Semiconductor Wafer Fabrication customers buying engineered solutions. The decrease in Canvys was due to temporarily decreased customer demand globally related to COVID-19. The increase in Healthcare was due to a significant increase in demand for the ALTA 750D TM tubes coupled with increased equipment sales in Latin America. During the first six months of fiscal 2021, consolidated net sales increased 1.2% compared to the first six months of fiscal 2020. Sales for PMT increased 5.0%, sales for Canvys decreased 11.4% and sales for Healthcare decreased 7.0%. The increase in PMT was mainly due to growth in the power grid tube business, strong growth in bookings and billings from our power conversion and RF and microwave components and continued growth in the Semiconductor Wafer Fab market. The decrease in Canvys was due to continuing struggles in the European market related to the COVID-19 impact on demand for equipment partially offset by strong sales in the North American market. The decrease in Healthcare was due to the impact of the global pandemic as well as ongoing economic issues in Latin America in the first quarter of fiscal 2021. Gross profit by segment and percent of net sales for the second quarter and first six months of fiscal 2021 and fiscal 2020 were as follows ( in thousands ): Gross Profit Three Months Ended November 28, 2020 % of Net Sales November 30, 2019 % of Net Sales PMT $ 11,251 34.2 % $ 9,349 31.6 % Canvys 2,379 35.5 % 2,585 32.9 % Healthcare 713 25.6 % 746 34.3 % Total $ 14,343 33.8 % $ 12,680 32.0 % Six Months Ended November 28, 2020 % of Net Sales November 30, 2019 % of Net Sales PMT $ 21,222 33.6 % $ 19,028 31.6 % Canvys 4,663 34.8 % 4,906 32.4 % Healthcare 817 17.6 % 1,697 34.0 % Total $ 26,702 32.9 % $ 25,631 31.9 % Gross profit reflects the distribution and manufacturing product margin less manufacturing variances, inventory obsolescence charges, customer returns, scrap and cycle count adjustments, engineering costs and other provisions. 21 Consolidated gross profit increased to $14.3 million during the second quarter of fiscal 2021 compared to $12.7 million during the second quarter of fiscal 2020. Consolidated gross margin as a percentage of net sales increased to 33.8% during the second quarter of fiscal 2021 from 32.0% during the second quarter of fiscal 2020, primarily due to improved manufacturing efficiencies in PMT and favorable product mix in both PMT and Canvys, partially offset by under absorbed manufacturing expenses in Healthcare. Consolidated gross profit increased to $26.7 million during the first six months of fiscal 2021 compared to $25.6 million during the first six months of fiscal 2020. Consolidated gross margin as a percentage of net sales increased to 32.9% during the first six months of fiscal 2021 from 31.9% during the first six months of fiscal 2020, primarily due to improved manufacturing efficiencies in PMT and favorable product mix in both PMT and Canvys as well as foreign currency change impact in Canvys, partially offset by under absorbed manufacturing expenses in Healthcare. Power and Microwave Technologies Group PMT net sales increased 11.2% to $32.9 million during the second quarter of fiscal 2021 from $29.6 million during the second quarter of fiscal 2020. The increase was mainly due to growth in various power grid tube product lines, strong growth from our Power and Microwave new technology partners in various applications including 5G infrastructure and increased revenue from our Semiconductor Wafer Fabrication customers buying engineered solutions. Gross margin as a percentage of net sales increased to 34.2% during the second quarter of fiscal 2021 as compared to 31.6% during the second quarter of fiscal 2020 primarily due to favorable product mix and improved manufacturing efficiencies. PMT net sales increased 5.0% to $63.2 million during the first six months of fiscal 2021 from $60.2 million during the first six months of fiscal 2020. The increase was mainly due to growth in the power grid tube business, strong growth in bookings and billings from our power conversion and RF and microwave components and continued growth in the Semiconductor Wafer Fab market. Gross margin as a percentage of net sales increased to 33.6% during the first six months of fiscal 2021 as compared to 31.6% during the first six months of fiscal 2020 due to favorable product mix and improved manufacturing efficiencies. Canvys Canvys net sales decreased 14.7% to $6.7 million during the second quarter of fiscal 2021 from $7.9 million during the second quarter of fiscal 2020 due to temporarily decreased customer demand globally related to COVID-19. Gross margin as a percentage of net sales increased to 35.5% during the second quarter of fiscal 2021 from 32.9% during the second quarter of fiscal 2020 due to favorable product mix. Canvys net sales decreased 11.4% to $13.4 million during the first six months of fiscal 2021 from $15.1 million during the first six months of fiscal 2020 primarily due to continuing struggles in the European market related to the COVID-19 impact on demand for equipment partially offset by strong sales in the North American market. Gross margin as a percentage of net sales increased to 34.8% during the first six months of fiscal 2021 as compared to 32.4% during the first six months of fiscal 2020 due to favorable product mix and foreign currency change impact. Healthcare Healthcare net sales increased 28.2% to $2.8 million during the second quarter of fiscal 2021 from $2.2 million during the second quarter of fiscal 2020. The increase in sales was primarily due to a significant increase in demand for the ALTA 750D TM tubes coupled with increased equipment sales in Latin America. Gross margin as a percentage of net sales decreased to 25.6% during the second quarter of fiscal 2021 as compared to 34.3% during the second quarter of fiscal 2020 primarily due to under absorbed manufacturing expenses. Healthcare net sales decreased 7.0% to $4.6 million during the first six months of fiscal 2021 from $5.0 million during the first six months of fiscal 2020 due to the impact of the global pandemic as well as ongoing economic issues in Latin America in the first quarter of fiscal 2021. Gross margin as a percentage of net sales decreased to 17.6% during the first six months of fiscal 2021 as compared to 34.0% during the first six months of fiscal 2020 due to under absorbed manufacturing expenses. Selling, General and Administrative Expenses Selling, general and administrative expenses increased to $13.5 million during the second quarter of fiscal 2021 from $13.2 million in the second quarter of fiscal 2020, primarily due to higher employee compensation and legal expenses, partially offset by lower travel and consulting expenses. Selling, general and administrative expenses increased to $26.5 million during the first six months of fiscal 2021 from $26.0 million in the first six months of fiscal 2020, primarily due to higher employee compensation and legal expenses, partially offset by lower travel and consulting expenses. 22 Other Income/Expense Other income/expense was expense of $0.1 million during the second quarter of fiscal 2021, compared to expense of $0.1 million during the second quarter of fiscal 2020. Other income/expense during the second quarter of fiscal 2021 included $0.1 million of foreign exchange losses. Other income/expense during the second quarter of fiscal 2020 included $0.1 million of investment/interest income offset by $0.2 million of foreign exchange losses. Our foreign exchange gains and losses are primarily due to the translation of U.S. dollars held in non-U.S. entities. We currently do not utilize derivative instruments to manage our exposure to foreign currency. Other income/expense was expense of $0.5 million during the first six months of fiscal 2021, compared to income of $0.2 million during the first six months of fiscal 2020. Other income/expense during the first six months of fiscal 2021 included $0.6 million of foreign exchange losses partially offset by less than $0.1 million of investment/interest income. Other income/expense during the first six months of fiscal 2020 included $0.2 million of investment/interest income. Income Tax Provision The income tax provision was $0.1 million for both the second quarter of fiscal 2021 and the second quarter of fiscal 2020. The effective income tax rate during the second quarter of fiscal 2021 was a tax provision of 7.1% as compared to a tax provision of (14.8)% during the second quarter of fiscal 2020. The difference in rate during the second quarter of fiscal 2021 as compared to the second quarter of fiscal 2020 reflects changes in our geographical distribution of income (loss). The 7.1% effective income tax rate differs from the federal statutory rate of 21% as a result of our geographical distribution of income (loss) and the movement of the valuation allowance against our U.S. state and federal net deferred tax assets. We recorded an income tax provision of $0.2 million and $0.3 million for the first six months of fiscal 2021 and the first six months of fiscal 2020, respectively. The effective income tax rate during the first six months of fiscal 2021 was a tax provision of (63.0)% as compared to a tax provision of (123.6)% during the first six months of fiscal 2020. The difference in rate during the first six months of fiscal 2021 as compared to the first six months of fiscal 2020 reflects changes in our geographical distribution of income (loss). The (63.0)% effective income tax rate differs from the federal statutory rate of 21% as a result of our geographical distribution of income (loss) and the movement of the valuation allowance against our U.S. state and federal net deferred tax assets. In the normal course of business, we are subject to examination by taxing authorities throughout the world. Generally, years prior to fiscal 2015 are closed for examination under the statute of limitation for U.S. federal, U.S. state and local or non-U.S. tax jurisdictions. We are currently under examination in Thailand (fiscal 2008 through 2011). Our primary foreign tax jurisdictions are Germany and the Netherlands. We have tax years open in Germany beginning in fiscal 2015 and the Netherlands beginning in fiscal 2018. Net Income (Loss) and Per Share Data Net income during the second quarter of fiscal 2021 was $0.7 million or $0.05 per diluted common share and $0.05 per Class B diluted common share as compared to net loss of $0.6 million during the second quarter of fiscal 2020 or ($0.05) per diluted common share and ($0.04) per Class B diluted common share. Net loss during the first six months of fiscal 2021 was $0.5 million or ($0.04) per diluted common share and ($0.03) per Class B diluted common share as compared to net loss of $0.5 million during the first six months of fiscal 2020 or ($0.04) per diluted common share and ($0.03) per Class B diluted common share. LIQUIDITY, FINANCIAL POSITION AND CAPITAL RESOURCES Our operations and cash needs have been primarily financed through cash on hand and investments. Cash and cash equivalents were $37.0 million at November 28, 2020. Investments included a CD classified as short-term investment of $9.0 million. Total cash and investments were $46.0 million at November 28, 2020. Cash, cash equivalents and investment at November 28, 2020 consisted of $26.8 million in North America, $9.1 million in Europe, $1.1 million in Latin America and $9.0 million in Asia/Pacific. Cash, cash equivalents and investments were $46.5 million at May 30, 2020. Cash, cash equivalents and investments at May 30, 2020, consisted of $30.6 million in North America, $8.3 million in Europe, $0.9 million in Latin America and $6.7 million in Asia/Pacific. We repatriated a total of $8.5 million to the United States in fiscal 2020 from several of our foreign entities. This amount includes $4.4 million from our entities in Germany and the Netherlands in the second quarter of fiscal 2020, $1.5 million from our entity in Japan in the third quarter of fiscal 2020 and $1.0 million from our entity in Italy in the fourth quarter of fiscal 2020. Although the Tax Cuts and Jobs Act generally eliminated federal income tax on future cash repatriation to the United States, cash repatriation may be subject to state and local taxes, withholding or similar taxes. See Note 9 Income Taxes of the notes to our consolidated financial statements in Part II, Item 8 of our Annual Report on Form 10-K for the year ended May 30, 2020, filed August 3, 2020 for further information. 23 The Company continues to monitor the impact of the COVID-19 outbreak on its supply chain, manufacturing and distribution operations, customers and employees, as well as the U.S. economy in general. However, due to the uncertainty as to when governmental restrictions on business will be fully lifted, the impact thereof, and the duration and widespread nature of the COVID-19 outbreak, the Company cannot currently predict the long-term impact on its operations and financial results. The uncertainties associated with the COVID-19 outbreak include potential adverse effects on the overall economy, the Companys supply chain, transportation services, employees and customers. The COVID-19 outbreak could adversely affect the Companys revenues, earnings, liquidity and cash flows and may require significant actions in response, including expense reductions. Conditions surrounding COVID-19 change rapidly and additional impacts of which the Company is not currently aware may arise. Based on past performance and current expectations, w e believe that the existing sources of liquidity, including current cash, will provide sufficient resources to meet known capital requirements and working capital needs through the next twelve months. Cash Flows from Operating Activities The cash provided by (used in) operating activities primarily resulted from net income (loss) adjusted for non-cash items and changes in our operating assets and liabilities. Operating activities provided $1.1 million of cash during the first six months of fiscal 2021. We had a net loss of $0.5 million during the first six months of fiscal 2021, which included non-cash stock-based compensation expense of $0.4 million associated with the issuance of stock option and restricted stock awards, $0.5 million for inventory reserve provisions and depreciation and amortization expense of $1.7 million associated with our property and equipment as well as amortization of our intangible assets. Changes in our operating assets and liabilities resulted in a use of cash of $1.0 million during the first six months of fiscal 2021, net of foreign currency exchange gains and losses, included a decrease of $2.5 million in accounts payable, an increase in inventory of $1.0 million and an increase in accounts receivable of $0.2 million, partially offset by an increase in accrued liabilities of $3.4 million. The decrease in our accounts payable was due to timing of payments for some of our larger vendors for both inventory and services. The majority of the inventory increase was to support the electron tube and semi-conductor wafer fab equipment business. The increase in accounts receivable was primarily due to the sales increase compared to the first quarter of fiscal 2021. The increase in accrued liabilities is mainly due to timing of employee compensation and payroll tax payments as well as the timing of other payments. Operating activities used $1.4 million of cash during the first six months of fiscal 2020. We had a net loss of $0.5 million during the first six months of fiscal 2020, which included non-cash stock-based compensation expense of $0.4 million associated with the issuance of stock option and restricted stock awards, $0.3 million for inventory reserve provisions and depreciation and amortization expense of $1.7 million associated with our property and equipment as well as amortization of our intangible assets. Changes in our operating assets and liabilities resulted in a use of cash of $3.3 million during the first six months of fiscal 2020, net of foreign currency exchange gains and losses, included an increase in inventory of $3.4 million, a decrease of $1.4 million in accounts payable and a decrease in accrued liabilities of $0.4 million partially offset by a decrease in accounts receivable of $1.8 million and a decrease of $0.2 million in prepaid expenses and other assets. The decrease in our accounts payable was due to timing of payments for some of our larger vendors for both inventory and services. The majority of the inventory increase was to support the continued growth of our electron tube and RF and Power Technologies groups. Cash Flows from Investing Activities The cash flow provided by and used in investing activities consisted primarily of purchases of investments and capital expenditures partially offset by proceeds from the maturities of investments. Cash provided by investing activities of $5.7 million during the first six months of fiscal 2021 included proceeds from the maturities of investments of $16.0 million, partially offset by purchases of investments of $9.0 million and $1.3 million in capital expenditures. Capital expenditures related primarily to capital used for our Healthcare business and our IT system. Cash used in investing activities of $5.8 million during the first six months of fiscal 2020 included purchases of investments of $13.0 million and $0.8 million in capital expenditures, partially offset by proceeds from the maturities of investments of $8.0 million. Capital expenditures related primarily to capital used for our IT system and Healthcare and LaFox manufacturing businesses. Our purchases of investments consisted of CDs. Purchasing of future investments may vary from period to period due to interest and foreign currency exchange rates. Cash Flows from Financing Activities The cash flow used in financing activities consisted primarily of cash dividends paid. Cash used in financing activities of $1.7 million during the first six months of fiscal 2021 primarily resulted from cash used to pay dividends. Cash used in financing activities of $1.6 million during the first six months of fiscal 2020 primarily resulted from cash used to pay dividends. 24 All future payments of dividends are at the discretion of the Board of Directors. Dividend payments will depend on earnings, capital requirements, operating conditions and such other factors that the Board may deem relevant. ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Risk Management and Market Sensitive Financial Instruments We are exposed to many different market risks with the various industries we serve. The primary financial risk we are exposed to is foreign currency exchange, as certain operations, assets and liabilities of ours are denominated in foreign currencies. We manage these risks through normal operating and financing activities. The interpretation and analysis of these disclosures should not be considered in isolation since such variances in exchange rates would likely influence other economic factors. Such factors, which are not readily quantifiable, would likely also affect our operations. Additional disclosure regarding various market risks are set forth in Part I, Item 1A, Risk Factors of our Annual Report on Form 10-K for the year ended May 30, 2020, filed August 3, 2020. ITEM 4. CONTROLS AND PROCEDURES (a) Evaluation of Disclosure Controls and Procedures Management of the Company, with the participation of the Chief Executive Officer and the Chief Financial Officer, evaluated the effectiveness of the design and operation of the Companys disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the Exchange Act)) as of November 28, 2020. Disclosure controls and procedures are intended to provide reasonable assurance that information required to be disclosed in the Companys Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the Securities and Exchange Commissions rules and forms, and that such information is accumulated and communicated to management, including the Companys Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Based on this evaluation, the Companys Chief Executive Officer and Chief Financial Officer have concluded that the Companys disclosure controls and procedures were effective as of the end of the period covered by this report. (b) Changes in Internal Control over Financial Reporting There were no changes in the Companys internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Exchange Act Rules 13a-15 or 15d-15 that occurred during the second quarter of fiscal 2021 that have materially affected, or are reasonably likely to materially affect, the Companys internal control over financial reporting. 25 PART II. OTHER INFORMATION ITEM 1. LEGAL PROCEEDINGS On October 15, 2018, Varex Imaging Corporation (Varex) filed its original Complaint (Case No. 1:18-cv-06911) against Richardson Electronics Ltd. (Richardson) in the Northern District of Illinois, which was subsequently amended on November 27, 2018. Varex alleged counts of infringement of U.S. Patent Nos. 6,456,692 and 6,519,317. Subsequently, on October 24, 2018, Varex filed a motion for preliminary injunction to stop the sale of Richardsons ALTA750 TM product. Richardson filed an opposition to the preliminary injunction. In January 2019, the Court took evidence on the preliminary injunction issue. On September 30, 2019, the Court denied Varexs Motion for Preliminary Injunction. On August 6, 2020, Varex amended its Complaint to add claims of trade secret misappropriation and Richardson moved to dismiss that Amended Complaint on September 9, 2020. Richardson believes the lawsuit to be without merit and a loss is not probable or estimable based on the information at the time the financial statements were issued. ITEM 1A. RISK FACTORS There have been no material changes to the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended May 30, 2020, filed August 3, 2020. ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS ITEM 5. OTHER INFORMATION 26 ITEM 6. EXHIBITS Exhibit Index Exhibit Number Description 3.1 Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Annex III of the Proxy Statement dated August 22, 2014). 3.2 Amended and Restated By-Laws of the Company (incorporated by reference to Exhibit 3.1 to the Companys Current Report on Form 8-K filed with the SEC on June 15, 2017). 31.1 Certification of Edward J. Richardson pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2 Certification of Robert J. Ben pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 32 Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 101 104 The following financial information from our Quarterly Report on Form 10-Q for the second quarter of fiscal 2021, filed with the SEC on January 7, 2021, formatted in Inline Extensible Business Reporting Language (iXBRL): (i) the Consolidated Balance Sheets, (ii) the Unaudited Consolidated Statements of Comprehensive Income (Loss), (iii) the Unaudited Consolidated Statements of Cash Flows, (iv) the Unaudited Consolidated Statement of Stockholders Equity and (v) Notes to Unaudited Consolidated Financial Statements. Cover Page Interactive Data File (embedded within the Inline XBRL document) 27 SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. RICHARDSON ELECTRONICS, LTD. Date: January 7, 2021 By: /s/ Robert J. Ben Robert J. Ben Chief Financial Officer and Chief Accounting Officer (on behalf of the Registrant and as Principal Financial Officer) 28' b'EX-31.1 2 rell-ex311_6.htm EX-31.1 rell-ex311_6.htm Exhibit 31.1 CERTIFICATION PURSUANT TO SECTION 302(a) OF THE SARBANES-OXLEY ACT OF 2002 I, Edward J. Richardson, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Richardson Electronics, Ltd. for the period ended November 28, 2020; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c) Evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d) Disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and 5. The registrants other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of the registrants board of directors (or persons performing the equivalent functions): a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting. Date: January 7, 2021 Signature: /s/ Edward J. Richardson Edward J. Richardson Chairman of the Board and Chief Executive Officer' b'EX-31.2 3 rell-ex312_7.htm EX-31.2 rell-ex312_7.htm Exhibit 31.2 CERTIFICATION PURSUANT TO SECTION 302(a) OF THE SARBANES-OXLEY ACT OF 2002 I, Robert J. Ben, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Richardson Electronics, Ltd. for the period ended November 28, 2020; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c) Evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d) Disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and 5. The registrants other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of the registrants board of directors (or persons performing the equivalent functions): a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting. Date: January 7, 2021 Signature: /s/ Robert J. Ben Robert J. Ben Chief Financial Officer and Chief Accounting Officer' b'EX-32 4 rell-ex32_8.htm EX-32 rell-ex32_8.htm Exhibit 32 CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report of Richardson Electronics, Ltd. (the Company) on Form 10-Q for the period ended November 28, 2020, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Edward J. Richardson, Chairman of the Board and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge: (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. /s/ Edward J. Richardson Edward J. Richardson Chairman of the Board and Chief Executive Officer January 7, 2021 CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report of Richardson Electronics, Ltd. (the Company) on Form 10-Q for the period ended November 28, 2020, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Robert J. Ben, Chief Financial Officer and Chief Accounting Officer of the Company, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge: (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. /s/ Robert J. Ben Robert J. Ben Chief Financial Officer and Chief Accounting Officer January 7, 2021'\"]"
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#Compare with the raw text.\n",
    "#You can see that the symbols are now removed.\n",
    "# Words are now converted to words for better semantics.\n",
    "\n",
    "raw_txt_sample = [sec_data.iloc[i,15] for i in range(20, 22)]\n",
    "raw_txt_sample"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "metadata": {},
   "outputs": [],
   "source": [
    "#Save the file as a pickle document\n",
    "import pickle\n",
    "#pickle.dump(sec_data, open(\"sec_data.p\", \"wb\"))\n",
    "doc = open(\"sec_data.p_new\",\"wb\")\n",
    "pickle.dump(sec_data,doc)\n",
    "doc.close()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Create Folds for Cross Validation\n",
    "**Below I create the train and test folds you must use for cross validation.  Here are the rules:**\n",
    "1. Everyone must use the 30 train and test folds below.\n",
    "2. Notice that the train data record counts for each fold increase by fold.  \n",
    "3. You will likely not be able to use all the training data for each fold due to processing time.\n",
    "4. In addition, older training data might make for stale predictions as well. You can test to find an optimal amount. \n",
    "\n",
    "# --- DO NOT MODIFY THIS CODE --- \n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [],
   "source": [
    "from datetime import date, timedelta\n",
    "\n",
    "def make_cv_folds():\n",
    "\n",
    "    retrain_after_days = 1 \n",
    "    current_date = sec_data['FileDate'].min()\n",
    "    end_dt = sec_data['FileDate'].max()\n",
    "    #end_dt = current_date + timedelta(days=3)\n",
    "\n",
    "    cv_data = []\n",
    "\n",
    "    while current_date <= end_dt:\n",
    "\n",
    "        # Get the start and end dates for the train and test period\n",
    "        train_end_dt = (current_date - timedelta(days=19))\n",
    "        test_start_dt = current_date\n",
    "        test_end_dt = (current_date +  timedelta(days=retrain_after_days-1))\n",
    "\n",
    "        # Create the train and test datasets for this fold\n",
    "        train_idx = sec_data[(sec_data.index <= train_end_dt)]\n",
    "        test_idx = sec_data[(sec_data.index >= current_date) &\n",
    "                             (sec_data.index <=  test_end_dt)]\n",
    "\n",
    "        # Get the record counts for the train and test datasets\n",
    "        train_records_ava = len(train_idx)\n",
    "        test_records_ava = len(test_idx)\n",
    "\n",
    "        cv_data.append([train_end_dt, test_start_dt, test_end_dt, \n",
    "                        train_records_ava, test_records_ava, train_idx, test_idx])\n",
    "\n",
    "        # Move the current date forward n days\n",
    "        current_date = test_end_dt + timedelta(days=1)\n",
    "\n",
    "    cv_folds = pd.DataFrame(cv_data, columns =['train_end_dt', 'test_start_dt', 'test_end_dt', \n",
    "                                               'train_records_ava', 'test_records_ava', 'train_idx', 'test_idx'])\n",
    "\n",
    "    # Get cv folds that at least have 1000 train records and >= 1 record to predict\n",
    "    cv_folds = cv_folds[(cv_folds.train_records_ava >= 1000) & \n",
    "                        (cv_folds.test_records_ava >= 1)].tail(30).reset_index(drop=True)\n",
    "    return cv_folds"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Total CV Folds: 30\n",
      "Test Start Date: 2021-05-13 00:00:00\n",
      "Test End Date: 2021-06-28 00:00:00\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>train_end_dt</th>\n",
       "      <th>test_start_dt</th>\n",
       "      <th>test_end_dt</th>\n",
       "      <th>train_records_ava</th>\n",
       "      <th>test_records_ava</th>\n",
       "      <th>train_idx</th>\n",
       "      <th>test_idx</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>2021-04-24</td>\n",
       "      <td>2021-05-13</td>\n",
       "      <td>2021-05-13</td>\n",
       "      <td>1203</td>\n",
       "      <td>312</td>\n",
       "      <td>CompanyCIK            CompanyName ...</td>\n",
       "      <td>CompanyCIK                        ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2021-04-25</td>\n",
       "      <td>2021-05-14</td>\n",
       "      <td>2021-05-14</td>\n",
       "      <td>1203</td>\n",
       "      <td>291</td>\n",
       "      <td>CompanyCIK            CompanyName ...</td>\n",
       "      <td>CompanyCIK                     Com...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2021-04-28</td>\n",
       "      <td>2021-05-17</td>\n",
       "      <td>2021-05-17</td>\n",
       "      <td>1415</td>\n",
       "      <td>490</td>\n",
       "      <td>CompanyCIK            CompanyName ...</td>\n",
       "      <td>CompanyCIK                        ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2021-04-29</td>\n",
       "      <td>2021-05-18</td>\n",
       "      <td>2021-05-18</td>\n",
       "      <td>1640</td>\n",
       "      <td>46</td>\n",
       "      <td>CompanyCIK               CompanyNa...</td>\n",
       "      <td>CompanyCIK                        ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2021-04-30</td>\n",
       "      <td>2021-05-19</td>\n",
       "      <td>2021-05-19</td>\n",
       "      <td>1835</td>\n",
       "      <td>28</td>\n",
       "      <td>CompanyCIK                        ...</td>\n",
       "      <td>CompanyCIK                        ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>2021-05-01</td>\n",
       "      <td>2021-05-20</td>\n",
       "      <td>2021-05-20</td>\n",
       "      <td>1835</td>\n",
       "      <td>29</td>\n",
       "      <td>CompanyCIK                        ...</td>\n",
       "      <td>CompanyCIK                        ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>2021-05-02</td>\n",
       "      <td>2021-05-21</td>\n",
       "      <td>2021-05-21</td>\n",
       "      <td>1835</td>\n",
       "      <td>43</td>\n",
       "      <td>CompanyCIK                        ...</td>\n",
       "      <td>CompanyCIK                        ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>2021-05-05</td>\n",
       "      <td>2021-05-24</td>\n",
       "      <td>2021-05-24</td>\n",
       "      <td>2493</td>\n",
       "      <td>227</td>\n",
       "      <td>CompanyCIK                       C...</td>\n",
       "      <td>CompanyCIK                        ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>2021-05-06</td>\n",
       "      <td>2021-05-25</td>\n",
       "      <td>2021-05-25</td>\n",
       "      <td>3088</td>\n",
       "      <td>50</td>\n",
       "      <td>CompanyCIK              CompanyNam...</td>\n",
       "      <td>CompanyCIK                        ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>2021-05-07</td>\n",
       "      <td>2021-05-26</td>\n",
       "      <td>2021-05-26</td>\n",
       "      <td>3611</td>\n",
       "      <td>24</td>\n",
       "      <td>CompanyCIK              CompanyNam...</td>\n",
       "      <td>CompanyCIK                        ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>2021-05-08</td>\n",
       "      <td>2021-05-27</td>\n",
       "      <td>2021-05-27</td>\n",
       "      <td>3611</td>\n",
       "      <td>40</td>\n",
       "      <td>CompanyCIK              CompanyNam...</td>\n",
       "      <td>CompanyCIK                        ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>2021-05-09</td>\n",
       "      <td>2021-05-28</td>\n",
       "      <td>2021-05-28</td>\n",
       "      <td>3611</td>\n",
       "      <td>42</td>\n",
       "      <td>CompanyCIK              CompanyNam...</td>\n",
       "      <td>CompanyCIK                        ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>2021-05-13</td>\n",
       "      <td>2021-06-01</td>\n",
       "      <td>2021-06-01</td>\n",
       "      <td>4462</td>\n",
       "      <td>23</td>\n",
       "      <td>CompanyCIK                  Compan...</td>\n",
       "      <td>CompanyCIK                        ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>2021-05-14</td>\n",
       "      <td>2021-06-02</td>\n",
       "      <td>2021-06-02</td>\n",
       "      <td>4753</td>\n",
       "      <td>23</td>\n",
       "      <td>CompanyCIK                   Compa...</td>\n",
       "      <td>CompanyCIK                        ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>2021-05-15</td>\n",
       "      <td>2021-06-03</td>\n",
       "      <td>2021-06-03</td>\n",
       "      <td>4753</td>\n",
       "      <td>37</td>\n",
       "      <td>CompanyCIK                   Compa...</td>\n",
       "      <td>CompanyCIK                        ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>2021-05-16</td>\n",
       "      <td>2021-06-04</td>\n",
       "      <td>2021-06-04</td>\n",
       "      <td>4753</td>\n",
       "      <td>48</td>\n",
       "      <td>CompanyCIK                   Compa...</td>\n",
       "      <td>CompanyCIK                        ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>2021-05-19</td>\n",
       "      <td>2021-06-07</td>\n",
       "      <td>2021-06-07</td>\n",
       "      <td>5317</td>\n",
       "      <td>21</td>\n",
       "      <td>CompanyCIK               CompanyNa...</td>\n",
       "      <td>CompanyCIK                        ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>2021-05-20</td>\n",
       "      <td>2021-06-08</td>\n",
       "      <td>2021-06-08</td>\n",
       "      <td>5346</td>\n",
       "      <td>36</td>\n",
       "      <td>CompanyCIK                        ...</td>\n",
       "      <td>CompanyCIK                        ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>2021-05-21</td>\n",
       "      <td>2021-06-09</td>\n",
       "      <td>2021-06-09</td>\n",
       "      <td>5389</td>\n",
       "      <td>39</td>\n",
       "      <td>CompanyCIK                   Compa...</td>\n",
       "      <td>CompanyCIK                        ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>2021-05-22</td>\n",
       "      <td>2021-06-10</td>\n",
       "      <td>2021-06-10</td>\n",
       "      <td>5389</td>\n",
       "      <td>31</td>\n",
       "      <td>CompanyCIK                   Compa...</td>\n",
       "      <td>CompanyCIK                        ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>2021-05-23</td>\n",
       "      <td>2021-06-11</td>\n",
       "      <td>2021-06-11</td>\n",
       "      <td>5389</td>\n",
       "      <td>25</td>\n",
       "      <td>CompanyCIK                   Compa...</td>\n",
       "      <td>CompanyCIK                        ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>2021-05-26</td>\n",
       "      <td>2021-06-14</td>\n",
       "      <td>2021-06-14</td>\n",
       "      <td>5690</td>\n",
       "      <td>46</td>\n",
       "      <td>CompanyCIK                  Compan...</td>\n",
       "      <td>CompanyCIK                        ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>2021-05-28</td>\n",
       "      <td>2021-06-16</td>\n",
       "      <td>2021-06-16</td>\n",
       "      <td>5772</td>\n",
       "      <td>11</td>\n",
       "      <td>CompanyCIK                        ...</td>\n",
       "      <td>CompanyCIK                        ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>2021-05-29</td>\n",
       "      <td>2021-06-17</td>\n",
       "      <td>2021-06-17</td>\n",
       "      <td>5772</td>\n",
       "      <td>8</td>\n",
       "      <td>CompanyCIK                        ...</td>\n",
       "      <td>CompanyCIK                      Co...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>2021-06-02</td>\n",
       "      <td>2021-06-21</td>\n",
       "      <td>2021-06-21</td>\n",
       "      <td>5818</td>\n",
       "      <td>26</td>\n",
       "      <td>CompanyCIK                    Comp...</td>\n",
       "      <td>CompanyCIK                        ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>2021-06-03</td>\n",
       "      <td>2021-06-22</td>\n",
       "      <td>2021-06-22</td>\n",
       "      <td>5855</td>\n",
       "      <td>21</td>\n",
       "      <td>CompanyCIK               CompanyNa...</td>\n",
       "      <td>CompanyCIK                        ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>2021-06-04</td>\n",
       "      <td>2021-06-23</td>\n",
       "      <td>2021-06-23</td>\n",
       "      <td>5903</td>\n",
       "      <td>7</td>\n",
       "      <td>CompanyCIK                     Com...</td>\n",
       "      <td>CompanyCIK                       C...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>2021-06-05</td>\n",
       "      <td>2021-06-24</td>\n",
       "      <td>2021-06-24</td>\n",
       "      <td>5903</td>\n",
       "      <td>8</td>\n",
       "      <td>CompanyCIK                     Com...</td>\n",
       "      <td>CompanyCIK                     Com...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>2021-06-06</td>\n",
       "      <td>2021-06-25</td>\n",
       "      <td>2021-06-25</td>\n",
       "      <td>5903</td>\n",
       "      <td>22</td>\n",
       "      <td>CompanyCIK                     Com...</td>\n",
       "      <td>CompanyCIK                        ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>2021-06-09</td>\n",
       "      <td>2021-06-28</td>\n",
       "      <td>2021-06-28</td>\n",
       "      <td>5999</td>\n",
       "      <td>11</td>\n",
       "      <td>CompanyCIK                        ...</td>\n",
       "      <td>CompanyCIK                        ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   train_end_dt test_start_dt test_end_dt  train_records_ava  \\\n",
       "0    2021-04-24    2021-05-13  2021-05-13               1203   \n",
       "1    2021-04-25    2021-05-14  2021-05-14               1203   \n",
       "2    2021-04-28    2021-05-17  2021-05-17               1415   \n",
       "3    2021-04-29    2021-05-18  2021-05-18               1640   \n",
       "4    2021-04-30    2021-05-19  2021-05-19               1835   \n",
       "5    2021-05-01    2021-05-20  2021-05-20               1835   \n",
       "6    2021-05-02    2021-05-21  2021-05-21               1835   \n",
       "7    2021-05-05    2021-05-24  2021-05-24               2493   \n",
       "8    2021-05-06    2021-05-25  2021-05-25               3088   \n",
       "9    2021-05-07    2021-05-26  2021-05-26               3611   \n",
       "10   2021-05-08    2021-05-27  2021-05-27               3611   \n",
       "11   2021-05-09    2021-05-28  2021-05-28               3611   \n",
       "12   2021-05-13    2021-06-01  2021-06-01               4462   \n",
       "13   2021-05-14    2021-06-02  2021-06-02               4753   \n",
       "14   2021-05-15    2021-06-03  2021-06-03               4753   \n",
       "15   2021-05-16    2021-06-04  2021-06-04               4753   \n",
       "16   2021-05-19    2021-06-07  2021-06-07               5317   \n",
       "17   2021-05-20    2021-06-08  2021-06-08               5346   \n",
       "18   2021-05-21    2021-06-09  2021-06-09               5389   \n",
       "19   2021-05-22    2021-06-10  2021-06-10               5389   \n",
       "20   2021-05-23    2021-06-11  2021-06-11               5389   \n",
       "21   2021-05-26    2021-06-14  2021-06-14               5690   \n",
       "22   2021-05-28    2021-06-16  2021-06-16               5772   \n",
       "23   2021-05-29    2021-06-17  2021-06-17               5772   \n",
       "24   2021-06-02    2021-06-21  2021-06-21               5818   \n",
       "25   2021-06-03    2021-06-22  2021-06-22               5855   \n",
       "26   2021-06-04    2021-06-23  2021-06-23               5903   \n",
       "27   2021-06-05    2021-06-24  2021-06-24               5903   \n",
       "28   2021-06-06    2021-06-25  2021-06-25               5903   \n",
       "29   2021-06-09    2021-06-28  2021-06-28               5999   \n",
       "\n",
       "    test_records_ava                                          train_idx  \\\n",
       "0                312              CompanyCIK            CompanyName ...   \n",
       "1                291              CompanyCIK            CompanyName ...   \n",
       "2                490              CompanyCIK            CompanyName ...   \n",
       "3                 46              CompanyCIK               CompanyNa...   \n",
       "4                 28              CompanyCIK                        ...   \n",
       "5                 29              CompanyCIK                        ...   \n",
       "6                 43              CompanyCIK                        ...   \n",
       "7                227              CompanyCIK                       C...   \n",
       "8                 50              CompanyCIK              CompanyNam...   \n",
       "9                 24              CompanyCIK              CompanyNam...   \n",
       "10                40              CompanyCIK              CompanyNam...   \n",
       "11                42              CompanyCIK              CompanyNam...   \n",
       "12                23              CompanyCIK                  Compan...   \n",
       "13                23              CompanyCIK                   Compa...   \n",
       "14                37              CompanyCIK                   Compa...   \n",
       "15                48              CompanyCIK                   Compa...   \n",
       "16                21              CompanyCIK               CompanyNa...   \n",
       "17                36              CompanyCIK                        ...   \n",
       "18                39              CompanyCIK                   Compa...   \n",
       "19                31              CompanyCIK                   Compa...   \n",
       "20                25              CompanyCIK                   Compa...   \n",
       "21                46              CompanyCIK                  Compan...   \n",
       "22                11              CompanyCIK                        ...   \n",
       "23                 8              CompanyCIK                        ...   \n",
       "24                26              CompanyCIK                    Comp...   \n",
       "25                21              CompanyCIK               CompanyNa...   \n",
       "26                 7              CompanyCIK                     Com...   \n",
       "27                 8              CompanyCIK                     Com...   \n",
       "28                22              CompanyCIK                     Com...   \n",
       "29                11              CompanyCIK                        ...   \n",
       "\n",
       "                                             test_idx  \n",
       "0               CompanyCIK                        ...  \n",
       "1               CompanyCIK                     Com...  \n",
       "2               CompanyCIK                        ...  \n",
       "3               CompanyCIK                        ...  \n",
       "4               CompanyCIK                        ...  \n",
       "5               CompanyCIK                        ...  \n",
       "6               CompanyCIK                        ...  \n",
       "7               CompanyCIK                        ...  \n",
       "8               CompanyCIK                        ...  \n",
       "9               CompanyCIK                        ...  \n",
       "10              CompanyCIK                        ...  \n",
       "11              CompanyCIK                        ...  \n",
       "12              CompanyCIK                        ...  \n",
       "13              CompanyCIK                        ...  \n",
       "14              CompanyCIK                        ...  \n",
       "15              CompanyCIK                        ...  \n",
       "16              CompanyCIK                        ...  \n",
       "17              CompanyCIK                        ...  \n",
       "18              CompanyCIK                        ...  \n",
       "19              CompanyCIK                        ...  \n",
       "20              CompanyCIK                        ...  \n",
       "21              CompanyCIK                        ...  \n",
       "22              CompanyCIK                        ...  \n",
       "23              CompanyCIK                      Co...  \n",
       "24              CompanyCIK                        ...  \n",
       "25              CompanyCIK                        ...  \n",
       "26              CompanyCIK                       C...  \n",
       "27              CompanyCIK                     Com...  \n",
       "28              CompanyCIK                        ...  \n",
       "29              CompanyCIK                        ...  "
      ]
     },
     "execution_count": 26,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "cv_folds = make_cv_folds()\n",
    "print('Total CV Folds:', len(cv_folds))\n",
    "print('Test Start Date:', cv_folds.test_start_dt.min())\n",
    "print('Test End Date:', cv_folds.test_end_dt.max())\n",
    "cv_folds"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Modify code below to build a better model! \n",
    "\n",
    "### Build a Pipeline"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "<class 'pandas.core.frame.DataFrame'>\n",
      "RangeIndex: 30 entries, 0 to 29\n",
      "Data columns (total 7 columns):\n",
      " #   Column             Non-Null Count  Dtype         \n",
      "---  ------             --------------  -----         \n",
      " 0   train_end_dt       30 non-null     datetime64[ns]\n",
      " 1   test_start_dt      30 non-null     datetime64[ns]\n",
      " 2   test_end_dt        30 non-null     datetime64[ns]\n",
      " 3   train_records_ava  30 non-null     int64         \n",
      " 4   test_records_ava   30 non-null     int64         \n",
      " 5   train_idx          30 non-null     object        \n",
      " 6   test_idx           30 non-null     object        \n",
      "dtypes: datetime64[ns](3), int64(2), object(2)\n",
      "memory usage: 1.8+ KB\n"
     ]
    }
   ],
   "source": [
    "cv_folds.info()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>train_end_dt</th>\n",
       "      <th>test_start_dt</th>\n",
       "      <th>test_end_dt</th>\n",
       "      <th>train_records_ava</th>\n",
       "      <th>test_records_ava</th>\n",
       "      <th>train_idx</th>\n",
       "      <th>test_idx</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>2021-04-24</td>\n",
       "      <td>2021-05-13</td>\n",
       "      <td>2021-05-13</td>\n",
       "      <td>1203</td>\n",
       "      <td>312</td>\n",
       "      <td>CompanyCIK            CompanyName ...</td>\n",
       "      <td>CompanyCIK                        ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2021-04-25</td>\n",
       "      <td>2021-05-14</td>\n",
       "      <td>2021-05-14</td>\n",
       "      <td>1203</td>\n",
       "      <td>291</td>\n",
       "      <td>CompanyCIK            CompanyName ...</td>\n",
       "      <td>CompanyCIK                     Com...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2021-04-28</td>\n",
       "      <td>2021-05-17</td>\n",
       "      <td>2021-05-17</td>\n",
       "      <td>1415</td>\n",
       "      <td>490</td>\n",
       "      <td>CompanyCIK            CompanyName ...</td>\n",
       "      <td>CompanyCIK                        ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2021-04-29</td>\n",
       "      <td>2021-05-18</td>\n",
       "      <td>2021-05-18</td>\n",
       "      <td>1640</td>\n",
       "      <td>46</td>\n",
       "      <td>CompanyCIK               CompanyNa...</td>\n",
       "      <td>CompanyCIK                        ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2021-04-30</td>\n",
       "      <td>2021-05-19</td>\n",
       "      <td>2021-05-19</td>\n",
       "      <td>1835</td>\n",
       "      <td>28</td>\n",
       "      <td>CompanyCIK                        ...</td>\n",
       "      <td>CompanyCIK                        ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  train_end_dt test_start_dt test_end_dt  train_records_ava  test_records_ava  \\\n",
       "0   2021-04-24    2021-05-13  2021-05-13               1203               312   \n",
       "1   2021-04-25    2021-05-14  2021-05-14               1203               291   \n",
       "2   2021-04-28    2021-05-17  2021-05-17               1415               490   \n",
       "3   2021-04-29    2021-05-18  2021-05-18               1640                46   \n",
       "4   2021-04-30    2021-05-19  2021-05-19               1835                28   \n",
       "\n",
       "                                           train_idx  \\\n",
       "0              CompanyCIK            CompanyName ...   \n",
       "1              CompanyCIK            CompanyName ...   \n",
       "2              CompanyCIK            CompanyName ...   \n",
       "3              CompanyCIK               CompanyNa...   \n",
       "4              CompanyCIK                        ...   \n",
       "\n",
       "                                            test_idx  \n",
       "0              CompanyCIK                        ...  \n",
       "1              CompanyCIK                     Com...  \n",
       "2              CompanyCIK                        ...  \n",
       "3              CompanyCIK                        ...  \n",
       "4              CompanyCIK                        ...  "
      ]
     },
     "execution_count": 28,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "cv_folds.head()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Other regression models"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {},
   "outputs": [],
   "source": [
    "from sklearn.ensemble import AdaBoostRegressor\n",
    "from sklearn.tree import DecisionTreeRegressor\n",
    "adareg = AdaBoostRegressor(DecisionTreeRegressor(max_depth=2), n_estimators=500, learning_rate=0.01, loss = 'exponential', random_state=123)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 97,
   "metadata": {},
   "outputs": [],
   "source": [
    "from sklearn.pipeline import Pipeline\n",
    "from sklearn.linear_model import Ridge\n",
    "from sklearn.feature_extraction.text import TfidfVectorizer\n",
    "from sklearn.feature_selection import VarianceThreshold\n",
    "from sklearn.preprocessing import StandardScaler\n",
    "from sklearn.compose import TransformedTargetRegressor\n",
    "from sklearn.preprocessing import QuantileTransformer\n",
    "\n",
    "reg = Ridge(alpha=20, max_iter=2000, normalize=False, tol=0.001, solver='sparse_cg')\n",
    "\n",
    "# Pipeline to transform X from text to matrix\n",
    "trans_pipe = Pipeline(steps=[('tfidf', TfidfVectorizer(binary=True, stop_words= {'english'}, ngram_range=(2, 3),\n",
    "                                                         smooth_idf=True,max_df=1.0,min_df= 1,\n",
    "                                                         norm='l2',strip_accents=None, lowercase=True,\n",
    "                                                         use_idf=True,sublinear_tf=True,\n",
    "                                                         token_pattern='\\\\b[^\\\\d\\\\W]{4,}\\\\b')), \n",
    "                                            ('vt',VarianceThreshold()),  \n",
    "                                            ('scaler', StandardScaler(with_mean=False))\n",
    "                                            ])\n",
    "\n",
    "# Tools to transform y to a normal distribution using quantiles \n",
    "quant_trans = QuantileTransformer(n_quantiles=1000,\n",
    "                                      output_distribution='normal',\n",
    "                                      random_state=100)\n",
    "\n",
    "ttr = TransformedTargetRegressor(regressor=reg,\n",
    "                                         transformer=quant_trans)\n",
    "ttr_adareg = TransformedTargetRegressor(regressor=adareg,transformer=quant_trans)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Applying dimensionality reduction  \n",
    "\n",
    "### Latent Semantic Analyses \n",
    "\n",
    "- Latent Semantic indexing is applied using TruncatedSVD in SKlearn"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 85,
   "metadata": {},
   "outputs": [],
   "source": [
    "from sklearn.pipeline import Pipeline\n",
    "from sklearn.linear_model import Ridge\n",
    "from sklearn.feature_extraction.text import TfidfVectorizer\n",
    "from sklearn.feature_selection import VarianceThreshold\n",
    "from sklearn.preprocessing import StandardScaler\n",
    "from sklearn.compose import TransformedTargetRegressor\n",
    "from sklearn.preprocessing import QuantileTransformer\n",
    "from sklearn.decomposition import TruncatedSVD\n",
    "\n",
    "\n",
    "reg = Ridge(alpha=30, max_iter=2000, normalize=False, tol=.000001, solver='sparse_cg', random_state=123)\n",
    "\n",
    "# Pipeline to transform X from text to matrix\n",
    "trans_pipe1 = Pipeline(steps=[('tfidf', TfidfVectorizer(binary=True, stop_words= {'english'}, ngram_range=(2, 3),\n",
    "                                                         smooth_idf=True,max_df=1.0,min_df= 1,\n",
    "                                                         norm='l2',strip_accents=None, lowercase=True,\n",
    "                                                         use_idf=True,sublinear_tf=True,\n",
    "                                                         token_pattern='\\\\b[^\\\\d\\\\W]{4,}\\\\b')),\n",
    "                                             ('LSA', TruncatedSVD(n_components=100, random_state=123)),\n",
    "                                            ('vt',VarianceThreshold()),  \n",
    "                                            ('scaler', StandardScaler(with_mean=False))\n",
    "                                            ])\n",
    "\n",
    "# Tools to transform y to a normal distribution using quantiles \n",
    "quant_trans = QuantileTransformer(n_quantiles=1000,\n",
    "                                      output_distribution='normal',\n",
    "                                      random_state=100)\n",
    "\n",
    "ttr = TransformedTargetRegressor(regressor=reg,\n",
    "                                         transformer=quant_trans)\n",
    "ttr_adareg = TransformedTargetRegressor(regressor=adareg,transformer=quant_trans)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 72,
   "metadata": {},
   "outputs": [],
   "source": [
    "from sklearn.pipeline import Pipeline\n",
    "from sklearn.linear_model import Ridge\n",
    "from sklearn.feature_extraction.text import TfidfVectorizer\n",
    "from sklearn.feature_selection import VarianceThreshold\n",
    "from sklearn.preprocessing import StandardScaler\n",
    "from sklearn.compose import TransformedTargetRegressor\n",
    "from sklearn.preprocessing import QuantileTransformer\n",
    "from sklearn.decomposition import TruncatedSVD\n",
    "\n",
    "\n",
    "reg = Ridge(alpha=30, max_iter=2000, normalize=False, tol=.000001, solver='sparse_cg', random_state=123)\n",
    "\n",
    "# Pipeline to transform X from text to matrix\n",
    "trans_pipe1 = Pipeline(steps=[('tfidf', TfidfVectorizer(binary=True, stop_words= {'english'}, ngram_range=(2, 3),\n",
    "                                                         smooth_idf=True,max_df=1.0,min_df= 1,\n",
    "                                                         norm='l2',strip_accents=None, lowercase=True,\n",
    "                                                         use_idf=True,sublinear_tf=True,\n",
    "                                                         token_pattern='\\\\b[^\\\\d\\\\W]{4,}\\\\b')),\n",
    "                                             ('LSA', TruncatedSVD(n_components=100, random_state=123)),\n",
    "                                            ('vt',VarianceThreshold()),  \n",
    "                                            ('scaler', StandardScaler(with_mean=False))\n",
    "                                            ])\n",
    "\n",
    "# Tools to transform y to a normal distribution using quantiles \n",
    "quant_trans = QuantileTransformer(n_quantiles=1000,\n",
    "                                      output_distribution='normal',\n",
    "                                      random_state=100)\n",
    "\n",
    "ttr = TransformedTargetRegressor(regressor=reg,\n",
    "                                         transformer=quant_trans)\n",
    "ttr_adareg = TransformedTargetRegressor(regressor=adareg,transformer=quant_trans)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Simulation Example 1\n",
    "* This is the most basic example using all of the available training data.\n",
    "* So each successive fold will take longer and longer to train. \n",
    "* Note this took 6 hours to run on a single thread using one of the fastest regressors in sklearn. \n",
    "* In this example I transform y as well using a TransformedTargetRegressor.\n",
    "* This uses quantiles to project y onto a normal distirbution before training the model. \n",
    "* The TransformedTargetRegressor also does an inverse_tranform on predict() so the values that the model predicts come back in the units that we expect prior to transformation.  "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "**Let's see the result of the transformation before we fit the model**  "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 98,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Wall time: 4h 51min 31s\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>CompanyCIK</th>\n",
       "      <th>CompanyName</th>\n",
       "      <th>FileType</th>\n",
       "      <th>FileDate</th>\n",
       "      <th>EdgarTextUrl</th>\n",
       "      <th>EdgarHtmlUrl</th>\n",
       "      <th>AccessionNumber</th>\n",
       "      <th>SecFileName</th>\n",
       "      <th>CompanyTicker</th>\n",
       "      <th>FileDate_ClosingPrice</th>\n",
       "      <th>FileDate_Plus_20</th>\n",
       "      <th>FileDate_Plus_20_Price</th>\n",
       "      <th>Pct_Change_20</th>\n",
       "      <th>FileName</th>\n",
       "      <th>file_text_length</th>\n",
       "      <th>f_text</th>\n",
       "      <th>y_pred</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1801777</td>\n",
       "      <td>Applied Molecular Transport Inc.</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-05-13</td>\n",
       "      <td>edgar/data/1801777/0001564590-21-027568.txt</td>\n",
       "      <td>edgar/data/1801777/0001564590-21-027568-index....</td>\n",
       "      <td>0001564590-21-027568</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>AMTI</td>\n",
       "      <td>41.090000</td>\n",
       "      <td>2021-06-02</td>\n",
       "      <td>45.570000</td>\n",
       "      <td>10.902895</td>\n",
       "      <td>1801777_0001564590-21-027568.txt</td>\n",
       "      <td>359191</td>\n",
       "      <td>b\"10-Q 1 amti-10q_20210331.htm AMT-Q1-2021.03....</td>\n",
       "      <td>-0.849479</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1533040</td>\n",
       "      <td>Phio Pharmaceuticals Corp.</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-05-13</td>\n",
       "      <td>edgar/data/1533040/0001683168-21-001971.txt</td>\n",
       "      <td>edgar/data/1533040/0001683168-21-001971-index....</td>\n",
       "      <td>0001683168-21-001971</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>PHIO</td>\n",
       "      <td>1.870000</td>\n",
       "      <td>2021-06-02</td>\n",
       "      <td>2.150000</td>\n",
       "      <td>14.973267</td>\n",
       "      <td>1533040_0001683168-21-001971.txt</td>\n",
       "      <td>83562</td>\n",
       "      <td>b'10-Q 1 phio_10q-033121.htm FORM 10-Q Table o...</td>\n",
       "      <td>-0.368479</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>1808805</td>\n",
       "      <td>ARYA Sciences Acquisition Corp III</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-05-13</td>\n",
       "      <td>edgar/data/1808805/0001140361-21-017275.txt</td>\n",
       "      <td>edgar/data/1808805/0001140361-21-017275-index....</td>\n",
       "      <td>0001140361-21-017275</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>ARYA</td>\n",
       "      <td>9.910000</td>\n",
       "      <td>2021-06-02</td>\n",
       "      <td>10.270000</td>\n",
       "      <td>3.632700</td>\n",
       "      <td>1808805_0001140361-21-017275.txt</td>\n",
       "      <td>110343</td>\n",
       "      <td>b'10-Q 1 brhc10024206_10q.htm 10-Q UNITED STAT...</td>\n",
       "      <td>-2.678961</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>1533743</td>\n",
       "      <td>Processa Pharmaceuticals, Inc.</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-05-13</td>\n",
       "      <td>edgar/data/1533743/0001493152-21-011311.txt</td>\n",
       "      <td>edgar/data/1533743/0001493152-21-011311-index....</td>\n",
       "      <td>0001493152-21-011311</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>PCSA</td>\n",
       "      <td>6.160000</td>\n",
       "      <td>2021-06-02</td>\n",
       "      <td>6.330000</td>\n",
       "      <td>2.759742</td>\n",
       "      <td>1533743_0001493152-21-011311.txt</td>\n",
       "      <td>94345</td>\n",
       "      <td>b'10-Q 1 form10-q.htm United States Securities...</td>\n",
       "      <td>-0.911164</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>1808865</td>\n",
       "      <td>iTeos Therapeutics, Inc.</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-05-13</td>\n",
       "      <td>edgar/data/1808865/0001564590-21-027588.txt</td>\n",
       "      <td>edgar/data/1808865/0001564590-21-027588-index....</td>\n",
       "      <td>0001564590-21-027588</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>ITOS</td>\n",
       "      <td>22.360001</td>\n",
       "      <td>2021-06-02</td>\n",
       "      <td>19.459999</td>\n",
       "      <td>-12.969595</td>\n",
       "      <td>1808865_0001564590-21-027588.txt</td>\n",
       "      <td>504089</td>\n",
       "      <td>b\"10-Q 1 itos-10q_20210331.htm 10-Q itos-10q_2...</td>\n",
       "      <td>-2.104825</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2060</th>\n",
       "      <td>1668010</td>\n",
       "      <td>Digital Brands Group, Inc.</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-06-28</td>\n",
       "      <td>edgar/data/1668010/0001104659-21-086107.txt</td>\n",
       "      <td>edgar/data/1668010/0001104659-21-086107-index....</td>\n",
       "      <td>0001104659-21-086107</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>DBGI</td>\n",
       "      <td>5.490000</td>\n",
       "      <td>2021-07-16</td>\n",
       "      <td>5.065000</td>\n",
       "      <td>-7.741343</td>\n",
       "      <td>1668010_0001104659-21-086107.txt</td>\n",
       "      <td>77002</td>\n",
       "      <td>b\"10-Q 1 dbgi-20210331x10q.htm FORM 10-Q Table...</td>\n",
       "      <td>0.778835</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2061</th>\n",
       "      <td>1170010</td>\n",
       "      <td>CARMAX INC</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-06-28</td>\n",
       "      <td>edgar/data/1170010/0001170010-21-000116.txt</td>\n",
       "      <td>edgar/data/1170010/0001170010-21-000116-index....</td>\n",
       "      <td>0001170010-21-000116</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>KMX</td>\n",
       "      <td>129.009995</td>\n",
       "      <td>2021-07-16</td>\n",
       "      <td>132.009995</td>\n",
       "      <td>2.325401</td>\n",
       "      <td>1170010_0001170010-21-000116.txt</td>\n",
       "      <td>103899</td>\n",
       "      <td>b'10-Q 1 kmx-20210531.htm 10-Q kmx-20210531 UN...</td>\n",
       "      <td>9.654822</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2062</th>\n",
       "      <td>82473</td>\n",
       "      <td>INNSUITES HOSPITALITY TRUST</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-06-28</td>\n",
       "      <td>edgar/data/82473/0001493152-21-015419.txt</td>\n",
       "      <td>edgar/data/82473/0001493152-21-015419-index.html</td>\n",
       "      <td>0001493152-21-015419</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>IHT</td>\n",
       "      <td>7.530000</td>\n",
       "      <td>2021-07-16</td>\n",
       "      <td>5.570000</td>\n",
       "      <td>-26.029216</td>\n",
       "      <td>82473_0001493152-21-015419.txt</td>\n",
       "      <td>149080</td>\n",
       "      <td>b'10-Q 1 form10-q.htm UNITED STATES SECURITIES...</td>\n",
       "      <td>1.510766</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2063</th>\n",
       "      <td>1819510</td>\n",
       "      <td>Atlantic Avenue Acquisition Corp</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-06-28</td>\n",
       "      <td>edgar/data/1819510/0001140361-21-022516.txt</td>\n",
       "      <td>edgar/data/1819510/0001140361-21-022516-index....</td>\n",
       "      <td>0001140361-21-022516</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>ASAQ</td>\n",
       "      <td>9.730000</td>\n",
       "      <td>2021-07-16</td>\n",
       "      <td>9.730000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1819510_0001140361-21-022516.txt</td>\n",
       "      <td>91305</td>\n",
       "      <td>b\"10-Q 1 brhc10026177_10q.htm 10-Q UNITED STAT...</td>\n",
       "      <td>0.336830</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2064</th>\n",
       "      <td>844887</td>\n",
       "      <td>DIAMONDHEAD CASINO CORP</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-06-28</td>\n",
       "      <td>edgar/data/844887/0001493152-21-015347.txt</td>\n",
       "      <td>edgar/data/844887/0001493152-21-015347-index.html</td>\n",
       "      <td>0001493152-21-015347</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>DHCC</td>\n",
       "      <td>0.400000</td>\n",
       "      <td>2021-07-16</td>\n",
       "      <td>0.370000</td>\n",
       "      <td>-7.500000</td>\n",
       "      <td>844887_0001493152-21-015347.txt</td>\n",
       "      <td>95432</td>\n",
       "      <td>b\"10-Q 1 form10-q.htm UNITED STATES SECURITIES...</td>\n",
       "      <td>0.478584</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2065 rows  17 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      CompanyCIK                         CompanyName FileType   FileDate  \\\n",
       "0        1801777    Applied Molecular Transport Inc.     10-Q 2021-05-13   \n",
       "1        1533040          Phio Pharmaceuticals Corp.     10-Q 2021-05-13   \n",
       "2        1808805  ARYA Sciences Acquisition Corp III     10-Q 2021-05-13   \n",
       "3        1533743      Processa Pharmaceuticals, Inc.     10-Q 2021-05-13   \n",
       "4        1808865            iTeos Therapeutics, Inc.     10-Q 2021-05-13   \n",
       "...          ...                                 ...      ...        ...   \n",
       "2060     1668010          Digital Brands Group, Inc.     10-Q 2021-06-28   \n",
       "2061     1170010                          CARMAX INC     10-Q 2021-06-28   \n",
       "2062       82473         INNSUITES HOSPITALITY TRUST     10-Q 2021-06-28   \n",
       "2063     1819510    Atlantic Avenue Acquisition Corp     10-Q 2021-06-28   \n",
       "2064      844887             DIAMONDHEAD CASINO CORP     10-Q 2021-06-28   \n",
       "\n",
       "                                     EdgarTextUrl  \\\n",
       "0     edgar/data/1801777/0001564590-21-027568.txt   \n",
       "1     edgar/data/1533040/0001683168-21-001971.txt   \n",
       "2     edgar/data/1808805/0001140361-21-017275.txt   \n",
       "3     edgar/data/1533743/0001493152-21-011311.txt   \n",
       "4     edgar/data/1808865/0001564590-21-027588.txt   \n",
       "...                                           ...   \n",
       "2060  edgar/data/1668010/0001104659-21-086107.txt   \n",
       "2061  edgar/data/1170010/0001170010-21-000116.txt   \n",
       "2062    edgar/data/82473/0001493152-21-015419.txt   \n",
       "2063  edgar/data/1819510/0001140361-21-022516.txt   \n",
       "2064   edgar/data/844887/0001493152-21-015347.txt   \n",
       "\n",
       "                                           EdgarHtmlUrl       AccessionNumber  \\\n",
       "0     edgar/data/1801777/0001564590-21-027568-index....  0001564590-21-027568   \n",
       "1     edgar/data/1533040/0001683168-21-001971-index....  0001683168-21-001971   \n",
       "2     edgar/data/1808805/0001140361-21-017275-index....  0001140361-21-017275   \n",
       "3     edgar/data/1533743/0001493152-21-011311-index....  0001493152-21-011311   \n",
       "4     edgar/data/1808865/0001564590-21-027588-index....  0001564590-21-027588   \n",
       "...                                                 ...                   ...   \n",
       "2060  edgar/data/1668010/0001104659-21-086107-index....  0001104659-21-086107   \n",
       "2061  edgar/data/1170010/0001170010-21-000116-index....  0001170010-21-000116   \n",
       "2062   edgar/data/82473/0001493152-21-015419-index.html  0001493152-21-015419   \n",
       "2063  edgar/data/1819510/0001140361-21-022516-index....  0001140361-21-022516   \n",
       "2064  edgar/data/844887/0001493152-21-015347-index.html  0001493152-21-015347   \n",
       "\n",
       "     SecFileName CompanyTicker  FileDate_ClosingPrice FileDate_Plus_20  \\\n",
       "0      2021-QTR2          AMTI              41.090000       2021-06-02   \n",
       "1      2021-QTR2          PHIO               1.870000       2021-06-02   \n",
       "2      2021-QTR2          ARYA               9.910000       2021-06-02   \n",
       "3      2021-QTR2          PCSA               6.160000       2021-06-02   \n",
       "4      2021-QTR2          ITOS              22.360001       2021-06-02   \n",
       "...          ...           ...                    ...              ...   \n",
       "2060   2021-QTR2          DBGI               5.490000       2021-07-16   \n",
       "2061   2021-QTR2           KMX             129.009995       2021-07-16   \n",
       "2062   2021-QTR2           IHT               7.530000       2021-07-16   \n",
       "2063   2021-QTR2          ASAQ               9.730000       2021-07-16   \n",
       "2064   2021-QTR2          DHCC               0.400000       2021-07-16   \n",
       "\n",
       "      FileDate_Plus_20_Price  Pct_Change_20                          FileName  \\\n",
       "0                  45.570000      10.902895  1801777_0001564590-21-027568.txt   \n",
       "1                   2.150000      14.973267  1533040_0001683168-21-001971.txt   \n",
       "2                  10.270000       3.632700  1808805_0001140361-21-017275.txt   \n",
       "3                   6.330000       2.759742  1533743_0001493152-21-011311.txt   \n",
       "4                  19.459999     -12.969595  1808865_0001564590-21-027588.txt   \n",
       "...                      ...            ...                               ...   \n",
       "2060                5.065000      -7.741343  1668010_0001104659-21-086107.txt   \n",
       "2061              132.009995       2.325401  1170010_0001170010-21-000116.txt   \n",
       "2062                5.570000     -26.029216    82473_0001493152-21-015419.txt   \n",
       "2063                9.730000       0.000000  1819510_0001140361-21-022516.txt   \n",
       "2064                0.370000      -7.500000   844887_0001493152-21-015347.txt   \n",
       "\n",
       "      file_text_length                                             f_text  \\\n",
       "0               359191  b\"10-Q 1 amti-10q_20210331.htm AMT-Q1-2021.03....   \n",
       "1                83562  b'10-Q 1 phio_10q-033121.htm FORM 10-Q Table o...   \n",
       "2               110343  b'10-Q 1 brhc10024206_10q.htm 10-Q UNITED STAT...   \n",
       "3                94345  b'10-Q 1 form10-q.htm United States Securities...   \n",
       "4               504089  b\"10-Q 1 itos-10q_20210331.htm 10-Q itos-10q_2...   \n",
       "...                ...                                                ...   \n",
       "2060             77002  b\"10-Q 1 dbgi-20210331x10q.htm FORM 10-Q Table...   \n",
       "2061            103899  b'10-Q 1 kmx-20210531.htm 10-Q kmx-20210531 UN...   \n",
       "2062            149080  b'10-Q 1 form10-q.htm UNITED STATES SECURITIES...   \n",
       "2063             91305  b\"10-Q 1 brhc10026177_10q.htm 10-Q UNITED STAT...   \n",
       "2064             95432  b\"10-Q 1 form10-q.htm UNITED STATES SECURITIES...   \n",
       "\n",
       "        y_pred  \n",
       "0    -0.849479  \n",
       "1    -0.368479  \n",
       "2    -2.678961  \n",
       "3    -0.911164  \n",
       "4    -2.104825  \n",
       "...        ...  \n",
       "2060  0.778835  \n",
       "2061  9.654822  \n",
       "2062  1.510766  \n",
       "2063  0.336830  \n",
       "2064  0.478584  \n",
       "\n",
       "[2065 rows x 17 columns]"
      ]
     },
     "execution_count": 98,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "%%time\n",
    "\n",
    "pred_data = []\n",
    "\n",
    "# Fit and predict on each train and test fold\n",
    "for train, test in zip(cv_folds.train_idx, cv_folds.test_idx):\n",
    "    \n",
    "    # Get X_train and y_train for this fold\n",
    "    X_train = train.norm_txt.values #I substituted the raw text for the normalized form\n",
    "    y_train = train.Pct_Change_20.values\n",
    "    \n",
    "    # Transform X_train using the pipeline\n",
    "    X_train_trans = trans_pipe.fit_transform(X_train,y_train)\n",
    "    # Transform y and fit model using ttr\n",
    "    ttr.fit(X_train_trans, y_train)\n",
    "    \n",
    "    # Get X_test and y_test for this fold\n",
    "    X_test = test.norm_txt.values\n",
    "    y_test = test.Pct_Change_20.values\n",
    "    \n",
    "    # Transform X_test for this fold\n",
    "    X_test_trans = trans_pipe.transform(X_test)\n",
    "    preds = ttr.predict(X_test_trans)\n",
    "    \n",
    "    # Select all but last column f_text of data\n",
    "    test = test.iloc[:,:-1].copy()\n",
    "    test['y_pred'] = preds\n",
    "    pred_data.append(test)\n",
    "\n",
    "pred_data = pd.concat(pred_data, axis=0, ignore_index=True)\n",
    "pred_data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 99,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "25.473127469607732"
      ]
     },
     "execution_count": 99,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "#save the predictions\n",
    "datapath = r'.\\pred_data_e1.gz' \n",
    "pred_data.to_pickle(datapath)\n",
    "\n",
    "from sklearn.metrics import mean_absolute_error\n",
    "mean_absolute_error(pred_data.Pct_Change_20, pred_data.y_pred)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Simulation Example 2\n",
    "* This model uses everything in Simulation 1.\n",
    "* However, it only uses the 1000 most recent filings for each training fold.\n",
    "* This dramatically speeds up fit() times and (in theory) forces the model to focus on only very recent market events.\n",
    "* I forgot to choose 'lowercase = True' and remove the stop words for my example 1.\n",
    "    - That is the difference between example 1 and 2."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Example 2 MAE: 25.482652584583093\n",
      "Wall time: 42min 48s\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>CompanyCIK</th>\n",
       "      <th>CompanyName</th>\n",
       "      <th>FileType</th>\n",
       "      <th>FileDate</th>\n",
       "      <th>EdgarTextUrl</th>\n",
       "      <th>EdgarHtmlUrl</th>\n",
       "      <th>AccessionNumber</th>\n",
       "      <th>SecFileName</th>\n",
       "      <th>CompanyTicker</th>\n",
       "      <th>FileDate_ClosingPrice</th>\n",
       "      <th>FileDate_Plus_20</th>\n",
       "      <th>FileDate_Plus_20_Price</th>\n",
       "      <th>Pct_Change_20</th>\n",
       "      <th>FileName</th>\n",
       "      <th>file_text_length</th>\n",
       "      <th>f_text</th>\n",
       "      <th>y_pred</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1801777</td>\n",
       "      <td>Applied Molecular Transport Inc.</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-05-13</td>\n",
       "      <td>edgar/data/1801777/0001564590-21-027568.txt</td>\n",
       "      <td>edgar/data/1801777/0001564590-21-027568-index....</td>\n",
       "      <td>0001564590-21-027568</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>AMTI</td>\n",
       "      <td>41.090000</td>\n",
       "      <td>2021-06-02</td>\n",
       "      <td>45.570000</td>\n",
       "      <td>10.902895</td>\n",
       "      <td>1801777_0001564590-21-027568.txt</td>\n",
       "      <td>359191</td>\n",
       "      <td>b\"10-Q 1 amti-10q_20210331.htm AMT-Q1-2021.03....</td>\n",
       "      <td>-2.355960</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1533040</td>\n",
       "      <td>Phio Pharmaceuticals Corp.</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-05-13</td>\n",
       "      <td>edgar/data/1533040/0001683168-21-001971.txt</td>\n",
       "      <td>edgar/data/1533040/0001683168-21-001971-index....</td>\n",
       "      <td>0001683168-21-001971</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>PHIO</td>\n",
       "      <td>1.870000</td>\n",
       "      <td>2021-06-02</td>\n",
       "      <td>2.150000</td>\n",
       "      <td>14.973267</td>\n",
       "      <td>1533040_0001683168-21-001971.txt</td>\n",
       "      <td>83562</td>\n",
       "      <td>b'10-Q 1 phio_10q-033121.htm FORM 10-Q Table o...</td>\n",
       "      <td>-2.105689</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>1808805</td>\n",
       "      <td>ARYA Sciences Acquisition Corp III</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-05-13</td>\n",
       "      <td>edgar/data/1808805/0001140361-21-017275.txt</td>\n",
       "      <td>edgar/data/1808805/0001140361-21-017275-index....</td>\n",
       "      <td>0001140361-21-017275</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>ARYA</td>\n",
       "      <td>9.910000</td>\n",
       "      <td>2021-06-02</td>\n",
       "      <td>10.270000</td>\n",
       "      <td>3.632700</td>\n",
       "      <td>1808805_0001140361-21-017275.txt</td>\n",
       "      <td>110343</td>\n",
       "      <td>b'10-Q 1 brhc10024206_10q.htm 10-Q UNITED STAT...</td>\n",
       "      <td>-3.487751</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>1533743</td>\n",
       "      <td>Processa Pharmaceuticals, Inc.</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-05-13</td>\n",
       "      <td>edgar/data/1533743/0001493152-21-011311.txt</td>\n",
       "      <td>edgar/data/1533743/0001493152-21-011311-index....</td>\n",
       "      <td>0001493152-21-011311</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>PCSA</td>\n",
       "      <td>6.160000</td>\n",
       "      <td>2021-06-02</td>\n",
       "      <td>6.330000</td>\n",
       "      <td>2.759742</td>\n",
       "      <td>1533743_0001493152-21-011311.txt</td>\n",
       "      <td>94345</td>\n",
       "      <td>b'10-Q 1 form10-q.htm United States Securities...</td>\n",
       "      <td>-1.916279</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>1808865</td>\n",
       "      <td>iTeos Therapeutics, Inc.</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-05-13</td>\n",
       "      <td>edgar/data/1808865/0001564590-21-027588.txt</td>\n",
       "      <td>edgar/data/1808865/0001564590-21-027588-index....</td>\n",
       "      <td>0001564590-21-027588</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>ITOS</td>\n",
       "      <td>22.360001</td>\n",
       "      <td>2021-06-02</td>\n",
       "      <td>19.459999</td>\n",
       "      <td>-12.969595</td>\n",
       "      <td>1808865_0001564590-21-027588.txt</td>\n",
       "      <td>504089</td>\n",
       "      <td>b\"10-Q 1 itos-10q_20210331.htm 10-Q itos-10q_2...</td>\n",
       "      <td>-3.124870</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2060</th>\n",
       "      <td>1668010</td>\n",
       "      <td>Digital Brands Group, Inc.</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-06-28</td>\n",
       "      <td>edgar/data/1668010/0001104659-21-086107.txt</td>\n",
       "      <td>edgar/data/1668010/0001104659-21-086107-index....</td>\n",
       "      <td>0001104659-21-086107</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>DBGI</td>\n",
       "      <td>5.490000</td>\n",
       "      <td>2021-07-16</td>\n",
       "      <td>5.065000</td>\n",
       "      <td>-7.741343</td>\n",
       "      <td>1668010_0001104659-21-086107.txt</td>\n",
       "      <td>77002</td>\n",
       "      <td>b\"10-Q 1 dbgi-20210331x10q.htm FORM 10-Q Table...</td>\n",
       "      <td>0.723133</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2061</th>\n",
       "      <td>1170010</td>\n",
       "      <td>CARMAX INC</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-06-28</td>\n",
       "      <td>edgar/data/1170010/0001170010-21-000116.txt</td>\n",
       "      <td>edgar/data/1170010/0001170010-21-000116-index....</td>\n",
       "      <td>0001170010-21-000116</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>KMX</td>\n",
       "      <td>129.009995</td>\n",
       "      <td>2021-07-16</td>\n",
       "      <td>132.009995</td>\n",
       "      <td>2.325401</td>\n",
       "      <td>1170010_0001170010-21-000116.txt</td>\n",
       "      <td>103899</td>\n",
       "      <td>b'10-Q 1 kmx-20210531.htm 10-Q kmx-20210531 UN...</td>\n",
       "      <td>0.401164</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2062</th>\n",
       "      <td>82473</td>\n",
       "      <td>INNSUITES HOSPITALITY TRUST</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-06-28</td>\n",
       "      <td>edgar/data/82473/0001493152-21-015419.txt</td>\n",
       "      <td>edgar/data/82473/0001493152-21-015419-index.html</td>\n",
       "      <td>0001493152-21-015419</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>IHT</td>\n",
       "      <td>7.530000</td>\n",
       "      <td>2021-07-16</td>\n",
       "      <td>5.570000</td>\n",
       "      <td>-26.029216</td>\n",
       "      <td>82473_0001493152-21-015419.txt</td>\n",
       "      <td>149080</td>\n",
       "      <td>b'10-Q 1 form10-q.htm UNITED STATES SECURITIES...</td>\n",
       "      <td>0.516626</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2063</th>\n",
       "      <td>1819510</td>\n",
       "      <td>Atlantic Avenue Acquisition Corp</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-06-28</td>\n",
       "      <td>edgar/data/1819510/0001140361-21-022516.txt</td>\n",
       "      <td>edgar/data/1819510/0001140361-21-022516-index....</td>\n",
       "      <td>0001140361-21-022516</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>ASAQ</td>\n",
       "      <td>9.730000</td>\n",
       "      <td>2021-07-16</td>\n",
       "      <td>9.730000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1819510_0001140361-21-022516.txt</td>\n",
       "      <td>91305</td>\n",
       "      <td>b\"10-Q 1 brhc10026177_10q.htm 10-Q UNITED STAT...</td>\n",
       "      <td>0.220027</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2064</th>\n",
       "      <td>844887</td>\n",
       "      <td>DIAMONDHEAD CASINO CORP</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-06-28</td>\n",
       "      <td>edgar/data/844887/0001493152-21-015347.txt</td>\n",
       "      <td>edgar/data/844887/0001493152-21-015347-index.html</td>\n",
       "      <td>0001493152-21-015347</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>DHCC</td>\n",
       "      <td>0.400000</td>\n",
       "      <td>2021-07-16</td>\n",
       "      <td>0.370000</td>\n",
       "      <td>-7.500000</td>\n",
       "      <td>844887_0001493152-21-015347.txt</td>\n",
       "      <td>95432</td>\n",
       "      <td>b\"10-Q 1 form10-q.htm UNITED STATES SECURITIES...</td>\n",
       "      <td>0.694716</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2065 rows  17 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      CompanyCIK                         CompanyName FileType   FileDate  \\\n",
       "0        1801777    Applied Molecular Transport Inc.     10-Q 2021-05-13   \n",
       "1        1533040          Phio Pharmaceuticals Corp.     10-Q 2021-05-13   \n",
       "2        1808805  ARYA Sciences Acquisition Corp III     10-Q 2021-05-13   \n",
       "3        1533743      Processa Pharmaceuticals, Inc.     10-Q 2021-05-13   \n",
       "4        1808865            iTeos Therapeutics, Inc.     10-Q 2021-05-13   \n",
       "...          ...                                 ...      ...        ...   \n",
       "2060     1668010          Digital Brands Group, Inc.     10-Q 2021-06-28   \n",
       "2061     1170010                          CARMAX INC     10-Q 2021-06-28   \n",
       "2062       82473         INNSUITES HOSPITALITY TRUST     10-Q 2021-06-28   \n",
       "2063     1819510    Atlantic Avenue Acquisition Corp     10-Q 2021-06-28   \n",
       "2064      844887             DIAMONDHEAD CASINO CORP     10-Q 2021-06-28   \n",
       "\n",
       "                                     EdgarTextUrl  \\\n",
       "0     edgar/data/1801777/0001564590-21-027568.txt   \n",
       "1     edgar/data/1533040/0001683168-21-001971.txt   \n",
       "2     edgar/data/1808805/0001140361-21-017275.txt   \n",
       "3     edgar/data/1533743/0001493152-21-011311.txt   \n",
       "4     edgar/data/1808865/0001564590-21-027588.txt   \n",
       "...                                           ...   \n",
       "2060  edgar/data/1668010/0001104659-21-086107.txt   \n",
       "2061  edgar/data/1170010/0001170010-21-000116.txt   \n",
       "2062    edgar/data/82473/0001493152-21-015419.txt   \n",
       "2063  edgar/data/1819510/0001140361-21-022516.txt   \n",
       "2064   edgar/data/844887/0001493152-21-015347.txt   \n",
       "\n",
       "                                           EdgarHtmlUrl       AccessionNumber  \\\n",
       "0     edgar/data/1801777/0001564590-21-027568-index....  0001564590-21-027568   \n",
       "1     edgar/data/1533040/0001683168-21-001971-index....  0001683168-21-001971   \n",
       "2     edgar/data/1808805/0001140361-21-017275-index....  0001140361-21-017275   \n",
       "3     edgar/data/1533743/0001493152-21-011311-index....  0001493152-21-011311   \n",
       "4     edgar/data/1808865/0001564590-21-027588-index....  0001564590-21-027588   \n",
       "...                                                 ...                   ...   \n",
       "2060  edgar/data/1668010/0001104659-21-086107-index....  0001104659-21-086107   \n",
       "2061  edgar/data/1170010/0001170010-21-000116-index....  0001170010-21-000116   \n",
       "2062   edgar/data/82473/0001493152-21-015419-index.html  0001493152-21-015419   \n",
       "2063  edgar/data/1819510/0001140361-21-022516-index....  0001140361-21-022516   \n",
       "2064  edgar/data/844887/0001493152-21-015347-index.html  0001493152-21-015347   \n",
       "\n",
       "     SecFileName CompanyTicker  FileDate_ClosingPrice FileDate_Plus_20  \\\n",
       "0      2021-QTR2          AMTI              41.090000       2021-06-02   \n",
       "1      2021-QTR2          PHIO               1.870000       2021-06-02   \n",
       "2      2021-QTR2          ARYA               9.910000       2021-06-02   \n",
       "3      2021-QTR2          PCSA               6.160000       2021-06-02   \n",
       "4      2021-QTR2          ITOS              22.360001       2021-06-02   \n",
       "...          ...           ...                    ...              ...   \n",
       "2060   2021-QTR2          DBGI               5.490000       2021-07-16   \n",
       "2061   2021-QTR2           KMX             129.009995       2021-07-16   \n",
       "2062   2021-QTR2           IHT               7.530000       2021-07-16   \n",
       "2063   2021-QTR2          ASAQ               9.730000       2021-07-16   \n",
       "2064   2021-QTR2          DHCC               0.400000       2021-07-16   \n",
       "\n",
       "      FileDate_Plus_20_Price  Pct_Change_20                          FileName  \\\n",
       "0                  45.570000      10.902895  1801777_0001564590-21-027568.txt   \n",
       "1                   2.150000      14.973267  1533040_0001683168-21-001971.txt   \n",
       "2                  10.270000       3.632700  1808805_0001140361-21-017275.txt   \n",
       "3                   6.330000       2.759742  1533743_0001493152-21-011311.txt   \n",
       "4                  19.459999     -12.969595  1808865_0001564590-21-027588.txt   \n",
       "...                      ...            ...                               ...   \n",
       "2060                5.065000      -7.741343  1668010_0001104659-21-086107.txt   \n",
       "2061              132.009995       2.325401  1170010_0001170010-21-000116.txt   \n",
       "2062                5.570000     -26.029216    82473_0001493152-21-015419.txt   \n",
       "2063                9.730000       0.000000  1819510_0001140361-21-022516.txt   \n",
       "2064                0.370000      -7.500000   844887_0001493152-21-015347.txt   \n",
       "\n",
       "      file_text_length                                             f_text  \\\n",
       "0               359191  b\"10-Q 1 amti-10q_20210331.htm AMT-Q1-2021.03....   \n",
       "1                83562  b'10-Q 1 phio_10q-033121.htm FORM 10-Q Table o...   \n",
       "2               110343  b'10-Q 1 brhc10024206_10q.htm 10-Q UNITED STAT...   \n",
       "3                94345  b'10-Q 1 form10-q.htm United States Securities...   \n",
       "4               504089  b\"10-Q 1 itos-10q_20210331.htm 10-Q itos-10q_2...   \n",
       "...                ...                                                ...   \n",
       "2060             77002  b\"10-Q 1 dbgi-20210331x10q.htm FORM 10-Q Table...   \n",
       "2061            103899  b'10-Q 1 kmx-20210531.htm 10-Q kmx-20210531 UN...   \n",
       "2062            149080  b'10-Q 1 form10-q.htm UNITED STATES SECURITIES...   \n",
       "2063             91305  b\"10-Q 1 brhc10026177_10q.htm 10-Q UNITED STAT...   \n",
       "2064             95432  b\"10-Q 1 form10-q.htm UNITED STATES SECURITIES...   \n",
       "\n",
       "        y_pred  \n",
       "0    -2.355960  \n",
       "1    -2.105689  \n",
       "2    -3.487751  \n",
       "3    -1.916279  \n",
       "4    -3.124870  \n",
       "...        ...  \n",
       "2060  0.723133  \n",
       "2061  0.401164  \n",
       "2062  0.516626  \n",
       "2063  0.220027  \n",
       "2064  0.694716  \n",
       "\n",
       "[2065 rows x 17 columns]"
      ]
     },
     "execution_count": 39,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "%%time\n",
    "\n",
    "pred_data = []\n",
    "\n",
    "# Fit and predict on each train and test fold\n",
    "for train, test in zip(cv_folds.train_idx, cv_folds.test_idx):\n",
    "    \n",
    "    # Take only the 1000 most recent filings so the model is focused on current filing events \n",
    "    # This only works since the file is indexed and sorted by FileDate!\n",
    "    train = train.tail(1000)\n",
    "    \n",
    "    # Get X_train and y_train for this fold\n",
    "    X_train = train.norm_txt.values\n",
    "    y_train = train.Pct_Change_20.values\n",
    "    \n",
    "    # Transform X_train using the pipeline\n",
    "    X_train_trans = trans_pipe.fit_transform(X_train,y_train)\n",
    "    # Transform y and fit model using ttr\n",
    "    ttr.fit(X_train_trans, y_train)\n",
    "    \n",
    "    # Get X_test and y_test for this fold\n",
    "    X_test = test.norm_txt.values\n",
    "    y_test = test.Pct_Change_20.values\n",
    "    \n",
    "    # Transform X_test for this fold\n",
    "    X_test_trans = trans_pipe.transform(X_test)\n",
    "    preds = ttr.predict(X_test_trans)\n",
    "    \n",
    "    # Select all but last column f_text of data\n",
    "    test = test.iloc[:,:-1].copy()\n",
    "    test['y_pred'] = preds\n",
    "    pred_data.append(test)\n",
    "    \n",
    "\n",
    "# Create the prediction file \n",
    "pred_data_2 = pd.concat(pred_data, axis=0, ignore_index=True)\n",
    "\n",
    "# Save the prediction file to disk\n",
    "datapath = r'.\\pred_data_e2.gz' \n",
    "pred_data_2.to_pickle(datapath)\n",
    "\n",
    "# Calculate the final MAE for our predictions \n",
    "from sklearn.metrics import mean_absolute_error\n",
    "mae = mean_absolute_error(pred_data_2.Pct_Change_20, pred_data_2.y_pred)\n",
    "\n",
    "# Display results\n",
    "print('Example 2 MAE:', mae)\n",
    "pred_data_2"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Model evaluation  \n",
    "- There was no improvement to the model lowercase was used. "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Simulation Example 2B\n",
    "* This model uses everything in Simulation 1.\n",
    "* However, it only uses the 1000 most recent filings for each training fold.\n",
    "* This dramatically speeds up fit() times and (in theory) forces the model to focus on only very recent market events.\n",
    "* I forgot to choose 'lowercase = True' for my example 1.\n",
    "    - That is the difference between example 1 and 2a.\n",
    "    \n",
    "* 2B uses the same text preprocessing step as 2a but now trained on adaboost regression\n",
    "\n",
    "* I used"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Example 2B MAE: 25.775784929951023\n",
      "Wall time: 2h 4min 36s\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>CompanyCIK</th>\n",
       "      <th>CompanyName</th>\n",
       "      <th>FileType</th>\n",
       "      <th>FileDate</th>\n",
       "      <th>EdgarTextUrl</th>\n",
       "      <th>EdgarHtmlUrl</th>\n",
       "      <th>AccessionNumber</th>\n",
       "      <th>SecFileName</th>\n",
       "      <th>CompanyTicker</th>\n",
       "      <th>FileDate_ClosingPrice</th>\n",
       "      <th>FileDate_Plus_20</th>\n",
       "      <th>FileDate_Plus_20_Price</th>\n",
       "      <th>Pct_Change_20</th>\n",
       "      <th>FileName</th>\n",
       "      <th>file_text_length</th>\n",
       "      <th>f_text</th>\n",
       "      <th>y_pred</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1801777</td>\n",
       "      <td>Applied Molecular Transport Inc.</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-05-13</td>\n",
       "      <td>edgar/data/1801777/0001564590-21-027568.txt</td>\n",
       "      <td>edgar/data/1801777/0001564590-21-027568-index....</td>\n",
       "      <td>0001564590-21-027568</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>AMTI</td>\n",
       "      <td>41.090000</td>\n",
       "      <td>2021-06-02</td>\n",
       "      <td>45.570000</td>\n",
       "      <td>10.902895</td>\n",
       "      <td>1801777_0001564590-21-027568.txt</td>\n",
       "      <td>359191</td>\n",
       "      <td>b\"10-Q 1 amti-10q_20210331.htm AMT-Q1-2021.03....</td>\n",
       "      <td>-6.723287</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1533040</td>\n",
       "      <td>Phio Pharmaceuticals Corp.</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-05-13</td>\n",
       "      <td>edgar/data/1533040/0001683168-21-001971.txt</td>\n",
       "      <td>edgar/data/1533040/0001683168-21-001971-index....</td>\n",
       "      <td>0001683168-21-001971</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>PHIO</td>\n",
       "      <td>1.870000</td>\n",
       "      <td>2021-06-02</td>\n",
       "      <td>2.150000</td>\n",
       "      <td>14.973267</td>\n",
       "      <td>1533040_0001683168-21-001971.txt</td>\n",
       "      <td>83562</td>\n",
       "      <td>b'10-Q 1 phio_10q-033121.htm FORM 10-Q Table o...</td>\n",
       "      <td>-7.637304</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>1808805</td>\n",
       "      <td>ARYA Sciences Acquisition Corp III</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-05-13</td>\n",
       "      <td>edgar/data/1808805/0001140361-21-017275.txt</td>\n",
       "      <td>edgar/data/1808805/0001140361-21-017275-index....</td>\n",
       "      <td>0001140361-21-017275</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>ARYA</td>\n",
       "      <td>9.910000</td>\n",
       "      <td>2021-06-02</td>\n",
       "      <td>10.270000</td>\n",
       "      <td>3.632700</td>\n",
       "      <td>1808805_0001140361-21-017275.txt</td>\n",
       "      <td>110343</td>\n",
       "      <td>b'10-Q 1 brhc10024206_10q.htm 10-Q UNITED STAT...</td>\n",
       "      <td>-3.387630</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>1533743</td>\n",
       "      <td>Processa Pharmaceuticals, Inc.</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-05-13</td>\n",
       "      <td>edgar/data/1533743/0001493152-21-011311.txt</td>\n",
       "      <td>edgar/data/1533743/0001493152-21-011311-index....</td>\n",
       "      <td>0001493152-21-011311</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>PCSA</td>\n",
       "      <td>6.160000</td>\n",
       "      <td>2021-06-02</td>\n",
       "      <td>6.330000</td>\n",
       "      <td>2.759742</td>\n",
       "      <td>1533743_0001493152-21-011311.txt</td>\n",
       "      <td>94345</td>\n",
       "      <td>b'10-Q 1 form10-q.htm United States Securities...</td>\n",
       "      <td>-5.346159</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>1808865</td>\n",
       "      <td>iTeos Therapeutics, Inc.</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-05-13</td>\n",
       "      <td>edgar/data/1808865/0001564590-21-027588.txt</td>\n",
       "      <td>edgar/data/1808865/0001564590-21-027588-index....</td>\n",
       "      <td>0001564590-21-027588</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>ITOS</td>\n",
       "      <td>22.360001</td>\n",
       "      <td>2021-06-02</td>\n",
       "      <td>19.459999</td>\n",
       "      <td>-12.969595</td>\n",
       "      <td>1808865_0001564590-21-027588.txt</td>\n",
       "      <td>504089</td>\n",
       "      <td>b\"10-Q 1 itos-10q_20210331.htm 10-Q itos-10q_2...</td>\n",
       "      <td>-6.158415</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2060</th>\n",
       "      <td>1668010</td>\n",
       "      <td>Digital Brands Group, Inc.</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-06-28</td>\n",
       "      <td>edgar/data/1668010/0001104659-21-086107.txt</td>\n",
       "      <td>edgar/data/1668010/0001104659-21-086107-index....</td>\n",
       "      <td>0001104659-21-086107</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>DBGI</td>\n",
       "      <td>5.490000</td>\n",
       "      <td>2021-07-16</td>\n",
       "      <td>5.065000</td>\n",
       "      <td>-7.741343</td>\n",
       "      <td>1668010_0001104659-21-086107.txt</td>\n",
       "      <td>77002</td>\n",
       "      <td>b\"10-Q 1 dbgi-20210331x10q.htm FORM 10-Q Table...</td>\n",
       "      <td>1.131370</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2061</th>\n",
       "      <td>1170010</td>\n",
       "      <td>CARMAX INC</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-06-28</td>\n",
       "      <td>edgar/data/1170010/0001170010-21-000116.txt</td>\n",
       "      <td>edgar/data/1170010/0001170010-21-000116-index....</td>\n",
       "      <td>0001170010-21-000116</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>KMX</td>\n",
       "      <td>129.009995</td>\n",
       "      <td>2021-07-16</td>\n",
       "      <td>132.009995</td>\n",
       "      <td>2.325401</td>\n",
       "      <td>1170010_0001170010-21-000116.txt</td>\n",
       "      <td>103899</td>\n",
       "      <td>b'10-Q 1 kmx-20210531.htm 10-Q kmx-20210531 UN...</td>\n",
       "      <td>0.310888</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2062</th>\n",
       "      <td>82473</td>\n",
       "      <td>INNSUITES HOSPITALITY TRUST</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-06-28</td>\n",
       "      <td>edgar/data/82473/0001493152-21-015419.txt</td>\n",
       "      <td>edgar/data/82473/0001493152-21-015419-index.html</td>\n",
       "      <td>0001493152-21-015419</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>IHT</td>\n",
       "      <td>7.530000</td>\n",
       "      <td>2021-07-16</td>\n",
       "      <td>5.570000</td>\n",
       "      <td>-26.029216</td>\n",
       "      <td>82473_0001493152-21-015419.txt</td>\n",
       "      <td>149080</td>\n",
       "      <td>b'10-Q 1 form10-q.htm UNITED STATES SECURITIES...</td>\n",
       "      <td>0.495593</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2063</th>\n",
       "      <td>1819510</td>\n",
       "      <td>Atlantic Avenue Acquisition Corp</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-06-28</td>\n",
       "      <td>edgar/data/1819510/0001140361-21-022516.txt</td>\n",
       "      <td>edgar/data/1819510/0001140361-21-022516-index....</td>\n",
       "      <td>0001140361-21-022516</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>ASAQ</td>\n",
       "      <td>9.730000</td>\n",
       "      <td>2021-07-16</td>\n",
       "      <td>9.730000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1819510_0001140361-21-022516.txt</td>\n",
       "      <td>91305</td>\n",
       "      <td>b\"10-Q 1 brhc10026177_10q.htm 10-Q UNITED STAT...</td>\n",
       "      <td>0.207364</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2064</th>\n",
       "      <td>844887</td>\n",
       "      <td>DIAMONDHEAD CASINO CORP</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-06-28</td>\n",
       "      <td>edgar/data/844887/0001493152-21-015347.txt</td>\n",
       "      <td>edgar/data/844887/0001493152-21-015347-index.html</td>\n",
       "      <td>0001493152-21-015347</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>DHCC</td>\n",
       "      <td>0.400000</td>\n",
       "      <td>2021-07-16</td>\n",
       "      <td>0.370000</td>\n",
       "      <td>-7.500000</td>\n",
       "      <td>844887_0001493152-21-015347.txt</td>\n",
       "      <td>95432</td>\n",
       "      <td>b\"10-Q 1 form10-q.htm UNITED STATES SECURITIES...</td>\n",
       "      <td>0.406148</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2065 rows  17 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      CompanyCIK                         CompanyName FileType   FileDate  \\\n",
       "0        1801777    Applied Molecular Transport Inc.     10-Q 2021-05-13   \n",
       "1        1533040          Phio Pharmaceuticals Corp.     10-Q 2021-05-13   \n",
       "2        1808805  ARYA Sciences Acquisition Corp III     10-Q 2021-05-13   \n",
       "3        1533743      Processa Pharmaceuticals, Inc.     10-Q 2021-05-13   \n",
       "4        1808865            iTeos Therapeutics, Inc.     10-Q 2021-05-13   \n",
       "...          ...                                 ...      ...        ...   \n",
       "2060     1668010          Digital Brands Group, Inc.     10-Q 2021-06-28   \n",
       "2061     1170010                          CARMAX INC     10-Q 2021-06-28   \n",
       "2062       82473         INNSUITES HOSPITALITY TRUST     10-Q 2021-06-28   \n",
       "2063     1819510    Atlantic Avenue Acquisition Corp     10-Q 2021-06-28   \n",
       "2064      844887             DIAMONDHEAD CASINO CORP     10-Q 2021-06-28   \n",
       "\n",
       "                                     EdgarTextUrl  \\\n",
       "0     edgar/data/1801777/0001564590-21-027568.txt   \n",
       "1     edgar/data/1533040/0001683168-21-001971.txt   \n",
       "2     edgar/data/1808805/0001140361-21-017275.txt   \n",
       "3     edgar/data/1533743/0001493152-21-011311.txt   \n",
       "4     edgar/data/1808865/0001564590-21-027588.txt   \n",
       "...                                           ...   \n",
       "2060  edgar/data/1668010/0001104659-21-086107.txt   \n",
       "2061  edgar/data/1170010/0001170010-21-000116.txt   \n",
       "2062    edgar/data/82473/0001493152-21-015419.txt   \n",
       "2063  edgar/data/1819510/0001140361-21-022516.txt   \n",
       "2064   edgar/data/844887/0001493152-21-015347.txt   \n",
       "\n",
       "                                           EdgarHtmlUrl       AccessionNumber  \\\n",
       "0     edgar/data/1801777/0001564590-21-027568-index....  0001564590-21-027568   \n",
       "1     edgar/data/1533040/0001683168-21-001971-index....  0001683168-21-001971   \n",
       "2     edgar/data/1808805/0001140361-21-017275-index....  0001140361-21-017275   \n",
       "3     edgar/data/1533743/0001493152-21-011311-index....  0001493152-21-011311   \n",
       "4     edgar/data/1808865/0001564590-21-027588-index....  0001564590-21-027588   \n",
       "...                                                 ...                   ...   \n",
       "2060  edgar/data/1668010/0001104659-21-086107-index....  0001104659-21-086107   \n",
       "2061  edgar/data/1170010/0001170010-21-000116-index....  0001170010-21-000116   \n",
       "2062   edgar/data/82473/0001493152-21-015419-index.html  0001493152-21-015419   \n",
       "2063  edgar/data/1819510/0001140361-21-022516-index....  0001140361-21-022516   \n",
       "2064  edgar/data/844887/0001493152-21-015347-index.html  0001493152-21-015347   \n",
       "\n",
       "     SecFileName CompanyTicker  FileDate_ClosingPrice FileDate_Plus_20  \\\n",
       "0      2021-QTR2          AMTI              41.090000       2021-06-02   \n",
       "1      2021-QTR2          PHIO               1.870000       2021-06-02   \n",
       "2      2021-QTR2          ARYA               9.910000       2021-06-02   \n",
       "3      2021-QTR2          PCSA               6.160000       2021-06-02   \n",
       "4      2021-QTR2          ITOS              22.360001       2021-06-02   \n",
       "...          ...           ...                    ...              ...   \n",
       "2060   2021-QTR2          DBGI               5.490000       2021-07-16   \n",
       "2061   2021-QTR2           KMX             129.009995       2021-07-16   \n",
       "2062   2021-QTR2           IHT               7.530000       2021-07-16   \n",
       "2063   2021-QTR2          ASAQ               9.730000       2021-07-16   \n",
       "2064   2021-QTR2          DHCC               0.400000       2021-07-16   \n",
       "\n",
       "      FileDate_Plus_20_Price  Pct_Change_20                          FileName  \\\n",
       "0                  45.570000      10.902895  1801777_0001564590-21-027568.txt   \n",
       "1                   2.150000      14.973267  1533040_0001683168-21-001971.txt   \n",
       "2                  10.270000       3.632700  1808805_0001140361-21-017275.txt   \n",
       "3                   6.330000       2.759742  1533743_0001493152-21-011311.txt   \n",
       "4                  19.459999     -12.969595  1808865_0001564590-21-027588.txt   \n",
       "...                      ...            ...                               ...   \n",
       "2060                5.065000      -7.741343  1668010_0001104659-21-086107.txt   \n",
       "2061              132.009995       2.325401  1170010_0001170010-21-000116.txt   \n",
       "2062                5.570000     -26.029216    82473_0001493152-21-015419.txt   \n",
       "2063                9.730000       0.000000  1819510_0001140361-21-022516.txt   \n",
       "2064                0.370000      -7.500000   844887_0001493152-21-015347.txt   \n",
       "\n",
       "      file_text_length                                             f_text  \\\n",
       "0               359191  b\"10-Q 1 amti-10q_20210331.htm AMT-Q1-2021.03....   \n",
       "1                83562  b'10-Q 1 phio_10q-033121.htm FORM 10-Q Table o...   \n",
       "2               110343  b'10-Q 1 brhc10024206_10q.htm 10-Q UNITED STAT...   \n",
       "3                94345  b'10-Q 1 form10-q.htm United States Securities...   \n",
       "4               504089  b\"10-Q 1 itos-10q_20210331.htm 10-Q itos-10q_2...   \n",
       "...                ...                                                ...   \n",
       "2060             77002  b\"10-Q 1 dbgi-20210331x10q.htm FORM 10-Q Table...   \n",
       "2061            103899  b'10-Q 1 kmx-20210531.htm 10-Q kmx-20210531 UN...   \n",
       "2062            149080  b'10-Q 1 form10-q.htm UNITED STATES SECURITIES...   \n",
       "2063             91305  b\"10-Q 1 brhc10026177_10q.htm 10-Q UNITED STAT...   \n",
       "2064             95432  b\"10-Q 1 form10-q.htm UNITED STATES SECURITIES...   \n",
       "\n",
       "        y_pred  \n",
       "0    -6.723287  \n",
       "1    -7.637304  \n",
       "2    -3.387630  \n",
       "3    -5.346159  \n",
       "4    -6.158415  \n",
       "...        ...  \n",
       "2060  1.131370  \n",
       "2061  0.310888  \n",
       "2062  0.495593  \n",
       "2063  0.207364  \n",
       "2064  0.406148  \n",
       "\n",
       "[2065 rows x 17 columns]"
      ]
     },
     "execution_count": 73,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "%%time\n",
    "\n",
    "pred_data = []\n",
    "\n",
    "# Fit and predict on each train and test fold\n",
    "for train, test in zip(cv_folds.train_idx, cv_folds.test_idx):\n",
    "    \n",
    "    # Take only the 1000 most recent filings so the model is focused on current filing events \n",
    "    # This only works since the file is indexed and sorted by FileDate!\n",
    "    train = train.tail(1000)\n",
    "    \n",
    "    # Get X_train and y_train for this fold\n",
    "    X_train = train.norm_txt.values\n",
    "    y_train = train.Pct_Change_20.values\n",
    "    \n",
    "    # Transform X_train using the pipeline\n",
    "    X_train_trans = trans_pipe1.fit_transform(X_train,y_train)\n",
    "    # Transform y and fit model using ttr\n",
    "    ttr.fit(X_train_trans, y_train)\n",
    "    \n",
    "    # Get X_test and y_test for this fold\n",
    "    X_test = test.norm_txt.values\n",
    "    y_test = test.Pct_Change_20.values\n",
    "    \n",
    "    # Transform X_test for this fold\n",
    "    X_test_trans = trans_pipe1.transform(X_test)\n",
    "    preds = ttr.predict(X_test_trans)\n",
    "    \n",
    "    # Select all but last column f_text of data\n",
    "    test = test.iloc[:,:-1].copy()\n",
    "    test['y_pred'] = preds\n",
    "    pred_data.append(test)\n",
    "    \n",
    "\n",
    "# Create the prediction file \n",
    "pred_data_2b = pd.concat(pred_data, axis=0, ignore_index=True)\n",
    "\n",
    "# Save the prediction file to disk\n",
    "datapath = r'.\\pred_data_e2b.gz' \n",
    "pred_data_2b.to_pickle(datapath)\n",
    "\n",
    "# Calculate the final MAE for our predictions \n",
    "from sklearn.metrics import mean_absolute_error\n",
    "mae = mean_absolute_error(pred_data_2b.Pct_Change_20, pred_data_2b.y_pred)\n",
    "\n",
    "# Display results\n",
    "print('Example 2B MAE:', mae)\n",
    "pred_data_2b"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Simulation Example 3\n",
    "* This example uses everything in Simulation 2.\n",
    "* It also adds the impute_y() function.\n",
    "* This function discretizes y into 20 equal-sized buckets and then:\n",
    " * Imuputes all values in the min decile to the min decile's max value\n",
    " * Imuputes all values in the max decile to the max decile's min value\n",
    "* The intention is to cap outliers (extreme gains or losses) in the model's training data.  "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Note  \n",
    "\n",
    "With decile technique: RANKED population is split up into 10 equal parts.  www.investopedia.com  \n",
    "    - my thought is that FileDate is our index so we sort the dataset according to filedate then we divide the y into 10 equal parts "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 74,
   "metadata": {},
   "outputs": [
    {
     "ename": "SyntaxError",
     "evalue": "cannot assign to operator (<ipython-input-74-18ca60a50821>, line 3)",
     "output_type": "error",
     "traceback": [
      "\u001b[1;36m  File \u001b[1;32m\"<ipython-input-74-18ca60a50821>\"\u001b[1;36m, line \u001b[1;32m3\u001b[0m\n\u001b[1;33m    non_linear = [i for 3*i**4 in np.random.randint(15, 100, size = 5)]\u001b[0m\n\u001b[1;37m                        ^\u001b[0m\n\u001b[1;31mSyntaxError\u001b[0m\u001b[1;31m:\u001b[0m cannot assign to operator\n"
     ]
    }
   ],
   "source": [
    "#test how decile works\n",
    "a = list(np.random.randint(15, 100, size = 10))\n",
    "non_linear = [i for 3*i**4 in np.random.randint(15, 100, size = 5)]\n",
    "outlier = [a + non_linear]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 121,
   "metadata": {},
   "outputs": [],
   "source": [
    "def impute_y(y):\n",
    "    df = pd.DataFrame()\n",
    "    df['y'] = y\n",
    "\n",
    "    # Discretize y into equal-sized buckets based on rank or based on sample quantiles.\n",
    "    buckets = 20\n",
    "    qcut = pd.qcut(df['y'], buckets, duplicates='drop').value_counts().sort_index()\n",
    "\n",
    "    # Create a new column with the decile number for each record\n",
    "    df['decile'] = pd.qcut(df['y'], buckets, labels=range(1,len(qcut)+1), duplicates='drop')\n",
    "\n",
    "    # Get the min and max decile nums\n",
    "    decile_num_min = df['decile'].min()\n",
    "    decile_num_max = df['decile'].max()\n",
    "\n",
    "    # Get the min and max values for the top and bottom decile \n",
    "    min_decile_val = df['y'][df['decile'] == decile_num_min].max()\n",
    "    max_decile_val = df['y'][df['decile'] == decile_num_max].min()\n",
    "\n",
    "    # Imput all values in the min and max deciles.\n",
    "    df.loc[df['decile'] == decile_num_min, 'y'] = min_decile_val\n",
    "    df.loc[df['decile'] == decile_num_max, 'y'] = max_decile_val\n",
    "\n",
    "    return df['y'].values "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 87,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Wall time: 48min 40s\n"
     ]
    }
   ],
   "source": [
    "%%time\n",
    "\n",
    "pred_data = []\n",
    "\n",
    "# Fit and predict on each train and test fold\n",
    "for train, test in zip(cv_folds.train_idx, cv_folds.test_idx):\n",
    "    \n",
    "    # Take only the 1000 most recent filings so the model is focused on current filing events \n",
    "    # This only works since the file is indexed and sorted by FileDate!\n",
    "    train = train.tail(1000)\n",
    "    \n",
    "    # Get X_train and y_train for this fold\n",
    "    X_train = train.norm_txt.values\n",
    "    # Impute y to cap extreme low and high repsonses in training data.\n",
    "    y_train = impute_y(train.Pct_Change_20.values)\n",
    "    \n",
    "    # Transform X_train using the pipeline\n",
    "    X_train_trans = trans_pipe.fit_transform(X_train,y_train)\n",
    "    # Transform y and fit model using ttr\n",
    "    ttr.fit(X_train_trans, y_train)\n",
    "    \n",
    "    # Get X_test and y_test for this fold\n",
    "    X_test = test.norm_txt.values\n",
    "    y_test = test.Pct_Change_20.values\n",
    "    \n",
    "    # Transform X_test for this fold\n",
    "    X_test_trans = trans_pipe.transform(X_test)\n",
    "    preds = ttr.predict(X_test_trans)\n",
    "    \n",
    "    # Select all but last column f_text of data\n",
    "    test = test.iloc[:,:-1].copy()\n",
    "    test['y_pred'] = preds\n",
    "    pred_data.append(test)\n",
    "    \n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 88,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Example 3 MAE: 25.59943038002577\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>CompanyCIK</th>\n",
       "      <th>CompanyName</th>\n",
       "      <th>FileType</th>\n",
       "      <th>FileDate</th>\n",
       "      <th>EdgarTextUrl</th>\n",
       "      <th>EdgarHtmlUrl</th>\n",
       "      <th>AccessionNumber</th>\n",
       "      <th>SecFileName</th>\n",
       "      <th>CompanyTicker</th>\n",
       "      <th>FileDate_ClosingPrice</th>\n",
       "      <th>FileDate_Plus_20</th>\n",
       "      <th>FileDate_Plus_20_Price</th>\n",
       "      <th>Pct_Change_20</th>\n",
       "      <th>FileName</th>\n",
       "      <th>file_text_length</th>\n",
       "      <th>f_text</th>\n",
       "      <th>y_pred</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1801777</td>\n",
       "      <td>Applied Molecular Transport Inc.</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-05-13</td>\n",
       "      <td>edgar/data/1801777/0001564590-21-027568.txt</td>\n",
       "      <td>edgar/data/1801777/0001564590-21-027568-index....</td>\n",
       "      <td>0001564590-21-027568</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>AMTI</td>\n",
       "      <td>41.090000</td>\n",
       "      <td>2021-06-02</td>\n",
       "      <td>45.570000</td>\n",
       "      <td>10.902895</td>\n",
       "      <td>1801777_0001564590-21-027568.txt</td>\n",
       "      <td>359191</td>\n",
       "      <td>b\"10-Q 1 amti-10q_20210331.htm AMT-Q1-2021.03....</td>\n",
       "      <td>-2.591990</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1533040</td>\n",
       "      <td>Phio Pharmaceuticals Corp.</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-05-13</td>\n",
       "      <td>edgar/data/1533040/0001683168-21-001971.txt</td>\n",
       "      <td>edgar/data/1533040/0001683168-21-001971-index....</td>\n",
       "      <td>0001683168-21-001971</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>PHIO</td>\n",
       "      <td>1.870000</td>\n",
       "      <td>2021-06-02</td>\n",
       "      <td>2.150000</td>\n",
       "      <td>14.973267</td>\n",
       "      <td>1533040_0001683168-21-001971.txt</td>\n",
       "      <td>83562</td>\n",
       "      <td>b'10-Q 1 phio_10q-033121.htm FORM 10-Q Table o...</td>\n",
       "      <td>-1.791963</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>1808805</td>\n",
       "      <td>ARYA Sciences Acquisition Corp III</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-05-13</td>\n",
       "      <td>edgar/data/1808805/0001140361-21-017275.txt</td>\n",
       "      <td>edgar/data/1808805/0001140361-21-017275-index....</td>\n",
       "      <td>0001140361-21-017275</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>ARYA</td>\n",
       "      <td>9.910000</td>\n",
       "      <td>2021-06-02</td>\n",
       "      <td>10.270000</td>\n",
       "      <td>3.632700</td>\n",
       "      <td>1808805_0001140361-21-017275.txt</td>\n",
       "      <td>110343</td>\n",
       "      <td>b'10-Q 1 brhc10024206_10q.htm 10-Q UNITED STAT...</td>\n",
       "      <td>-3.170566</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>1533743</td>\n",
       "      <td>Processa Pharmaceuticals, Inc.</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-05-13</td>\n",
       "      <td>edgar/data/1533743/0001493152-21-011311.txt</td>\n",
       "      <td>edgar/data/1533743/0001493152-21-011311-index....</td>\n",
       "      <td>0001493152-21-011311</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>PCSA</td>\n",
       "      <td>6.160000</td>\n",
       "      <td>2021-06-02</td>\n",
       "      <td>6.330000</td>\n",
       "      <td>2.759742</td>\n",
       "      <td>1533743_0001493152-21-011311.txt</td>\n",
       "      <td>94345</td>\n",
       "      <td>b'10-Q 1 form10-q.htm United States Securities...</td>\n",
       "      <td>-1.903032</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>1808865</td>\n",
       "      <td>iTeos Therapeutics, Inc.</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-05-13</td>\n",
       "      <td>edgar/data/1808865/0001564590-21-027588.txt</td>\n",
       "      <td>edgar/data/1808865/0001564590-21-027588-index....</td>\n",
       "      <td>0001564590-21-027588</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>ITOS</td>\n",
       "      <td>22.360001</td>\n",
       "      <td>2021-06-02</td>\n",
       "      <td>19.459999</td>\n",
       "      <td>-12.969595</td>\n",
       "      <td>1808865_0001564590-21-027588.txt</td>\n",
       "      <td>504089</td>\n",
       "      <td>b\"10-Q 1 itos-10q_20210331.htm 10-Q itos-10q_2...</td>\n",
       "      <td>-3.225807</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2060</th>\n",
       "      <td>1668010</td>\n",
       "      <td>Digital Brands Group, Inc.</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-06-28</td>\n",
       "      <td>edgar/data/1668010/0001104659-21-086107.txt</td>\n",
       "      <td>edgar/data/1668010/0001104659-21-086107-index....</td>\n",
       "      <td>0001104659-21-086107</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>DBGI</td>\n",
       "      <td>5.490000</td>\n",
       "      <td>2021-07-16</td>\n",
       "      <td>5.065000</td>\n",
       "      <td>-7.741343</td>\n",
       "      <td>1668010_0001104659-21-086107.txt</td>\n",
       "      <td>77002</td>\n",
       "      <td>b\"10-Q 1 dbgi-20210331x10q.htm FORM 10-Q Table...</td>\n",
       "      <td>0.610197</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2061</th>\n",
       "      <td>1170010</td>\n",
       "      <td>CARMAX INC</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-06-28</td>\n",
       "      <td>edgar/data/1170010/0001170010-21-000116.txt</td>\n",
       "      <td>edgar/data/1170010/0001170010-21-000116-index....</td>\n",
       "      <td>0001170010-21-000116</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>KMX</td>\n",
       "      <td>129.009995</td>\n",
       "      <td>2021-07-16</td>\n",
       "      <td>132.009995</td>\n",
       "      <td>2.325401</td>\n",
       "      <td>1170010_0001170010-21-000116.txt</td>\n",
       "      <td>103899</td>\n",
       "      <td>b'10-Q 1 kmx-20210531.htm 10-Q kmx-20210531 UN...</td>\n",
       "      <td>0.304579</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2062</th>\n",
       "      <td>82473</td>\n",
       "      <td>INNSUITES HOSPITALITY TRUST</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-06-28</td>\n",
       "      <td>edgar/data/82473/0001493152-21-015419.txt</td>\n",
       "      <td>edgar/data/82473/0001493152-21-015419-index.html</td>\n",
       "      <td>0001493152-21-015419</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>IHT</td>\n",
       "      <td>7.530000</td>\n",
       "      <td>2021-07-16</td>\n",
       "      <td>5.570000</td>\n",
       "      <td>-26.029216</td>\n",
       "      <td>82473_0001493152-21-015419.txt</td>\n",
       "      <td>149080</td>\n",
       "      <td>b'10-Q 1 form10-q.htm UNITED STATES SECURITIES...</td>\n",
       "      <td>0.493037</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2063</th>\n",
       "      <td>1819510</td>\n",
       "      <td>Atlantic Avenue Acquisition Corp</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-06-28</td>\n",
       "      <td>edgar/data/1819510/0001140361-21-022516.txt</td>\n",
       "      <td>edgar/data/1819510/0001140361-21-022516-index....</td>\n",
       "      <td>0001140361-21-022516</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>ASAQ</td>\n",
       "      <td>9.730000</td>\n",
       "      <td>2021-07-16</td>\n",
       "      <td>9.730000</td>\n",
       "      <td>0.000000</td>\n",
       "      <td>1819510_0001140361-21-022516.txt</td>\n",
       "      <td>91305</td>\n",
       "      <td>b\"10-Q 1 brhc10026177_10q.htm 10-Q UNITED STAT...</td>\n",
       "      <td>0.232872</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2064</th>\n",
       "      <td>844887</td>\n",
       "      <td>DIAMONDHEAD CASINO CORP</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-06-28</td>\n",
       "      <td>edgar/data/844887/0001493152-21-015347.txt</td>\n",
       "      <td>edgar/data/844887/0001493152-21-015347-index.html</td>\n",
       "      <td>0001493152-21-015347</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>DHCC</td>\n",
       "      <td>0.400000</td>\n",
       "      <td>2021-07-16</td>\n",
       "      <td>0.370000</td>\n",
       "      <td>-7.500000</td>\n",
       "      <td>844887_0001493152-21-015347.txt</td>\n",
       "      <td>95432</td>\n",
       "      <td>b\"10-Q 1 form10-q.htm UNITED STATES SECURITIES...</td>\n",
       "      <td>0.698908</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2065 rows  17 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "      CompanyCIK                         CompanyName FileType   FileDate  \\\n",
       "0        1801777    Applied Molecular Transport Inc.     10-Q 2021-05-13   \n",
       "1        1533040          Phio Pharmaceuticals Corp.     10-Q 2021-05-13   \n",
       "2        1808805  ARYA Sciences Acquisition Corp III     10-Q 2021-05-13   \n",
       "3        1533743      Processa Pharmaceuticals, Inc.     10-Q 2021-05-13   \n",
       "4        1808865            iTeos Therapeutics, Inc.     10-Q 2021-05-13   \n",
       "...          ...                                 ...      ...        ...   \n",
       "2060     1668010          Digital Brands Group, Inc.     10-Q 2021-06-28   \n",
       "2061     1170010                          CARMAX INC     10-Q 2021-06-28   \n",
       "2062       82473         INNSUITES HOSPITALITY TRUST     10-Q 2021-06-28   \n",
       "2063     1819510    Atlantic Avenue Acquisition Corp     10-Q 2021-06-28   \n",
       "2064      844887             DIAMONDHEAD CASINO CORP     10-Q 2021-06-28   \n",
       "\n",
       "                                     EdgarTextUrl  \\\n",
       "0     edgar/data/1801777/0001564590-21-027568.txt   \n",
       "1     edgar/data/1533040/0001683168-21-001971.txt   \n",
       "2     edgar/data/1808805/0001140361-21-017275.txt   \n",
       "3     edgar/data/1533743/0001493152-21-011311.txt   \n",
       "4     edgar/data/1808865/0001564590-21-027588.txt   \n",
       "...                                           ...   \n",
       "2060  edgar/data/1668010/0001104659-21-086107.txt   \n",
       "2061  edgar/data/1170010/0001170010-21-000116.txt   \n",
       "2062    edgar/data/82473/0001493152-21-015419.txt   \n",
       "2063  edgar/data/1819510/0001140361-21-022516.txt   \n",
       "2064   edgar/data/844887/0001493152-21-015347.txt   \n",
       "\n",
       "                                           EdgarHtmlUrl       AccessionNumber  \\\n",
       "0     edgar/data/1801777/0001564590-21-027568-index....  0001564590-21-027568   \n",
       "1     edgar/data/1533040/0001683168-21-001971-index....  0001683168-21-001971   \n",
       "2     edgar/data/1808805/0001140361-21-017275-index....  0001140361-21-017275   \n",
       "3     edgar/data/1533743/0001493152-21-011311-index....  0001493152-21-011311   \n",
       "4     edgar/data/1808865/0001564590-21-027588-index....  0001564590-21-027588   \n",
       "...                                                 ...                   ...   \n",
       "2060  edgar/data/1668010/0001104659-21-086107-index....  0001104659-21-086107   \n",
       "2061  edgar/data/1170010/0001170010-21-000116-index....  0001170010-21-000116   \n",
       "2062   edgar/data/82473/0001493152-21-015419-index.html  0001493152-21-015419   \n",
       "2063  edgar/data/1819510/0001140361-21-022516-index....  0001140361-21-022516   \n",
       "2064  edgar/data/844887/0001493152-21-015347-index.html  0001493152-21-015347   \n",
       "\n",
       "     SecFileName CompanyTicker  FileDate_ClosingPrice FileDate_Plus_20  \\\n",
       "0      2021-QTR2          AMTI              41.090000       2021-06-02   \n",
       "1      2021-QTR2          PHIO               1.870000       2021-06-02   \n",
       "2      2021-QTR2          ARYA               9.910000       2021-06-02   \n",
       "3      2021-QTR2          PCSA               6.160000       2021-06-02   \n",
       "4      2021-QTR2          ITOS              22.360001       2021-06-02   \n",
       "...          ...           ...                    ...              ...   \n",
       "2060   2021-QTR2          DBGI               5.490000       2021-07-16   \n",
       "2061   2021-QTR2           KMX             129.009995       2021-07-16   \n",
       "2062   2021-QTR2           IHT               7.530000       2021-07-16   \n",
       "2063   2021-QTR2          ASAQ               9.730000       2021-07-16   \n",
       "2064   2021-QTR2          DHCC               0.400000       2021-07-16   \n",
       "\n",
       "      FileDate_Plus_20_Price  Pct_Change_20                          FileName  \\\n",
       "0                  45.570000      10.902895  1801777_0001564590-21-027568.txt   \n",
       "1                   2.150000      14.973267  1533040_0001683168-21-001971.txt   \n",
       "2                  10.270000       3.632700  1808805_0001140361-21-017275.txt   \n",
       "3                   6.330000       2.759742  1533743_0001493152-21-011311.txt   \n",
       "4                  19.459999     -12.969595  1808865_0001564590-21-027588.txt   \n",
       "...                      ...            ...                               ...   \n",
       "2060                5.065000      -7.741343  1668010_0001104659-21-086107.txt   \n",
       "2061              132.009995       2.325401  1170010_0001170010-21-000116.txt   \n",
       "2062                5.570000     -26.029216    82473_0001493152-21-015419.txt   \n",
       "2063                9.730000       0.000000  1819510_0001140361-21-022516.txt   \n",
       "2064                0.370000      -7.500000   844887_0001493152-21-015347.txt   \n",
       "\n",
       "      file_text_length                                             f_text  \\\n",
       "0               359191  b\"10-Q 1 amti-10q_20210331.htm AMT-Q1-2021.03....   \n",
       "1                83562  b'10-Q 1 phio_10q-033121.htm FORM 10-Q Table o...   \n",
       "2               110343  b'10-Q 1 brhc10024206_10q.htm 10-Q UNITED STAT...   \n",
       "3                94345  b'10-Q 1 form10-q.htm United States Securities...   \n",
       "4               504089  b\"10-Q 1 itos-10q_20210331.htm 10-Q itos-10q_2...   \n",
       "...                ...                                                ...   \n",
       "2060             77002  b\"10-Q 1 dbgi-20210331x10q.htm FORM 10-Q Table...   \n",
       "2061            103899  b'10-Q 1 kmx-20210531.htm 10-Q kmx-20210531 UN...   \n",
       "2062            149080  b'10-Q 1 form10-q.htm UNITED STATES SECURITIES...   \n",
       "2063             91305  b\"10-Q 1 brhc10026177_10q.htm 10-Q UNITED STAT...   \n",
       "2064             95432  b\"10-Q 1 form10-q.htm UNITED STATES SECURITIES...   \n",
       "\n",
       "        y_pred  \n",
       "0    -2.591990  \n",
       "1    -1.791963  \n",
       "2    -3.170566  \n",
       "3    -1.903032  \n",
       "4    -3.225807  \n",
       "...        ...  \n",
       "2060  0.610197  \n",
       "2061  0.304579  \n",
       "2062  0.493037  \n",
       "2063  0.232872  \n",
       "2064  0.698908  \n",
       "\n",
       "[2065 rows x 17 columns]"
      ]
     },
     "execution_count": 88,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Create the prediction file \n",
    "pred_data_3 = pd.concat(pred_data, axis=0, ignore_index=True)\n",
    "\n",
    "# Save the prediction file to disk\n",
    "datapath = r'.\\pred_data_e3.gz' \n",
    "pred_data_3.to_pickle(datapath)\n",
    "\n",
    "# Calculate the final MAE for our predictions \n",
    "from sklearn.metrics import mean_absolute_error\n",
    "mae = mean_absolute_error(pred_data_3.Pct_Change_20, pred_data_3.y_pred)\n",
    "\n",
    "# Display results\n",
    "print('Example 3 MAE:', mae)\n",
    "pred_data_3"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Exotic feature engineering models"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 112,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Collecting tensorflow-hub\n",
      "  Downloading tensorflow_hub-0.12.0-py2.py3-none-any.whl (108 kB)\n",
      "Requirement already satisfied: numpy>=1.12.0 in c:\\users\\john olanipekun\\anaconda3\\envs\\tf2.4\\lib\\site-packages (from tensorflow-hub) (1.19.5)\n",
      "Requirement already satisfied: protobuf>=3.8.0 in c:\\users\\john olanipekun\\anaconda3\\envs\\tf2.4\\lib\\site-packages (from tensorflow-hub) (3.17.2)\n",
      "Requirement already satisfied: six>=1.9 in c:\\users\\john olanipekun\\anaconda3\\envs\\tf2.4\\lib\\site-packages (from protobuf>=3.8.0->tensorflow-hub) (1.15.0)\n",
      "Installing collected packages: tensorflow-hub\n",
      "Successfully installed tensorflow-hub-0.12.0\n"
     ]
    }
   ],
   "source": [
    "#import tensorflow_hub as hub\n",
    "!pip install tensorflow-hub"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 114,
   "metadata": {},
   "outputs": [],
   "source": [
    "import tensorflow_hub as hub\n",
    "import numpy as np\n",
    "import pandas as pd\n",
    "import tensorflow as tf"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 115,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Num GPUs Available:  1\n"
     ]
    }
   ],
   "source": [
    "print(\"Num GPUs Available: \", len(tf.config.list_physical_devices('GPU')))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Simulation 4"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Create model architecture  \n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 208,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Model: \"sequential_4\"\n",
      "_________________________________________________________________\n",
      "Layer (type)                 Output Shape              Param #   \n",
      "=================================================================\n",
      "keras_layer_12 (KerasLayer)  (None, 50)                48190600  \n",
      "_________________________________________________________________\n",
      "dense_9 (Dense)              (None, 256)               13056     \n",
      "_________________________________________________________________\n",
      "module_wrapper_7 (ModuleWrap (None, 256)               1024      \n",
      "_________________________________________________________________\n",
      "dense_10 (Dense)             (None, 64)                16448     \n",
      "_________________________________________________________________\n",
      "module_wrapper_8 (ModuleWrap (None, 64)                256       \n",
      "_________________________________________________________________\n",
      "dense_11 (Dense)             (None, 1)                 65        \n",
      "=================================================================\n",
      "Total params: 48,221,449\n",
      "Trainable params: 48,220,809\n",
      "Non-trainable params: 640\n",
      "_________________________________________________________________\n"
     ]
    }
   ],
   "source": [
    "#Idea from Tensorflow tutorial BUT my own architecture\n",
    "\n",
    "from keras.layers import BatchNormalization\n",
    "embedding = \"https://tfhub.dev/google/nnlm-en-dim50/2\"\n",
    "hub_layer = hub.KerasLayer(embedding, input_shape=[], \n",
    "                           dtype=tf.string, trainable=True)\n",
    "model = tf.keras.Sequential()\n",
    "model.add(hub_layer)\n",
    "model.add(tf.keras.layers.Dense(256, activation='relu'))\n",
    "model.add(BatchNormalization(momentum=0.9))\n",
    "model.add(tf.keras.layers.Dense(64, activation='relu'))\n",
    "model.add(BatchNormalization(momentum=0.9))\n",
    "model.add(tf.keras.layers.Dense(1))\n",
    "\n",
    "model.summary()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Compile  \n",
    "- At this compile stage we select our optimizer.\n",
    "- Mean Absolute Error is template error metric we received and it is usually more suitable for heavily skewed non-normal distribution."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 209,
   "metadata": {},
   "outputs": [],
   "source": [
    "model.compile(loss=\"mean_absolute_error\",\n",
    "              optimizer=\"adam\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 213,
   "metadata": {},
   "outputs": [],
   "source": [
    "EPOCHS=20\n",
    "# create a \"chkp\" directory before training so that\n",
    "# ModelCheckpoint will write history inside\n",
    "callbacks = [\n",
    "    \n",
    "    keras.callbacks.ModelCheckpoint(\n",
    "        './chkp_nlp',\n",
    "        verbose=1, save_freq='epoch'),\n",
    "]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "**Fit**  \n",
    "- Batch size is commonly selected in power of 2s;\n",
    "- Commonly between 32 and 512.\n",
    "- The power of 2s has something to do with alignment between GPU processors and virtual processors.  \n",
    "- I am not taking validation_split since it will reduce the portion of training data we are required to do.  \n",
    "- I save the checkpoint so I can use it for prediction next time."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 218,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Epoch 1/20\n",
      "16/16 [==============================] - 4s 228ms/step - loss: 2.4107\n",
      "\n",
      "Epoch 00001: saving model to .\\chkp_nlp\n",
      "INFO:tensorflow:Assets written to: .\\chkp_nlp\\assets\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "INFO:tensorflow:Assets written to: .\\chkp_nlp\\assets\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Epoch 2/20\n",
      "16/16 [==============================] - 4s 228ms/step - loss: 2.4716\n",
      "\n",
      "Epoch 00002: saving model to .\\chkp_nlp\n",
      "INFO:tensorflow:Assets written to: .\\chkp_nlp\\assets\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "INFO:tensorflow:Assets written to: .\\chkp_nlp\\assets\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Epoch 3/20\n",
      "16/16 [==============================] - 4s 229ms/step - loss: 2.4336 2s -\n",
      "\n",
      "Epoch 00003: saving model to .\\chkp_nlp\n",
      "INFO:tensorflow:Assets written to: .\\chkp_nlp\\assets\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "INFO:tensorflow:Assets written to: .\\chkp_nlp\\assets\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Epoch 4/20\n",
      "16/16 [==============================] - 4s 233ms/step - loss: 2.3816 2s - l\n",
      "\n",
      "Epoch 00004: saving model to .\\chkp_nlp\n",
      "INFO:tensorflow:Assets written to: .\\chkp_nlp\\assets\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "INFO:tensorflow:Assets written to: .\\chkp_nlp\\assets\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Epoch 5/20\n",
      "16/16 [==============================] - 4s 228ms/step - loss: 2.2949\n",
      "\n",
      "Epoch 00005: saving model to .\\chkp_nlp\n",
      "INFO:tensorflow:Assets written to: .\\chkp_nlp\\assets\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "INFO:tensorflow:Assets written to: .\\chkp_nlp\\assets\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Epoch 6/20\n",
      "16/16 [==============================] - 4s 230ms/step - loss: 2.2802\n",
      "\n",
      "Epoch 00006: saving model to .\\chkp_nlp\n",
      "INFO:tensorflow:Assets written to: .\\chkp_nlp\\assets\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "INFO:tensorflow:Assets written to: .\\chkp_nlp\\assets\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Epoch 7/20\n",
      "16/16 [==============================] - 4s 228ms/step - loss: 2.3202\n",
      "\n",
      "Epoch 00007: saving model to .\\chkp_nlp\n",
      "INFO:tensorflow:Assets written to: .\\chkp_nlp\\assets\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "INFO:tensorflow:Assets written to: .\\chkp_nlp\\assets\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Epoch 8/20\n",
      "16/16 [==============================] - 4s 229ms/step - loss: 2.5223\n",
      "\n",
      "Epoch 00008: saving model to .\\chkp_nlp\n",
      "INFO:tensorflow:Assets written to: .\\chkp_nlp\\assets\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "INFO:tensorflow:Assets written to: .\\chkp_nlp\\assets\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Epoch 9/20\n",
      "16/16 [==============================] - 4s 228ms/step - loss: 2.8734\n",
      "\n",
      "Epoch 00009: saving model to .\\chkp_nlp\n",
      "INFO:tensorflow:Assets written to: .\\chkp_nlp\\assets\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "INFO:tensorflow:Assets written to: .\\chkp_nlp\\assets\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Epoch 10/20\n",
      "16/16 [==============================] - 4s 223ms/step - loss: 2.1472\n",
      "\n",
      "Epoch 00010: saving model to .\\chkp_nlp\n",
      "INFO:tensorflow:Assets written to: .\\chkp_nlp\\assets\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "INFO:tensorflow:Assets written to: .\\chkp_nlp\\assets\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Epoch 11/20\n",
      "16/16 [==============================] - 4s 227ms/step - loss: 2.5897\n",
      "\n",
      "Epoch 00011: saving model to .\\chkp_nlp\n",
      "INFO:tensorflow:Assets written to: .\\chkp_nlp\\assets\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "INFO:tensorflow:Assets written to: .\\chkp_nlp\\assets\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Epoch 12/20\n",
      "16/16 [==============================] - 4s 225ms/step - loss: 2.8227\n",
      "\n",
      "Epoch 00012: saving model to .\\chkp_nlp\n",
      "INFO:tensorflow:Assets written to: .\\chkp_nlp\\assets\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "INFO:tensorflow:Assets written to: .\\chkp_nlp\\assets\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Epoch 13/20\n",
      "16/16 [==============================] - 4s 231ms/step - loss: 2.2877 2s\n",
      "\n",
      "Epoch 00013: saving model to .\\chkp_nlp\n",
      "INFO:tensorflow:Assets written to: .\\chkp_nlp\\assets\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "INFO:tensorflow:Assets written to: .\\chkp_nlp\\assets\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Epoch 14/20\n",
      "16/16 [==============================] - 4s 219ms/step - loss: 2.5858\n",
      "\n",
      "Epoch 00014: saving model to .\\chkp_nlp\n",
      "INFO:tensorflow:Assets written to: .\\chkp_nlp\\assets\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "INFO:tensorflow:Assets written to: .\\chkp_nlp\\assets\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Epoch 15/20\n",
      "16/16 [==============================] - 4s 230ms/step - loss: 2.1319\n",
      "\n",
      "Epoch 00015: saving model to .\\chkp_nlp\n",
      "INFO:tensorflow:Assets written to: .\\chkp_nlp\\assets\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "INFO:tensorflow:Assets written to: .\\chkp_nlp\\assets\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Epoch 16/20\n",
      "16/16 [==============================] - 4s 230ms/step - loss: 2.2339\n",
      "\n",
      "Epoch 00016: saving model to .\\chkp_nlp\n",
      "INFO:tensorflow:Assets written to: .\\chkp_nlp\\assets\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "INFO:tensorflow:Assets written to: .\\chkp_nlp\\assets\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Epoch 17/20\n",
      "16/16 [==============================] - 4s 229ms/step - loss: 2.0823\n",
      "\n",
      "Epoch 00017: saving model to .\\chkp_nlp\n",
      "INFO:tensorflow:Assets written to: .\\chkp_nlp\\assets\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "INFO:tensorflow:Assets written to: .\\chkp_nlp\\assets\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Epoch 18/20\n",
      "16/16 [==============================] - 4s 231ms/step - loss: 2.6437\n",
      "\n",
      "Epoch 00018: saving model to .\\chkp_nlp\n",
      "INFO:tensorflow:Assets written to: .\\chkp_nlp\\assets\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "INFO:tensorflow:Assets written to: .\\chkp_nlp\\assets\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Epoch 19/20\n",
      "16/16 [==============================] - 4s 229ms/step - loss: 2.1475 2s - l\n",
      "\n",
      "Epoch 00019: saving model to .\\chkp_nlp\n",
      "INFO:tensorflow:Assets written to: .\\chkp_nlp\\assets\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "INFO:tensorflow:Assets written to: .\\chkp_nlp\\assets\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Epoch 20/20\n",
      "16/16 [==============================] - 4s 227ms/step - loss: 1.9244\n",
      "\n",
      "Epoch 00020: saving model to .\\chkp_nlp\n",
      "INFO:tensorflow:Assets written to: .\\chkp_nlp\\assets\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "INFO:tensorflow:Assets written to: .\\chkp_nlp\\assets\n"
     ]
    },
    {
     "ename": "InvalidArgumentError",
     "evalue": "indices[1] = [0,27028117] is out of order. Many sparse ops require sorted indices.\n    Use `tf.sparse.reorder` to create a correctly ordered copy.\n\n [Op:SerializeManySparse]",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mInvalidArgumentError\u001b[0m                      Traceback (most recent call last)",
      "\u001b[1;32m<timed exec>\u001b[0m in \u001b[0;36m<module>\u001b[1;34m\u001b[0m\n",
      "\u001b[1;32m~\\AppData\\Roaming\\Python\\Python38\\site-packages\\tensorflow\\python\\keras\\engine\\training.py\u001b[0m in \u001b[0;36mpredict\u001b[1;34m(self, x, batch_size, verbose, steps, callbacks, max_queue_size, workers, use_multiprocessing)\u001b[0m\n\u001b[0;32m   1694\u001b[0m                         '. Consider setting it to AutoShardPolicy.DATA.')\n\u001b[0;32m   1695\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m-> 1696\u001b[1;33m       data_handler = data_adapter.get_data_handler(\n\u001b[0m\u001b[0;32m   1697\u001b[0m           \u001b[0mx\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mx\u001b[0m\u001b[1;33m,\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   1698\u001b[0m           \u001b[0mbatch_size\u001b[0m\u001b[1;33m=\u001b[0m\u001b[0mbatch_size\u001b[0m\u001b[1;33m,\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\AppData\\Roaming\\Python\\Python38\\site-packages\\tensorflow\\python\\keras\\engine\\data_adapter.py\u001b[0m in \u001b[0;36mget_data_handler\u001b[1;34m(*args, **kwargs)\u001b[0m\n\u001b[0;32m   1362\u001b[0m   \u001b[1;32mif\u001b[0m \u001b[0mgetattr\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[1;33m[\u001b[0m\u001b[1;34m\"model\"\u001b[0m\u001b[1;33m]\u001b[0m\u001b[1;33m,\u001b[0m \u001b[1;34m\"_cluster_coordinator\"\u001b[0m\u001b[1;33m,\u001b[0m \u001b[1;32mNone\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   1363\u001b[0m     \u001b[1;32mreturn\u001b[0m \u001b[0m_ClusterCoordinatorDataHandler\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;33m*\u001b[0m\u001b[0margs\u001b[0m\u001b[1;33m,\u001b[0m \u001b[1;33m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m-> 1364\u001b[1;33m   \u001b[1;32mreturn\u001b[0m \u001b[0mDataHandler\u001b[0m\u001b[1;33m(\u001b[0m\u001b[1;33m*\u001b[0m\u001b[0margs\u001b[0m\u001b[1;33m,\u001b[0m \u001b[1;33m**\u001b[0m\u001b[0mkwargs\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m   1365\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   1366\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\AppData\\Roaming\\Python\\Python38\\site-packages\\tensorflow\\python\\keras\\engine\\data_adapter.py\u001b[0m in \u001b[0;36m__init__\u001b[1;34m(self, x, y, sample_weight, batch_size, steps_per_epoch, initial_epoch, epochs, shuffle, class_weight, max_queue_size, workers, use_multiprocessing, model, steps_per_execution, distribute)\u001b[0m\n\u001b[0;32m   1152\u001b[0m     \u001b[0madapter_cls\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mselect_data_adapter\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mx\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0my\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   1153\u001b[0m     \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0m_verify_data_adapter_compatibility\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0madapter_cls\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m-> 1154\u001b[1;33m     self._adapter = adapter_cls(\n\u001b[0m\u001b[0;32m   1155\u001b[0m         \u001b[0mx\u001b[0m\u001b[1;33m,\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   1156\u001b[0m         \u001b[0my\u001b[0m\u001b[1;33m,\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\AppData\\Roaming\\Python\\Python38\\site-packages\\tensorflow\\python\\keras\\engine\\data_adapter.py\u001b[0m in \u001b[0;36m__init__\u001b[1;34m(self, x, y, sample_weights, sample_weight_modes, batch_size, steps, shuffle, **kwargs)\u001b[0m\n\u001b[0;32m    594\u001b[0m     \u001b[0minputs\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mpack_x_y_sample_weight\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mx\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0my\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0msample_weights\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    595\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 596\u001b[1;33m     \u001b[0mdataset\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mdataset_ops\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mDatasetV2\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mfrom_tensor_slices\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0minputs\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    597\u001b[0m     \u001b[0mnum_samples\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mint\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mnest\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mflatten\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mx\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m[\u001b[0m\u001b[1;36m0\u001b[0m\u001b[1;33m]\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mshape\u001b[0m\u001b[1;33m[\u001b[0m\u001b[1;36m0\u001b[0m\u001b[1;33m]\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    598\u001b[0m     \u001b[1;32mif\u001b[0m \u001b[0mshuffle\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\AppData\\Roaming\\Python\\Python38\\site-packages\\tensorflow\\python\\data\\ops\\dataset_ops.py\u001b[0m in \u001b[0;36mfrom_tensor_slices\u001b[1;34m(tensors)\u001b[0m\n\u001b[0;32m    758\u001b[0m       \u001b[0mDataset\u001b[0m\u001b[1;33m:\u001b[0m \u001b[0mA\u001b[0m\u001b[0;31m \u001b[0m\u001b[0;31m`\u001b[0m\u001b[0mDataset\u001b[0m\u001b[0;31m`\u001b[0m\u001b[1;33m.\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    759\u001b[0m     \"\"\"\n\u001b[1;32m--> 760\u001b[1;33m     \u001b[1;32mreturn\u001b[0m \u001b[0mTensorSliceDataset\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mtensors\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    761\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    762\u001b[0m   \u001b[1;32mclass\u001b[0m \u001b[0m_GeneratorState\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mobject\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\AppData\\Roaming\\Python\\Python38\\site-packages\\tensorflow\\python\\data\\ops\\dataset_ops.py\u001b[0m in \u001b[0;36m__init__\u001b[1;34m(self, element)\u001b[0m\n\u001b[0;32m   3320\u001b[0m     \u001b[0melement\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mstructure\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mnormalize_element\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0melement\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   3321\u001b[0m     \u001b[0mbatched_spec\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mstructure\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mtype_spec_from_value\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0melement\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m-> 3322\u001b[1;33m     \u001b[0mself\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0m_tensors\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mstructure\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mto_batched_tensor_list\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mbatched_spec\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0melement\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m   3323\u001b[0m     self._structure = nest.map_structure(\n\u001b[0;32m   3324\u001b[0m         lambda component_spec: component_spec._unbatch(), batched_spec)  # pylint: disable=protected-access\n",
      "\u001b[1;32m~\\AppData\\Roaming\\Python\\Python38\\site-packages\\tensorflow\\python\\data\\util\\structure.py\u001b[0m in \u001b[0;36mto_batched_tensor_list\u001b[1;34m(element_spec, element)\u001b[0m\n\u001b[0;32m    362\u001b[0m   \u001b[1;31m# pylint: disable=protected-access\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    363\u001b[0m   \u001b[1;31m# pylint: disable=g-long-lambda\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 364\u001b[1;33m   return _to_tensor_list_helper(\n\u001b[0m\u001b[0;32m    365\u001b[0m       lambda state, spec, component: state + spec._to_batched_tensor_list(\n\u001b[0;32m    366\u001b[0m           component), element_spec, element)\n",
      "\u001b[1;32m~\\AppData\\Roaming\\Python\\Python38\\site-packages\\tensorflow\\python\\data\\util\\structure.py\u001b[0m in \u001b[0;36m_to_tensor_list_helper\u001b[1;34m(encode_fn, element_spec, element)\u001b[0m\n\u001b[0;32m    337\u001b[0m     \u001b[1;32mreturn\u001b[0m \u001b[0mencode_fn\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mstate\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mspec\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mcomponent\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    338\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 339\u001b[1;33m   return functools.reduce(\n\u001b[0m\u001b[0;32m    340\u001b[0m       reduce_fn, zip(nest.flatten(element_spec), nest.flatten(element)), [])\n\u001b[0;32m    341\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\AppData\\Roaming\\Python\\Python38\\site-packages\\tensorflow\\python\\data\\util\\structure.py\u001b[0m in \u001b[0;36mreduce_fn\u001b[1;34m(state, value)\u001b[0m\n\u001b[0;32m    335\u001b[0m   \u001b[1;32mdef\u001b[0m \u001b[0mreduce_fn\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mstate\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mvalue\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    336\u001b[0m     \u001b[0mspec\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mcomponent\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0mvalue\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 337\u001b[1;33m     \u001b[1;32mreturn\u001b[0m \u001b[0mencode_fn\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mstate\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mspec\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mcomponent\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    338\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    339\u001b[0m   return functools.reduce(\n",
      "\u001b[1;32m~\\AppData\\Roaming\\Python\\Python38\\site-packages\\tensorflow\\python\\data\\util\\structure.py\u001b[0m in \u001b[0;36m<lambda>\u001b[1;34m(state, spec, component)\u001b[0m\n\u001b[0;32m    363\u001b[0m   \u001b[1;31m# pylint: disable=g-long-lambda\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    364\u001b[0m   return _to_tensor_list_helper(\n\u001b[1;32m--> 365\u001b[1;33m       lambda state, spec, component: state + spec._to_batched_tensor_list(\n\u001b[0m\u001b[0;32m    366\u001b[0m           component), element_spec, element)\n\u001b[0;32m    367\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\AppData\\Roaming\\Python\\Python38\\site-packages\\tensorflow\\python\\framework\\sparse_tensor.py\u001b[0m in \u001b[0;36m_to_batched_tensor_list\u001b[1;34m(self, value)\u001b[0m\n\u001b[0;32m    368\u001b[0m       raise ValueError(\n\u001b[0;32m    369\u001b[0m           \"Unbatching a sparse tensor is only supported for rank >= 1\")\n\u001b[1;32m--> 370\u001b[1;33m     return [gen_sparse_ops.serialize_many_sparse(\n\u001b[0m\u001b[0;32m    371\u001b[0m         \u001b[0mvalue\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mindices\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mvalue\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mvalues\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mvalue\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mdense_shape\u001b[0m\u001b[1;33m,\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    372\u001b[0m         out_type=dtypes.variant)]\n",
      "\u001b[1;32m~\\AppData\\Roaming\\Python\\Python38\\site-packages\\tensorflow\\python\\ops\\gen_sparse_ops.py\u001b[0m in \u001b[0;36mserialize_many_sparse\u001b[1;34m(sparse_indices, sparse_values, sparse_shape, out_type, name)\u001b[0m\n\u001b[0;32m    493\u001b[0m       \u001b[1;32mreturn\u001b[0m \u001b[0m_result\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    494\u001b[0m     \u001b[1;32mexcept\u001b[0m \u001b[0m_core\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0m_NotOkStatusException\u001b[0m \u001b[1;32mas\u001b[0m \u001b[0me\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m--> 495\u001b[1;33m       \u001b[0m_ops\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mraise_from_not_ok_status\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0me\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mname\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m    496\u001b[0m     \u001b[1;32mexcept\u001b[0m \u001b[0m_core\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0m_FallbackException\u001b[0m\u001b[1;33m:\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m    497\u001b[0m       \u001b[1;32mpass\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\AppData\\Roaming\\Python\\Python38\\site-packages\\tensorflow\\python\\framework\\ops.py\u001b[0m in \u001b[0;36mraise_from_not_ok_status\u001b[1;34m(e, name)\u001b[0m\n\u001b[0;32m   6895\u001b[0m   \u001b[0mmessage\u001b[0m \u001b[1;33m=\u001b[0m \u001b[0me\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mmessage\u001b[0m \u001b[1;33m+\u001b[0m \u001b[1;33m(\u001b[0m\u001b[1;34m\" name: \"\u001b[0m \u001b[1;33m+\u001b[0m \u001b[0mname\u001b[0m \u001b[1;32mif\u001b[0m \u001b[0mname\u001b[0m \u001b[1;32mis\u001b[0m \u001b[1;32mnot\u001b[0m \u001b[1;32mNone\u001b[0m \u001b[1;32melse\u001b[0m \u001b[1;34m\"\"\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   6896\u001b[0m   \u001b[1;31m# pylint: disable=protected-access\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[1;32m-> 6897\u001b[1;33m   \u001b[0msix\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mraise_from\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0mcore\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0m_status_to_exception\u001b[0m\u001b[1;33m(\u001b[0m\u001b[0me\u001b[0m\u001b[1;33m.\u001b[0m\u001b[0mcode\u001b[0m\u001b[1;33m,\u001b[0m \u001b[0mmessage\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m,\u001b[0m \u001b[1;32mNone\u001b[0m\u001b[1;33m)\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0m\u001b[0;32m   6898\u001b[0m   \u001b[1;31m# pylint: enable=protected-access\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[1;33m\u001b[0m\u001b[0m\n\u001b[0;32m   6899\u001b[0m \u001b[1;33m\u001b[0m\u001b[0m\n",
      "\u001b[1;32m~\\anaconda3\\envs\\tf2.4\\lib\\site-packages\\six.py\u001b[0m in \u001b[0;36mraise_from\u001b[1;34m(value, from_value)\u001b[0m\n",
      "\u001b[1;31mInvalidArgumentError\u001b[0m: indices[1] = [0,27028117] is out of order. Many sparse ops require sorted indices.\n    Use `tf.sparse.reorder` to create a correctly ordered copy.\n\n [Op:SerializeManySparse]"
     ]
    }
   ],
   "source": [
    "%%time\n",
    "import time\n",
    "\n",
    "pred_data_vec = []\n",
    "\n",
    "# Fit and predict on each train and test fold\n",
    "tf.random.set_seed(123)\n",
    "for train, test in zip(cv_folds.train_idx, cv_folds.test_idx):\n",
    "    \n",
    "    # Take only the 1000 most recent filings so the model is focused on current filing events \n",
    "    # This only works since the file is indexed and sorted by FileDate!\n",
    "    train = train.tail(1000)\n",
    "    \n",
    "    # Get X_train and y_train for this fold\n",
    "    X_train = train.norm_txt.values\n",
    "    # Impute y to cap extreme low and high repsonses in training data.\n",
    "    y_train = impute_y(train.Pct_Change_20.values)\n",
    "    \n",
    "    # Transform X_train using the pipeline\n",
    "    #X_train_trans = trans_pipe.fit_transform(X_train,y_train)\n",
    "    \n",
    "    # Transform y and fit model using ttr\n",
    "    #ttr.fit(X_train_trans, y_train)\n",
    "    history = model.fit(\n",
    "                    X_train,\n",
    "                    y_train,\n",
    "                    verbose=1,\n",
    "                    epochs=EPOCHS,\n",
    "                    batch_size = 64,\n",
    "                    #validation_split=0.15,\n",
    "                    shuffle = True,\n",
    "                    callbacks=callbacks\n",
    "                )\n",
    "        \n",
    "    # Get X_test and y_test for this fold\n",
    "    X_test = test.norm_txt.values\n",
    "    y_test = test.Pct_Change_20.values\n",
    "    \n",
    "    # Transform X_test for this fold\n",
    "    #X_test_trans = trans_pipe.transform(X_test)\n",
    "\n",
    "    preds = model.predict(X_test_trans)\n",
    "    \n",
    "    # Select all but last column f_text of data\n",
    "    test = test.iloc[:,:-1].copy()\n",
    "    test['y_pred'] = preds\n",
    "    pred_data_vec.append(test)\n",
    "    \n",
    "\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Explanations: Possible consideration for extra effort.\n",
    "\n",
    "- I carefully selected and regularized the architecture.\n",
    "- I used sentence level embedding layer that was pretrained on seven billion words \n",
    "    - It will capture the inherent semantics and context within the text.\n",
    "    \n",
    "- I expected a much better performance than the traditional Bag of Words vectorizer model (TFIDF Vectorizer);\n",
    "    -These do not capture semantics and context of the text.\n",
    "    \n",
    "**Result: Error**  \n",
    "- The model trained successfully for 20 epochs\n",
    "     - That is it was displaying reduction in error, which can be erratic sometimes.\n",
    "         - Can be tuned by varying the decay_rate or train for for iterations by increasing the epoch size.\n",
    "\n",
    "**- The error that occured post-training is new to me and I did not have enough time to debug it.**"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Interesting Observations"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "**Is 25% Mean Absolute Error really high?**\n",
    "* It appears that a few penny stocks are dramatically inflating the MAE\n",
    "* The current model is gettting the direction correct 57% of the time during the simulation.\n",
    "* The model is currently more accurate at predicting decreases.  "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 106,
   "metadata": {},
   "outputs": [],
   "source": [
    "# ************* Change this to the predictions for your best simulation! *************\n",
    "all_fold_preds = pred_data_3"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 107,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>CompanyCIK</th>\n",
       "      <th>CompanyName</th>\n",
       "      <th>FileType</th>\n",
       "      <th>FileDate</th>\n",
       "      <th>EdgarTextUrl</th>\n",
       "      <th>EdgarHtmlUrl</th>\n",
       "      <th>AccessionNumber</th>\n",
       "      <th>SecFileName</th>\n",
       "      <th>CompanyTicker</th>\n",
       "      <th>FileDate_ClosingPrice</th>\n",
       "      <th>...</th>\n",
       "      <th>Pct_Change_20</th>\n",
       "      <th>FileName</th>\n",
       "      <th>file_text_length</th>\n",
       "      <th>f_text</th>\n",
       "      <th>y_pred</th>\n",
       "      <th>Predicted_Direction</th>\n",
       "      <th>Actual_Direction</th>\n",
       "      <th>Correct_Direction</th>\n",
       "      <th>Correct_Increase</th>\n",
       "      <th>Correct_Decrease</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>639</th>\n",
       "      <td>1399306</td>\n",
       "      <td>Simlatus Corp</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-05-17</td>\n",
       "      <td>edgar/data/1399306/0001399306-21-000020.txt</td>\n",
       "      <td>edgar/data/1399306/0001399306-21-000020-index....</td>\n",
       "      <td>0001399306-21-000020</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>SIML</td>\n",
       "      <td>0.0008</td>\n",
       "      <td>...</td>\n",
       "      <td>13961.750268</td>\n",
       "      <td>1399306_0001399306-21-000020.txt</td>\n",
       "      <td>125625</td>\n",
       "      <td>b'10-Q 1 form-10q.htm FORM 10-Q UNITED STATES ...</td>\n",
       "      <td>-3.424462</td>\n",
       "      <td>Decrease</td>\n",
       "      <td>Increase</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>718</th>\n",
       "      <td>1662574</td>\n",
       "      <td>Grom Social Enterprises, Inc.</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-05-17</td>\n",
       "      <td>edgar/data/1662574/0001683168-21-002065.txt</td>\n",
       "      <td>edgar/data/1662574/0001683168-21-002065-index....</td>\n",
       "      <td>0001683168-21-002065</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>GRMM</td>\n",
       "      <td>0.2400</td>\n",
       "      <td>...</td>\n",
       "      <td>2925.000163</td>\n",
       "      <td>1662574_0001683168-21-002065.txt</td>\n",
       "      <td>121351</td>\n",
       "      <td>b'10-Q 1 grom_10q-033121.htm QUARTERLY REPORT ...</td>\n",
       "      <td>-8.931839</td>\n",
       "      <td>Decrease</td>\n",
       "      <td>Increase</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>955</th>\n",
       "      <td>1101026</td>\n",
       "      <td>Zivo Bioscience, Inc.</td>\n",
       "      <td>10-Q</td>\n",
       "      <td>2021-05-17</td>\n",
       "      <td>edgar/data/1101026/0001078782-21-000455.txt</td>\n",
       "      <td>edgar/data/1101026/0001078782-21-000455-index....</td>\n",
       "      <td>0001078782-21-000455</td>\n",
       "      <td>2021-QTR2</td>\n",
       "      <td>ZIVO</td>\n",
       "      <td>0.1300</td>\n",
       "      <td>...</td>\n",
       "      <td>3200.000092</td>\n",
       "      <td>1101026_0001078782-21-000455.txt</td>\n",
       "      <td>116920</td>\n",
       "      <td>b'10-Q 1 f10q033121_10q.htm FORM 10Q QUARTERLY...</td>\n",
       "      <td>-2.374593</td>\n",
       "      <td>Decrease</td>\n",
       "      <td>Increase</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>3 rows  22 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     CompanyCIK                    CompanyName FileType   FileDate  \\\n",
       "639     1399306                  Simlatus Corp     10-Q 2021-05-17   \n",
       "718     1662574  Grom Social Enterprises, Inc.     10-Q 2021-05-17   \n",
       "955     1101026          Zivo Bioscience, Inc.     10-Q 2021-05-17   \n",
       "\n",
       "                                    EdgarTextUrl  \\\n",
       "639  edgar/data/1399306/0001399306-21-000020.txt   \n",
       "718  edgar/data/1662574/0001683168-21-002065.txt   \n",
       "955  edgar/data/1101026/0001078782-21-000455.txt   \n",
       "\n",
       "                                          EdgarHtmlUrl       AccessionNumber  \\\n",
       "639  edgar/data/1399306/0001399306-21-000020-index....  0001399306-21-000020   \n",
       "718  edgar/data/1662574/0001683168-21-002065-index....  0001683168-21-002065   \n",
       "955  edgar/data/1101026/0001078782-21-000455-index....  0001078782-21-000455   \n",
       "\n",
       "    SecFileName CompanyTicker  FileDate_ClosingPrice  ... Pct_Change_20  \\\n",
       "639   2021-QTR2          SIML                 0.0008  ...  13961.750268   \n",
       "718   2021-QTR2          GRMM                 0.2400  ...   2925.000163   \n",
       "955   2021-QTR2          ZIVO                 0.1300  ...   3200.000092   \n",
       "\n",
       "                             FileName  file_text_length  \\\n",
       "639  1399306_0001399306-21-000020.txt            125625   \n",
       "718  1662574_0001683168-21-002065.txt            121351   \n",
       "955  1101026_0001078782-21-000455.txt            116920   \n",
       "\n",
       "                                                f_text    y_pred  \\\n",
       "639  b'10-Q 1 form-10q.htm FORM 10-Q UNITED STATES ... -3.424462   \n",
       "718  b'10-Q 1 grom_10q-033121.htm QUARTERLY REPORT ... -8.931839   \n",
       "955  b'10-Q 1 f10q033121_10q.htm FORM 10Q QUARTERLY... -2.374593   \n",
       "\n",
       "    Predicted_Direction  Actual_Direction Correct_Direction Correct_Increase  \\\n",
       "639            Decrease          Increase             False            False   \n",
       "718            Decrease          Increase             False            False   \n",
       "955            Decrease          Increase             False            False   \n",
       "\n",
       "     Correct_Decrease  \n",
       "639             False  \n",
       "718             False  \n",
       "955             False  \n",
       "\n",
       "[3 rows x 22 columns]"
      ]
     },
     "execution_count": 107,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Look at the outliers\n",
    "all_fold_preds[all_fold_preds.Pct_Change_20 > 1000]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 108,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "MAE Excluding Outliers: 15.88813885447523\n"
     ]
    }
   ],
   "source": [
    "# Look at the adjusted MAE when the outliers are removed\n",
    "p = all_fold_preds[all_fold_preds.Pct_Change_20 < 1000]\n",
    "mae = mean_absolute_error(p.Pct_Change_20, p.y_pred)\n",
    "print('MAE Excluding Outliers:', mae)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 109,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Total Predictions: 2065 \n",
      "\n",
      "Correct_Direction\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "False    0.581598\n",
       "True     0.418402\n",
       "Name: Correct_Direction, dtype: float64"
      ]
     },
     "execution_count": 109,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "all_fold_preds['Predicted_Direction'] = np.where(all_fold_preds['y_pred'] < 0, 'Decrease', 'Increase')\n",
    "all_fold_preds['Actual_Direction'] = np.where(all_fold_preds['Pct_Change_20'] < 0, 'Decrease', 'Increase') \n",
    "all_fold_preds['Correct_Direction'] = all_fold_preds['Actual_Direction'] == all_fold_preds['Predicted_Direction']\n",
    "all_fold_preds['Correct_Increase'] = np.where((all_fold_preds['Actual_Direction'] == 'Increase')\n",
    "                                              & (all_fold_preds['Correct_Direction'] == True),\n",
    "                                              True, False)\n",
    "all_fold_preds['Correct_Decrease'] = np.where((all_fold_preds['Actual_Direction'] == 'Decrease')\n",
    "                                              & (all_fold_preds['Correct_Direction'] == True),\n",
    "                                              True, False)\n",
    "\n",
    "print('Total Predictions:', len(all_fold_preds.index) ,'\\n')\n",
    "print('Correct_Direction')\n",
    "all_fold_preds['Correct_Direction'].value_counts(normalize=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 110,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Total_Increases:  1382\n",
      "Correct_Increases:  479\n",
      "Percent_Correct: 34.65991316931983\n"
     ]
    }
   ],
   "source": [
    "ti = len(all_fold_preds['Actual_Direction'][all_fold_preds.Actual_Direction == 'Increase']) \n",
    "print('Total_Increases: ', ti)\n",
    "ci = all_fold_preds['Correct_Increase'].sum()\n",
    "print('Correct_Increases: ', ci)\n",
    "print('Percent_Correct:', (ci/ti) * 100)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 105,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Total_Decreases:  683\n",
      "Correct_Decreases:  385\n",
      "Percent_Correct: 56.36896046852124\n"
     ]
    }
   ],
   "source": [
    "td = len(all_fold_preds['Actual_Direction'][all_fold_preds.Actual_Direction == 'Decrease']) \n",
    "print('Total_Decreases: ', td)\n",
    "cd = all_fold_preds['Correct_Decrease'].sum()\n",
    "print('Correct_Decreases: ', cd)\n",
    "print('Percent_Correct:', (cd/td) * 100)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.10"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
